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Abstract 
 
Protein-protein interactions (PPIs) mediate a number of essential cellular 
processes and their implication in numerous diseased states - including HIV and 
cancer - makes them desirable targets for therapeutic intervention. It is however 
still unclear how to target them, considering their relative lack of defining 
features. A large proportion of PPIs however involve binding of an α-helix into a 
hydrophobic cleft on the other protein’s surface and a few key residues located 
along one helical face have been identified as a recurring and critical pattern for 
binding. Mimicking the helical core and replicating the spatial arrangement of 
these residues has therefore become a desirable strategy to abolish such 
interactions. Building on previous studies from the group, the work described in 
this thesis aimed to use an N-alkylated oligoamide scaffold to target α-helix 
mediated PPIs. In particular, the study focused on the assembly and screening of 
a library of oligobenzamides against two key oncogenic targets (p53/hDM2 and 
Noxa B/Mcl-1), with a view to setting the basis for a generic approach towards 
the selective inhibition of α-helix mediated PPIs. The model interactions for this 
study and their biological context are described in Chapter 1, as well as the 
different approaches that have emerged to achieve α-helix mimicry. An 
automated microwave assisted solid phase methodology has been developed 
which makes use of the Fmoc protection strategy and is reported in Chapter 2. 
The robustness of this methodology was demonstrated through the assembly of a 
library of 75 compounds. This library is described in Chapter 3, along with its 
biophysical assessment and preliminary cell assays. Chapter 4 describes the 
design and synthesis of oligoureas and their potential as helix mimetics was 
assessed against the p53/hDM2 PPI.  
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Chapter 1  
 
 
Protein-Protein Interactions  
as Therapeutic Targets 
 
Section 1.2.2 of this Chapter contributed to a review article published in Nature 
Chemistry.1 
 
 
Protein-protein interactions (PPIs) mediate a number of essential cellular 
processes and their implication in numerous diseased states makes them 
desirable targets for therapeutic intervention. Inhibiting PPIs, however, was 
initially considered asa daunting challenge, as it was unclear how to effectively 
and selectively target them using small molecules. Recent advances in the field 
have contributed to change the collective perception on PPIs and new strategies 
have been developed that are turning PPIs into more tractable targets. These 
strategies will be discussed later in this Chapter and have been recently 
reviewed.2 PPI inhibitors must cover 800-1100 Å² of a protein surface and 
complement the projection of hydrophobic and charged domains on a relatively 
flat surface. PPIs are therefore very different from the more traditional enzyme-
substrate kind of interaction where a small substrate binds in a well-defined 
cavity on the enzyme. In the latter case, structural features of the substrate or the 
cavity itself can guide the design of competitive inhibitors, whereas PPIs lack 
those defining features, which caused them to be considered undruggable until a 
few decades ago. PPIs bring into play electrostatic, hydrophobic and hydrophilic 
interactions, however studies have shown that hydrophobic interactions are 
generally the driving force for the formation of protein-protein complexes.3 
Common methods to discover inhibitors of PPIs are: the investigation of peptides 
derived from short contiguous sequences at the interface (e.g. peptidomimetics)4 
and the development of biopharmaceutical compounds that usually bind to PPI 
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surfaces e.g. monoclonal antibodies5 or polypeptide hormones.6 High throughput 
screening (HTS) has also been exploited to this end, but only showed limited 
success in identifying inhibitors of PPIs (e.g. the Nutlins).7 Other conventional 
methodologies used in drug discovery to identify lead compounds have also 
proven rather unsuccessful when applied to PPIs. These approaches are limited 
for several reasons.4 The relatively large and featureless interface makes it hard 
for a small molecule to be competitive and to achieve selective binding to an 
individual protein. Furthermore, the binding of protein partners often involves 
areas of the protein surfaces that are far apart and thus cannot be mimicked by 
simple synthetic peptides. Few “drug-like” small molecules have been identified 
from library screening as effective PPIs disruptors; however several starting 
compounds with Kd in the mid-micromolar range have been identified by HTS. 
Medicinal chemistry approaches have then improved the properties of these hits 
and generated compounds with Kd in the mid/low nanomolar range (this was the 
case for binders of IL-2, Bcl-xL, hDM2 and HPV E2).8 One reason for which HTS of 
existing libraries does not provide efficient PPI disruptors is that these libraries 
are the result of past research effort into GPCRs (G-Protein coupled receptors),9, 
10 and more traditional, druggable targets. Despite these facts, intense research 
efforts have yielded successful approaches to the modulation of PPIs and 
examples of the inhibition of two protein partners with low molecular weight 
ligands have been reported, some of them are currently in clinical trials.7  
The α-helix is the most prominent structural motif in proteins and as such 
is commonly found at protein-protein interfaces.11, 12 The α-helix was the first-
described secondary structure discovered by Linus Pauling in 1951, after William 
Astbury’s pioneering studies at Leeds on the X-ray diffraction of keratin.13 This 
discovery constitutes one of the major breakthroughs in contemporary science. 
An ideal alpha helix consists of H-bonds between every ith CO and (i + 4)th NH, 
with 3.6 residues per turn and a pitch of 5.4 Å, the contiguous arrays of hydrogen 
bonds giving rise to a rigid rod-like structure (Fig. 1.1).14 In many α-helix 
mediated PPIs, a few key residues located along one face of the helix insert deep 
in a cleft on the partner protein and are critical for binding. The existence of such 
“hot-spot residues” at the interface of two interacting proteins was first 
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evidenced by a mutagenesis study conducted by Clackson and Wells,15 and was 
more widely discussed by Stites in 1997.16  
 
 
Figure 1.1 The alpha-helix. a. Intramolecular H-bond network within the α-helix (side 
chain atoms are omitted for clarity). b. View of an α-helix along the helical axis, the side 
chains are represented by purple balls, except for those at positions i, i + 4 and i + 7 
which are represented in green. c. Torsion angles in polypeptide bonds.  
 
The intrinsic properties of α-helices17 dictate that hot-spot residues located on 
the same helical face should be located at defined positions on the helix, namely i, 
i + 3 or i + 4, i + 7 or i + 8 etc. Mutagenesis studies have confirmed that this 
combination of residues is a recurrent pattern in a number of therapeutically 
relevant interactions, such as the gp41 protein, responsible for the fusion process 
enabling HIV infection,18 the p53/hDM2 interaction19-22 and the Bcl-2 family of 
interactions.23-25 These key oncogenic targets will be described in the next 
section. Designing a molecule that could mimic the spatial presentation of the key 
residues is an attractive strategy adopted by several research groups (Fig. 1.2).  
 
 
 
Figure 1.2 Disruption of an α-helix mediated PPI by a designed inhibitor 
replicating the spatial presentation of key binding residues. 
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Three main categories of mimetics arise: peptide-based scaffolds, 
proteomimetics26 and small molecules; they will be described in the third section 
of this Chapter. The development of α-helix mimetics is a key field of research in 
the Wilson group. As illustrated in Fig. 1.2, the strategy is to design a scaffold that 
would mimic the spatial projection of key residues from protein A to achieve 
competitive binding with protein B, thereby allowing protein A to play a 
beneficial role. The p53/hDM2 and related p53/hDMX PPIs were chosen as 
starting points for this study, as they are suitable model targets to elaborate a 
general approach to the disruption of α-helix mediated PPIs.  
 
1.1 Targets and insight into their biological context  
1.1.1 The p53/hDM2 interaction  
1.1.1.1 Generalities and structure of p53 
 
p53 plays a pivotal role in the cell cycle, but also in a cell’s defence against cancer, 
as a powerful growth suppressor and pro-apoptotic protein.27 It was identified in 
1979 by Lionel Crawford, David P. Lane, Arnold Levine and Lloyd Old and was 
named for its apparent molecular mass on SDS-PAGE: 53 kDa; however its real 
mass calculated from its amino acid residues is only 43.7 kDa. This difference is 
due to the high number of proline residues in the protein, which slow its 
migration in SDS-PAGE, making it appear heavier than it actually is.28 The protein 
is 393 amino acids long and is constituted of six domains: 
- the N-terminal transcription-activation domain (TAD), also known as 
activation domain 1 (AD1) which activates transcription factors and contains 
the hDM2 binding site (residues 1-42); 
-   the activation domain 2 (AD2) important for apoptotic activity (residues 43-
63); 
-  the proline rich domain important for the apoptotic activity (residues 64-92); 
- the central DNA-binding core domain (DBD, Fig. 1.3), which contains one zinc 
atom and several arginine amino acids (residues ~ 100-300). 90% of p53 
mutations found in human cancers occur in this region which contains highly 
conserved domains; 
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- the homo-oligomerisation domain (OD, residues 307-355), consists of a β-
strand followed by an α-helix necessary for dimerisation, as p53 is composed 
of a dimer of dimers. Tetramerisation is essential for the activity of p53 in 
vivo. The OD also includes a nuclear export signal (NES, residues 316-325); 
- the C-terminal domain contains three nuclear localisation signals (NLS) and a 
non-specific DNA binding domain that binds to damaged DNA. This region is 
also involved in down regulation of DNA binding of the central 
domain (residues 356-393). 
 
 
 
Figure 1.3 p53 directly binds DNA to exert its post-transcriptional activity. a. 
Domain structure of p53. b. 3D structure of the central DNA-binding domain of p53 (PDB 
ID: 3EXJ), helix 2 has the ability to bind to DNA. c. p53 core domain as an oligomer 
(ribbons) bound to DNA (surface), (PDB ID: 1TSR). 
 
p53 plays a central role in cell cycle regulation. Its major role is to maintain the 
stability of the genome by preventing the multiplication of any cell whose DNA 
has undergone mutations, and it is thus involved in preventing cancer. p53 has 
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several anti-cancer functions: activation of DNA repair, inducing growth arrest by 
holding the cell cycle, or initiation of apoptosis if the DNA cannot be repaired. The 
TP53 gene, which encodes for p53 is affected in approximately half of all cases of 
human tumours, either by mutation or deletion.29 Some mutant p53s can no 
longer bind to DNA, therefore p21 (a cyclin-dependant kinase inhibitor whose 
expression is tightly controlled by p53) cannot be produced and play its role as a 
stop-signal for cell division, which becomes uncontrollable, thus resulting in the 
formation of tumours.30 Mutations that deactivate p53 in cancer usually occur in 
the DNA-binding domain, preventing the protein from binding to its target DNA 
sequences and activating the transcription of these genes.31 The p53 protein is 
activated in response to stressful stimuli such as DNA damage, hypoxia, spindle 
damage, nitric oxide, heat/cold shock, viral infection and oncogenic activation.32 
Upon activation, the association between p53 and its negative regulator hDM2 is 
abolished, the half-life of the protein is drastically increased, which induces its 
accumulation in the nucleus and a conformational change allows p53 to take on 
an active role as a transcription factor in these cells. The critical event leading to 
the activation of p53 is the phosphorylation of its N-terminal domain. This 
domain contains a large number of phosphorylation sites and is therefore one of 
the primary targets for protein kinases transducing stress signals. In the response 
phase, p53 activates the transcription of a large number of p53-regulated genes 
that are responsible for cell cycle arrest or apoptosis. If the cell cycle is arrested, 
the cell can trigger repair mechanisms, some of which are directly activated by 
p53. Genes involved in cell cycle arrest include hDM2 and p21; and those 
involved in the intrinsic apoptotic pathway encode pro-apoptotic members of the 
Bcl-2 family such as Bax, Noxa B and Puma.33 Once the repair is completed, the 
concentration of p53 returns to a normal level and the cell cycle resumes. If the 
cell is too damaged to be repaired, it then undergoes apoptosis. In this 
mechanism, the role of p53 is to activate the transcription of the Bax and Bak 
genes. Bax and Bak can then form oligomers, which perforate the mitochondrial 
membrane and allow cytochrome c to reach the cytoplasm, where it activates the 
caspase cascade, a key event in the process of apoptosis.34 However, it is still 
unclear how and why some cells undergo apoptosis whilst others go through cell 
cycle arrest.  
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1.1.1.2 Structures and functions of hDM2 and hDMX 
As p53 mediates growth arrest and apoptosis under stressful conditions, it is 
essential to keep its activity under control during normal development. p53 is 
thus tightly regulated under both normal and stressful conditions by nuclear 
export and degradation via the ubiquitin-dependant proteasome pathway.35, 36 
This degradation is mediated by interactions with two negative regulators: hDM2 
and hDMX. mDM2 (murine double minute 2) designates the gene and the 491-
amino acid long protein for which this gene codes in mice.22 The human 
homologue of this protein was later identified and is referred to as hDM2. hDM2 
is one of the major regulators of p53 and both proteins control one another’s 
cellular levels. hDM2 is also a responsive gene : its transcription can be activated 
by p53, thus when p53 is stabilised, the transcription of hDM2 is also induced, 
resulting in higher hDM2 protein levels. Increased hDM2 levels regulate p53 
activity in three ways:   
- hDM2 binds to the N-terminal domain of p53, blocking its   transcriptional 
activity;  
- hDM2 induces nuclear export of p53; 
- hDM2 stimulates degradation of p53 via the E3 ubiquitin ligase - proteasome 
pathway : it covalently attaches ubiquitin to p53, marking it for proteasome 
degradation.  
It was demonstrated that mice lacking the mDM2 gene are embryonic-
lethal (die early in development), but this lethality was fully rescued by deletion 
of p53, suggesting that the activity of p53 is regulated by hDM2.37, 38 hDMX (also 
known as hDM4) is a structural homologue of hDM2 possessing 490 amino acid 
residues and shares the same arrangement of structural domains, except that 
hDMX lacks the ubiquitin-ligase function. Like hDM2, a knockout of hDMX in mice 
resulted in embryonic-lethality, and the double knockout of hDMX and p53 was 
shown to be viable.39 hDM2 and hDMX are directly involved in p53 functional 
inactivation in approximately 40% of tumours, making them attractive drug 
targets40 and they both repress p53 transcriptional activity by binding to an 
amphiphilic helix of its N-terminal domain. Several lysine residues in the p53 C-
terminus have been identified as the sites of ubiquitination. hDM2 is capable of 
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auto-polyubiquitination, and in complex with p300, a cooperating E3 ubiquitin 
ligase, is capable of polyubiquitinating p53.35 In this manner, hDM2 and p53 are 
both members of a negative feedback control loop that keeps the level of p53 low 
in the absence of p53-stabilising signals. This loop can be interfered with by 
kinases and genes like p14arf when p53 activation signals including DNA damage 
are high. However, ubiquitination of p53 is reversible through a ubiquitin specific 
protease (HAUSP).41 This is one way by which p53 is stabilised in response to 
oncogenic insults. hDMX also binds to p53 and inhibits p53-dependent 
transcription. hDMX is overexpressed in 10-20% of various tumours, again 
resulting in the suppression of p53 activity.42  
 In contrast to hDM2, hDMX cannot act as a ubiquitin ligase to control the 
stability of p53, but instead is mainly responsible for regulating its 
transcriptional activity.43 As the loss of hDM2 or hDMX leads to embryonic 
lethality,37 their expression is necessary for regulation of p53 during normal 
development. On the other hand, the overexpression of hDM2 abolishes the 
ability of p53 to induce cell cycle arrest and apoptosis.44 An overexpression of 
hDM2 is observed in 40-60% of human oestrogenic sarcomas and about 30% of 
soft tissues sarcomas, where wild type p53 is retained.45 hDM2 was initially 
validated as a drug target for antisense oligonucleotides, monoclonal antibodies 
and small peptides.46, 47 In antisense oligonucleotide therapy, the oligoDNA 
sequences are complementary to the DNA or RNA sequence of their target gene. 
Antisense oligonucleotides that inhibit expression of hDM2 also demonstrate 
significant activation of p53, resulting in growth arrest and/or apoptosis in 
cancer cells. Some second generation antisense oligonucleotides displayed 
antitumor activity both in vitro and in vivo.40 Acting synergistically in tumour 
cells, hDM2 and hDMX have become two of the most attractive molecular targets 
for cancer therapy.40 
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Figure 1.4 The p53/hDM2 and related p53/hDMX interactions. a. Structure of hDM2 
bound to p53 (PDB ID: 1YCR), the 3 key residues of p53 (green) insert deep into a 
hydrophobic cleft on hDM2. b. The native p53 helix. c. Overlay of the crystal structures of 
p53 bound to hDM2 (blue, a) and hDMX (gold, PDB ID: 3DAC), highlighting the structural 
homology between the two proteins. d. Interfacial residues are shown for both p53 
(green) and hDM2 (yellow).  
 
 
A crystal structure of p53 (residues 15-29) bound to the p53-binding domain of 
hDM2 (residues 19-102) showed that p53 forms an amphiphilic α-helix 
interaction with a deep hydrophobic cleft on hDM2, where three key hydrophobic 
residues play an essential role in the binding : Phe19, Trp23 and Leu26 located at 
positions i, i + 4 and i + 7 of the p53 helix22 (Fig. 1.4). Since the loss or mutation of 
p53 function is associated with tumour growth, reactivating wild type (WT) p53 
in tumours where its function has been suppressed by hDM2 and related 
regulators has become an attractive approach for novel anticancer therapeutic 
strategies.21 This justifies the intensive search for a small molecule inhibitor that 
could disrupt the p53/hDM2 interaction by specifically binding to this area, and 
release p53 which in turn would activate the p53 pathway. Recent structural 
studies revealed extensive similarity between the p53-binding site of hDM2 and 
hDMX in overall folding and the shapes of their p53-binding pockets, however a 
few sequence differences result in a smaller hydrophobic cleft in hDMX that 
prevents efficient binding of some compounds that show a good affinity with 
hDM2.48 In general, antagonists designed for hDM2 inhibition are significantly 
less efficient against hDMX, which limits their potential as ‘drugs’. 
 
Chapter 1: Protein-Protein Interactions as Therapeutic Targets 
 
10 
 
1.1.2  The Bcl-2 family of interactions  
1.1.2.1 Generalities and structure of the Bcl-2 family 
Bcl-2 (B-cell lymphoma 2) designates a family of mammalian genes and the 
proteins they produce. 25 genes in the Bcl-2 family are known to date and the 
number of family members identified is constantly growing. They govern 
mitochondrial outer membrane permeabilisation (MOMP) and can be either pro-
apoptotic (i.e. Bax, Bak, Noxa B, and Puma) or pro-survival (including Bcl-2 
proper, Bcl-xL and Mcl-1). The most well known Bcl-2 family members and their 
binding partners are reported in Table 1.1.  
 
Table 1.1 Bcl-2 family members and their binding partners. 
Sub-family 
   Protein         
   name 
Known binding partners  
(PDB ID indicated where applicable) 
Anti-apoptotic 
members 
Bcl-2 Bim (4B4S), Bid, Bad, Bax (2XAO), Puma, Bmf 
Bcl-xL 
Bim (3FDL, 1PQ1), Bad (2BZW), Puma, Bax 
(3PL7), Bak (2LP8), Bid, Bad (1G5J), Bmf 
Mcl-1 
Noxa B (2NLA), Bim (2NL9), Puma (2ROC), Bax 
(3PK1), Noxa A (2ROD), Bim (3KJO), Puma, Bmf, 
Bid (2KBW) 
A1 Bim (2VM6), Puma (2VOF), Bak (2VOH), Bid 
(2VOI), Bmf (2VOG), Noxa B 
Bcl-w Bim, Puma, Bid (1ZY3), Bad, Bmf, Bax 
Multidomain 
Pro-apoptotic 
members 
Bak A1, Bcl-xL, Bax, Bid 
Bax Bak, Bcl-2, Bcl-w, Bcl-xL, Mcl-1, Bid 
BH3-only  
Pro-apoptotic 
 members 
Bim Mcl-1, A1, Bcl-xL, Bcl-w, Bcl-2 
Bad Bcl-xL, Bcl-w, Bcl-2 
Noxa B Mcl-1, A1 
Bid Bcl-w, Mcl-1, A1, Bcl-xL, Bak (2M5B) 
Puma A1, Mcl-1, Bcl-xL, Bcl-w, Bcl-2 
    Bmf Bcl-2, A1, Bcl-xL, Bcl-w, Mcl-1 
 
The members of the Bcl-2 family share one or more of the four characteristic 
domains of homology entitled the Bcl-2 homology (BH) domains, named BH1, 
BH2, BH3 and BH4. These domains are known to be crucial for function, as 
deletion of these domains affects survival/apoptosis rates.49-51 The Bcl-2 family 
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comprises three subfamilies that contain between one and four BH domains. The 
anti-apoptotic subfamily comprises proteins that conserve all four BH domains. 
The pro-apoptotic Bax-like subfamily lacks BH4 domains whereas another pro-
apoptotic subfamily of proteins only have the BH3 domain, and are called the 
BH3-only proteins (Bad, Puma, Noxa B, etc.). The multi-domain Bcl-2 family 
members (anti-apoptotic and the Bax-like proteins) also share a C-terminal 
membrane-anchoring sequence and a similar 3D structure : an eight-helix bundle 
that creates a groove into which helical BH3-domain peptides bind.52 The 
sequence that determines whether the protein will carry out a pro-apoptotic or 
pro-survival function remains elusive. In a viable cell, the pro-apoptotic Bcl-2 
family members Bax, Bak, and BH3-only proteins are antagonised by anti-
apoptotic members. In response to an apoptotic stimulus, BH3-only members are 
activated and prevent anti-apoptotic Bcl-2 members from inhibiting pro-
apoptotic members. In addition, they might directly induce a conformational 
change of Bax and Bak which subsequently oligomerise and insert into the 
mitochondrial outer membrane where they form pores either by themselves or 
by associating with the permeability transition pore complex (Fig. 1.5).53   
 
 
 
Figure 1.5 Role of the Bcl-2 proteins in the induction of apoptosis. In cancer cells 
where the apoptotic pathway is not impaired, the multidomain pro-apoptotic members 
(Bax and Bak, red) can oligomerise, thereby releasing cytochrome c from the 
mitochondrion and in turn trigger apoptosis. In cases where anti-apoptotic members 
(blue) are overexpressed, apoptosis is blocked and the cancer cell survives. 
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In consequence, apoptotic factors such as cytochrome c are released from the 
inner mitochondrial membrane into the cytosol, which contributes to the 
formation of the apoptosome and the subsequent activation of the caspase 
cascade and the induction of apoptotic cell death.25  
 
1.1.2.2 Pro-apoptotic members of the Bcl-2 family 
 
Interactions between pro-survival and pro-apoptotic proteins govern cell-fate 
and the pro-apoptotic BH3-only proteins play a pivotal role in promoting 
apoptosis. Bak and Bax are both essential for apoptosis, given that cells in which 
they were both deleted are essentially resistant to apoptosis.54, 55 Various 
apoptotic stimuli induce expression and/or activation of specific BH3-only family 
members, which translocate to the mitochondria and initiate Bax/Bak-dependant 
apoptosis, however the “life/death switch” mechanism is still elusive. The binding 
profiles of the BH3-only proteins have been established, and their crystal 
structures in complex with their targets constituted a starting point for the 
design of the first inhibitors (Fig. 1.6). Subsequently, many non-natural BH3 
sequences have been synthesised and showed new binding profiles, indicating 
that target-selective small molecule antagonists might be found.  
Noxa B is one of the BH3-only pro-apoptotic members of the Bcl-2 family. 
It only shows weak pro-apoptotic activity on its own, but appears to be crucial in 
the mitochondrial Bcl-2-regulated pathway of apoptosis, by targeting the pro-
survival protein Mcl-1 for proteasomal degradation. Studies showed that in 
certain tissues, Noxa B induction in response to DNA damage could occur in a 
p53-independant manner, and also suggested a possible tumour suppressor 
function for Noxa B independent of the p53 status of a cell.56 Apoptosis induced 
by Noxa B is accompanied by cytochrome c release and subsequent caspase 
activation. No binding of Noxa B to pro-apoptotic Bak or Bax has been reported 
so far, suggesting that it inhibits anti-apoptotic members of the Bcl-2 family.57 
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Figure 1.6 Crystal structures of pro-survival proteins (surface) with BH3 ligands 
(ribbons), key residues are represented in green. a. Bcl-xL/Bim BH3 (PDB ID: 3FDL 
using Bcl-xL 1-209 and deletion of residues 27-82). b. Bcl-xL/Bak (PDB ID: 1BXL using Bcl-xL 
1-221). c. Mcl-1/Bim BH3 (PDB ID: 2NL9). d. Mcl-1/Noxa B (PDB ID: 2JM6, NMR structure).  
 
 
Compared to other BH3-only proteins like Bim and Puma, which bind all survival 
Bcl-2 proteins with comparable affinities, Noxa B selectively binds to Mcl-1 (and 
A1 albeit with a lower affinity).58 The possible involvement of Noxa B in 
oncogenesis is still under investigation, however its importance as a drug target 
became evident when analysing the efficiency of the BH3-mimetic ABT-737, 
mentioned in a later section of this chapter.  
 
1.1.2.3 Pro-survival members of the Bcl-2 family 
Many cancer cells overexpress the anti-apoptotic family members Bcl-2, Bcl-xL 
and Mcl-1 to evade apoptosis.52 It has also been shown that overexpression of 
Bcl-2 can inhibit the potency of many currently available anticancer drugs by 
blocking the apoptotic pathway.59 The anti-apoptotic Bcl-2 proteins block 
apoptosis by preventing BH3-only protein-induced oligomerisation of the pro-
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apoptotic Bcl-2 family members Bax and/or Bak in mitochondrial outer 
membranes, which would otherwise lead to the efflux of cytochrome c and other 
mitochondrial intermembrane space proteins. The anti-apoptotic Bcl-2 proteins 
differentially bind to the BH3-only proteins. Some BH3-only proteins (for 
example Bid and Bim) interact with essentially all anti-apoptotic Bcl-2 proteins, 
whereas others (for example Noxa B) interact only with certain Bcl-2 family 
members.56  Mcl-1 seems to have a different behaviour to the other anti-apoptotic 
proteins, as some studies reveal that Mcl-1 degradation during cell death is 
uniquely associated with the formation of the Mcl-1/Noxa B complex, whereas 
the Mcl-1/Bim or Mcl-1/Puma interactions lead to its stabilisation. Moreover, 
ABT-737 efficiently antagonises Bcl-2, Bcl-xL and Bcl-w, but is ineffective in 
killing tumour cells expressing high levels of Mcl-1. Knockdown of Mcl-1 helped 
to restore the sensitivity to ABT-737 treatment in resistant colon and bladder cell 
lines.60 The development of a Noxa B-like BH3 mimetic or a mimetic that also 
targets Mcl-1 is therefore highly desirable to overcome ABT resistance and 
should significantly increase treatment efficiency of current and novel treatment 
strategies against cancer. 
 
1.2   Inhibition of α-helix mediated PPIs 
 
Several approaches have been adopted by research groups to achieve inhibition 
of α-helix mediated PPIs by replicating the hot-spot residues involved in the 
binding event. These strategies can be divided into three categories according to 
the nature of the backbones they employ: 
- Type I mimetics mimic the local topography of the structural motif; for 
example peptide backbone mimetics. The analogy is applicable at the atomic 
level.  
- Type II mimetics are the functional mimetics, which are generally small 
non-peptide molecules that bind to the corresponding receptors. These 
functional mimetics need not mimic the structure of the original motifs.  
- Type III mimetics are in general non-peptide scaffolds that serve as 
topographical mimetics, with their substituents mimicking the side-chains of 
important amino acid residues. 
Chapter 1: Protein-Protein Interactions as Therapeutic Targets 
 
15 
 
This section will be focused on inhibition of PPIs that involve binding through a 
single helical face, such as the p53/hDM2, p53/hDMX, gp41 fusion and Bcl-2 
family of interactions. The discussion will therefore be limited to inhibitors that 
can mimic the i, i + 4 and i + 7 (and where applicable i + 11) positions of an α-
helix. 
 
1.2.1  Small molecule inhibitors 
 
High throughput screening (HTS) has provided most of the small molecule 
inhibitors reported,61, 62 including the Nutlins7 – a series of compounds 
containing some of the most potent and clinically advanced inhibitors of the 
p53/hDM2 interaction known to date.63 Other potent inhibitors have been 
identified through structure-based design,63, 64 or a combination of screening 
methods and structure-based design.65  
 
 1.2.1.1 Small molecule inhibitors of PPIs discovered by HTS 
 
- A series of cis-imidazoline analogues known as the Nutlins were 
identified from a high-throughput screen by Vassiliev and co-workers at Roche.7 
They are the first potent and selective small molecule inhibitors of the p53 – 
hDM2 interaction, and represent the best characterised class of inhibitors to date. 
Nutlins bind to the p53-binding site of hDM2 by mimicking the interaction with 
the three key residues. They display IC50 values against p53/hDM2 PPI in the 
range of 90-260 nM with eudismic ratios of 150-200 (quotient of activities of the 
enantiomers). Nutlins-1, 2 and 3 (compounds 1, 2 and 3, Fig. 1.7) were shown to 
have good cell permeability. Studies have shown that the Nutlins activate the p53 
pathway in cancer cells, leading to cell cycle arrest, apoptosis and inhibition of 
tumour growth in mice.7 Compound 3 (Fig. 1.7) has been the most extensively 
studied. In vivo experiments with osteosarcoma SJSA-1 tumour xenograft in nude 
mice demonstrated that this compound was well tolerated, inhibited 90% of 
tumour growth and caused tumour shrinkage. These studies provided the first in 
vivo proof-of-concept that activation of WT p53 by small molecule inhibitors of 
the p53/hDM2 PPI is viable and may provide excellent therapeutic potential in 
cancer therapy. 
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Figure 1.7 Structures of the Nutlin compounds (1, 2 and 3, active enantiomers) and 
crystal structure of Nutlin-2 bound to hDM2 (PBD ID: 1RV1).7 
 
 
Some studies showed that the Nutlins did not bind to hDMX and that 
overexpressed hDMX could block the ability of cis-imidazolines to induce 
apoptosis, thus limiting the clinical effectiveness of these inhibitors. However, 
combination therapy may be an effective way to overcome cis-imidazolines 
resistance in cancers with hDMX aberrations.66 Clinical trials on the Nutlin 
compounds are still underway.67 
 
- Benzodiazepinediones68 (BDP) are another well-documented series of 
p53/hDM2 inhibitors that were discovered using HTS at Johnson and Johnson. 
They were found to decrease the proliferation of cancer cells. A co-crystal 
structure of hDM2 with compound 4 (Fig. 1.8) showed that it projected its three 
phenyl rings into the p53 binding site of hDM2 by mimicking the spatial 
arrangement of the p53 triad motif. However, this BDP exhibited poor 
pharmacokinetic properties and poor cellular permeability. 
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Figure 1.8 Benzodiazepinediones as inhibitors of the p53/hDM2 interaction. a. 
Structure of two BDP inhibitors (4 and 5) and b. Crystal structure of BDP inhibitor 4 in 
complex with hDM2 (PDB ID: 1T4E).68 
 
 
Further optimisation led to the BDP 5 which was studied in a combination 
therapy and was proved to enhance Doxorubicin activity in vivo.69 79% of tumour 
growth inhibition was achieved with a combination of both compounds at doses 
that were inactive alone. Moreover, the combination dosage resulted in reduced 
toxicity due to the lower dosages required. This supported in vivo evidence that a 
small molecule hMD2 antagonist may offer therapeutic benefit as a combination 
therapy. 
Screening of natural products libraries yielded some Bcl-2 inhibitors: 
- A prodigiosin (bipyrrole containing natural product) was identified in a 
screen of a library of natural products. Lead optimisation resulted in compound 6 
(also known as Obatoclax, Fig. 1.9), which binds to Bcl-2, Bcl-xL, Bcl-w and Mcl-1 
with low-micromolar affinity.62 This compound was shown to disrupt the 
Bak/Mcl-1 complex.70 In vitro and in vivo studies confirmed the activity of 6 as a 
single agent in multiple cancer cell lines. Several modes of action have been 
suggested for this compound and doubts remain over the utility of this compound 
as its biological activity appears non-specific. 
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Figure 1.9 Structures of two natural product-derived Bcl-2 inhibitors. 
 
- AT-101 (7, Fig. 1.9) is the development name for (-)-gossypol, a natural 
product derived from cotton plant and used in a wide range of therapeutic 
contexts. The active enantiomer was found to bind Bcl-2 (Ki = 320 nM), Bcl-xL (Ki 
= 480 nM) and Mcl-1 (Ki = 180 nM).71 In studies conducted at Ascenta, AT-101 
showed a similar cytotoxic potency to that of GX15-070 despite an approximately 
five fold tighter binding to Bcl-2 targets. As it displays good pharmacokinetic 
properties and manageable side effects, many gossypol derivatives have been 
developed.72 
 
1.2.1.2 Structure-based design of small molecule inhibitors of PPIs 
 
Over the last decade, the explosion in the number of crystal structures that have 
been elucidated allowed several families of compounds to be developed to inhibit 
PPIs using structure-based design. The most potent/biologically active ones are 
described below: 
- Compounds containing a spiro-oxindole scaffold were identified using 
structure-based drug design as inhibitors of the p53/hDM2 interaction. It has 
been shown that the oxindole ring mimics the side chain of Trp23, critical for 
binding to hDM2; and the hydrophobic- substituted spiropyrrolidine ring mimics 
the side chains of Phe19 and Leu26.73 Primary optimisations of the first 
compounds obtained in this series led to compound 8 in Fig. 1.10, with a Ki of 
86 nM in a fluorescence anisotropy-based assay. Further analysis of the crystal 
structure of p53/hDM2 revealed that the residue Leu22 was also critical for 
binding, which led to the inhibitor known as MI-63 (compound 9, Fig. 1.10), with 
an improved Ki of 3 nM.74 Despite its potent in vitro activity, compound 9 was 
unsuitable for in vivo evaluation due to a poor pharmacokinetic profile. 
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Figure 1.10 Spiro-oxindole inhibitors of the p53/hDM2 interaction. 
 
 
Recently, extensive chemical optimisation of 9 yielded a modified analogue 10 
(Fig. 1.10) containing a more solubilising side chain, with an improved 
pharmacokinetic profile and a Ki of 5 nM in the FA-based assay.63  
 
- ABT-737 (11): Using SAR by NMR (Structure-Activity Relationship by 
Nuclear Magnetic Resonance), a proprietary technology developed by an Abbott 
team led by S. Fesik, Abbott researchers created three-dimensional maps of these 
proteins and discovered small molecules that bound tightly to the Bcl-2 family of 
proteins and demonstrated greater potency than any previously discovered 
compounds. This fragment screening allowed the development of ligands with 
high affinity for the hydrophobic groove of Bcl-xL65, 75 (Fig. 1.11). The technique 
requires the screening of diverse fragments and identification of fragments that 
can simultaneously bind to proximal sites on the protein surface. Based on 
structural information, these fragments can be linked to produce a ligand whose 
binding affinity is theoretically the sum of the individual pieces76 – providing that 
they can be linked in a way that allows the different moieties to bind in the same 
way as they do individually. Several ligands with low-nanomolar affinities have 
been developed through this method: A-385358, targeting Bcl-xL (Ki = 0.8 nM) 
and Bcl-2 (Ki = 67 nM) displays cell-killing activity. Further studies and extensive 
chemical optimisation from A-385358 yielded compound 11 (ABT-737) which 
was reported to restore cell death to cancerous cells, thus inducing regression of 
solid tumours. Additionally, Abbott Bcl-2 family inhibitors were found to enhance 
the effects of chemotherapy and radiation in other types of cancer, such as non-
small cell lung cancer. 
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Figure 1.11 Abbott inhibitors of the Bcl-xL/Bak interaction. a. Close up view of the 
crystal structure of 11 bound to Bcl-xL (PDB ID: 2YXJ).77 b. Structures of 11 (ABT-737) 
and 12. 
 
 
The linking process for this molecule proved difficult and required multiple 
synthetic strategies. Although fragment screening can identify the individual 
building blocks and their preferred binding orientation in the protein pocket, it 
can be challenging to link the moieties whilst maintaining the desired binding 
modes. Further modifications have resulted in a clinical candidate, 12 (ABT-263), 
which retains potency for Bcl-2, Bcl-xL and Bcl-w and has a moderate oral 
bioavailability (F) in animal models (F = 20%).63 This compound is currently in 
Phase II clinical trials.78 
 
1.2.2   Peptide inhibitors 
 
Because of their large interacting surfaces, peptides offer the prospect of 
enhanced potency and high specificity in addition to a low toxicity. Early efforts 
to develop inhibitors of PPIs employed peptides that were directly derived from 
the native helical protein segments; however these presented rather poor cell 
penetration and were susceptible to proteolytic degradation. Most of the peptidic 
and peptidomimetic inhibitors of the p53/hDM2 interaction examined to date 
only bind hDM2 with affinities ranging from high nanomolar to low micromolar, 
and none is nearly as effective as the Nutlins (small molecule inhibitors 
developed by Roche, cf. Section 1.2.1) in tumour killing in vitro.7, 40 Numerous 
synthetic peptides, as well as natural product hDM2 inhibitors have been 
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identified; however, the most potent of these peptides only exhibited modest 
cellular activity due to poor cell permeability.79, 80 Several short peptides 
mimicking BH3-only proteins have been designed, but only displayed poor 
binding affinities to anti-apoptotic proteins probably due to a lack of helicity.81 
Two main approaches to the stabilisation of a helical conformation are described 
in this section; they include constrained peptides made of natural α-amino acids, 
and the use of β-peptides82-86 and α/β-peptides,87-90 which display enhanced 
helicity and also offer the advantage of being stable against proteolytic 
degradation in vitro and in vivo.  
 
 1.2.2.1 Constrained peptides  
 
The small difference (5–15 kcal/mol) in free energy between the folded and the 
unfolded states drives the equilibrium towards the formation of the folded 
structure. The contribution to this free energy is the result of the balance 
between enthalpic and entropic factors. Different strategies have been developed 
to stabilise peptides in a helical conformation, and are described in more details 
in the Wilson group’s Nature Chemistry review.1 
 
- α-Helix stabilisation by natural and non-natural amino acids: Amino acids 
exhibit varied preferences for different secondary structures.91 Specific 
interactions between neighbouring side-chains (ion pairing or hydrophobic) can 
modulate the intrinsic propensities of various amino acids to stabilise or 
destabilise the helical structure.  
-  Helix capping strategy: Another strategy is the design of templates that 
can induce a particular conformation, when incorporated at the right position. In 
an α-helix, the first few residues at each terminus lack some intrahelical 
hydrogen bonds, thus only possessing limited helical character. The “helix 
capping”92 strategy refers to the stabilisation of the helical conformation within 
these terminal residues by introducing a template that forms a specific pattern of 
hydrophobic interactions and hydrogen-bonds.  
-  Helix stabilisation by cross linking: The induction of helicity by covalently 
cross linking the side-chains of otherwise unfolded peptide is an attractive 
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alternative for generating short and stable α-helical structures.93 Several 
approaches have been developed, each of them making use of different cross-
linking residues (both natural and unnatural), i.e. disulfide bridges, lactam 
bridges, hydrocarbon staples and hydrogen-bond surrogates (Fig. 1.12). These 
anchoring residues for cross-linking are in most cases inserted along a single 
helical face, ideally on the opposite side to where the hot-spot residues are 
located. The cross-link is therefore installed between residues at positions i and 
i + 4 or i and i + 7 depending on the length of the linker considered. 
 
 
 
Figure 1.12 Covalent cross-linking strategies for the stabilisation of α-helical 
conformations (H-bonds are represented by a dashed line). a. Native α-helix. b. 
Disulfide bridge. c. Lactam bridge. d. Hydrocarbon staple. e. Hydrogen-bond surrogate.  
 
- Helix stabilisation via disulfide bridges (Fig. 1.12b): Schultz et al. reported a 
short α-helical peptide stabilised by an intramolecular disulfide bond bridging 
the i and i + 7 residues.94 Several other groups have investigated the use of 
disulfide bridges to stabilise α-helical peptides and inhibit PPIs,95, 96 but none of 
them were targeted to the p53/hDM2 PPI or the Bcl-2 family of interactions and 
will therefore not be discussed in this manuscript. 
- Helix stabilisation via lactam bridges (Fig. 1.12c): Rosenblatt and co-
workers have initiated studies on lactam bridges as a method to stabilise α-
helices.97 The lactam link was installed between Lys and Asp at positions i and 
i + 4. As for the disulfide bridges, no helix stabilised via a lactam bridge was 
targeted to the model PPIs discussed in this manuscript and they will therefore 
not be described further. 
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- Helix stabilisation via olefin metathesis (Fig. 1.12d): Grubbs and co-workers 
inserted non natural amino acids bearing a side chain with a terminal alkene (O-
allyl serines) into peptide sequences and demonstrated that cross-linking these 
residues via ring closing metathesis could yield peptides where the helical 
conformation is stabilised by the resulting macrocycle.98 This strategy was 
slightly modified by Verdine and co-workers, who made use of α,α-disubstituted 
non natural amino acids instead of monosubstituted O-allyl serines. Disubstituted 
residues were already known to enhance helical propensity and were introduced 
in the sequence of p53 in place of two non-essential residues to yield a stabilized 
and potent inhibitor of the p53/hDM2 PPI (Fig. 1.13a).99 Korsmeyer and co-
workers generated analogues of the Bid-BH3 peptide with staples at positions i 
and i + 4, and obtained peptides with enhanced α-helicity, improved biological 
activities (these stabilised helical peptides were shown to bind to Bcl-xL) as well 
as resistance to proteases both in vitro and in vivo.100  
 
 
Figure 1.13 Crystal structures of stapled peptides inhibitors bound to their target 
proteins. a. Verdine’s group stapled p53 peptide bound to hDM2 (PDB ID: 3V3B)99 and 
b. Walensky’s stapled Mcl-1 peptide bound to Mcl-1 (PDB ID: 3MK8).101 
 
The group also developed a series of ligands based on the Bid-BH3 domain that 
were shown to activate the pro-apoptotic protein Bax through direct binding.102 
Later, the Walensky group designed a series of stapled peptides with high 
affinities towards Mcl-1 which were derived from  the BH3 domain of Mcl-1 itself, 
rather than one of its known binding partners (Fig. 1.13b).101 Verdine and co-
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workers have also used their disubstituted stapled peptide strategy to target the 
interaction between the transcription factor NOTCH 1 and its co-activator 
peptide MAML 1. This interaction plays a central role in the NOTCH signalling 
pathway involved in cell-fate determination. The authors have demonstrated that 
their peptides were able to achieve competitive binding to NOTCH 1 and in vivo 
studies also attributed them anti-leukaemic activity.103 These studies also 
highlighted that constrained peptides could display good cell permeability and 
indicated a potential therapeutic window. In addition, this approach could be 
applied to other transcription factor complexes that were until then considered 
as chemically untractable. Recently, Walensky and co-workers used hydrocarbon 
double-stapling as a means to stabilise longer helical domains. These peptides 
presented improved antiviral activity compared to singly-stapled or natural 
peptides when tested for inhibition of the gp41 assembly. They also displayed 
enhanced resistance to proteases in vitro and in vivo, as well as evidence of oral 
bioavailability in mice.104 
- Covalent hydrogen bond surrogates (HBS, Fig. 1.12e): The α-helix is defined 
by a pattern of sequential (i + 4 ··· i) hydrogen-bonds. Generally, hydrogen-bonds 
alone are weak and inadequate for stabilising short peptides into a well defined 
conformation. Replacement of hydrogen-bonds in α-helices with a covalent mimic 
and thus constraining the peptide to adopt an α-helical conformation was 
envisioned and developed by Satterthwait and co-workers.105 Subsequently, 
Arora and co-workers have synthesized a highly helical HBS analogue of the Bak 
BH3 α-helix which displayed a Kd value of 69 nM against Bcl-xL. Moreover, this 
peptide proved to be 60-fold more resistant to trypsin-mediated proteolysis than 
the linear analogue.106 They then applied this strategy to the inhibition of gp41-
mediated cell fusion, another HBS-helix derived from the C-terminal peptide from 
gp41 was shown to inhibit formation of the six-helix bundle with an IC50 value of 
43 μM.107 
 - β-Turns as α-helix mimetics: Robinson and co-workers designed and 
synthesised a series of β-turn cyclic peptides that mimic short α-helices. The β-
hairpin structure is promoted by the presence of a D-Pro-L-Pro dipeptide 
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template.108, 109 Optimization of the mimetics lead to high affinity towards hDM2, 
with IC50’s as low as 140 nM for compound 13 (Fig. 1.14).  
 
 
Figure 1.14 β-Hairpin inhibitor 13 of the p53/hDM2 interaction.109 a. Structure of 
13, proline residues are represented in light mauve, key interacting residues in dark 
purple (Phe1, 6-ClTrp3, Leu4). b. Close up view on the crystal structure of 13 bound to 
hDM2 (PDB ID: 2AXI) with the same colour coding as in a., the remaining backbone of the 
cyclic peptide in dark green, non-backbone atoms are omitted for clarity; hDM217-125 
represented as a surface. 
 
1.2.2.2 Foldamers adopting a helical conformation 
The smallest backbone alteration of α-amino acids is the addition of a methylene 
unit (Fig. 1.15a,b). This minor backbone modification furnishes β-peptides which 
have an enhanced resistance to proteolysis and a more favorable 
pharmacodynamic profile than their natural counterparts.110 In most α-helix 
mediated PPIs, a small subset of residues located along one face of the helical 
binding partner accounts for most of the binding energy. The functional mimicry 
of α-helices by β- and mixed α/β-peptides therefore aims at mimicking the spatial 
presentation of this binding epitope while maintaining a stable helical 
conformation. Because the extra methyl group of β-amino acids introduces an 
additional degree of freedom and thus flexibility in the peptide backbone, it was 
initially thought that β-peptides would be entropically disfavored from adopting 
well defined folded states in solution.111 However, in depth structural studies 
have shown that suitably substituted β-peptides possess a higher propensity to 
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fold into stable secondary structures than α-peptides,112 making it possible to 
observe a defined structure within relatively short sequences.  
 
 
 
Figure 1.15 α- versus β-peptides: Comparison of the most common helical 
conformations accessible to natural peptides and foldamers. a. Structure of an α-
amino acid. b. Structure of a β3-amino acid. c. Lateral and top views of the backbone of an 
α-helix (PBD ID: 2NLA). d. Lateral and top views of the backbone of a 12-helix stabilized 
by cyclobutane containing residues (CCDC ID: 742823). e. Table summarizing the 
characteristic properties of the α- 12- and 14-helices.  
 
 
The correlation between β-amino acids substitution pattern and their folding 
preferences has been extensively reviewed.113 The best characterized secondary 
structures in β-peptides are the 14-helix and the 12-helix (named after the 
number of backbone atoms per hydrogen-bond ring, Fig. 1.15). Several such 
scaffolds have been targeted to the inhibition of PPIs.  
Note: Using this nomenclature, the α-helix is also referred to as 413-
helix, denoting a hydrogen bond between every carbonyl oxygen and the α-amino 
nitrogen of the 4th residue toward the C-terminus, and 13 atoms being involved in 
the ring.  
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-  Biologically active β-peptides: Human cytomegalovirus (HCMV, 
alternatively known as herpesvirus-5) is a significant pathogen that can be life-
threatening for immune-compromised patients. α-Peptides derived from the 
HCMV proteins gB and gH elicited poor inhibitory activity, hence Gellman and co-
workers designed a series of β-peptides to mimic five key residues in the gB 
heptad repeat that are involved in the coiled coil formation that is crucial to viral 
entry.114 Assessment of a small library of compounds provided an inhibitor with 
an IC50 of 30 M, whereas α-peptide analogues were inactive at 100 M. These 
foldamers are proposed to target HCMV fusion machinery by adopting a 12-
helical structure and mimicking the gB heptad repeat, thus blocking the helix 
bundle formation and HCMV infection. 
The Schepartz group designed a β3-homodecamer targeting the 
p53/hDM2 PPI whose 14-helical conformation was promoted by stabilization of 
the electrostatic macrodipole and intramolecular salt bridges.85 The most potent 
compound achieved comparable affinity to that of the native peptide for hDM2 (< 
2.5 fold lower), displaying some selectivity towards the targeted interaction.115  
Subsequent SAR studies improved potency by 10 fold through introduction of a 
6-chloro-β3-amino acid analogue in place of the key W23 residue of p53.116, 117 
Schepartz and co-workers also applied this approach to the identification of a 
β3-decapeptide inhibitor of gp41 fusion that achieved comparable affinity to that 
of most potent α-helical inhibitors (Kd = 1.2 µM).82  
The selective transport of lipid through the brush-border membrane in 
the small intestine of mammals is mediated by two types of class B scavenger 
receptors (SR-BI and SR-BII).118 Inhibition of the cholesterol and fat absorption at 
this level has been demonstrated to occur through binding of an amphipathic α-
helix motif to class B scavenger receptors. Whilst α-peptide inhibitors were 
inefficient in whole cell assays due to proteolysis, Seebach and co-workers 
demonstrated that amphipathic 14-helical β-peptide mimetics could be used to 
circumvent this degradation whilst retaining biological activity.119 Taken 
together, these results underscore the ability of 14-helical β-peptides to 
functionally mimic α-helices, despite having subtle structural differences and 
opposite macrodipole directions. 
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-  Mixed α/β-peptides as α-helix mimetics: Gellman and co-workers sought to 
apply β- and α/β-foldamers to the inhibition of the Bcl-2 family of PPIs. Screening 
of over 200 peptides based on pure β- or α/β-backbones adopting different 
helical conformations failed to identify potent ligands for Bcl-xL with the best 
compound identified, a 14/15-helical α/β-peptide, only exhibiting moderate 
inhibition of the Bcl-xL/Bak interaction (Ki = 4.2 µM).87 Building on these 
preliminary results, a potent chimeric inhibitor was designed in which an 
unnatural 14/15-helical portion was designed to mimic the N-terminal segment 
of Bak; whereas key side chains in the C-terminal region were replicated by an α-
segment to give a nanomolar ligand for Bcl-xL (Ki = 2 nM),87 proving that the α/β-
14/15-helical backbone is suitable to mimic the presentation of hot-spot residues 
of an α-helix.  
 
 
Figure 1.16 α/β-Peptide inhibitors of the Bcl-2 family. a. The pro-apoptotic protein 
Bim bound to Bcl-xL (PDB ID: 3FDL). b. Chimeric Bim-mimetic (α/β + α)-peptide 14 
binds Bcl-xL similarly to natural BH3 domains and triggers cytochrome c release – 
leading to apoptosis (PDB ID: 3FDM). c. View of the α/β-foldamer along the helical axis 
(PDB ID: 3FDM). 
 
A crystal structure of the most potent chimeric peptide mimicking the Bim-BH3 
peptide 14 bound to Bcl-xL was published shortly after (Fig. 1.16b).90 Whilst this 
approach clearly resulted in the identification of potent inhibitors of PPIs, the 
work also highlighted that for some PPIs, simply presenting key side chains along 
one face of a helical scaffold may not be sufficient and that a more subtle 
matching of the α-helix may be necessary. The Gellman group therefore adapted 
the approach through sequence-based design of a Puma analogue – another pro-
apoptotic member of the Bcl-2 family.89 The strategy relies upon placement of α-
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residues at some but not all positions within an α-helix to give a hybrid foldamer 
with enhanced stability and properties. The study of seven analogues containing 
the ααβαααβ repeat (placing the β-residues along one face of the helix and shown 
by X-ray crystallography to form helical structures) demonstrated that both the 
affinity and selectivity of hybrid peptides for Bcl-xL and Mcl-1 are largely 
dependent on the position of the β-residues along the helix. The design and 
screening of these seven peptides identified a peptide which binds both Bcl-xL 
and Mcl-1 (Ki = 1 nM and 150 nM respectively), and whose binding to Bcl-xL is 
even tighter than that of the chimeric peptide obtained (see above) after 
screening of 200 peptides and structure-based optimisation. The first co-crystal 
structure between a sequence-based designed α/β-peptide mimicking Puma and 
Bcl-xL revealed key geometrical parameters that the foldamer helix needs to 
reproduce in order to achieve tight binding.120 Despite the introduction of six β-
amino acids in the sequence, key contacts between the hot-spot residues of the 
native helix and Bcl-xL were maintained, and the ααβαααβ heptad repeat gives 
rise to a more regular helix than any 1:1 α/β-peptide or chimeric foldamers. The 
success of the sequence based approach prompted the Gellman group to develop 
a two-step sequence based design of an α/β-peptide that prevents the formation 
of the six-helix bundle of the HIV membrane protein gp41 - a much longer and 
therefore challenging α-helical target.88 Firstly, the same strategy as for the 
design of the Puma analogue was used: β3-residues were inserted into the α-
sequence of the C-terminal heptad repeat domain (CHR) of gp41 to form 
ααβαααβ repeats. In the second step, selected β3-residues were replaced by 
cyclically constrained β-residues, to overcome the entropic penalty associated 
with the pre-organisation required for more flexible analogues. This approach 
allowed the structural and functional mimicry of 10 turns of an α-helical CHR 
domain (Fig. 1.17a-c), and the most potent peptide (15, Ki = 9 nM), represented a 
~380-fold improvement on the analogous acyclic α/β-peptide. This peptide also 
displayed an antiviral activity comparable to that of the native α-peptide and 
enhanced resistance to proteolysis (~280 fold).88  
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Figure 1.17 α/β-Foldamers applied to the inhibition of the gp41 fusion interaction. 
a. View along the helix bundle axis and b. lateral view of the six helix bundle formed by 
NHR α-peptides and the α/β-foldamers 15, β-residues are colored in light purple. c. 
Close up view of α/β-inhibitor 15 bound to the NHR core helices, interfacial residues are 
represented in purple, β-residues are highlighted in light purple (PDB ID: 3G7A).  
 
 
- Other foldamers as α-helix mimetics: In principle any abiotic 
backbone reproducing the α-helical conformation can be used as a template for 
inhibitor design. For instance Appella and co-workers used peptoids as inhibitors 
of p53/hDM2.121 These compounds were initially selected on the basis of their 
propensity to adopt a type II polyproline helical conformation and modelling 
studies that indicated a suitably functionalized peptoid could bind to hDM2 in 
this conformation. Although inhibitors were identified, the authors noted that the 
most potent compounds were less helical in the absence of protein than other 
compounds in the series that might have been expected to show greater potency 
as a consequence of being more helical.  A subsequent study from the same group 
exploited N-acylpolyamine scaffold pre-organised into an active conformation 
through intramolecular hydrogen-bonding for inhibition of p53/hDM2.122  This 
elegant report illustrated that other secondary structures can recapitulate 
essential molecular recognition features of α-helices. Cyclic peptides containing 
Phe, Trp and Leu at positions 1, 3 and 4 of the sheet were found to project 
residues matched to the geometrical projection of Phe19, Trp23 and Leu26 in the 
p53 α-helix. Ultimately, low nM inhibitors of this interaction were identified using 
this approach. Benkovic and co-workers also investigated the use of cyclic 
peptides in the context of HIV fusion inhibition.123 HIV propagation requires the 
recruitment of host proteins such as TSG101 to mediate its release from the 
plasma membrane of infected cells. It was thus thought that targeting the 
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interaction between Gag (a virally encoded protein that contains a tetrapeptide 
motif essential for the viral budding event) and TSG101 would offer a new 
approach for antiviral therapy that would circumvent the resistance of mutant 
forms of HIV. They assembled a library of cyclic peptides using a SICLOPPS 
methodology (Split Intein-mediated Circular Ligation of Peptides and Proteins)124 
then subjected it to a bacterial reverse two-hybrid screening. Hits identified were 
then chemically re-synthesised using SPPS (Solid Phase Peptide Synthesis) and 
tested for HIV budding inhibition in mammalian cells. Eventually, one Tat-tagged 
cyclic peptide was shown to inhibit viral budding with an IC50 of 7 µM, 
demonstrating the therapeutic potential in this approach.123 Overall the use of 
foldamers containing α-residues within contiguous sequences or as individual 
“mutations” to an α-amino acid backbone or use of completely abiotic backbones 
such as the peptoids represents a valid strategy for elaborating ligands with 
enhanced properties and the ability to selectively perturb PPIs. However due to 
subtle topological differences between such sequences and native α-helices, 
considerable iteration is still required to identify optimal ligands.  
 
1.2.3 Proteomimetics 
 
Despite the unfavorable features of protein surfaces for inhibitor design, a 
rational approach based on the role of secondary structure at the interface – and 
in particular the α-helix – is under intense investigation. The ability to design a 
scaffold to mimic the surface of an α-helix opens perspective for versatility: a 
unique scaffold could be used as a generic helical core mimic. Appropriate 
modifications of the side chains displayed and their spatial presentation could 
allow this single scaffold to be applied to the inhibition of several PPIs. This 
approach presents major advantages compared to the two previously described 
approaches: Type II mimetics lack versatility, meaning that for every single PPI a 
new inhibitor needs to be designed from scratch (either using HTS or structure-
based design, cf. section 1.2.1). Type I mimetics are often designed after the 
sequence of the native helix, however the position, length and nature of the 
constraining element need to be optimized, and the synthesis of the required 
unnatural amino acids can be relatively complex. Considering that the hot-spot 
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residues for binding are often aligned along one helical face and located one 
helical turn apart, efforts have been devoted to develop synthetic blocks that 
could mimic the display of side chains separated by one helical turn. This way, 
mimicking the arrangement of side chains at positions i, i + 4 and i + 7 (or indeed i 
+ 11) of an α-helix would only require 3 or 4 of these designed blocks. The 
proteomimetics approach could therefore benefit from a modular and expedient 
synthesis, as well as a more drug-like character due to their reduced molecular 
weight as compared to peptide mimetics. Different classes of designed 
proteomimetics have emerged and some have been shown to effectively act as α-
helix mimetics and selectively disrupt targeted PPIs. The field of proteomimetics 
has been largely pioneered by Hamilton and co-workers; the terphenyl scaffold 
(Fig. 1.18) reported in 2001 was one of the first true helix mimetics.26  
 
 
 
Figure 1.18 Terphenyl scaffold developed by the Hamilton group. a. The terphenyl 
scaffold allows mimicry of positions i, i + 4 and i + 7 of an α-helix. b. Terphenyl-based 
inhibitors: 16 was a Bcl-xL binder, 17 inhibited the assembly of the gp41 core, 18 was 
initially tested against p53/hDM2 and was recently shown to act as a pan-Bcl inhibitor.  
 
The terphenyl scaffold has been targeted to a number of therapeutically relevant 
PPI targets, including the p53/hDM2 and the Bcl-2/Bak interactions.125 
Substitution of this terphenyl scaffold at the ortho positions allows mimicry of the 
spatial arrangement of the i, i + 4 and i + 7 substituents of an α-helix, as shown in 
Figure 1.18a. Several terphenyl-based helix mimetics of p53 have been described 
Chapter 1: Protein-Protein Interactions as Therapeutic Targets 
 
33 
 
and others have been targeted to the inhibition of the hexameric coiled-coil 
assembly of gp41, for example terphenyl 17 (Fig. 1.18) displayed an IC50 value of 
24.87 ± 4.8 µM,126 again evidencing the versatility of this scaffold. Terphenyl-
based structures were also applied to the mimicry of BH3-only proteins, which 
led to molecules with inhibition constants as low as 114 nM against the Bcl-
xL/Bak interaction, the critical residues for binding being: Val74, Leu78, Ile81 and 
Ile85. Terphenyl 16 (containing a 2-naphthyl side chain, Fig. 1.18) binds to hDM2 
over 100-fold more strongly than its analogue with a 1-naphthylmethylene side 
chain and has a 14:82 fold selectivity over Bcl-xL/Bcl-2.125 This is consistent with 
the deeper pocket in hDM2 for Trp23 at the i + 4 position compared to the Leu78 
pocket of Bcl-xL or Bcl-2. These results confirm that the terphenyl scaffold can 
mimic the side chain-induced selectivity of α-helices. Compound 18 (Fig. 1.18b) 
presented a Ki value of 3.5 ± 1.0 µM against the p53/hDM2 PPI125 and was 
recently tested against the Bcl-2 family in a series of whole cell experiments, 
where it was renamed BH3-M6. The compound was shown to be a pan-Bcl-2 
antagonist, as it was able to disrupt interactions between anti-apoptotic Bcl-xL, 
Bcl-2, Mcl-1 and pro-apoptotic members Bax, Bak, Bim and Bad, both in cell free 
and in intact human cancer cells.127 Several scaffolds have also been designed in 
an attempt to improve the poor solubility of the original terphenyl compounds. In 
2003, the Hamilton group published the synthesis of a new trispyridylamide 
scaffold (Fig. 1.19a), which exhibited low micromolar affinities when tested 
against the Bcl-xL/Bak PPI.128 In this scaffold, bifurcated hydrogen bonds render 
the backbone planar and position the side chains on one side of the molecule, as 
confirmed by X-ray structures. Residues at positions i, i + 4 and i + 7 of an α-helix 
are however not located on a straight line; Ahn and co-workers therefore sought 
to slightly increase the backbone flexibility by replacing the pyridine rings with 
benzyl rings, thereby releasing the backbone from the constrain exerted by the 
bifurcated hydrogen bonds. Two examples of the resulting O-alkylated tris-
benzamide scaffold have been prepared and will be investigated as potential 
glucagon antagonists.129 The Wilson group developed a solution phase synthesis 
of O-alkylated aromatic oligoamide rods and extended the synthesis to the 
pentamer,130 then demonstrated that this scaffold was suitable for α-helix 
mimicry as similar potency to the native peptide in disrupting the p53/hDM2 PPI 
Chapter 1: Protein-Protein Interactions as Therapeutic Targets 
 
34 
 
was achieved (IC50 = 1.0 µM and IC50 = 1.2 µM respectively).131 Hamilton and co-
workers have also attempted to improve the solubility of their terphenyl scaffold 
by replacing the benzyl core with pyridine rings. The resulting terpyridine 
scaffold (Fig. 1.19c) presented an increased solubility but required a lengthy 15-
step synthesis132 and has not been tested for binding yet. 
 
 
 
Figure 1.19 Proteomimetic scaffolds designed after the terphenyl scaffold. 
Hydrogen bonds are represented in blue. a. Trispyridylamide. b. 3-O-Alkylated 
oligobenzamide. c. Terpyridine. d. Terephthalamide. e. 4,4-Dicarboxamide. f. 
Oligobenzoylurea. g. Oligophenylenaminones. h. Pyrrolopyrimidine. 
 
The next generations of scaffolds were designed to present both improved 
solubility and more modular syntheses: a series of terephthalamides133, 134 (Fig. 
1.19d) achieved sub-micromolar inhibition of the Bcl-xL/Bak interaction. Other 
attempts to increase the solubility of the scaffold have met limited success: Rebek 
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and co-workers have developed an oxazole-pyridazine-piperazine scaffold to 
reproduce the i, i + 4 and i + 7 residues of the Bak helix.135 The use of heterocyclic 
rings was intended to enhance the solubility as the solvent-exposed face of the 
mimetic is rich in hydrogen-bond donors and acceptors. These however failed to 
overcome the potency of their terphenyl analogues. Families of 4,4-
dicarboxamides136 (Fig. 1.19e) and oligobenzoylureas137 (Fig. 1.19f) were 
investigated as they offer the possibility to mimic an additional hot-spot residue 
from BH3-only proteins, however no improvement in affinity for the target 
proteins was reported (Ki = 1.8 ± 0.63 µM and Ki = 2.4 ± 0.3 µM respectively, 
against Bcl-xL/Bak). Hamilton and co-workers have also developed an 
oligophenylenaminone scaffold where the intramolecular H-bond places the 
three side chains along a single helical face (Fig. 1.19g), as predicted by modelling 
studies.138 This scaffold presents the advantages of being synthetically accessible 
and proved to be amenable to longer oligomer synthesis. The group therefore 
sought to apply it to the mimicry of extended helices such as leucine-zippers 
(structural motifs in the DNA-binding region of transcription factor proteins). A 
compound was reported to structurally mimic 10 helical turns of a leucine zipper, 
as confirmed using X-ray crystallography, and this constitutes the longest 
proteomimetic characterized to date.139 The biological activity of this series of 
compounds has however not yet been assessed. 
The proteomimetic approach is highly desirable as it offers versatility: 
different interactions can be selectively targeted using a single scaffold only by 
changing the side chain appendage. Fully exploiting the potential of this strategy 
however requires building large libraries of compounds for screening and even 
though modular syntheses have been developed, only a few are amenable to 
library assembly. Several libraries of proteomimetics have been reported in 
solution phase, but fewer examples of solid phase assembled libraries have been 
described to date. Guy and co-workers have designed several scaffolds targeting 
the p53/hDM2 interaction in silico and identified an oligobenzamide scaffold as 
the most potent out of the 4 considered for synthesis. In this scaffold, side chains 
are directly attached to the benzyl rings via carbon-carbon bonds and assembly 
of over a hundred compounds in solution phase yielded low-micromolar 
inhibition of the target PPI.140 The Boger group has recently reported another 
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solution phase synthesis of the O-alkylated oligobenzamide scaffold, targeted to 
the p53/hDM2 PPI.141 They then explored permutations of C- and N-terminal 
aromatic units with more flexible corresponding natural amino acids. The most 
potent compound (IC50 = 8 µM) contained two α-residues mimicking Phe19 and 
Leu26 and a middle aromatic residue bearing an indole side chain (Trp23 mimic). 
This compound then served as a template for an 8000-member library made of 
all the possible combinations of 20 C-terminal α-residues, 20 central aryl units 
containing proteinogenic side chains as well as unnatural analogues, and another 
20 N-terminal α-residues. Testing and ranking of each side chain revealed that 
the most potent compound was, unsurprisingly, the one bearing side chains 
corresponding to the native p53 peptide, and which served as a template for this 
library.141  
Although the assembly of libraries of compounds in solution has been 
exemplified by several research groups, fewer have been reported using solid 
phase synthesis (SPS). Oligobenzamide proteomimetic inhibitors constitute an 
attractive class of ligands for α-helix mediated PPI inhibition, as they exhibit 
predictable folding patterns imposed by the preferred conformation of the Aryl-
NHCO-Aryl bond. They are also an attractive template for solid phase synthesis, 
as coupling and protecting strategies can be derived from those used in classical 
peptide synthesis. Recently, Lim and co-workers reported the solid phase 
assembly of a library of 900 compounds targeted to the p53/hDM2 and 
p53/hDMX interactions, based on a novel pyrrolopyrimidine scaffold (Fig. 1.19h). 
Biological assessment of 90 of these compounds in fluorescence anisotropy 
competition assays revealed dual inhibitors, with sub-micromolar inhibition 
constants against both targeted interactions. In addition, this scaffold presents 
enhanced aqueous solubility as compared to terphenyl-derived scaffolds, exhibits 
high cell-permeability and induces p53 level and activity in cells. The Kilbinger 
group reported the SPS of an N-alkylated oligobenzamide scaffold via acylation of 
secondary aromatic amines on a Wang resin support, extending the synthesis to 
the decamer.142 This scaffold had however not been applied to α-helix mimicry 
until a few years later when Wilson and co-workers published their manual solid 
phase methodology to assemble a library of 24 such compounds and identified 
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potent inhibitors of the p53/hDM2 interaction (Fig. 1.20, 19 presented an IC50 of 
2.8 µM compared to the native peptide IC50 = 1.2 µM).143  
      
 
 
Figure 1.20 Wilson’s N-alkylated oligobenzamide scaffold as a helix mimetic. a. 
hDM2 binding domain of p53. b. General structure of the N-alkylated oligobenzamides. c. 
Minimum energy conformation of one of the most potent compound produced so far 
with the N-alkylated scaffold. d. Overlay of the proteomimetic and a p53 peptide. 
 
 
These encouraging results led to further synthetic developments, and notably the 
transposition of the SPS to an automated methodology using a CEM Liberty® 
microwave assisted peptide synthesiser144 (cf. Chapter 2). This new methodology 
allowed the assembly of a large library of proteomimetics that were assessed 
against two model interactions: p53/hDM2 and Noxa B/Mcl-1 (cf. Chapter 3). In 
the event that co-crystal structures of these oligobenzamides with the target 
protein can be obtained, these will be used to guide the design of more potent 
inhibitors. Hits identified in the preliminary screening of the library can also be 
refined based on the SAR established from these assays, and selectivity enhanced 
via introduction of unnatural amino acids – this will be discussed in the next 
Chapters. 
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1.3 Project aims 
 
As discussed in this chapter, intense efforts are directed towards the 
inhibition of PPIs, and several approaches have emerged. Small molecules have 
provided some of the most potent inhibitors so far, but only offer tailored 
answers to each PPI target. On the other hand, proteomimetics and foldamers 
present the prospect of a versatile approach to each class of PPIs. With this in 
view, the Wilson group has developed a scaffold to mimic the alignment of side 
chains that are critical to the binding of several α-helix mediated PPIs. This 
scaffold possesses the advantage of an accessible and modular synthesis. 
Previously within the group, a small library of N-alkylated oligobenzamides has 
been designed to disrupt the p53/hDM2 interaction, and was built using manual 
solid phase synthesis (SPS).143 Preliminary binding studies using a fluorescence 
anisotropy assay suggested the scaffold to be suitable for α-helix mimicry: the 
most potent compound that was then identified displayed an IC50 comparable to 
that of the native peptide.143 
The present work aimed at further investigating this N-alkylated 
oligobenzamide scaffold. This included the development of an automated 
methodology for SPS using a microwave assisted peptide synthesiser144 that 
would allow the generation of a large library of compounds. The library was 
mainly focused on the p53/hDM2 PPI, although a small sub-library targeting the 
Bcl-2 family was also assembled. These libraries were to be tested in the 
previously used fluorescence anisotropy assay firstly against the model 
interactions (p53/hDM2 and p53/hDMX), then against the Bcl-2 family in order 
to establish the versatility of the scaffold. Further biophysical characterisation of 
the most potent compounds was to be acquired using techniques that have not 
yet been applied to this scaffold, and assessment of the cellular uptake was also 
envisioned.
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Chapter 2 
 
 
Microwave assisted  
solid phase synthesis of  
N-alkylated oligobenzamide  
α-helix mimetics  
 
 
The work reported in this chapter formed the basis of the following publication:  
K. Long, T. A. Edwards and A. J. Wilson, Bioorg. Med. Chem. 2013, 
dx.doi.org/10.1016/j.bmc.2012.09.053.144 
 
 
 
Oligomers that adopt preferential conformations are named foldamers;112, 145-147  
their stable and predictable folding into well-defined structures has been 
exploited in various areas of research. The relative synthetic accessibility of 
foldamers from monomer building blocks also confers adaptability, versatility, 
and the possibility to modify their inherent properties. These features make them 
attractive utensils to modulate biological processes.148 Previously, the Wilson 
group reported the manual solid phase synthesis (SPS) of an N-alkylated 
aromatic oligoamide scaffold (Fig. 2.1) and demonstrated that it was suitable for 
α-helix mimicry through identification of low μM inhibitors of the helix mediated 
p53/hDM2 interaction.143 In its extended all trans conformation, substituents 
appended to the nitrogen atoms are displayed in such a manner as to match the 
spatial presentation of side chains located at the i, i + 4 and i + 7 positions of an α-
helix. This subset of residues located along one helical face has been shown to be 
a recurrent pattern in α-helix mediated protein-protein interactions (PPIs),12, 147, 
149 where they account for most of the binding energy and are referred to as ‘hot-
spot’ residues.15, 16 
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Figure 2.1 The N-alkylated oligobenzamide scaffold as a helix mimetic. a. Mimicry 
of the spatial presentation of residues i, i + 4, i + 7 (coloured circles) in an α-helix by our 
N-alkylated proteomimetic scaffold. b. Cartoon representing the exploitation of α-helix 
mimicry in achieving competitive inhibition. 
 
PPIs possess features that largely differentiate them from more conventional 
enzyme-substrate interactions that are traditionally targeted by medicinal 
chemistry efforts.2 Such interactions include the gp41 fusion protein, responsible 
for the fusion process enabling HIV infection;18 the interaction between p53 and 
its negative regulators hDM2 and hDMX –p53’s function is inhibited by direct 
binding to hDM2 and hDMX in about 10-15% of all cases of human cancers;19-22 
and the Bcl-2 family of interactions23-25 involved in the regulation of apoptosis, a 
form of programmed cell death that is crucial during the development of 
multicellular organisms and in avoiding tumourigenesis. Although small molecule 
inhibitors4, 7, 63, 65, 126, 150 and constrained helical peptides102, 103, 151 or oligomers 
retaining the helical conformation152-154 have been used to target these and 
related PPIs, designing scaffolds that allow mimicry of key interfacial residues on 
an α-helix involved at a PPI interface offers considerable potential for the 
elaboration of generic approaches.147 With this in mind, several such 
proteomimetic26 scaffolds have been designed over the last decade; Hamilton’s 
terphenyl scaffold was the first true helix mimetic, displaying IC50s in the 
micromolar range against several important PPI targets.26, 125, 126 Subsequently, 
several further scaffolds were described that were synthetically more accessible 
and presented more lead-like properties including the terephthalamide,134 the 
4,4-dicarboxamide,136 and the oligobenzoylurea137 templates amongst others.135, 
138, 155, 156 Aromatic oligoamides157 represent an attractive class of foldamers,128, 
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129, 131, 136, 141, 158, 159 as their constitutive units can be easily prepared and then 
assembled into functional structures using modular syntheses. As they are 
somewhat similar to natural peptides in that they are made of amino acid 
subunits linked to one another by amide bonds, they are investigated as 
structural peptide mimetics. Although methods are already well-established for 
natural peptide synthesis, the assembly of aromatic oligomers has proven rather 
troublesome due to the reduced reactivity of the monomers as compared to 
natural amino acids, making assembly of screening libraries challenging.140, 141, 156 
In order to achieve the objectives set out in this thesis, it was necessary to 
address this challenge. In the present chapter, we report an automated 
methodology for the preparation of N-alkylated aromatic oligoamides using a 
state of the art microwave assisted peptide synthesizer. This method provides 
enhanced yields and purities as well as reduced handling and coupling times. The 
tolerance of our coupling method towards functionalities encountered in 
proteinogenic amino acids is demonstrated, along with some more tailored, 
unnatural side chains.  
 
 
 
Figure 2.2 N-alkylated oligobenzamides preferentially adopt a cis-conformation in 
solution. a. The cis-trans equilibrium. b. 1H-NMR of compound 20 (300 MHz, MeOD). c. 
Expansion on the aromatic region of the NOESY spectrum of compound 20 (300 MHz, 
MeOD); cross peaks between protons 1-H3 and 3-H2 illustrates the preference for the 
cis-conformer in methanol.  
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The preferred cis geometry of the amide bond in these molecules160 (Fig. 2.2) has 
been shown to facilitate the cyclisation of such trimers,161 but it has also been 
demonstrated that the compounds may adopt the trans conformation (Fig. 2.1) 
upon binding to the target protein. 
Our strategy for automated solid phase peptide synthesis (SPPS) of N-
alkylated oligobenzamides centers on the use of a microwave assisted peptide 
synthesizer and the well established Fmoc strategy,162 providing orthogonality 
with side chain protecting groups. One of the key features of this oligoamide 
backbone is its synthetic accessibility. The scaffold is based on trimers of 
N-alkylated p-aminobenzoic acid units linked by sequentially installed amide 
bonds.  
 
2.1   Monomer synthesis  
 
In order to develop a method amenable to the generation of a library of diversely 
functionalized tribenzamides, a range of monomers 22a-n was prepared 
following the previously reported route (Scheme 2.1a).143  
 
 
Scheme 2.1 Synthetic route to Fmoc protected building blocks. a. Synthesis of Fmoc 
protected N-alkylated p-aminobenzoic acid monomers from commercially available 
aldehydes. b. Preliminary Swern oxidation of ionic side chain. c. Synthetic route for the 
preparation of the aldehyde precursor of the acidic monomer. 
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Although the Wilson group’s prior study confirmed that hydrophobic side chains 
were privileged for the design of inhibitors of the p53/hDM2 interaction (and a 
considerable number of others),12 we sought to incorporate the whole range of 
functionalities encountered in natural amino acids into the monomer set so as to 
scope the functional group tolerance of our method. In the case of amine 
containing side chains where the starting aldehydes were not commercially 
available, Swern oxidation163 was performed on the parent alcohol (Scheme 
2.1b), whilst one further side chain, containing an acidic functionality, was 
prepared using a different route (Scheme 2.1c). 
 
2.2   Solid Phase Peptide Synthesis 
 
Trimeric oligoamides 26-37 were built from sequential coupling of N-alkylated p-
aminobenzoic acid monomers via SPS using the well established Fmoc strategy, 
widely employed in natural peptide synthesis.162 The previously reported SPS on 
this scaffold143 was adapted for a CEM Liberty® automated microwave assisted 
peptide synthesizer. Experiments focused on the use of Wang resin preloaded 
with Gly as the solid support, although it should be noted that a limited number of 
experiments using unfunctionalized Wang resin were also performed. Direct 
loading onto the Wang resin however proved less efficient and robust than with 
the preloaded resin. The same protection strategy as for natural amino acid 
coupling was sought for the N-alkylated oligobenzamide scaffold so as to avoid 
the development of an entirely new permanent and semi-permanent protecting 
group strategy, hence the prime synthetic objective was to optimize amide bond 
formation; however the deactivated secondary aniline is significantly less 
nucleophilic than a primary amine. Coupling agents that are classically used in 
peptide synthesis (HCTU,164 PyBOP,165 TFFH,166 EDCI,167 DIC,167 HOBt,168 
MSNT,162 etc.) proved inefficient when applied to the present scaffold under 
microwave heating (as had been the case in the earlier manual SPS study).168 
Initially, temperature and coupling time were set to 60 °C and 30 min 
respectively, and 4 eq. of monomer were used per coupling. Under these standard 
conditions (Table 2.1), all these reagents were able to load the aromatic 
monomers onto the Gly-preloaded Wang resin, but no dimer could be formed. 
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Previous studies on the solution phase synthesis of these trimers revealed that 
the monomers required activation as acyl chlorides in order for the coupling 
reaction to take place. Acyl chlorides of the monomers 22a-n can be obtained by 
reaction with dichlorotriphenylphosphorane169 (Cl2PPh3) at elevated 
temperatures, or with Ghosez’s reagent170 at room temperature. Both reagents 
were assessed under microwave heating conditions and optimal coupling 
conditions have been carefully determined. As the activation using the 
phosphorane required heating, both the monomer and the coupling agent had to 
be dissolved in the desired solvent and placed on the synthesizer’s manifold; the 
acyl chloride was then obtained in situ within the reaction vessel. Under these 
unoptimized conditions, a respectable percentage of conversion could be 
obtained with a dimer/loaded monomer ratio of 65-35 (Table 2.1, Entry 7). 
Because Ghosez’s reagent could generate the reactive species at room 
temperature, the acyl chloride could either be generated in situ, (Table 2.1, Entry 
8) or obtained by preactivation (Table 2.1, Entry 9).  
 
Table 2.1 Screening of activating agents under standard conditions (Single 
coupling, 60 °C, 30 min). % conversions estimated from the UV chromatograms of the 
crude cleavage product. 
 Entry  Activator Solvent Microwave method Base 
1st 
residue  
loaded 
% 
dimer 
1 HCTU DMF Single, 60 °C, 30 min DIPEA Yes 0 
2 PyBOP CHCl3 Single, 60 °C, 30 min  DIPEA Yes 65% 
3 TFFH CHCl3 Single, 60 °C, 30 min / Yes 10% 
4 EDCI CHCl3 Single, 60 °C, 30 min / Yes 0 
5 DIC CHCl3 Single, 60 °C, 30 min / Yes 0 
6 MSNT CHCl3 Single, 60 °C, 30 min / Yes 0 
7 Cl2PPh3 CHCl3 Single, 60 °C, 30 min / Yes 65% 
8 Ghosez CHCl3 Single, 60 °C, 30 min NMI Yes 25% 
9 
Preactiv. 
Ghosez 
CHCl3 Single, 60 °C, 30 min NMI Yes 50% 
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Due to the water sensitivity of these coupling agents and the low reactivity of the 
aniline towards acyl chlorides at room temperature, significant care was required 
to exclude water from the preactivation step and coupling reaction. At first, 
coupling was optimized for the formation of dimers using 
dichlorotriphenylphosphorane, as it is easier to handle than Ghosez’s reagent. 
Again, the standard set of coupling conditions was used to allow the study of each 
parameter (base, solvent, temperature and coupling time) independently. 
Different solvents were tested, with the pre-requisite that all reagents should be 
soluble in the considered solvent. Single couplings in dioxane, tetrahydrofuran or 
dichloroethane provided no or low conversion to dimer, whereas conversions 
from 55 to 60% were obtained in chloroform or DMF. In DMF, conversion could 
be somewhat enhanced by raising the coupling temperature to 90 °C. Further 
optimization was carried out in parallel for both solvents (Table 2.2). Prolonging 
the coupling time to 45 min or 1 hour did not improve the conversion, but 
reducing the coupling time to 20 min was not detrimental either. Finally, 
switching to a double coupling improved conversion to the dimer from 60% with 
a single coupling to quantitative (Table 2.2, Entry 6).  
 
Table 2.2 Optimisation of the coupling time using Cl2PPh3.  
Entry Activator Solvent   Coupling T (°C) t Base % conversion 
1 Cl2PPh3 CHCl3 Single 60 30 min / 
Dimer – 
Monomer 55-45 
2 Cl2PPh3 CHCl3 Single 60 60 min / 
Dimer – 
Monomer 5-95 
3 Cl2PPh3 CHCl3 Single 60 20 min / 
Dimer – 
Monomer  60-40 
4 Cl2PPh3 DMF Single 60 30 min / 
Dimer – 
Monomer 60-40 
5 Cl2PPh3 DMF Single 60 20 min / 
Dimer– 
Monomer 60-40 
6 Cl2PPh3 DMF Double 60 20 min / 100% Dimer 
 
Despite these encouraging preliminary results, dichlorotriphenylphosphorane 
proved to be unreliable from batch to batch and in subsequent studies on the 
functional tolerance of the method. Further studies on Ghosez’s α-chloroenamine 
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were then performed in chloroform. Under the optimized coupling conditions 
established with the first acylating agent (Table 2.2, Entry 6), complete 
conversion could also be obtained with the α-chloroenamine. Couplings also 
proved to be much more reproducible than with dichlorotriphenylphosphorane 
and Ghosez’s reagent was therefore established as the coupling reagent of choice 
for these monomers. 
 
 
Further optimization of the coupling time, temperature, number of equivalents of 
monomer to the resin and solvent (Scheme 2.2) led to complete conversion to 
trimers in good yields. Because double couplings are required, using 4 eq. of 
monomer 22a-n per coupling means that a large amount of monomer is 
consumed. After further optimization, the minimum number of equivalents of 
monomer to the resin was identified as 2.5 eq. per coupling, and the coupling 
time was maintained at 20 minutes. Standard microwave assisted deprotection 
Scheme 2.2 Outline of procedure used for solid-phase synthesis of N-alkylated 
aromatic oligoamide α-helix mimetics. 1. Preactivation: Monomer (2 × 2.5 eq. to resin, 
0.5 mmol) in anhydrous CHCl3 (5.5 mL), pre-activated with Ghosez’s reagent (0.95 eq. to 
the monomer, 0.48 mmol) for a minimum of 1 hour; 2. Loading: resin (0.1 mmol, 127 
mg) swelled in 5 mL DMF, monomer loaded using a double coupling method (2 × 20 min, 
60 °C). In the case of acid labile side chain protecting groups, NaHCO3 (solid, excess) can 
be added to the resin tube; 3. Coupling: same method as for the loading; 4. Deprotection: 
20% piperidine in DMF, standard microwave method used (two cycles, 75 °C, 3 min, cf. 
experimental section); 5. Manual cleavage: DCM-TFA (1–1, 0.7 mL), 2 × 20 min, r.t. 
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was used and didn’t require any optimization. Including the wash cycles, this new 
method therefore yields trimers in 4 hours, which is a dramatic improvement on 
the 4 days previously required using the manual SPS method.143 Although 
cleavage from the resin can be performed on the synthesizer, this would require 
additional and extensive washes of the reactor. We therefore chose to carry out 
the cleavages manually (cf. Experimental Section), which also allowed to optimize 
the productivity of the synthesizer. For side chains containing a reactive 
functionality that needs to be protected during the coupling, our strategy was to 
use acid-labile protecting groups. These protecting groups would thus remain 
untouched during the basic Fmoc deprotection step, but would be removed 
during acidic cleavage from the resin. During coupling however, one equivalent of 
hydrochloric acid is generated and this acidity could potentially deprotect the 
side chains. To quench this acidity, the presence of a base was required during 
coupling and the base tolerance of the present method was thus assessed. Firstly, 
N-methyl imidazole was tested, but this base presented the major inconvenience 
of being highly hygroscopic, thus requiring distillation and storage under strictly 
anhydrous conditions prior to use; the reagent was therefore considered 
incompatible with the microwave synthesizer. For this reason, a solid inorganic 
base seemed more reasonable and couplings were thus tested in presence of 
sodium bicarbonate, which was introduced in excess at the same time as the 
resin. Using a solid base presents the additional advantage that it is retained in 
the reaction vessel after each round of filtered washes following couplings and is 
therefore introduced only once, again minimizing entry points for water. The 
bicarbonate is readily removed by rinsing the resin with water prior to the 
cleavage step. It was then necessary to thoroughly test the functional group 
tolerance of the method by assembly of a small library. These studies were 
carried out in chloroform, as it is much less hygroscopic than DMF. The present 
library was designed to assess the ability of monomers 22a-n to be coupled to 
another monomer already attached to the resin to form a dimer, as well as the 
ability of these dimers to couple to another activated monomer to provide 
trimers 26-37. To obtain consistent data, the same monomers were used at the 
N- and C-termini for each trimer, respectively the benzyl 22d and isobutyl 22a 
monomers. The optimized coupling conditions afforded the desired trimers with 
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good conversion and yield (Table 2.3) and the crude material was in most cases 
more than 90% pure as observed on the LC-MS spectrum.  
 
Table 2.3 Library of N-alkylated tribenzamides with the side chains sequence.  
Unless otherwise specified, the reported purity and yield correspond to crude 
compounds. 
Trimer 
number 
R3 R2 R1 Purity Yield 
26 d 
 
b 
 
a 
 
85% 85% 
27 d 
 
d 
 
a 
 
95% 100% 
28 d 
 
e 
 
a 
 
~90% ~ 95% 
29 d 
 
i 
 
a 
 
70% ~ 90% 
30 d 
 
h 
 
a 
 
99% 100% 
31 d 
 
f 
 
a 
 
99% a 
(crude 80%) 
7% a 
32 d 
 
k 
 
a 
 
80% ~ 85% 
33 d 
 
l 
 
a 
 
99% b 
(crude 75%) 
22% b 
34 f 
 
j 
 
a 
 
~ 95% c 10% 
35 a 
 
m  a  
99% a 
(crude 80%) 
~ 6% a 
36 d 
 
o 
 
a 
 
99% 100% 
37 f 
 
h 
 
c 
 
99% 100% 
a Purified by precipitation.  
b Purified by MS-directed preparative HPLC 
c Purified by column chromatography 
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When the purity of the crude material was judged unsatisfactory, purification was 
attempted. Several methods were used including column chromatography, 
preparative TLC, preparative HPLC, mass directed preparative HPLC or 
precipitation, which improved purity but considerably affected the isolated yields 
of pure compounds.  In the range of monomers that were submitted to coupling, 
the indole containing monomer 22j was problematic, in agreement with previous 
observations.143 LC-MS analysis of the cleavage product indicated that the 
coupling occurs, but that the indole functionality is lost, presumably due to acid 
catalyzed elimination of the Boc-protecting group during the TFA-cleavage step, 
followed by cascade elimination of the indole ring (Scheme 2.3).  
 
 
 
This issue was addressed by using milder conditions for the cleavage step. The 
cleaving cocktail was diluted from a 1-1 mixture of dichloromethane-TFA down 
to a 25%, then 10% TFA in dichloromethane solution (Table 2.4). Diluting the 
cleavage cocktail indeed solved the elimination issue, but the isolated product 
was then still Boc-protected. Adjusting the length of the cleavage also failed to 
yield the desired deprotected trimer, as it seemed impossible to reach a 
compromise between Boc-deprotection and preservation of the indole side chain. 
For side chains containing a functional group that is prone to elimination, it might 
be necessary to adjust cleavage mixture and cleavage time to achieve neat 
cleavage from the resin as well as complete deprotection whilst preserving the 
side chain. It was envisaged that the isolated Boc-protected trimer could be 
Scheme 2.3 Cascade elimination of the indole functionality during acidic cleavage 
from the resin. 
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selectively deprotected via thermolysis,171 however only eliminated indole was 
isolated under the reported conditions. 
 
Table 2.4 Indole deprotection versus side chain elimination 
Entry Cleavage cocktail Cleavage time Observed products (LC-MS) 
1 Neat TFA 30 min Mostly eliminated indole 
2 50% TFA in CH2Cl2 30 min Mostly eliminated indole 
3 25% TFA in CH2Cl2 10 min 
Mostly Boc-protected trimer and  
traces of eliminated indole 
4 10% TFA in CH2Cl2 5 min Mostly Boc-protected trimer 
5 10% TFA in CH2Cl2 10 min Mostly Boc-protected trimer 
6 10% TFA in CH2Cl2 15 min Mostly Boc-protected trimer 
7 10% TFA in CH2Cl2 30 min Mostly eliminated indole 
 
The library demonstrates the tolerance of this method towards: aliphatic chains 
and hence analogues of Ala, Val, Leu, Ile residues (trimers 26 and 37, Table 2.1), 
aromatics analogues of Phe and halogenated aromatics (27-31), sulfur containing 
side chains (32), tyrosine analogues (33), tryptophan analogues (34), basic and 
acidic chains analogues of Lys, Asp and Glu (35 and 36). The incorporation of an 
aliphatic sulfur containing side chain (i.e. a Met analogue) was also investigated, 
but the synthesis and purification of the corresponding monomer was 
problematic, and its limited solubility in chloroform is potentially responsible for 
the inefficiency of the coupling. In the case of an imidazole bearing monomer (i.e. 
a His analogue), two protecting groups were considered, namely Boc and Trt, but 
in both cases the Fmoc protection step proved cumbersome and fully protected 
monomer was not isolated. Functional tolerance towards a few remaining 
proteinogenic side chains still remains to be demonstrated; notably proline, 
cysteine, arginine, asparagine/glutamine and histidine, however the method that 
has been developed is sufficiently powerful for exploration of SAR space. In 
addition, α-amino acids can be coupled to the N-terminus of the oligobenzamide, 
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rendering the approach entirely compatible with standard oligopeptide synthesis 
(noting that amino acids loaded to the resin demonstrate this feature for the C-
terminus, Figure 2.2). 
 The robustness of the method towards synthesizing longer oligomers, 
which might allow the mimicry of longer helical domains, has also been 
investigated. The optimized coupling conditions described in Scheme 2.2 have 
been applied in this study, using ten rounds of deprotection-coupling cycles. Test 
cleavages on small aliquots of resin were performed at different stages. This LC-
MS analysis was useful to determine whether the coupling step was complete or 
not, but was not accurate enough to quantify the decrease in coupling efficiency 
after the pentamer. Tetramers and a pentamer have been made with purity 
confirmed by NMR as well as HRMS (cf. Experimental section) and it has been 
possible to extend the synthesis as far as the decamer (Figure 2.3, compound 
40).144   
 
 
 
 
  
Figure 2.3 Extending the scope of the present SPS methodology. The method is 
compatible with natural amino acids both at the N- and C-terminus (compounds 38 and 
39) and can be extended to the synthesis of a decamer (40). 
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2.3   Conclusions 
 
A robust automated SPS methodology has been established for the synthesis of N-
alkylated oligobenzamides using a microwave assisted peptide synthesizer, 
allowing facile library generation of diversely functionalized compounds. A wide 
range of monomers has been prepared and incorporated into trimers to 
demonstrate the reproducibility and functional tolerance of our method. Side 
chains compatible with this method cover the whole range of hydrophobic side 
chains, which are the most commonly involved in PPI interfaces. Combinations of 
side chains give access to a wide variety of oligomers, and thus allow mimicry of 
numerous potential helix surfaces. The synthesis of oligomers up to the decamer 
has also been established, which broadens the range of possible applications for 
both this method and the present scaffold. Our ongoing efforts are directed 
towards the synthesis of a library and its screening against a diverse range of α-
helix mediated PPIs. 
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Chapter 3 
 
 
 
Testing the hypothesis:  
Assembly and Screening of  
a library of proteomimetics 
 
 
 
 
As discussed in Chapter 1, targeting protein-protein interactions (PPIs) presents 
considerable therapeutic potential, as they regulate virtually every cellular 
process and are involved in a number of diseased states. Modulating them 
however constitutes a daunting challenge, given their intrinsic lack of defining 
features. Given the number of existing PPIs, a desirable approach would be to 
have adaptable and synthetically accessible lead molecules that can selectively 
target several PPIs via minor changes rather than tailoring a new chemical 
modulator from scratch for each PPI. A possible strategy would be to design 
compounds that are amenable to library assembly for screening. Intense research 
efforts have yielded several approaches to disrupt PPIs, though only a few are 
amenable to library generation.140, 141, 172 In the Wilson group, several 
oligobenzamide proteomimetics have been developed131, 143, 158 and in the case of 
the N-alkylated scaffold a modular solid phase synthesis (SPS) was established to 
build libraries of compounds. This methodology makes use of a state of the art 
microwave assisted peptide synthesiser and was described in Chapter 2. In the 
present chapter, the design, synthesis and biological testing of a library of 75 
proteomimetics will be detailed. This library was mostly made of compounds 
targeted to the p53/hDM2 and p53/hDMX interactions (cf. Chapter 1), but also 
contained a sub-library of compounds designed to disrupt the Bcl-2 family of 
interactions. 
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3.1   Targeting the p53/hDM2 interaction 
 
3.1.1 The library 
 
A 60-member library was generated using the SPS described in Chapter 2, which 
illustrated the robustness of the newly developed methodology. The set of 
monomers used in this library were mostly made of aromatic and aliphatic side 
chains, as shown in Figure 3.1. 
  
Figure 3.1 Monomer synthesis and set of monomers used in the library assembly 
using the automated SPS methodology described in Chapter 2. The monomers are 
colour-coded according to the p53 residues they are designed to mimic (red: Phe19 
mimics, green: Trp23 mimics, blue: Leu26 mimics, grey: protecting groups that are 
removed during cleavage from the resin, named ‘PG’ in the synthetic scheme).  
 
 
As described in the previous chapter, the first set of compounds was designed to 
assess the functional tolerance of the newly established coupling method and 
thus side chains R1 and R3 were fixed while all monomers were incorporated in 
the middle position. The library consisted of 60 trimers (Fig. 3.2), which were 
generally obtained in purities above 85-90% (judging from UV chromatograms 
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and NMR spectra). This was deemed as a high enough purity threshold for testing 
in the fluorescence anisotropy (FA) assay; considering that none of the 
purification methods tested was found to be efficient or high yielding (cf. Chapter 
2). It was decided that when compounds with lower purities displayed good 
activities in the biophysical assay, they would be re-synthesised in order for the 
pure compound to be re-tested. 
 
 
 
Figure 3.2 The library of 60 proteomimetics targeting the p53/hDM2 interaction. 
The side chains are named using the nomenclature reported in Figure 3.1. 
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Monomers q and s (5-methoxy indole and 5-chloro indole respectively) have not 
been successfully included in the library, due to a technical limitation that was 
discussed in Chapter 2 (during acidic cleavage from the resin, the indole side 
chains were eliminated along with the Boc-deprotection), hence only limited 
amounts of these compounds - if any - were obtained in sufficient purity for 
preliminary testing.  In one instance, a small amount of the desired unprotected 
Boc-indole trimer could be isolated (compound 53) and on another occasion, 
some Boc-protected indole containing trimer was isolated (89). In order to yield 
a relatively focused library of p53 mimetics, the benzyl monomer was chosen as 
the N-terminal residue (Phe19 mimic) and the isobutyl monomer as the C-
terminal one (Leu26 mimic). The next few compounds were then obtained by 
replacing one of the terminal side chains with a structural analogue, i.e. Bn was 
replaced with EtPh or a halogenated aromatic side chain whilst iBu was replaced 
with a cyclopropyl ring or other aliphatic side chains. A few trimers with 
mismatched sequences were also prepared. The first 15 compounds were tested 
in a manual single point assay (cf. Section 3.1.2.2); these results were used to 
establish some structure-activity relationships which guided the design of the 
next series of compounds.  
 
3.1.2 Biophysical evaluation of the library of oligobenzamides  
 
Initially, it was planned that the library of oligobenzamides would be tested 
against both the p53/hDM2 and the p53/hDMX interactions. I expressed His-
hDM217-126 L33E with the assistance of Dr. A. Bartlett at the Astbury Centre for 
Structural Molecular Biology, following a procedure that was established 
previously in the group.131 As no hDMX clone was available, molecular cloning 
experiments were carried out in an attempt to obtain hDMX constructs 
containing different tags (cf. Experimental Section):  
- His-hDMX: could be used in Fluorescence Anisotropy (FA) assays, the His-
tag being useful for purification. 
- His-Tev-GFP-PreS-hDMX: a hDMX construct that contains a removable 
fluorescent tag; the resulting protein could be used as such in FRET assays, or the 
GFP-tag could be cleaved via the PreS site (a recognition sequence that can be 
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specifically cleaved by a PreScission protease – a genetically engineered 
protease) to yield a non-fluorescent protein for FA assays. 
- GST-hDMX: could be used in FA assays, GST is also known to enhance the 
solubility of other proteins. 
- SUMO-hDMX: could be used in FA assays, crystallisation trials and is 
known to enhance the solubility of the protein.  
Of all the attempts to prepare these constructs, the only recombinant DNA that 
was successfully prepared was His-Tev-GFP-PreS-hDMX26-110, as confirmed by 
sequencing. Tev designates a recognition site that can be specifically cleaved by a 
TEV protease (from Tobacco Etch Virus); it is commonly used to remove affinity 
tags such as the His-tag from proteins following purification.173 This construct 
would be suitable for future FRET assays as a fluorescent tag is attached to the 
protein, but not for the FA assay. Cleavage of the GFP-tag using PreScission 
protease was then attempted to obtain the non-fluorescent protein for FA assay, 
but the cleavage unexpectedly failed. This protein could thus not be used to 
screen the library, and time did not allow for further molecular cloning and 
construct investigation to be carried out at that point. Further efforts have been 
dedicated by the Edwards group (Dr. A. Bartlett and S. Hussain) towards 
obtaining a hDMX construct that would be suitable for use in fluorescence 
anisotropy assays. An additional non-fluorescent GST-hDMX construct was 
successfully produced and expressed, but it however proved to be relatively 
unstable. Only one compound could be tested using this protein, the results are 
presented in Section 3.3. The library has therefore only been assessed on the 
p53/hDM2 interaction using a FA assay, first in single point, then in a competition 
assay that allowed a better quantification of the efficiency of the compounds. 
 
3.1.2.1 The fluorescence anisotropy assay 
The library was tested against p53/hDM2 in a previously reported FA 
competition assay (Fig. 3.3).85 In this assay, the change in anisotropy is measured 
upon displacement of a fluorescein-labelled p53 peptide from hDM2 by the 
proteomimetic (Fig. 3.3). This assay is also employed by other research groups to 
test new potential inhibitors.29, 125, 174, 175 In order to determine the limits of 
anisotropy that can be observed in this assay, the binding of the native p53 tracer 
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to hDM2 was assessed. A serial dilution of the protein into the tracer (Fig. 3.3c) 
allowed the determination of the dissociation constant (Kd = 164.4 ± 10.8 nM), 
which was in the range of values that were previously obtained in the group. A 
dose-response titration was also carried out with Nutlin-3a (which served as 
positive control in the experiments described thereafter) and provided an IC50 of 
353.9 ± 6.59 nM (Fig. 3.3d), which was in the nanomolar range, as initially 
reported by Vassilev and co-workers using a surface plasmon resonance assay 
(IC50 = 90 nM).7  
 
 
 
Figure 3.3 The fluorescence anisotropy assay. a. The p53 tracer (Flu-p5315-31). b. At 
low concentrations of protein (His-hDM217-126 L33E) the tracer is free to tumble in 
solution: the directionality of the polarized excitation light is lost. At high concentrations 
of protein, the tracer is engaged in a much bigger complex: the tumbling is reduced hence 
an increase in anisotropy. At high concentrations of proteomimetic: the tracer is freed 
from its complex with the protein, the anisotropy decreases again. c. Direct titration of 
protein. d. Displacement assay using Nutlin-3a. 
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In this competition assay, the concentration of protein and tracer were kept 
constant (150 nM and 50 nM respectively) while the proteomimetic was serially 
diluted from 100 µM down to 9 nM (cf. competition assay with Nutlin-3a, Fig. 
3.3d). Previous experience with competition assays on this PPI within the group 
has revealed that the equilibrium taking place was not a simple two state 
competition and likely involved aggregation/interaction of the tracer with all 
other component present, as depicted in Figure 3.4. This complex equilibrium 
prevented the determination of Kd values. The fluorescently tagged p53 was not 
only interacting with hDM2, but also itself, as well as with the proteomimetic131 
and the positive controls (unlabelled p53 and Nutlin-3a). These undesired 
interactions generated additional contributions to the overall anisotropy. 
 
 
Figure 3.4 The equilibrium preventing Kd determination. In this assay, aggregation of 
the tracer during the direct titration (left plot, contribution to the anisotropy = r1) 
prevents determination of r0 (theoretic minimum anisotropy). Interaction of the tracer 
with the proteomimetic during the displacement assay (right plot, contribution to the 
anisotropy = r2) precludes measurement of the expected end-point (rmin). 
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The minimum anisotropy rmin was determined during the direct titration of the 
tracer by hDM2. It should correspond to a solution where the tracer would be 
completely free to tumble. But given that the tracer has been found to interact 
with itself (r1), the anisotropy value at the beginning of the titration was actually 
above the theoretical value (rmin > r0). During the competition assay, the tracer 
was progressively displaced from the interaction, but the concentration of 
proteomimetic at the end point was much higher than the concentration of tracer. 
The probability to find the tracer aggregated with another tracer molecule was 
thus much lower than the probability for tracer-inhibitor complexes to form, and 
the latter species would bring a smaller contribution to the anisotropy (r2). 
 
 
3.1.2.2 Initial screening: manual single point assay 
 
Considering the large number of compounds to be tested and the amount of 
protein that would be required to test all of them in a dose-response competition 
assay, a rapid screening of the library was necessary. This was designed as a 
relatively crude experiment which although unlikely to provide quantitative data, 
would allow establishment of a rough ranking of the compounds and 
identification of the most potent inhibitors in order to further test them in a full 
competition assay. Subsets of compounds were tested manually in a 96-well 
plate, where each compound was tested in triplicate and one blank was 
measured. This allowed screening 15 compounds per plate and the concentration 
of proteomimetic was fixed at 10 µM. A positive control known to bind the target 
protein was present on each plate, in the case of the p53/hDM2 interaction, 
unlabelled p53 and Nutlin-3a (one of the most potent inhibitors of the p53/hDM2 
PPI known to date,7 cf. Chapter 1) was chosen and used as a reference to assess 
the potency of the N-alkylated tribenzamides. In the case of Nutlin-3a, a 
concentration of 10 µM effected displacement of the tracer; compounds that gave 
anisotropies values close to that of Nutlin-3a were thus likely to have IC50 values 
in the low micromolar/nanomolar range. Compounds that were not significantly 
displacing the tracer at this concentration were considered inactive.  
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Figure 3.5 Results from a single point assay on the first subset of 15 compounds at 
10 µM, presented as a percentage of Nutlin-3a efficiency.  In this assay, the positive 
control is Nutlin-3a (set to 100% efficiency) and the negative control is a well where the 
inhibitor is replaced with buffer (0% efficiency). The least active compound is 48, and 
the most active ones are 46, 47 and 53. 
 
 
In order to get data that is easily comparable between compounds tested on 
different plates, a relative efficacy compared to the positive control was 
calculated for each compound (the efficacy of the positive control was set to 
100%) and the results are presented as a bar diagram. Results from this single 
point screening are reported in Figure 3.5; the relative efficiency of each 
Chapter 3: Assembly and screening of a library of proteomimetics 
 
62 
 
compound compared to Nutlin-3a was represented by a bar. From this initial 
screening, it appeared that these first 15 compounds presented a broad range of 
efficacies. Compounds 32, 48 and 26 were poorly active against the target PPI (< 
40% Nutlin-3a efficiency). These compounds all had suitable side chains to mimic 
Phe19 and Leu26, but a mismatched side chain at the Trp23 position 
(respectively: 4-methylthiobenzyl, 3-aminopropyl, and cyclopropyl). On the other 
hand, compounds 42, 46, 47 and 53 presented efficiencies above 85% of that 
from Nutlin-3a. These four compounds all possessed appropriate side chains to 
mimic the three p53 hot-spot residues, and in particular bulky aromatic residues 
in the middle position. These compounds, along with the least active 48 were 
then tested in a full competition assay; the resulting binding curves are overlayed 
in Figure 3.6. In the design of the next compounds, bulky aromatics as well as 
halogenated benzyl rings were thus prioritised.  
 
 
 
Figure 3.6 Dose-response curves for hits identified in the single point screening 
against p53/hDM2 (compounds 46, 47, 53) along with the least potent compound 
in this series (compound 48). 
 
 
Compounds 46, 47 and 53 had been tested on the same plate in the single point 
assay, and their %Nutlin-3a efficiencies were 88.2%, 97.3% and 99.6% 
respectively. The IC50s determined in this competition assay did not confirm the 
preliminary ranking established from the single point assay, but rather that 
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compound 47 is the most potent one (IC50 = 7.12 ± 0.27 µM, Fig. 3.6), followed by 
compound 46 (IC50 = 8.92 ± 0.56 µM) and then compound 53 (IC50 = 9.06 ± 0.20 
µM). As a comparison, Nutlin-3a displayed an IC50 of 354 ± 67 nM. These results 
suggest that the single point assay is not accurate enough to provide a definite 
ranking of compounds, but that it is a useful tool to identify the most potent 
compounds within a series. For compound 48, which was identified as the least 
potent in the single point assay, the lower asymptote was not reached in the 
dose-response assay (Fig. 3.6, green curve). This means that even at 100 µM, 48 
was not able to completely displace the tracer from its interaction with hDM2. 
The binding curve was plotted using a fixed anisotropy corresponding to the 
lower plateau that should be reached upon complete displacement, which 
allowed measuring an apparent IC50 of 77.70 ± 1.97 µM.  
 
The second set of compounds was tested on another 96-well plate; results 
from this single point screen are presented in Figure 3.7. Some of the compounds 
appeared to exceed the 100% efficiency set for the positive control in this assay - 
this was probably due to compound-tracer interactions. It is worth noting that 
among the most potent compounds from this series, the vast majority fitted the 
design rules: small aromatic ring in R1, bulky aromatic side chain in R2 and 
aliphatic side chain in R3. Less potent compounds generally presented 
mismatched side chains at the R2 position, whether aliphatic (60, 54), 
hydrophilic (36), or polar aromatic (33). 
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Figure 3.7 Single point screening on the second subset of 15 compounds. The most 
potent compounds were 56, 59, 62, 63, 64, 65, 66 (purple circles) and the least potent 
ones were 54, 33, 36 (pink squares).  
 
 
Four hits from this subset, i.e. compounds 56, 62, 63, 66 as well as the least 
potent 33 were tested in a full competition assay. The resulting dose-response 
curves are presented in Figure 3.8. As expected, compounds that displayed more 
than 100% efficiency in the single point assay presented a lower IC50 than Nutlin-
3a when tested in the full competition assay. Compounds 57 and 58 displayed 
similar % efficiencies, suggesting that there was no significant impact of 
reversing the compound’s macrodipole on the potency.  
Chapter 3: Assembly and screening of a library of proteomimetics 
 
65 
 
 
 
Figure 3.8 Dose-response curves for hits identified in the single point assay 
(compounds 56, 62, 63, 66) as well as for the least potent compound 33.  
 
 
As was the case for the first series of compounds, the real ranking of the 
compounds established in the competition assay did not reflect the one that was 
observed in the single point assay. 
 
Results from the third subset of compounds (60 – 77, Fig. 3.9) suggested that 
compounds 60, 67, 69 and 70 were the least potent ones. Compounds 60 lacked 
an aromatic ring at the R2 position and 67 was a mismatched sequence, so they 
were both expected to be poorly active. It was thought that the other two 
compounds (69 and 70) would be good mimetics, as they display a side chain 
arrangement that matches that of the p53 hot-spots. Their poor efficiency was 
especially surprising when considering that 68 and 71 were two of the most 
potent ones, and only differed from 69 and 70 (respectively) by the position of 
the substituent of the benzyl at the R2 position. Compounds 71 to 77 all fitted the 
initial design rules (aromatic ring at R1, substituted aromatic ring at R2 and 
aliphatic chain at R3) and appeared to be efficient in this assay. This confirmed 
the design rule and validated the use of the 2-methylbutyl side chain as a Leu26 
mimic but it also suggested that there might have been a problem with 
compounds 68 - 70 during the testing. Repeating the assay on compounds 60 and 
67-71 confirmed the ranking, but the gap in efficiencies between 68/69 and 
70/71 was reduced (%Nutlin-3a efficiencies were: 71%/56% and 51%/69% 
respectively and 25% for 67, data in Appendix I). 
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Figure 3.9. Results from single point screening on the third and fourth set of 
compounds against p53/hDM2, at 10 µM. Sets of compounds reported on either side 
of the controls (no inhibitor and Nutlin-3a, green) have been tested together. Compounds 
in red (92-101) have an additional natural amino acid attached to their C-terminus (Y). 
 
 
The influence of the position of the substituent on the benzyl ring at R2 was 
studied through comparison of compounds 68 and 69. The single point screen 
indicated that 68 (para-substituted) was more active than the meta-substituted 
compound (86% for 68 against 37% for 69 in the first screening, ranking 
confirmed by repeating the experiment). Comparison of their binding curves 
revealed only a slight preference towards substitution at the para position, 
although the difference in affinity was relatively small (5 µM, Fig. 3.10) and could 
be compound-dependent.  
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Figure 3.10. Comparing para (68) and meta (69) substitution on the benzyl ring at 
position R2. These compounds were tested on the Hamilton robot. 
 
 
The fourth subset of compounds (30, 37, 78-101) presented more homogenous 
results, with efficiencies between 78-98%. The subset of compounds displaying 3 
side chains (in blue, Fig. 3.9) was relatively focused, with bulky aromatics at the 
R2 position; most potent compounds included 37 and 81. Interestingly, the last 
subset of hybrid compounds containing an additional α-residue displayed good 
activity despite presenting only one aromatic side chain out of four substituents. 
This confirmed that the presence of an aromatic ring at R2 was a sufficient 
condition for binding to hDM2. The most potent hybrid compounds were the two 
that contained the bulkiest substituent (2-naphthyl, 98, 99).  
 
 
Figure 3.11. Dose-response curves for hits on the fourth subset of compounds (78-
101). Compound 81 was tested in 96-well plates whereas 98 needed to be tested in 384-
well plates, which explains the different titration start points. 
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The most potent tribenzamide 81 and the most potent hybrid oligoamide 98 
were tested for dose-response (Fig. 3.11). Both displayed low micromolar IC50s 
(6.52 ± 0.47 µM for 81, 2.79 ± 0.09 µM for 98). The anisotropy value at the start 
of the titration is different for these compounds because 98 was tested in a 384-
well plate, whereas 81 was tested in a 96-well plate; however this should not 
affect the IC50 value. It is worth noting that 60 had already been tested with the 
previous set of compounds (Fig. 3.7) and despite being one of the least active 
compounds then, it still displayed a ~68% efficiency (but the most active 
compounds from this screen displayed efficiencies above 100%). When re-tested 
with the third set of compounds (Fig. 3.9), 60 was again one of the least active 
compounds, this time displaying a 40% efficiency. This illustrated that although 
the raw values extracted from these assays – and therefore the relative ranking of 
compounds - were not necessarily reproducible, hits and inactive compounds 
could still be reliably identified.  
 
Taking together observations from all these separate single point experiments, it 
appeared that testing all the compounds in one single experiment could 
potentially improve the accuracy and representativeness of the results. Using 
different batches and stocks of reagents indeed introduced some variability into 
this assay. Different batches of tracer will present different behaviours towards 
aggregation and protein stocks prepared on separate occasions were likely to 
present slight fluctuations in concentration and protein folding, especially if the 
stocks were made with different batches of buffer. It therefore seemed necessary 
to test the compounds under the exact same assay conditions, and considering 
the time required to plate manually a set of 15 compounds, this would only be 
achievable using an automated method. 
 
3.1.2.3 Automated single point screening of the library 
 
It appeared that the reproducibility of the assay was variable for compounds 
tested separately – and therefore using different protein and tracer solutions. In 
order to maximize the accuracy of the results, an automated method was 
developed by Dr. C. J. Empson to test the library in single point on a Hamilton Star 
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Microlab robot. This method allowed for the whole library to be tested within 3 
hours and made use of 384-well plates, which helped reduce the consumption of 
protein and tracer. No reproducible conditions could be found for the single point 
on the robot using 384-well plates, and the broad range of relative efficiencies 
that corresponded to previously identified hits indicated that results from this 
automated screening failed to reproduce results from the initial screens carried 
out manually in 96-well plates. Results from the automated screening of the 
library were thus not exploitable (cf. Appendix II). Performing the assay manually 
in 96-well plates however presented two drawbacks: it was highly time 
consuming, and used a lot of material. A method could be developed to carry out 
the assay on 96-well plates on the robot, which would make it more time-
efficient, but this has not been attempted as it would have consumed a large 
amount of reagents for information that was already available. It might however 
be worth considering for screening against other PPI targets in the future.  
 
3.2  Targeting the Bcl-2 family of interactions 
 
As mentioned in Chapter 1, the interactions between pro- and anti-apoptotic 
members of the Bcl-2 family involve 4 key binding residues. The two main 
interactions targeted in this study were the Bcl-2/Bak and the Mcl-1/Noxa B 
interactions, as is the case for the other interactions within this family, the hot-
spot residues involved in the binding are mostly aliphatic (Fig. 3.12a-c). The 
Hamilton group reported that in the case of the Bcl-xL/Bak interaction, only 3 
consecutive hot-spot residues from Bak needed to be mimicked in order to 
achieve competitive binding to Bcl-xL,176 and mimicking the fourth key residue 
using an alternative scaffold even proved to be detrimental to the activity,136, 137 
although it is not excluded that the loss of potency might be due to the scaffold 
itself. For the purposes of this study we chose to adapt the N-alkylated 
oligobenzamide scaffold so as to mimic all four key side chains. Both sub-libraries 
were then tested against both targets, in order to study the versatility and 
selectivity of each scaffold. 
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Figure 3.12 Targeting the Bcl-2 family: model interactions and SPS strategy. a. The 
Bim helix (PDB ID: 1PQ1). b. The Bak helix involved in binding to Bcl-xL (PDB ID: 1BXL). 
c. The Noxa B helix involved in binding to Mcl-1 (PDB ID: 2JM6). d. Binding profiles for 
the main Bcl-2 family members. e. SPS scheme leading to proteomimetics displaying 4 
side chains. 
 
 
As mentioned in Chapter 2, the library of trimers targeting the p53/hDM2 PPI 
was built on solid phase, using a Wang resin pre-loaded with Gly. It was 
envisaged that this SPS methodology could directly be transposed to the 
synthesis of proteomimetics displaying 4 key side chains by simply using a resin 
pre-loaded with a different α-amino acid (Fig. 3.12e). This approach yielded 
proteomimetics where three hot-spot residues would be mimicked by the 
aromatic building blocks, whereas the fourth one would be mimicked by the α-
residue preloaded on the resin. Given that the pro-apoptotic members of the Bcl-
2 family are mostly made of combinations of aliphatic residues, monomers 
bearing an aliphatic side chain were prioritised in this library (Fig. 3.13).  
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Figure 3.13 Library of proteomimetics bearing 4 side chains and targeted to the 
Bcl-2 family of interactions. 
 
 
A few unnatural side chains were also explored, as Hamilton and co-workers 
reported a terphenyl bearing a 2-naphthyl side chain at the i + 4 position to be 
one of their most potent Bcl-xL/Bak inhibitors (Ki = 114 nM).176 The library of Bcl 
inhibitors is represented in Figure 3.13. Most of the library members were made 
of three aromatic monomers followed by a natural amino acid at the C-terminus, 
except for 96, which had an additional α-valine at the N-terminus. This 
compound illustrated the compatibility of the methodology with natural systems. 
 
3.2.1 Testing against the Mcl-1/Noxa B interaction 
 
The versatility of the N-alkylated oligobenzamide scaffold was then studied. At 
first, two PPIs that are part of the Bcl-2 family of interactions were envisaged, and 
the corresponding proteins and tracers were prepared by two post-doctoral 
members of the group (molecular cloning and expression of Mcl-1172-327 and Bcl-
xL1-209: Dr. A. Bartlett; synthesis of FITC-Noxa B68-87 and carboxyfluorescein-Ahx-
Bid80-99: Dr. P. Prabhakaran, Flu-Ahx-Bad103-128 was purchased from Peptide 
Science Research Ltd.). The versatility of the developed proteomimetic scaffold 
was thus only studied on the Mcl-1/Noxa B interaction, and an isolated 
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compound was tested against the p53/hDMX PPI. Conditions for the Mcl-1/Noxa 
B assay were optimized. A direct titration of the tracer by the protein was 
performed and led to the determination of a Kd value of 32.46 ± 1.14 nM, which 
was in agreement with values reported in the literature.177 Conditions for the 
displacement assay using the unlabelled Noxa B peptide were optimized in a joint 
effort (with D. J. Yeo and V. Azzarito) and provided an IC50 of 704 ± 35 nM, using 
150 nM protein and 50 nM tracer. No workable assays have been produced yet 
for the interaction of Bcl-xL with Bad and Bid peptides and these PPIs were 
therefore not investigated within the context of this study. As discussed earlier, it 
was of crucial importance to test the compounds in the same conditions in order 
to obtain reliable and exploitable data. The whole library of oligobenzamides was 
thus subjected to a single point screen using the automated method described in 
the previous Section, as these assay conditions might be suitable for this 
particular interaction.  
 
3.2.1.1 Single point assay against the Mcl-1/Noxa B PPI 
 
In this assay, an unlabelled Noxa B peptide was used as the positive control. 
Screening against this target interaction was carried out on the Hamilton Star 
Microlab robot, using the same method as for the screening against p53/hDM2. 
Results for the screening of the whole library in this assay are presented as a bar 
diagram (Fig. 3.14). These results indicate that five oligoamides seemed to be 
active against the target PPI: compounds 72, 89, 98, 100, and 105 displayed 
between 25 and 60% Noxa B efficiency. Although this might not seem like a very 
high threshold to select potent compounds, the four most potent ones (72, 89, 98 
and 105) were tested in a full competition assay. It is worth noting that a 
considerable number of compounds displayed anisotropy values that exceeded 
that of the fully bound tracer (wells containing only protein, tracer and buffer). 
This was attributed to the DMSO, as a concentration of 10% was present in the 
test wells, whereas the negative control (wells only containing protein and 
tracer) did not contain any. At this concentration, it is possible that the viscosity 
of the solution and the structure of the protein itself were affected; both of which 
could affect the resulting anisotropy. 
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Figure 3.14 Results from the single point screening of the library against Mcl-
1/Noxa B. Blue: results for compounds initially designed to target p53/hDM2 and 
containing only 3 side chains; red: sub-library targeting the Bcl-2 family; green: controls. 
a. Raw anisotropies are reported for each compound tested at 10 µM. b. Results 
presented as a percentage of Noxa B efficiency – most of the compounds exhibited 
negative efficiencies due to their unexpectedly high anisotropy values (scale limited to -
20%). 
 
 
Although for some of the compounds the error over the three repeats was 
significant, all the compounds identified as hits presented acceptable errors (Fig. 
3.14b). Considering that the amount of protein available was a limiting factor, it 
was decided that this assay would not be repeated, as the resulting data was still 
exploitable, and was confirmed by further competition assays.  
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3.2.1.2 Competition assays against the Mcl-1/Noxa B PPI 
 
Using the optimized conditions (150 nM protein, 50 nM tracer), the ‘hits’ 
identified in the single point assay as well as some of the less potent compounds 
were tested (Fig. 3.15). 
 
 
 
Figure 3.15 Compounds tested against Mcl-1 in a dose-response assay (structures 
in Fig. 3.14). a. Hits from the single point screening. b. Dose-response curve for 102. 
 
 
These assays allowed the identification of low micromolar inhibitors of the 
Noxa B/Mcl-1 interaction: compound 72, IC50 = 9.37 ± 1.9 µM; 89, IC50 = 13.24 ± 
1.4 µM and 98, IC50 = 17.34 ± 3.1 µM. Compounds 102, 103 and 104 (cf. Fig. 3.14 
for structures) which were specifically designed to mimic Noxa B turned out to be 
amongst the least active compounds of the library, with 102 displaying an 
apparent IC50 = 245 ± 49.3 µM. This might be due to the proteomimetic not being 
able to display the acidic side chain the same way as the native Noxa B helix. As 
was the case for inactive compounds in the case of the p53/hDM2 PPI, the lower 
asymptote was not reached for 102, meaning that a concentration of 100 µM was 
not high enough to displace the fluorescent Noxa B from the interaction with Mcl-
1. This result however confirmed predictions of the single point screening. It is 
worth noting that two of the most potent compounds against p53/hDM2 were 
also among the best inhibitors of the Noxa B/Mcl-1 PPI (although 89 only weakly 
inhibited this PPI). Furthermore, among the sub-library that was initially 
designed to inhibit the Bcl-2 family of PPIs, the most potent compounds all 
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included an aromatic side chain. The selectivity of the oligobenzamide scaffold 
was further investigated, using data from both single point screenings and 
additional competition assays. The results are discussed in the next Section. 
 
3.3 Selectivity of the scaffold 
 
Hits from each of the single point screening were tested in dose-response 
competition assay on both the p53/hDM2 and the Noxa B/Mcl-1 interactions, in 
order to study the selectivity of the scaffold and its possible use in a general 
approach to the disruption of α-helix mediated PPIs. The results for compounds 
against both targets are presented in Figure 3.16. Some compounds including 72, 
98 and 105 have been found to inhibit both the p53/hDM2 and Noxa B/Mcl-1 
PPIs. 98 inhibited p53/hDM2 with an IC50 of 2.79 ± 0.13 µM and Noxa B/Mcl-1 
with an IC50 of 17.34 ± 3.1 µM (Fig. 3.16c) whilst 72 inhibited p53/hDM2 with an 
IC50 of 3.05 ± 0.22 µM and Noxa B/Mcl-1 with an IC50 of 12.82 ± 2.44 µM (Fig. 
3.16e). Compound 47 which was one of the initial hits against p53/hDM2 (IC50 of 
7.12 ± 0.26 µM) had been predicted by the single point screening to be inactive 
against Noxa B/Mcl-1. The competition assay revealed 47 also inhibited this 
second PPI (IC50 of 9.18 ± 2.7 µM against Noxa B/Mcl-1, Fig. 3.16d). Taken 
together, these results suggest that these compounds may be acting as non-
specific inhibitors, which may be explained by the general hydrophobicity of the 
scaffold and side chains required.  
Compound 89 containing a Boc-protected bromoindole however acted as a 
specific p53/hDM2 inhibitor (20-fold selectivity for p53/hDM2 with an IC50 of 
0.67 ± 0.06 µM). Although this Boc-trimer was not the initially desired 
unprotected compound, it was decided that it should be included in the testing 
phase, as this additional Boc-group might provide a better fit within the binding 
pocket. It is not excluded that this additional hydrophobic group might just bring 
some additional hydrophobic and non-specific interactions. Other potent 
inhibitors of the p53/hDM2 PPI have been tested against Noxa B/Mcl-1 and 
generally displayed lower affinities for the second PPI, but none was as selective 
as 89.  
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Figure 3.16 Assessment of the selectivity of the N-alkylated oligobenzamide 
scaffold (in red: against p53/hDM2, in black: against Noxa B/Mcl-1). a. Compound 
89. b. Compound 105. c. Compound 98. d. Compound 47. e. Compound 72. 
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From the subset of compounds tested on both targets, four of the most potent 
ones (72, 89, 98, 105) presented IC50s below 3 µM against p53/hDM2. Two of 
them included two aromatic side chains matching Phe19 and Trp23 from. The 
other two compounds were initially designed to target the Bcl-2 family but 
included a naphthyl ring at the R2 position (98 and 105). This confirmed that the 
presence of a substituted aromatic ring at the R2 position was a prerequisite for 
activity, and that the presence of a fourth aliphatic side chain in the sequence 
might lead to enhanced activities. 
 It is worth noting that the most potent inhibitor of Noxa B/Mcl-1 was the 
one that presented four side chains, three of which were aliphatic (105, IC50 = 
4.88 ± 0.5 µM). This suggested that the scaffold designed was suitable for mimicry 
of BH3-only peptides. Compounds 47, 72 and 89 which presented two aromatic 
substituents out of a total of three side chains, were slightly less active against 
Noxa B/Mcl-1 (IC50s ranging from 9 to 13 µM), suggesting that for this scaffold, 
the mimicry of four side chains enhanced the binding affinity for Mcl-1. 
Compound 102, which possessed a side chain arrangement matching that of the 
native Noxa B helix was inactive against Noxa B/Mcl-1, and displayed poor 
activity against the p53/hDM2 PPI (IC50 of 245 ± 49.3 µM against Noxa B/Mcl-1 
and 28.1 ± 0.33 µM against p53/hDM2, cf. Appendix III). No specific Mcl-1 binder 
has been identified yet.  
 
The selectivity of the oligobenzamide scaffold was also assessed against the 
p53/hDMX interaction. As mentioned earlier in this Chapter, Dr. A. Bartlett and S. 
Hussain from the Edwards group had successfully expressed a GST-hDMX 
protein, and have tested the most potent inhibitor of the p53/hDM2 that had 
been identified at that time (compound 47, IC50 = 7.12 ± 0.27 µM). The 
corresponding dose-response curve (Fig. 3.17) provided an IC50 value of 18.81 ± 
0.96 µM against p53/hDMX.  
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Figure 3.17 Preliminary testing against the p53/hDMX PPI. Compound 47, one of the 
most potent p53/hDM2 inhibitors (IC50 7.12 ± 0.27 µM) identified in this study displayed 
an IC50 of 18.81 ± 0.96 µM against p53/hDMX. 
 
 
Although this IC50 was higher than that against p53/hDM2, it illustrated that 47 
was a non-specific inhibitor of all three targeted PPIs (p53/hDM2: 7.12 µM, 
p53/hDMX 18.8 µM, Noxa B/Mcl-1: 9.2 µM). The higher IC50 against p53/hDMX 
could be explained by the shallower binding cleft in hDMX (Nutlin-3a which 
displays a low nanomolar IC50 against p53/hDM2 is inactive against p53/hDMX).7 
It is probable that screening of the whole library against this PPI would provide 
some more efficient and specific inhibitors, especially those which possess a 
smaller aromatic ring at R2. The GST-hDMX fusion protein was however found to 
be highly unstable, so 47 was the only compound that could be tested against this 
PPI. Current efforts are dedicated to the isolation of a more stable construct that 
would allow further investigation of this PPI.  
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3.4 Proteolytic studies 
 
One of the oligobenzamides (99) was selected as a representative member of the 
library to undergo proteolytic studies against a range of proteases. The 
experiment was carried out by Dr. P. Prabhakaran. As expected, the 
oligobenzamide displayed resistance to all tested proteases, and when tested 
against the non-selective proteinase K, only the C-terminal α-amino acid was 
cleaved. This demonstrates the enhanced resistance of aromatic amide bonds 
towards proteolysis, a highly desirable feature for testing in a biological context. 
The results are summarized in Figure 3.18. 
 
 
 
Figure 3.18 Proteolytic study on compound 99. a. Structure of the compound and 
table summarizing the result from proteolytic studies against 5 proteases; a measured in 
buffer and in a mixture of buffer and DMSO, b tested in a mixture of buffer and DMSO 
(29%), c only the C-terminal α-residue was cleaved by proteinase K (data not included), 
none of the aromatic amide bonds were cleaved. b. Analytical HPLC traces of 99 (black), 
after treating with α-chymotrypsin (pink) and Trypsin (blue) for 15 minutes at r. t. c. 
Analytical HPLC traces of Bak (black), and after treating with α-chymotrypsin (blue) for 
15 minutes at r. t.  
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3.5 Cell assays 
 
A limited number of whole cell experiments were carried out on a selection of 40 
oligobenzamides. The compounds were tested by Dr. H. Martin and in 
collaboration with Dr. D. C. Tomlinson (Leeds Institute of Molecular Medicine and 
Astbury Centre, University of Leeds) using immunofluorescence techniques on 
the U2OS cell line, which is a human osteosarcoma cell line expressing WT p53. 
These cells were thus suitable to assess whether the inhibitors were able to 
restore p53 function in cells, as this could result in the activation of the p53 
pathway and in turn trigger cell death by apoptosis.21, 26, 178 U2OS cells were 
exposed to 2 doses of each compound (5 and 10 µM), and the response was 
monitored at two time points (24 h and 48 h). Parameters observed included the 
number of cells, the percentage of abnormal cells (looking at alteration in the cell 
and nucleus size and brightness, DAPI was used to stain the nuclei) and the 
percentage of histone H3 positive cells (looking at mitotic arrest or delay). Cross-
analysis of the results allowed some preliminary observations. Three compounds 
that showed decreased H3 staining and increased cell size were likely to induce 
cell cycle arrest/delay in the G1 phase (44, 55, 96). Compounds that displayed 
increased H3 staining were likely to induce cell cycle arrest/delay in the M phase 
(37). Results from this preliminary screening did not allow a definite conclusion 
as to whether the compounds were actually penetrating the cells, as they only 
seemed to display an effect at the highest dose and exposure time (10 µM, 48 h). 
This may suggest that the compounds display a general cytotoxicity, and this 
possibility will need to be investigated in future experiments (such as MTT 
assays). Different compounds have however been found to generate different 
effects on the cell cycle arrest, number of cells, size and shape of cells and nuclei, 
which suggested that these might be able to penetrate the cell. Fluorescence 
microscopy images of cells exposed to 42 and 97 showed a difference in cells 
shapes and density and suggested that they might be inducing apoptosis (Fig. 
3.19), although the evidence is not clear-cut and will need further confirmation. 
From the set of 40 compounds tested in the cell assay, only 17 were identified as 
‘hits’ in the single point FA screen, and conversely, not all the ‘hits’ have been 
tested in cells so definite conclusions cannot be drawn at that stage.  
Chapter 3: Assembly and screening of a library of proteomimetics 
 
81 
 
 
 
Figure 3.19 Fluorescence microscopy images showing limited evidence of 
apoptosis.  a. Compound 97. b. Negative control = 1% DMSO. c. Compound 42, seemed 
to cause nuclei condensation and disruption of the cytosolic staining. d. Positive control 
= 0.1 µM Taxol. 
 
 
Compounds that seemed potentially active in these cell assays which had not 
been identified as hits in the preliminary single point screen were tested in a 
dose-response assay against p53/hDM2 (Fig. 3.20). Out of these 6 compounds, 
five presented IC50 values between 8.9 and 15.65 µM (37, 42, 44, 55, and 97) and 
one was inactive (96, cf. Fig. 3.20 for IC50s). Although these results do not 
demonstrate that these compounds can actually penetrate cells to trigger 
apoptosis, they show that the compounds are relatively potent inhibitors of 
p53/hDM2. This suggests that if they do penetrate cells, then it is plausible that 
they will exert their inhibitory role. Compound 96, which displayed some 
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evidence of cellular activity but was inactive in the FA competition assay, might 
have been identified as a false positive in the cell assay. 
 
 
 
 
Figure 3.20 Dose-response curves on compounds that appeared to be potentially 
active in cell assays. Compounds 44, 55, 96 were likely to induce cell-cycle arrest/delay 
in the G1 phase; compound 37 was likely to induce cell-cycle arrest/delay in the M 
phase; compounds 42 and 97 displayed limited evidence of apoptosis in the high content 
screening. 
 
 
As these preliminary observations were encouraging, further experiments will be 
carried out in the near future in order to investigate more deeply the cellular 
activity of the entire library of oligobenzamides. Additional cytotoxicity assays 
will also be carried out by collaborators. Recent studies in U2OS cells have 
revealed that Nutlin-3a was inducing cytoskeletal rearrangement, decreasing the 
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formation of lamellipodia (cytoskeletal actin extension of the cell that is crucial 
for motility) and consequently decreasing cell migration and invasion, in addition 
to holding the cell cycle in the G1 phase.179 Results from initial cell studies on 
Nutlin-3a conducted by Vassilev and co-workers could not be used as a reference 
for this study as they were using different cell lines (SJSA, HCT116 and RKO).7 
Disrupting the p53/hDM2 PPI would also include other phenotypes including p53 
stabilization, upregulation of downstream proteins including Bax, but these 
would not be observable with the set of techniques available for this study. 
Inhibitors of the Bcl-2 family of interactions (ABT-737,77 binding to Bcl-2 and Bcl-
xL and Obatoclax,62 binding to Mcl-1) both seemed to induce formation of 
autophagosomes as well as inducing apoptosis via caspase-3 activation in the 
U2OS cell line.180, 181 In future experiments, each compound will therefore be 
monitored for: autophagy status (using anti-LC3 antibody),180, 181 caspase-3 
activation, changes to the cytoskeleton and overall cytotoxicity. 
   
3.6 Discussion 
 
Protein-protein interactions have become highly desirable targets for therapy, 
however classically used approaches to modulate PPIs have only met with limited 
success. It seems that appropriate tools to modulate these unconventional 
interactions are still to be developed. As a vast proportion of PPIs are mediated 
by an α-helix, which is a very well characterized protein secondary structure; this 
type of interactions represent a common starting point for study. The present 
study aimed at disrupting α-helix mediated PPIs by using an oligobenzamide 
scaffold as a mimetic of the helical core. Using such a scaffold to display side 
chains in an arrangement that replicates that of the native helix is an attractive 
approach as it opens the perspective of versatility: using a single scaffold to target 
several PPIs. Two PPIs served as a model for studying the target 
selectivity/specificity of the N-alkylated oligoamide scaffold: p53/hDM2 and 
Noxa B/Mcl-1. In an attempt to establish design rules for a generic approach to α-
helix mediated PPI disruption, two libraries of oligobenzamides were assembled.  
The first library was made of 60 trimers and targeted to the p53/hDM2 
interaction; it therefore contained combinations of aromatic and aliphatic side 
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chains. Unnatural substituents such as halogenated aromatic rings have been 
incorporated in an attempt to enhance the potency and selectivity of these 
compounds towards the targeted PPI. The second sub-library was designed to 
disrupt the Bcl-2 family of interactions by mimicking the BH3 domains involved 
in the binding and therefore contained mostly aliphatic side chains. The 
interaction of BH3 proteins with their binding partners however involves four 
key side chains. For this 16-member library, the SPS methodology was therefore 
transposed to a Wang resin pre-loaded with an α-residue corresponding to the 
fourth hot-spot residue of the native helix instead of glycine. Both libraries were 
tested in a fluorescence anisotropy assay against model PPIs, first in a single 
point screen in order to identify the most active compounds, and then these hits 
were tested in a full competition assay to determine IC50s. The manual screening 
against p53/hDM2 reliably lead to hit identification and whilst testing subsets of 
compounds, several low-micromolar inhibitors have been identified and used to 
establish basic SARs. These SARs confirmed that bulky aromatics at the R2 
position were a prerequisite for activity. This was illustrated by the low 
micromolar IC50s measured for compounds that were initially designed to target 
the Bcl-2 family such as 98 and 105, which only display one aromatic ring, and 
present an aliphatic chain in place of the key Phe19 residue of p53. The most 
potent inhibitor of p53/hDM2 identified was compound 89, a trimer containing a 
Boc-protected 5-bromoindolyl side chain at R2 (IC50 = 0.67 ± 0.06 µM). The 
biological relevance of compound 89 however needs to be questioned, as the Boc 
group may be cleaved under biological conditions. Ideally, the corresponding 
unprotected compound should also be tested, but this was precluded by the 
technical limitations discussed previously, which meant that the Boc group could 
not be removed without resulting in the elimination of the indole ring. 53, which 
was the only indole-containing compound for which some Boc-deprotected 
product could be isolated, displayed an IC50 value of 9.06 ± 0.20 µM. Compounds 
89 and 53 can however not be directly compared, as their R1 substituent were 
different (phenethyl and benzyl, respectively) and they were tested on separate 
occasions.  
It appeared that the amount of reagents used as well as the handling time 
could be reduced by adapting the assay to an automated methodology. This was 
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also likely to enhance the accuracy and comparability of the results, and could 
potentially allow the establishment of a relative ranking of the compounds. The 
whole library was thus subjected to an automated single point screen where all 
the compounds could be tested at once. Transposing the assay to an automated 
method however proved more challenging than initially expected, and no 
reproducible conditions have been found yet. Screening against the Mcl-1/Noxa B 
PPI using the automated assay proved more fruitful, and allowed the 
identification of 5 hits. When tested in a full competition assay, four of them 
presented IC50s in the low micromolar range (<10 µM). Within the whole library, 
a few dual inhibitors have been identified (47, 72), along with specific p53/hDM2 
inhibitors such as 89, however no specific Mcl-1 binder has been identified yet. 
Interestingly, compounds 102 – 104 which had side chains specifically designed 
to mimic those of Noxa B were among the least active compounds of the library. 
This might be due to the proteomimetic not being able to display the acidic side 
chain the same way as the native Noxa B helix.  A longer linker might be needed 
for the acidic side chain to reach into the binding pocket in Mcl-1 and make the 
required interactions with neighbouring residues. This illustrates that despite the 
structural data available to help the design of inhibitors, further research efforts 
are required in order to gain a better understanding of how PPIs can be 
interfered with. 
 
 
3.7 Summary and conclusions 
 
In summary, a library of 75 compounds (divided into two sub-libraries) has been 
assembled using the newly developed microwave assisted SPS methodology144 
reported in Chapter 2, which further illustrates its robustness and efficiency. 
Testing this library against two PPIs (p53/hDM2 and Noxa B/Mcl-1) using a 
fluorescence anisotropy assay led to the identification of inhibitors with IC50s in 
the low micromolar range, whether specific (89), or dual inhibitors (105, 47, 72 
and 98). Although N-alkylated oligobenzamide inhibitors did not display 
unprecedented potencies against the model interactions, low micromolar 
inhibition was attained, and this study demonstrated that target selectivity could 
be achieved. Given its synthetic accessibility, this scaffold is suitable for further 
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studies, including the assembly of a larger library targeting the Bcl-2 family, with 
a view to identify some specific Mcl-1 or Bcl-xL binders. In addition, the 
proteolytic stability of these aromatic oligoamides was confirmed against a panel 
of enzymes - proteinase K seemed to be able to cleave the terminal α-amino acid 
off, but left the aromatic amides untouched. Preliminary cell assays on half of the 
library of oligobenzamides provided encouraging results, suggesting that some of 
the compounds might be able to penetrate the cells and trigger apoptosis. Further 
cellular investigation on the entire library will be carried out in order to gain a 
better insight into their cellular behaviour. 
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Solid phase synthesis  
and biological evaluation  
of oligoureas as α-helix mimetics  
 
The work described in this chapter relates to a short term scientific mission 
(STSM) that results from a collaboration between the Wilson group (University of 
Leeds) and the Guichard group (Institut Européen de Chimie et Biologie, IECB, 
Université de Bordeaux, France). The synthetic work was carried out over 2 
months at the IECB, whilst the biological evaluation of the compounds was done 
in Leeds. This STSM was funded by COST (Europeen Cooperation in Science and 
Technology). 
 
 
Over the last decade, inhibition of protein-protein interactions (PPIs) has become 
a distinct field of research and α-helix mimicry represents an intensely explored 
route towards this goal. In order to circumvent natural peptides’ intrinsic 
susceptibility to proteolytic degradation, new peptide backbone mimetics were 
sought.182-184 As mentioned in Chapter 1, a variety of strategies have been 
reported to stabilize helical structures in α-peptides, and a number of non-
natural foldamers have also been shown to act as α-helix mimetics. In this 
context, oligoureas have received increasing attention as they are inherently 
resistant to proteolysis185 and are structurally very similar to γ-peptides. Several 
solid phase syntheses (SPS) have been reported after K. Burgess’ initial 
methodology using phthaloyl-isocyanates as activated building blocks in 1995.186, 
187  The following year, Schultz published an alternative method using an azide to 
mask the N-terminal amine and a nitrophenyl carbamate as the activating 
group.188 Liskamp and co-workers have then transposed this methodology to the 
Fmoc system.189 The Guichard group has been developing an SPS methodology 
using succinimidyl carbamates as the activating moiety. These carbamates 
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combine excellent stability with high reactivity and are therefore attractive 
activating groups. Their first method made use of Fmoc protection for the N-
terminal amine, and the monomer synthesis started from β3-amino acids.190 The 
synthesis was then adapted to use the more widely available α-residues as 
starting material191 (either Boc- Z- or Fmoc-protected) and finally in 2012, this 
methodology was adapted to microwave assisted SPS192 – this will be described 
in Section 2 of this Chapter. The Guichard group has also reported most of the 
structural characterisation of oligoureas to date.193-197 They have investigated the 
use of oligoureas as antibacterial agents198, 199 and foldamers,194, 197 studied their 
self assembling properties200  and exploited them as anion transporters,201 but 
their potential as α-helix mimetics and inhibitors of PPIs has not yet been studied. 
This collaborative project was thus aimed at combining the knowledge and 
expertise of the Guichard and Wilson groups to develop oligourea scaffolds and 
apply them to the disruption of the p53/hDM2 PPI.21, 22 The synthetic strategy to 
access these oligoureas was already established and made use of a recently 
published microwave assisted SPS.192 A small library of oligoureas was 
assembled at the IECB, and then tested in the same fluorescence anisotropy (FA) 
assay85, 125, 131 as the oligobenzamides, in Leeds (cf. Section 4).  
 
4.1 Oligoureas as α-helix mimetics 
 
The α-helix is the most prominent secondary structure found in proteins and is 
often found at the interface between two interacting proteins. Manipulating these 
α-helix mediated interactions by replicating the helical structure has thus been a 
major concern in modern chemical biology. Several approaches to generate stable 
helical conformations have emerged, using different building blocks and 
stabilizing strategies (cf. Chapter 1, section 1.2). Certain building blocks are the 
primary focus of investigation; these include natural or engineered α-amino 
acids, longer homologues such as β- and γ-amino acids, cyclic aliphatic and 
aromatic residues.84, 99, 157, 202, 203 The use of non-natural residues is also expected 
to provide the resulting oligomer with additional proteolytic stability, which is 
one of the main limitations of natural peptides. Among linear amino acids, the 2-
azido-2-substituted ethyl carbamate monomers described in this Chapter are 
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closer to γ-amino acids as they result from the formal replacement of the α-
carbon in the γ-residue by a nitrogen atom to generate the urea function. This 
additional nitrogen atom provides oligoureas with enhanced helix stability due to 
a greater backbone conformational restriction and additional intramolecular 
hydrogen bonds (Fig. 4.1a).  
 
 
 
Figure 4.1 Oligourea scaffold as a helix mimetic. a. The bifurcated H-bond pattern in 
N,N’-linked oligoureas. b. The H-bond pattern in γ-peptides. c. The dense network of 
bifurcated H-bonds in the oligourea stabilizes the helical conformation (side chains 
atoms are omitted for clarity). d. View of the oligourea backbone along the helical axis, 
side chains are represented by purple balls. e. Using the oligourea backbone as a helix 
mimetic to disrupt the p53/hDM2 PPI.   
 
Oligoureas were first described as peptide backbone mimics in 1995 by K. 
Burgess and co-workers.186, 187 Oligomers made of more than five residues have 
previously been shown by the Guichard group to adopt a 2.5 helical conformation 
that is reminiscent of the 2.6 helical structure found in γ4-peptides.193, 194 The 
urea linkage is particularly interesting as it shares some structural features with 
amide bonds: rigidity, planarity, polarity and H-bonding ability. The oligourea 
backbone also allows the projection of side chains along a single helical face, as 
illustrated in Figure 4.1d. Their use as peptidomimetics therefore is the focus of 
significant interest. 
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4.1.1 Design and preliminary modelling studies 
 
The ability of oligoureas to mimic α-helices was to be tested against the model 
p53/hDM2 interaction. Different substitution patterns of the oligoureas were 
investigated in order to obtain the best possible match between the projections of 
the key side chains in both scaffolds. Preliminary modelling studies using Maestro 
9.0.7 were conducted in order to determine which positions of the oligoureas 
should be considered as anchoring residues for the side chains designed to mimic 
the hot-spot residues in p53. In this study, crystal structures of oligoureas 108 -
110 have been superimposed onto the crystal structure of the native p53 peptide 
(Fig. 4.2). RMSD (Root Mean Square Deviation) values have been calculated to 
estimate the geometrical match between the positions of the α-carbons of the 
hot-spot residues in p53 and backbone atoms from the oligourea (highlighted in 
yellow in Fig. 4.2), arranged into different substitution patterns. The oligourea 
scaffold that provided the lowest RMSD value should theoretically have been the 
most appropriate to mimic the p53 helix. The modelling studies presented in this 
Chapter have been performed by V. Azzarito in Leeds, using crystal structures 
previously elucidated by the Guichard group.195 Three different oligourea crystal 
structures have been modelled against the p53 helix (Fig. 4.2a) and the results 
are summarized in Figure 4.2b-j. The crystal structure examined in Figure 4.2b-d 
was that of an octamer capped at the N-terminus (108) with key side chains at 
positions 2, 5 and 8. When overlayed onto the p53 helix, this scaffold presented 
an attractive RMSD of 0.7968, however this was a relatively long sequence, and 
assembling a library of octamers would have been both material and time 
consuming. The next scaffold (Fig. 4.2e-g) envisaged was a tetramer and also 
provided an interesting RMSD value. In this case, residues 1, 2 and the capping 
element on residue 4 were considered for key lateral chain appendage. 
Substitution at the C-terminal oligourea amine could however only be attained by 
solution phase synthesis, as the SPS methodology used in this project resulted in 
unsubstituted ureas at the C-terminus. This scaffold, which would have required a 
relatively lengthy and time consuming synthesis in solution phase was thus left 
aside. 
Chapter 4: SPS and biological evaluation of oligoureas as α-helix mimetics 
 
91 
 
 
 
Figure 4.2 Preliminary modelling studies. Atoms from the oligourea backbone 
considered for RMSD calculation are highlighted in yellow. a. Crystal structure of the 
native p53 helix (residues 15-31). b.e.h. Crystal structures of oligoureas 108, 109 and 
110 elucidated by the Guichard group. c.f.i. Corresponding linear structures. d.g.j. 
Overlay of crystal structures b.e.h. with that of p53, with calculated RMSD values.  
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Hexamer 110 (Fig. 4.2h-j) with anchoring points at residues 2, 4 and capped 6 
presented the best RMSD value (0.4623) among the different substitution 
patterns investigated and was therefore chosen as a starting point for the 
synthesis of a small library of oligourea helix mimetics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
4.2  Synthesis 
 
A small library of oligoureas has been assembled using a methodology recently 
reported by the Guichard group.192 In this method, activated monomers are 
coupled on a solid support under microwave heating. For each monomer, the 
terminal amide group is activated for nucleophilic substitution as a succinimidyl 
carbamate, whereas the terminal primary amine was masked as an azide group 
(Fig. 4.3). Because the azide reduction proved to be more efficient under 
Staudinger conditions,192 the solid support used in this synthesis needed to be 
compatible with aqueous conditions – the resin should possess adequate swelling 
properties in water, a NovaPEG Rink amide resin was therefore chosen.  
 
4.2.1 Building blocks synthesis 
 
 
Figure 4.3 Monomers used for the synthesis of oligoureas. a. Monomers previously 
made available 111 - 115. b. Monomers bearing unnatural side chains synthesised 
during the STSM, 116 - 118. 
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Due to the time constraints imposed on this STSM and to ensure the best use of 
this time in order to assemble the target library of oligoureas, a few building 
blocks (111 – 115, Fig. 4.3a) had previously been synthesised by Dr. K. Pulka 
(Guichard group), so that the solid phase assembly of oligomers could start 
straight away. Three additional building blocks were also prepared as part of the 
project. Unnatural side chains (116 – 118, Fig. 4.3b) were chosen in order to 
introduce some more diversified mimics of p53’s hot-spot residues. The synthetic 
route to these monomers was recently reported192 and is described in Scheme 
4.1. 
 
 
 
Scheme 4.1 Synthetic route to azido-carbamate building blocks.  
 
 
The synthesis started from commercially available α-amino acids and led to the 
activated azido-succinimidyl carbamates 116 - 118 in 6 steps. Firstly, the 
carboxylic acid was reduced to the corresponding alcohol 120 via formation of an 
asymmetric anhydride using isobutyl chloroformate (IBCF). The amine was then 
deprotected then converted to the azide 122 using N3SO2Im.HCl204– this azide 
transfer agent had to be prepared beforehand. The alcohol was then converted to 
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a phthalimide 123 under Mitsunobu conditions187 and subsequently reduced to 
the primary amine 124. Nucleophilic attack of the primary amine onto 
disuccinimidyl carbamate eventually led to the activated monomers 116 - 118. 
Three new blocks were successfully prepared with varying overall yields: 34% 
for the Serine analogue, 12% for the cyclohexylalanine block and 18% for the 
dichlorophenylalanine block. Throughout the rest of the Chapter, these 
succinimidyl (2-azido-2-substituted ethyl) carbamate monomers (or the 
corresponding moiety within an oligourea sequence)  will be referred to as the 
name of the natural amino acid they were designed to mimic, preceded by a ‘U’, 
hence the serine analogue 116 will be referred to as USer, etc. 
 
4.2.2 Solid phase synthesis of oligoureas 
 
In order to mimic the native p53 helix and potentially achieve competitive 
binding with the target protein hDM2, several oligourea scaffolds were designed, 
resulting from different arrangements of the hot-spot residues. For each 
substitution pattern on pure oligourea backbones, two examples have been 
synthesised in order to study the effect of the overall macrodipole of the 
oligourea on its stability and binding efficiency. One of the derivatives is capped 
at the N-terminus, whilst the other one has its N-terminus being left as a free 
amine (Fig. 4.4a,b). The macrodipole effect was also studied through a 
substitution pattern where the Trp mimic was introduced at position 4 instead of 
3 (Fig. 4.4c), which could potentially induce the mimetic to bind in the opposite 
orientation within the hDM2 binding cleft. Some hybrid scaffolds with α- or γ-
amino acids attached to one or both termini have also been envisaged (Fig. 4.4d-
f), as they can introduce more flexibility that might lead to a better fit of the 
inhibitor into the targeted binding cleft. The oligourea indeed gives rise to a 
compact cylindrical core, maintained by a dense hydrogen bonding network that 
might benefit from some additional flexibility. For hybrid scaffolds made of 
oligoureas bearing an α-amino acid at the N-terminus, no capping was performed 
and the oligomer was left with a free terminal amine. A series of 11 oligoureas 
(125 - 135) was prepared using the previously reported methodology, using a 
CEM Discovery microwave reactor. 
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Figure 4.4 Oligourea and hybrid scaffolds designed for the mimicry of the p53 
helix. a. Pure oligourea scaffold with i, i + 2 and i + 5 substitution pattern and capped N-
terminus. b. Same oligourea with free N-terminus. c. Pure oligourea scaffold with i, i + 3 
and i + 5 substitution pattern. d. Mixed oligourea-amide scaffold with an α-amino acid at 
the i + 5 position. e. Same hybrid scaffold with two additional α-residues at the 
C-terminus, one of them mimicking the i position. f. Hybrid oligourea scaffold with a γ-
residue mimicking the i position. 
 
 
Crude yields were relatively low (25-60%) and after cleavage, the crude 
oligomers were subjected to purification by HPLC (preparative or semi-
preparative). These purifications were usually relatively low yielding (~ 10%) 
and in some cases the amount of pure material collected (less than 1 mg) did not 
allow characterisation and preliminary binding assays to be carried out. It was 
then decided to double the amount of resin used in SPS. Two possible 
explanations arise for these low yields: the loading of the first azido-carbamate 
onto the resin was incomplete, or the reduction of the azide into the primary 
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amine under Staudinger conditions was not complete. Incomplete loading would 
not be detectable on the HPLC chromatogram but would result in a low crude 
yield; whereas incomplete azide reduction would lead to the isolation of 
oligomers of different lengths after cleavage from the resin, which would show on 
the HPLC chromatogram. These low yields could also be due to a combination of 
both factors, although completion of each step (coupling and reduction) was 
checked using a chloranil test. Crude HPLC chromatograms indicated that in most 
cases the SPS was clean, although in some instances the product was 
contaminated with shorter oligomers. In order to push the loading of the first 
residue to completion, a double coupling of 30 minutes with 2 equivalents of 
monomer to the resin was carried out, and for the next residues a double 
coupling of 15 minutes using 1.5 equivalent of monomer was maintained. An 
alternative to the Staudinger azide reduction reported in the literature was also 
investigated, using TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) as the 
reducing agent. This reagent was reported to achieve complete reduction of an 
azide group at room temperature after 2 hours and offered the additional 
advantage to be solid and thus less susceptible to oxidation, which was the case 
for the trimethylphosphine. It appeared however, that reduction of these azides 
on solid support using TCEP under standard microwave conditions was 
unsuccessful, so reduction of the azides using trimethylphosphine was resumed. 
By using a new batch of this reducing agent, the yield and purity of the synthesis 
were in general improved. 
 Straight after purification, oligourea 125 was sent to Leeds for testing, as 
the resulting data would guide the design of the next examples to be synthesized. 
This first compound was tested by Dr. A. Bartlett (Wilson/Edwards group) and 
the result is presented in Figure 4.6. This suggested that oligourea 125 (Fig. 4.6a) 
was indeed binding to hDM2, although the compound presented limited solubility 
in the assay conditions. It was then reasoned that in the next examples, the non-
interacting phenylalanine mimic at position 5 would be replaced by a solubilising 
residue such as Orn or Ser. Table 4.1 summarizes the sequences of oligoureas 
that were synthesized, as well as the crude and isolated yields.  
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Table 4.1 The library of oligoureas. Oligourea residues are preceded by a U, natural 
residues are preceded by α, hot-spot residues mimicking those of p53 are in green, the 
capping elements are indicated in purple. 
 
 * Yield of isolated material after preparative (or semi-preparative) HPLC purification; 
oligoureas 129-135 were purified by Dr. Casassus (Guichard group). 
 
 
As mentioned previously in this section, the relatively low crude yields obtained 
for the first few oligoureas prompted for the SPS to be scaled up, so the 
consumption of monomer was higher than initially planned. The synthesis of this 
library used up all of the Leu and Trp monomers, and as it was envisaged that the 
collaboration would continue after this STSM, it was decided that new batches of 
these monomers would be synthesized during the last weeks of the mission in 
Bordeaux, while Dr. Casassus (Guichard group) would purify the last 7 oligoureas 
(129 - 135) and send them to Leeds for testing. 
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Because some of the monomers had been entirely used, the variant where the key 
Phe residue is introduced as the capping element on residue 6 and the hybrid 
scaffold containing a C-terminal γ-residue could not be investigated. These two 
scaffolds constitute important directions for future investigation on this project. 
 
 
4.3 Biophysical evaluation 
 
The small library of oligoureas was assessed using the previously reported FA 
assay used to assess N-alkylated oligobenzamides,85, 125, 131 cf. Chapter 3. The 
change in fluorescence anisotropy is measured upon displacement of the probe 
by the oligourea (Fig. 4.5). The protein used in this assay (His-hDM217-126) has 
been expressed in-house at the Astbury Centre as part of this research project (cf. 
Experimental section). 
 
 
 
Figure 4.5 Cartoon representation of the fluorescence anisotropy (FA) assay. 
Firstly, the tracer is titrated with the target protein and fluorescence anisotropy 
increases upon binding to this much larger entity. The oligourea is then added and 
competitively binds to the target protein: the fluorescence anisotropy decreases as the 
tracer becomes free to tumble in solution again. 
 
Previous experience with FA assays on oligobenzamides has revealed that 
undesired interactions of the p53 tracer with itself as well as with the 
oligobenzamides were precluding determination of a Kd value. The existence of a 
potential interaction of the oligoureas with the tracer was thus investigated. The 
results are reported in the Appendix IV. From this experiment, no evidence of 
interaction between the oligourea and the tracer could be observed. 
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4.3.1 Competition assay on the original oligourea 
 
The first oligoureas were tested under the same conditions as the 
oligobenzamides: a fluorescence anisotropy competition assay where the 
concentration of oligourea is serially diluted from 100 µM down to 9 nM in 
triplicate.  
 
 
 
Figure 4.6 Results from the FA competition assay on the first synthesized 
oligourea. a. Structure of the first synthesized oligourea 125. b. Intensities for all three 
replicates are plotted against the concentration of 125. c. Average anisotropy versus 
concentration in oligourea. 
 
 
The competition assay on compound 125 suggested that it was binding to hDM2 
in the micromolar range, although the binding curve (Fig. 4.6c) did not clearly 
present the characteristic sigmoidal shape that is expected for ligands that are 
potent inhibitors of the targeted interaction. From this set of data, it was however 
not possible to quantify the binding, as the anisotropy did not present the 
expected lower plateau that is usually reached at high concentrations of inhibitor. 
The fact that this curve did not present a clear sigmoidal shape also prevented 
extraction of an IC50 value. While testing this first oligourea it was noted that the 
compound presented a limited solubility in the conditions of the assay. The next 
oligomers were therefore designed with additional solubilising side chains.  
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4.3.2 Competition assays – an attempt to automation 
 
Due to the lack of apparent reproducibility of the manual assay on the first few 
compounds, it was decided that the library would be tested using an automated 
method. Assays on the Hamilton Microlab Star robot made use of 384-well plates, 
thus reducing the amount of reagents used, in addition to being automated. 
Anisotropy plots for five oligoureas tested both on the robot and manually are 
reported in Figure 4.7. Results from assays conducted on the robot were however 
not faultless, as the overall intensity across the plate was not constant as it should 
be but rather presenting the same distinctive pattern (Fig. 4.7a). This defect also 
affected the anisotropy, masking the plateau that should be observed at the 
lowest concentrations in oligourea. This was attributed to sticking of the 
compounds to the pipette tips that are used on the robot (different tips were used 
in the manual assay). Optimizing this automated method would require the usage 
of a large amount of tips, as well as making the method much longer, which was 
not deemed as a good compromise. Figure 4.7 indicates that with the exception of 
compound 128, better results can be obtained when the assay is carried out 
manually.  
 Whilst acceptable results had previously been obtained with the 
oligobenzamide series of compounds on the robot; it appeared more challenging 
to acquire exploitable data on the oligourea series. The oligoureas were thus re-
tested manually, and eventually presented binding curves with more usual 
shapes; these results are presented thereafter. With the exception of 125, all the 
oligoureas were soluble in the conditions required for the FA assay. It is worth 
noting that within the range of inhibitor concentration studied (100 µM – 9 nM), 
in most cases the tracer was not fully displaced from its complex with hDM2. This 
is translated on the binding curves presented in Figure 4.7 by the absence of a 
lower plateau for the anisotropy.  
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Figure 4.7 Comparing results from FA assays conducted on the robot to assays 
carried out manually. Anisotropy plots for compounds tested in both methods are 
overlayed. a. Distinctive intensity plot typically obtained on the robot, here with 
compound 127. b. Oligourea 126. c. Oligourea 128. d. Oligourea 129. e. Oligourea 131. f. 
Oligourea 135. 
 
 
It was thought that the first few compounds tested had a low binding affinity for 
the target protein, but screening of the whole library revealed that none of the 
oligoureas presented a complete binding curve (cf. Section 3.2). For the purposes 
of this study, binding curves were fit in Origin 8.6 using a fixed minimum, which 
corresponded to the lower plateau of anisotropy reached in the displacement 
assay using the unlabelled p53 peptide. If the oligoureas had been able to fully 
displace the tracer from the interaction, then the anisotropy should indeed have 
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returned to this value. Using this fitting parameter allowed the determination of 
apparent IC50 values that were then used as a tool to establish a preliminary 
comparison of the compounds. For the best inhibitors identified, efforts will then 
be devoted to the obtention of a full binding curve, in order to determine IC50 
values. 
 
4.3.2 Establishment of Structure-Activity Relationships 
 
Derivatives 126 and 127 were then prepared, with the Phe → Orn replacement at 
position 5. An improvement in solubility was noted with these compounds and 
results from FA assays are reported in Figure 4.8. This substitution pattern Phe-
Orn-Ala-Trp-Orn-Leu then became the standard pattern and the next oligoureas 
were designed to study the effect of modifications to this standard on the binding 
affinity. 
 
 
 
Figure 4.8 Results from the FA competition assay on oligoureas containing an 
additional solubilizing Orn residue. a. Structure of the oligoureas: 126 was capped at 
the N-terminus with isopropyl isocyanate (purple) and 127 was left as a free amine. b, c. 
Intensity and average anisotropy of compound 126, the experiment was carried out on 
the Hamilton robot. d, e. Intensity and average anisotropy of compound 127, the 
experiment was carried out manually. 
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Compound 126 was tested on the robot, and the corresponding intensity curves 
present the usual shape, whereas the intensities for compound 127 tested 
manually displayed a flat intensity profile. Fitting in Origin 8.6 using a fixed lower 
plateau suggested that both compounds were poor inhibitors, although the 
capped analogue 126 seemed to be relatively more potent (apparent IC50 of 124.8 
± 10.9 µM against 223.9 ± 81.9 for 127).  
The next compounds synthesised aimed at studying the effect of the 
macrodipole on the binding affinity. The Phe5 → Orn replacement was 
maintained, but Trp3 was swapped with Ala4, meaning that the key residues 
were in positions i, i + 3 and i + 5 of the oligourea backbone. Results from the FA 
assay on the free amine analogue are reported in Figure 4.9. 
 
 
 
Figure 4.9 Effect of the macrodipole orientation on binding: the i, i + 3 and i + 5 
substitution pattern. a. Structure of the oligoureas: 128. b. Comparison to the analogue 
oligourea with the ‘standard’ i, i + 2 and i + 5 pattern. 
 
 
The comparison of binding curves for compound 128 and 127 showed that 
placing the Trp at position 3 rather than 2 makes no difference in terms of 
inhibition (cf. Fig. 4.9) and 128 was equally inactive. This might be explained by 
the fact that reversing the oligourea macrodipole did not affect the binding, or 
that the oligourea might still bind in the same orientation, due to induced-fit of 
the protein around the Trp side chain. 
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 Next was the replacement of the key UPhe residue at position 6 by its 
natural α-amino acid analogue, yielding the hybrid oligomer 129 (Fig. 4.10). The 
α-residue was introduced as an Fmoc-amino acid, and the coupling was carried 
out in presence of PyBOP as the coupling agent, under the same microwave 
conditions as for N-succinimidyl carbamates. The final Fmoc-deprotection was 
carried out manually, without microwave heating. In this case, because the 
sequence was terminated by a natural amino acid, the oligomer was just left as a 
free amine and no capped analogue was prepared. The replacement of the key 
interacting UPhe residue by its natural analogue somewhat weakens the natural 
oligourea H-bonding network, as one N-terminal bifurcated H-bond is missing. It 
was thought that this could potentially be favourable to the binding event, as 
additional flexibility was brought to the terminus, which could lead to a better fit 
of the side chain within the binding pocket on the surface of hDM2. On the other 
hand, the hybrid scaffold displays a shorter distance between the UTrp and α-Phe 
in the hybrid scaffold as compared to that between UTrp and UPhe (Fig. 4.4d and b 
respectively), which might be either beneficial or detrimental to the binding.  
 
 
Figure 4.10 Structures of hybrids oligoureas 129 and 130 (Binding curves in 
Appendix V). 
 
 
Judging from the FA results (Appendix V), the replacement of the UPhe for its 
natural analogue did not have a dramatic effect on the binding (129, apparent 
IC50 = 177.8 ± 61.4 µM against 223.8 ± 81.8 µM for the all-oligourea analogue 
127). It has been noted from the literature that several crystal structures of the 
p53 helix had an additional serine residue immediately following Leu26 at the C-
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terminus and it was thought that this residue might be beneficial for crystal 
formation. The analogue of compound 129 with an α-Leu and an additional α-Ser 
at the C-terminus was thus synthesized, resulting in hybrid oligourea 130 (Fig. 
4.10). 130 displayed an apparent IC50 of 263.4 ± 31.3 µM, which showed that 
replacing the key Leu residue by its natural counterpart and adding an extra 
amino acid at the C-terminus was somewhat detrimental to the binding. 
Compounds 127 and 130 presented similar apparent IC50s, which indicated that 
the simultaneous replacement of both terminal key residues in the initial 
designed scaffold by their α-amino acid analogues did not result in a significant 
change in the binding of the oligourea to hDM2. Hybrid scaffolds containing α-
residues were therefore not investigated further. 
The next two oligoureas prepared contained an all-oligourea backbone, to 
study the effect of the Orn5 → Ser replacement. Serine was chosen as it displayed 
a shorter chain as Orn but should still play a solubilising role. Comparison of 
binding curves for 131 and 132 (Appendix V) did not reveal a significant 
difference in binding affinity between the capped and free compounds. Changing 
Orn5 for a Ser at position 5 did not affect the binding affinity either, as shown by 
comparison of 131 with 127 (131, apparent IC50 of 224.3 ± 45.5 µM and 127 
apparent IC50 of 223.8 ± 81.8 µM Appendix V). 
 
 
 
 
 
Figure 4.11 Structures of oligoureas 131 (capped) and 132 (uncapped). 
 
Inverting the Orn and Ser residues at position 2 and 5 yielded the pair of 
oligoureas 133 and 134. The capped analogue 133 seemed to present a lower 
IC50 as the uncapped oligourea (Fig. 4.12c), suggesting that in this case the capped 
analogue was binding to the target protein with a higher affinity, although the 
large error on the IC50 value for 134 precluded a definitive conclusion. When 
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comparing this capped oligomer with 131, its analogue with inverted positions 
for Orn and Ser, it appeared that placing Ser at position 2 and Orn at position 5 
resulted in a significant increase in affinity for hDM2 (apparent IC50 of 42.9 ± 4.3 
µM for 133 and 224.3 ± 45.5 µM for 131). This might be due to a reduced steric 
hindrance with the Ser residue, or to additional H-bonding to interfacial residues 
of hDM2.  
 
 
Figure 4.12 Swapping positions of Orn and Ser. a. Structure of oligoureas 133 and 
134. b. d. Intensity plots for 133 and 134 respectively. c. Overlay of binding curves for 
compounds 133, 134 and 127. e. Overlay of binding curves for compounds 133, and 
131.  
 
 
The last oligourea synthesised saw its Ala residue replaced by a Leu, which had 
been reported to be a ‘secondary’ hot-spot residue for the binding of p53 to 
Chapter 4: SPS and biological evaluation of oligoureas as α-helix mimetics 
 
107 
 
hDM2.205, 206 Due to the low amount of monomers left, only the capped variant of 
this oligomer was prepared (Fig. 4.13).  
 
 
 
Figure 4.13 Introducing an additional key residue: the Leu22 mimic. a. Structure of 
oligourea 135 with the 4 key interacting side chains in green. b. Intensity plots for 135. 
c. Overlay of binding curves for 135 and 131. 
 
 
Comparing the data to that obtained for compound 131 (containing an UAla in 
place of the ULeu4 mimic), it appeared that the introduction of this additional Leu 
mimic was indeed beneficial to the binding (apparent IC50 value lowered by ~130 
µM, cf. Fig. 4.13). This suggested that the oligourea scaffold was suitable for the 
mimicry of two consecutive residues of an α-helix.  
 
At first, the library was tested in a manual assay using 96-well plates, then as the 
amount of some of the oligoureas was precluding further tests to be carried out, 
the assay was moved to 384-well plates. Although the 384-well plates proved to 
be more technically challenging to use, this allowed reducing by a third the 
amount of oligourea needed per assay. Table 4.2 summarizes all the results 
obtained from the library of oligoureas that was synthesized. The compounds 
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were compared pairwise in order to extract Structure-Activity Relationships 
(SAR) that will guide the design of future generations of oligourea helix mimetics. 
 
Table 4.2 Summary of the design of the library of oligoureas and Structure-Activity 
Relationships established based on FA assay results.  
 
Compounds 
compared 
  Modification Effect 
125 vs 126 UPhe5 → Orn 
Enhanced solubility 
No real improvement in activity 
126 vs 127 N-term capping Both compounds are weak inhibitors 
127 vs 128 UTrp3 ↔ UAla4 
Potential inversion of the macrodipole: 
No marked effect 
127 vs 129 UPhe6 → αPhe6 
Replacement of the key Phe by its α-analogue: 
No marked effect 
129 vs 130   ULeu1 → αLeu-Ser 
α-Residues at both termini: 
No marked effect 
131 vs 132 N-term capping No marked effect 
132 vs 127 UOrn5 → USer No marked effect 
133 vs 134 N-term capping 
The capped analogue 133 is  
significantly more active 
134 vs  127 
133 vs 126 
UOrn2 → USer Slight preference for Ser over Orn at position 2 
133 vs 131 Orn ↔ Ser 
Preference for the Ser2-Orn5 over  
the Orn2-Ser5 combination 
135 vs 131 UAla4 → ULeu 
Significant increase in affinity upon addition of 
the additional key Leu22 mimic 
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Efforts have then been focused on obtaining the entire binding curve for the two 
most potent oligoureas, compounds 133 and 135, in order to quantify their 
potency in terms of IC50. It was reasoned that lowering the concentration of 
protein should shift the IC50 towards lower values, however when the assay was 
carried out with 50 nM of protein (a third of the initial concentration), the lower 
plateau was still not reached with 100 µM inhibitor (cf. Appendix VI). Because the 
tracer was never fully displaced from the interaction even at the highest 
concentrations in oligoureas, it was not excluded that the drop in anisotropy was 
due to non specific interactions, however the observations made in this chapter 
are only preliminary, and will need further investigation to ascertain that the 
oligoureas are indeed able to compete away the tracer – even if only weakly. In 
order to support the hypothesis that the binding event was taking place, some 
structural studies were carried out and are described in the next section.  
 
4.4 Conformational investigation of oligourea 133 
Compound 133 was identified as the potentially most active compound in the 
series, but no full binding curve could be obtained, which suggests that the drop 
in anisotropy could just be due to non-specific binding of the compound at high 
concentrations. Further structural evidence was therefore sought in order to 
support the hypothesis that the oligoureas were indeed binding into the targeted 
hydrophobic cleft of hDM2. The helicity of 133 was then confirmed by circular 
dichroism (CD) and the result is reported in Figure 4.14. Oligourea 133 presented 
an ECD signature with a maximum in the positive molar ellipticity at ∼203 nm, 
indicative of the expected 2.5-helical folding in MeOH. 
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Figure 4.14 Investigating the helicity of oligourea 133 and potential binding to 
hDM2. a. CD spectrum recorded in MeOH at room temperature at a concentration of 0.2 
mM. The maximum at 203 nm is indicative of 2.5 helix formation. b. CD Temperature 
scan of 133 in MeOH for λ = 203 nm. c. Manual docking of 133 onto the crystal structure 
of hDM2 (from PDB ID: 1YCR). 
 
 
This CD pattern of 133 in MeOH was not sensitive to increase in temperature 
(Fig. 4.14b). The intensity of the maximum at 203 nm recorded between 20 and 
65 °C decreased only slowly upon temperature increase, following a linear trend 
and no melting was observed in the temperature range studied. A conformational 
search was performed on 133 and the lowest energy conformation was manually 
docked into the p53-binding cleft of hDM2 (Fig. 4.14c). This illustrated that the 
oligourea could be accommodated into this binding pocket, and all three key 
interacting residues could indeed be oriented towards the inside of the binding 
cleft without any major steric clash. Taken together, these results suggest that 
oligourea 133 indeed adopted a 2.5-helical conformation required to obtain the 
alignment of key side chains along one helical face. The manual docking 
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experiment also showed that the oligourea should in theory be able to bind into 
the targeted cleft on hDM2. 
 
4.5  Target selectivity 
 
The library of oligoureas has also been screened in a single point assay against 
the Mcl-1/Noxa B interaction,177, 207 in order to study their selectivity. Results 
from this single point screening are reported in Figure 4.15.  
 
 
 
Figure 4.15 Investigating the target selectivity of the library of oligoureas: single 
point screening against the Mcl-1/Noxa B PPI. 
 
 
The result from this screening shows that none of the oligoureas is active against 
the Mcl-1/Noxa B PPI: the designed inhibitors (and most importantly compounds 
133 and 135) are therefore p53/hDM2 specific. As the library of oligoureas was 
tested in the same assay as the N-alkylated oligobenzamides (cf. Chapter 3), the 
anisotropies measured here were also higher than that of the negative control. As 
explained in the previous chapter, this was due to the fact that the test wells 
contained 10% DMSO whereas the control wells did not. DMSO could have either 
affected the viscosity of the solution, or the structure of the protein or binding 
cleft itself, thus altering the binding of the inhibitor. 
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Screening against Noxa B/Mcl-1 (10 µM) 
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4.6 Conclusions and future work 
A library of 11 oligoureas has been assembled using a microwave assisted solid 
phase methodology. Testing of this library in a fluorescence anisotropy 
competition assay against the p53/hDM2 interaction allowed the establishment 
of basic SAR. It seems that effect of the N-terminal capping is variable from one 
sequence to another, in agreement with previously reported results.197 Ser and 
Orn have both been investigated as solubilising side chains, and it appeared that 
their respective position could actually affect the binding, possibly through 
interaction with neighboring side chains in the hDM2 binding cleft. The last 
oligourea (135) also displayed a Leu22 mimic, which made it one of the two most 
potent p53/hDM2 inhibitors of this library (along with compound 133). Using 
the SAR from these preliminary experiments, a next generation of oligourea 
inhibitors was designed, they combine the features described above: Ser at 
position 2, the additional Leu4 mimic, Orn at position 5 (Fig. 4.16). Along with 
these designed scaffolds, other initially foreseen examples could not be 
investigated due to time restrictions, such as the hybrid oligourea/γ-peptide (Fig. 
4.16c) and variants of 133 and 135 bearing the dichlorophenylalanine and 
cyclohexylalanine side chains (Fig. 4.16e-g). Whilst manually docking the 
oligourea, it was also observed that the Phe side chain was not reaching into the 
binding pocket as deeply as it could. It seemed that shortening the distance 
between this Phe and the preceding Orn residue might provide a better fit. This 
would correspond to the analogue where the oligourea is capped with benzyl 
isocyanate, which had already been envisaged. It was also reasoned (from Fig. 
4.14c) that replacing Ala by an acidic residue such as Asp might provide an 
additional ionic interaction with the neighbouring negatively charged domain on 
the surface of hDM2. Towards the C-terminus, it seemed that replacing the Leu 
for a Val residue might provide a better fit, as the Leu presented minor steric 
clashes with the surface of hDM2. The synthesis and biophysical evaluation of 
these new designed oligoureas (including ITC experiments in order to obtain 
more information on the thermodynamics of the binding) form the future work 
on this project.  
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Figure 4.16 The next generation of oligourea. The suggested modifications are 
coloured in pink. a. Capped and uncapped variants of 135 with a Ser in position 2. b. 
Variants of 135 with a Ser in positions 2 and 5. c. Analogue of scaffold a. using a γ-
residue as the Leu1 mimic. d. Analogue of scaffold a. capped with benzyl isocyanate as 
the Phe mimic. e. and f. Analogues of a. including cyclohexyl rings as mimics of Leu1 and 
Leu4. g. Analogue of a. including the dichlorophenyl monomer as the Phe mimic.  
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Thesis summary  
and Future directions 
 
 
 
α-Helix mediated PPIs are the primary focus of intense research efforts, as they 
are involved in the development of diseases such as HIV and cancer and therefore 
present a considerable therapeutic potential. Although small molecules have 
provided some of the most potent inhibitors so far, they only offer tailored 
answers; for each PPI target the design of inhibitors has to start from scratch. 
Considering the number of PPIs that involve binding through an α-helix, an 
attractive strategy would be to use a generic scaffold to mimic the helical core, 
and side chain appendages to mimic the hot-spot residues that are critical for the 
interaction. Foldamers and proteomimetics are two approaches that use this 
strategy. While foldamers are usually peptide-based and actually mimic the 
helical secondary structure, proteomimetics only replicate the spatial projection 
of the key side chains from the helix. Both approaches have yielded versatile 
scaffolds able to disrupt distinct PPIs. In this context, an automated SPS has been 
developed that allowed the assembly of a library of N-alkylated oligobenzamides. 
In previous studies, this scaffold was demonstrated to be a potent helix mimetic 
and also presented an accessible and modular synthesis. The newly developed 
methodology made use of a state of the art microwave assisted peptide 
synthesiser, and allowed facile library generation of diversely functionalized 
compounds. The oligomer assembly was compatible with a variety of side chains 
and could be extended to a decamer; the number of possible combinations thus 
meant that a wide range of potential helix surfaces could be mimicked. A few 
proteinogenic side chains proved more troublesome, whether during the 
monomer synthesis, or during the oligomer assembly – these will require further 
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investigation. The set of monomers compatible with the method however allowed 
SAR study on the model interactions chosen for this project. The robustness of 
the method was illustrated by the assembly of a 75-member library of 
tribenzamides. This library was divided into two sub-libraries, each designed to 
target one of the model PPIs: p53/hDM2 and Noxa B/Mcl-1. The library was 
tested in a fluorescence anisotropy competition assay, first in single point for hit 
identification and then dose-response assay on these hits provided IC50 values 
that served as a basis for SAR studies. Manually screening the library proved 
cumbersome and an attempt has been made to adapt the assay to an automated 
method. In addition to being less time-consuming, this would also reduce the 
amount of reagents used. Automating the assay was however not as 
straightforward as anticipated and further optimization will be required to 
produce a workable assay. The manual screening nevertheless provided reliable 
hit identification, from which potent inhibitors of both interactions were 
identified, with IC50s in the low micromolar range. Preliminary testing of dual 
inhibitor 47 against p53/hDMX suggested that this compound could be a non-
specific inhibitor. It is not excluded that other hits might also owe their apparent 
potency to their hydrophobicity, giving rise to non-specific binding within the 
hydrophobic cleft of their target protein.  A selectivity study however revealed 
that up to 20-fold selectivity could be attained (compound 89); these studies 
therefore brought the first piece of evidence for the versatility of this scaffold. 
Efforts are currently ongoing within the group towards obtaining a co-crystal 
structure of an oligoamide bound to hDM2. This would not only establish 
whether these compounds are actually selective inhibitors or not, but would also 
serve as a guide for the design of future generations of compounds. Furthermore, 
the proteolytic stability of these aromatic oligoamides was established against a 
panel of proteases and a preliminary high content screening suggested that some 
of the compounds might be able to penetrate the cells and trigger apoptosis, 
although this will need to be confirmed by further experiments. Future 
investigations will include testing this library of oligobenzamides against 
different PPIs, e.g. interactions involving the Bcl-xL antiapoptotic protein and 
further experiments against p53/hDMX. These will require additional molecular 
biology work, and setting up workable assays with these proteins. The studied 
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interactions will also be characterised using other biophysical methods, including 
ITC. This would circumvent the intrinsic limitations of the FA assay which 
precluded the determination of dissociation constants. Further cellular 
investigation on the entire library will also be carried out by collaborators in 
order to confirm observations and hypotheses from the initial cell assays.   
A collaboration with the Guichard group (IECB, Université de Bordeaux, 
France) was established, and as a part of this PhD a 2-month scientific mission 
was carried out, for which independent funding was obtained from the European 
COST Action CM0803, Functional peptidomimetic foldamers: from unnatural 
amino acids to self-assembling nanomaterials. This collaboration aimed at 
applying oligoureas to helix mimicry, and testing them in the FA assay developed 
at Leeds. A small library of oligoureas has been assembled using a microwave 
assisted SPS. Testing this library against the p53/hDM2 interaction allowed the 
establishment of basic SAR and identified 2 potential inhibitors. This joint 
research project will continue with the design of a second generation of 
oligoureas based on the SAR from these preliminary experiments. Their synthesis 
and biophysical evaluation form the future work on this project.  
During this PhD, two scaffolds have been investigated for α-helix mimicry 
– the N-alkylated oligobenzamide scaffold, and the N,N’-linked oligourea scaffold. 
Two other O-alkylated scaffolds are also being investigated within the group; 
their potential as helix mimetics has been established and further biophysical 
assessment is currently ongoing. Once thorough SAR studies have been carried 
out on these scaffolds, the study of hybrid scaffolds will be envisaged. This could 
potentially lead to the identification of inhibitors with improved potencies and 
selectivities  
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Chapter 6: Experimental section  
General considerations 
All reagents were obtained from Aldrich, Alfa Aesar, Acros or Fluka and used 
without further purification. All solvents used were HPLC grade. Analytical TLC 
was performed using 0.2 mm silica gel 60 F254 pre-coated aluminium sheets 
(Merck) and visualised using UV irradiation or, in the case of amine 
intermediates, by staining with a ninhydrin solution. Flash column 
chromatography was carried out on silica gel 60 (35 to 70 micron particles, 
FluoroChem). Solvent ratios are described where appropriate. Solvents were 
removed under reduced pressure using a Büchi rotary evaporator at diaphragm 
pump pressure. Samples were freed of remaining traces of solvents under high 
vacuum. 1H and 13C NMR spectra were measured on a Bruker DPX300 or a Bruker 
Avance 500 spectrometer using an internal deuterium lock. Chemical shifts are 
reported in parts per million (ppm) downfield from TMS in δ units and coupling 
constants are given in hertz (Hz). Coupling constants are reported to the nearest 
0.1 Hz. TMS is defined as 0 ppm for 1H NMR spectra and the centre line of the 
triplet of CDCl3 was defined as 77.10 ppm for 13C NMR spectra. When describing 
1H NMR data the following abbreviations are used; s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet. Melting points were determined using a Griffin 
D5 variable temperature apparatus and are uncorrected. Microanalyses were 
obtained on a Carlo Erba Elemental Analyser MOD 1106 instrument, found 
composition is reported to the nearest 0.05%. Infrared spectra were recorded on 
a Perkin-Elmer FTIR spectrometer and samples analysed as solids (unless 
stated). Mass spectra (HRMS) were recorded in house using a Micromass GCT 
Premier, using electron impact ionisation (EI) or a Bruker Daltonics micrOTOF, 
using electron spray ionisation (ES). LC-MS experiments were run on a Waters 
Micromass ZQ spectrometer, samples ionised by electrospray and analysed by a 
time-of-flight mass spectrometer, or a Bruker Daltronics HCTUltraTM series 
spectrometer. All experiments were run through a C18 column on an 
acetonitrile–water gradient (typically 0–95% acetonitrile over 3 min). A 
representative example of each synthetic procedure is provided with all 
examples described in the ESI. 
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Numbering system  
To simplify the numbering and NMR assignment of our trimers, we have devised 
a new sequential nomenclature, where each of the monomer building blocks is 
considered separately. The monomers are numbered from 1 to 3 starting from 
the N-terminal, and the glycine is numbered 4. Within each monomer, the 
numbering is the same: the carbons from the aminobenzoic acid are numbered 
using the standard system (the aromatic carbon bearing the carboxylic acid is C1, 
the one bearing the amine is C4). Then, the lateral chain is numbered: the carbon 
attached to the nitrogen is the Cα, and the numbering of the aliphatic part of the 
side chain continues with Cβ, etc. In the case of aromatic side chains, the aromatic 
carbons are numbered CAr1, CAr2, etc. The numbering of the protons is calqued 
on the carbon numbering. To differentiate each individual carbon/proton, the 
monomer number is added as a prefix to the carbon/proton number. 
The same nomenclature is applied to the Fmoc-protected monomers, and the 
protons corresponding to the Fmoc system are differentiated by the prefix F. The 
protons from the CH2 group will therefore be numbered FHα, the neighbouring 
CH will be FHβ, and the aromatic Fmoc protons are numbered FH2 to FH5. 
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6.1  Assembling a library of N-alkylated oligobenzamides (Chapters 2 and 3) 
6.1.1  Monomer building blocks 
Compounds 21a, d, i, j, m, v, 22a, d, i, j, m, v and 23 have been previously 
reported and fully characterised (Campbell, F., Plante, J. P., Edwards, T. A., 
Warriner, S. L. & Wilson, A. J. N-alkylated oligoamide α-helical proteomimetics. 
Org. Biomol. Chem. 8, 2344-2351, DOI: 10.1039/c001164a (2010). These 
compounds were re-synthesised and the characterisation matched the previously 
reported data. 
 
4-(Cyclopropylmethylamino)benzoic acid 21b 
4-Aminobenzoic acid (1.95 g, 14.3 mmol), cyclopropane carboxaldehyde (1.00 g, 
14.3 mmol) and picoline-borane complex (1.68 g, 15.7 mmol) were stirred at 
room temperature in methanol (50 mL) for 14 hours. A white precipitate formed. 
The precipitate was filtered and dried under high vacuum to yield the desired 
compound (0.85 g, 31%) as a colourless powder; RF 0.20 (hexane – ethyl acetate 
1-1); (Found: C, 69.10; H, 6.85; N, 7.20%; C11H13NO2 requires: C, 69.09; H, 6.85; N, 
7.32%); δH (500 MHz, MeOD) 0.28 (m, 2H, Hγ/γ’), 0.57 (m, 2H, Hγ’/γ), 1.12 (m, 
1H, Hβ), 3.04 (d, 2H, J = 6.7 Hz, Hα), 6.63 (d, 2H, J = 8.8 Hz, H3), 7.79 (d, 2H, J = 8.8 
Hz, H2); δC (75 MHz, DMSO-d6) 3.47, 10.36, 46.80, 110.68, 116.54, 131.09, 152.63, 
167.49; νmax/cm-1 (solid state) =  3375 – 3403 (NH), ~3000 (COOH),  1736 (C=O), 
1360 (C-N), 1216 (C-O); ESI-HRMS found m/z 192.1023 [M+H]+ C11H14NO2 
requires 192.1019. 
4-((((9H-Fluoren-9-
yl)methoxy)carbonyl)(cyclopropylmethyl)amino)benzoic acid 22b 
To a refluxing solution of 4-(cyclopropylmethylamino)benzoic acid 21b (0.85 g, 
4.4 mmol) in tetrahydrofuran (8 mL) was added dropwise a solution of Fmoc-
chloride (1.21 g, 4.7 mmol) in tetrahydrofuran (5 mL). The reaction mixture was 
then stirred at reflux overnight. The solvents were evaporated, then the residue 
was purified by Flash column chromatography (Biotage, 50g SNAP cartridge, 
Mobile phase : dichloromethane − methanol gradient) to yield pure target 
material (1.20 g, 66%) as an off-white amorphous solid; RF 0.47 (40% hexane in 
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ethyl acetate); δH (300 MHz, CDCl3) 0.05-0.10 (m, 2H, Hγ/γ’), 0.38-0.44 (m, 2H, 
Hγ’/γ), 0.85-0.97 (m, 1H, Hβ), 3.53 (d, 2H, J = 7.3 Hz, Hα), 4.12 (t, 1H, J = 6.2 Hz, 
FHβ), 4.50 (d, 2H, J = 6.2 Hz, FHα), 7.20-7.31 (m, 6H, FH4, FH5, H3), 7.37 (t, 2H, J = 
7.3 Hz, FH3), 7.71 (d, 2H, J = 7.2 Hz, FH2), 8.09 (d, 2H, J = 8.7 Hz, H2); δC (75 MHz, 
CDCl3) 3.69, 10.21, 47.11, 54.66, 67.38, 119.93, 124.87, 126.96, 127.33, 127.66, 
127.69, 131.07, 141.35, 143.69, 146.94, 155.01, 171.41; νmax/cm-1 (solid state) = 
~3013 (COOH), 1738 (CO), 1365 (C-N), 1217 (C-O); ESI-HRMS found m/z 
412.1552 [M-H]- C26H22NO4 requires 412.1554. 
4-((2-Methylbutyl)amino)benzoic acid 21c 
4-Aminobenzoic acid (3.00 g, 21.8 mmol), 2-methylbutyraldehyde (2.3 mL, 21.8 
mmol) and picoline-borane complex (2.64 g, 24.7 mmol) were stirred at room 
temperature in methanol (60 mL) for 14 hours. The reaction mixture was then 
acidified with 1N hydrochloric acid (~pH 4) and extracted with ethyl acetate (2 × 
100 mL). The combined organic layers were washed with brine (50 mL), dried 
over magnesium sulphate, filtered, concentrated and dried under high vacuum to 
yield the desired compound (4.51 g, 100%) as a colourless powder; RF 0.22 
(hexane – ethyl acetate 1-1); δH (300 MHz, MeOD) 0.96 (t, 3H, J = 7.6 Hz, Hδ), 0.98 
(t, 3H, J = 6.6 Hz, Hε), 1.22 (m, 1H, Hγ), 1.54 (m, 1H, Hγ’), 1.69 (m, 1H, Hβ), 2.93 
(dd, 1H, J1 = 13.0 Hz, J2 = 7.3 Hz, Hα), 3.08 (dd, 1H, J1 = 13.0 Hz, J2 = 6.3 Hz, Hα’), 
6.57 (d, 2H, J = 8.9 Hz, H3), 7.78 (d, 2H, J = 8.9 Hz, H2); δC (75 MHz, MeOD) 11.72, 
17.77, 28.31, 35.60, 50.11, 111.89, 117.65, 132.78, 154.86, 170.89; νmax/cm-1 
(solid state) =  3375 – 3403 (NH), ~3000 (COOH),  1736 (C=O); ESI-HRMS found 
m/z 208.1325 [M+H]+ C12H18NO2 requires 208.1332. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(2-methylbutyl)amino)benzoic 
acid 22c 
To a refluxing solution of 21c (4.51 g, 21.8 mmol) in chloroform (50 mL) was 
added dropwise a solution of Fmoc-chloride (5.63 g, 24.0 mmol) in chloroform 
(10 mL). The reaction mixture was then stirred at reflux overnight and turned 
yellow. The solvents were evaporated, then the residue was purified by Flash 
column chromatography (Stationary phase : silica, 50 g; Mobile phase : hexane – 
ethyl acetate gradient). The resulting solid was then crystallised (diethyl ether – 
hexane) to yield pure target material (5.42 g, 58%) as colourless crystals; RF 0.48 
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(40% hexane in ethyl acetate); δH (300 MHz, CDCl3) 0.68 (d, 3H, J = 6.3 Hz, Hε), 
0.71 (t, 3H, J = 7.3 Hz, Hδ), 0.93 (m, 1H, Hγ), 1.21 (m, 1H, Hγ’), 1.36 (m, 1H, Hβ), 
3.44 (m, 2H, Hα), 4.05 (t, 1H, J = 5.8 Hz, FHβ), 4.47 (d, 2H, J = 5.8 Hz, FHα), 7.08 (d, 
2H, J = 8.5 Hz, H3), 7.16 (t, 2H, J = 7.5 Hz, FH4), 7.25 (d, 2H, J = 7.5 Hz, FH5), 7.30 
(t, 2H, J = 7.5 Hz, FH3), 7.65 (d, 2H, J = 7.5 Hz, FH2), 7.97 (d, 2H, J = 8.5 Hz, H2); δC 
(125 MHz, CDCl3) 11.04, 16.57, 26.60, 33.49, 47.27, 55.49, 67.14, 119.92, 124.78, 
124.79, 126.96, 126.98, 127.65, 131.00, 141.41, 143.71, 146.88, 155.25, 171.10; 
νmax/cm-1 (solid state) = ~3000 (COOH), 1712 (C=O); ESI-MS found m/z 452.0 
[M+Na]+; ESI-HRMS found m/z 430.2009 [M+H]+ C27H28NO4 requires 430.2013. 
4-(Phenethylamino)benzoic acid 21e 
4-Aminobenzoic acid (5.84 g, 42.6 mmol), phenylacetaldehyde (5.0 mL, 42.6 
mmol) and picoline-borane complex (5.02 g, 46.9 mmol) were stirred at room 
temperature in methanol (130 mL) for 14 hours. The solvent was removed under 
reduced pressure and the pH of the oily residue was adjusted to 4 by addition of 
1N HCl and the mixture was placed in an ice bath to afford the target compound 
as off-white crystals (6.79 g, 66%); RF 0.48 (hexane – ethyl acetate 1-1);  m.p. 
128-130 oC; (Found: C, 74.35; H, 6.30; N, 5.65%; C15H15NO2 requires: C, 74.67; H, 
6.27; N, 5.81%); δH (300 MHz, CDCl3) 2.96 (t, 2H, J = 6.9 Hz, Hβ), 3.50 (t, 2H, J = 6.9 
Hz, Hα), 6.60 (d, 2H, J = 8.7 Hz, H3), 7.23-7.31 (m, 3H, HAr3, HAr4), 7.34-7.38 (m, 
2H, HAr2), 7.95 (d, 2H, J = 8.7 Hz, H2); δC (75 MHz, CDCl3) 35.23, 44.34, 111.61, 
117.42, 126.68, 128.75, 132.39, 138.66, 152.30, 172.19 (missing 1 13C resonance); 
νmax/cm-1 (solid state) =  3378 (NH), ~3028 (COOH),  1739 (CO), 1365 (C-N), 
1217 (C-O); ESI-HRMS found m/z 242.1172 [M+H]+ C15H16NO2 requires 
242.1176. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)phenethylamino)benzoic acid 
22e 
To a refluxing solution of 4-(benzylmethylamino)benzoic acid 21e (2.29 g, 9.5 
mmol) in chloroform (30 mL) was added dropwise a solution of Fmoc-chloride 
(2.58 g, 9.9 mmol) in chloroform (10 mL). The reaction mixture was then stirred 
at reflux overnight. The solvents were evaporated, then the residue was 
crystallised from neat methanol to yield the pure target material (1.22 g, 28%) as 
colourless crystals; RF 0.32 (hexane – ethyl acetate 1-1); (Found: C, 77.45; H, 5.45; 
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N, 3.00%; C30H25NO4 requires: C, 77.74; H, 5.44; N, 3.02%); δH (300 MHz, MeOD) 
2.62 (t, 2H, J = 6.7 Hz, Hβ), 3.73 (t, 2H, J = 6.7 Hz, Hα), 4.14 (t, 1H, J = 5.1 Hz, FHβ), 
4.63 (d, 2H, J = 5.1 Hz, FHα), 6.92-6.98 (m, 4H, H3, HAr2), 7.15-7.24 (m, 3H, HAr3, 
HAr4), 7.27 (t, 2H, J = 7.5 Hz, FH4), 7.38 (t, 2H, J = 7.4 Hz, FH3),  7.43 (d, 2H, J = 7.4 
Hz, FH5), 7.76 (d, 2H, J = 7.4 Hz, FH2), 7.86 (d, 2H, J = 8.6 Hz, H2); δC (75 MHz, 
MeOD) 33.80, 46.68, 50.89, 66.28, 120.04, 124.77, 126.20, 126.27, 126.94, 127.53, 
128.02, 128.27, 128.61, 129.80, 138.23, 140.84, 143.66, 145.39, 153.95, 166.74; 
νmax/cm-1 (solid state) = ~3005 (COOH), 1738 (CO), 1365 (C-N), 1217 (C-O); ESI-
HRMS found m/z 462.1728 [M-H]- C30H24NO4 requires 462.1711.  
4-((4-Chlorobenzyl)amino)benzoic acid 21f 
4-Aminobenzoic acid (2.00 g, 14.6 mmol), 4-chlorobenzaldehyde (2.10 g, 14.6 
mmol) and picoline-borane complex (1.87 g, 17.5 mmol) were stirred at room 
temperature in methanol (20 mL) for 14 hours. A white precipitate formed. The 
reaction mixture was filtered, and the precipitate was dried under high vacuum 
to yield the desired compound (3.03 g, 70%) as colourless crystals; RF 0.35 (ethyl 
acetate – hexane 1-1); m.p. 214-216 oC; (Found: C, 64.25; H, 4.60; N, 5.20%; 
C14H12ClNO2 requires: C, 64.25; H, 4.62; N, 5.35%); δH (300 MHz, MeOD) 4.28 (s, 
2H, Hα), 6.49 (d, 2H, J = 9.0 Hz, H3), 7.20-7.26 (m, 4H, HAr2-HAr3), 7.66 (d, 2H, J = 
9.0 Hz, H2); δC (75 MHz, CDCl3) 47.34, 112.77, 118.98, 129.88, 130.06, 132.99, 
133.96, 139.93, 154.44, 170.99; νmax/cm-1 (solid state) = 3426 (NH), ~3000 
(COOH), 1738 (CO); ESI-HRMS found m/z 262.0633 [M+H]+ C14H13ClNO2 requires 
262.0629. 
4-(((9H-Fluoren-9-yl)methoxy)carbonyl)(4-chlorobenzyl)amino)benzoic 
acid 22f  
To a refluxing solution of 4-(chlorobenzyl)aminobenzoic acid 21f (1.66 g, 6.4 
mmol) in tetrahydrofuran (15 mL) was added dropwise a solution of Fmoc-
chloride (1.81 g, 7.0 mmol) in tetrahydrofuran (5 mL). The reaction mixture was 
then stirred at reflux overnight. The solvents were evaporated, then the target 
material was precipitated from tetrahydrofuran – hexane to yield a white 
amorphous solid (2.90 g, 94%); RF 0.45 (7% methanol in dichloromethane); δH 
(300 MHz, MeOD) 4.13 (t, 1H, J = 4.9 Hz, FHβ), 4.67 (d, 2H, J = 4.9 Hz, FHα), 4.69 
(s, 2H, Hα), 6.90–6.95 (m, 4H, H3 and HAr2), 7.18–7.26 (m, 4H,  HAr3 and FH4), 
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7.34 (t, 2H, J = 7.5 Hz, FH3), 7.38 (d, 2H, J = 7.5 Hz, FH5), 7.74 (d, 2H, J = 7.5 Hz, 
FH2), 7.82 (d, 2H, J = 8.5 Hz, H2); δC (75 MHz, MeOD) 48.58, 53.71, 68.18, 120.96, 
125.80, 127.75, 128.10, 128.74, 129.61, 129.80, 130.27, 131.45, 134.19, 137.43, 
142.79, 145.04, 146.63, 156.69, 169.05; νmax/cm-1 (solid state) = ~3010 (COOH), 
1739 (CO), 1365 (C-N), 1216 (C-O); ESI-HRMS found m/z 482.1167 [M-H]- 
C29H21ClNO4 requires 482.1165. 
4-((4-Fluorobenzyl)amino)benzoic acid 21g 
4-Aminobenzoic acid (3.83 g, 27.9 mmol), 4-fluorobenzaldehyde (3.0 mL, 27.9 
mmol) and picoline-borane complex (3.58 g, 33.5 mmol) were stirred at room 
temperature in methanol (90 mL) for 14 hours. A white precipitate formed. The 
reaction mixture was filtered, and the filtrate acidified (~pH 4) with 1N 
hydrochloric acid to induce further precipitation. The combined precipitates 
were dried under high vacuum to yield the desired compound (4.98 g, 73%) as a 
colourless powder; RF 0.30 (5% methanol in dichloromethane); (Found: C, 68.30; 
H, 4.90; N, 5.65%; C14H12FNO2 requires: C, 68.56; H, 4.93; N, 5.71%); δH (300 MHz, 
DMSO-d6) 4.32 (d, 2H, J = 6.0 Hz, Hα), 6.59 (d, 2H, J = 8.9 Hz, H3), 7.06 (t, 1H, J = 
6.0 Hz, NH), 7.12-7.19 (m, 2H, HAr2), 7.34-7.41 (m, 2H, HAr3), 7.64 (d, 2H, J = 8.9 
Hz, H2); δC (75 MHz, DMSO-d6) 45.05, 111.15, 114.92, 115.20, 117.21, 128.97, 
131.04, 135.51, 152.21, 167.41; νmax/cm-1 (solid state) = 3426 (NH), ~3015 
(COOH), 1736 (CO), 1365, 1216; ESI-HRMS found m/z 244.0771 [M-H]- 
C14H11FNO2 requires 244.0779.  
4-(((9H-Fluoren-9-yl)methoxy)carbonyl)(4-fluorobenzyl)amino)benzoic 
acid   22g    
To a refluxing solution of 4-(fluorobenzyl)aminobenzoic acid 21g (4.04 g, 16.3 
mmol) in tetrahydrofuran (50 mL) was added dropwise a solution of Fmoc-
chloride (4.44 g, 17.2 mmol) in tetrahydrofuran (10 mL). The reaction mixture 
was then stirred at reflux overnight. The solvents were evaporated, then the 
residue was purified by column chromatography (Stationary phase: silica, Mobile 
phase: 1% to 10% methanol in dichloromethane). The product was then 
crystallised from dichloromethane-hexane to yield pure target material (7.00 g, 
92%) as colourless crystals; RF 0.45 (10% methanol in dichloromethane); m.p. 
142-143 oC; δH (300 MHz, CDCl3) 4.04 (t, 1H, J = 6.2 Hz, FHβ), 4.52 (d, 2H, J = 6.2 
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Hz, FHα), 4.69 (s, 2H, Hα), 6.85 (t, 2H, J = 8.7 Hz, HAr2), 6.92 (d, 2H, J = 8.6 Hz, 
H3), 6.96 (t, 2H, J = 7.7 Hz, HAr3), 7.14 (t, 2H, J = 7.4 Hz, FH3), 7.22 (d, 2H, J = 7.4 
Hz, FH4), 7.29 (t, 2H, J = 7.4 Hz, FH2), 7.63 (d, 2H, J = 7.4 Hz, FH1), 7.91 (d, 2H, J = 
8.6 Hz, H2); δC (75 MHz, CDCl3) 47.16, 53.08, 67.48, 115.34, 115.63, 119.97, 
124.76, 126.69, 127.01, 127.71, 129.35, 129.46, 131.05, 132.81, 141.37, 143.51, 
146.35, 155.05, 171.01; νmax/cm-1 (solid state) = ~3067 (COOH), 1681 (CO), 
1272);  ESI-HRMS found m/z 466.1469 [M-H]- C29H21FNO4 requires 466.1460. 
4-((3-(Trifluoromethyl)benzyl)amino)benzoic acid 21h 
4-Aminobenzoic acid (3.00 g, 21.9 mmol), 3-trifluoromethylbenzaldehyde (3.00 
mL, 21.9 mmol) and picoline-borane complex (2.57 g, 24.1 mmol) were stirred at 
room temperature in methanol (20 mL) for 14 hours. A white precipitate formed. 
The reaction mixture was filtered, and the filtrate acidified with 1N hydrochloric 
(~15 mL) acid to induce further precipitation. The combined precipitates were 
dried under high vacuum to yield the desired compound (4.41 g, 68%) as a 
colourless powder; RF 0.43 (ethyl acetate – hexane 1-1); δH (500 MHz, CDCl3) 4.48 
(s, 2H, Hα), 6.61 (d, 2H, J = 8.7 Hz, H3), 7.52-7.58 (m, 2H, HAr5-HAr6), 7.66 (d, 1H, 
J = 7.5 Hz, HAr4), 7.71 (s, 1H, HAr2), 7.79 (d, 2H, J = 8.7 Hz, H2); δC (75 MHz, 
CDCl3) 47.67, 112.94, 119.39, 121.60, 125.14, 125.19, 130.71, 132.30, 132.70 (q), 
133.11, 142.82, 154.43, 171.02; νmax/cm-1 (solid state) = 3458 (NH), ~3000 
(COOH), 1670 (CO), 1100-1275 (CF3); ESI-MS m/z 296 [M+H]+; ESI-HRMS found 
m/z 294.0755 [M-H]- C15H11F3NO2 requires 294.0747. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(3-
(trifluoromethyl)benzyl)amino)benzoic acid 22h  
To a refluxing solution of 21h (0.79 g, 2.7 mmol) in tetrahydrofuran (4 mL) was 
added dropwise a solution of Fmoc-Cl (0.77 g, 2.9 mmol) in tetrahydrofuran (4 
mL). The reaction mixture was stirred at reflux for 14 hours. The solvents were 
evaporated and the residue was crystallised (tetrahydrofuran – hexane) to yield 
the target compound (0.40 g, 27%) as colourless crystals; RF 0.29 (2% methanol 
in dichloromethane); δH (500 MHz, CDCl3) 4.11 (t, 1H, J = 5.6 Hz, FHβ), 4.60 (d, 
2H, J = 5.6 Hz, FHα), 4.84 (s, 2H, Hα), 7.05 (d, 2H, J = 8.9 Hz, H3), 7.20 (t, 2H, J = 7.5 
Hz, FH4), 7.22-7.28 (m, 3H, ArCH), 7.32-7.37 (m, 4H, ArCH), 7.49 (d, 1H, J = 8.0 Hz, 
HAr4), 7.68 (d, 2H, J = 7.5 Hz, FH2), 7.97 (d, 2H, J = 8.9 Hz, H2); δC (75 MHz, CDCl3) 
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47.53, 53.75, 68.07, 120.38, 124.67, 124.89, 125.11, 126.81, 127.43, 127.69, 
128.15, 129.60, 131.20, 131.31 (q), 131.55, 138.54, 141.76, 143.85, 146.64, 
155.49, 171.66 (missing 1 13C resonance); νmax/cm-1 (solid state) = ~3000 
(COOH), 1690 (CO), 1120-1280 (CF3); ESI-MS m/z 540 [M+Na]+; ESI-HRMS found 
m/z 516.1450 [M-H]- C30H21F3NO4 requires 516.1428. 
4-(4-Methylthiobenzylamino)benzoic acid 21k 
4-Aminobenzoic acid (0.79 g, 5.7 mmol), 4-methylthiobenzaldehyde (1.0 mL, 5.7 
mmol) and picoline-borane complex (0.67 g, 6.31 mmol) were stirred at room 
temperature in methanol (20 mL) for 14 hours. The solvent was evaporated to 10 
mL and the resulting mixture was acidified (~pH 4) with 1N hydrochloric acid 
then left to crystallise to yield the desired compound (1.24 g, 79%) as white 
crystals; RF 0.37 (40% hexane in ethyl acetate); m.p. 191-193 oC; (Found: C, 
65.60; H, 5.55; N, 5.10%; C15H15NO2S requires: C, 65.91; H, 5.53; N, 5.12%); δH 
(300 MHz, DMSO-d6) 2.44 (s, 3H, SMe), 4.29 (d, 2H, J = 6.2 Hz, Hα), 6.58 (d, 2H, J = 
8.7 Hz, H3), 7.05 (t, 1H, J = 6.2 Hz, NH), 7.22 (d, 2H, J = 8.3 Hz, HAr2), 7.29 (d, 2H, J 
= 8.3 Hz, HAr3), 7.65 (d, 2H, J = 8.7 Hz, H2); δC (75 MHz, DMSO-d6) 14.81, 45.33, 
111.15, 117.12, 126.07, 127.80, 131.03, 136.13, 136.26, 152.27, 167.42; νmax/cm-1 
(solid state) = 3356 (NH), ~3016 (COOH), 1737 (CO), 1365 (C-N), 1216 (C-O); 
ESI-HRMS found m/z 272.0747 [M-H]- C15H14NO2S requires 272.0751. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(4-
methylthiobenzylamino)benzoic acid 22k  
To a refluxing suspension of 4-(methylthiobenzylamino)benzoic acid 21k (1.10 g, 
4.0 mmol) in chloroform (12 mL) was added dropwise a solution of Fmoc-
chloride (1.10 g, 4.2 mmol) in chloroform (5 mL). The reaction mixture was then 
stirred at reflux overnight. The solvent was removed under reduced pressure and 
the residue was precipitated from dichloromethane – hexane to afford the title 
compound as an off-white amorphous solid (1.13 g, 60%); RF 0.25 (ethyl acetate – 
hexane 1-1); δH (300 MHz, DMSO-d6) 2.42 (s, 3H, MeS), 4.00 (t, 1H, J = 5.6 Hz, 
FHβ), 4.52 (d, 2H, J = 5.6 Hz, FHα), 4.86 (s, 2H, Hα), 6.90 (d, 2H, J = 8.4 Hz, H3), 
7.05-7.13 (m, 4H, HAr2, HAr3), 7.27 (t, 2H, J = 7.5 Hz, FH4), 7.37-7.45 (m, 4H, FH3, 
FH5), 7.73 (d, 2H, J = 8.4 Hz, H2), 7.88 (d, 2H, J = 7.4 Hz, FH2); δC (75 MHz, DMSO-
d6) 14.51, 46.72, 53.82, 66.57, 120.03, 124.88, 125.76, 126.14, 126.93, 127.54, 
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127.82, 129.72, 131.45, 133.77, 136.83, 140.85, 143.58, 149.76, 166.65, 171.86; 
νmax/cm-1 (solid state) = ~3016 (COOH), 1738 (CO), 1365 (C-N), 1217 (C-O); ESI-
HRMS found m/z 518.1390 [M+Na]+ C30H25NaNO4S requires 518.1397. 
4-(4-tert-Butoxybenzylamino)benzoic acid 21l                    
4-Aminobenzoic acid (0.77 g, 5.6 mmol), 4-tert-butoxybenzaldehyde (1.00 g, 5.6 
mmol) and picoline-borane complex (0.69 g, 6.2 mmol) were stirred at room 
temperature in methanol (20 mL) for 14 hours. A white precipitate formed. The 
reaction mixture was filtered, and the filtrate acidified with 1N hydrochloric acid 
(~15 mL) to induce further precipitation. The combined precipitates were dried 
under high vacuum to yield the desired compound (1.14 g, 68%) as a colourless 
powder; RF 0.37 (40% hexane in ethyl acetate); (Found: C, 71.90; H, 7.10; N, 
4.70%; C18H21NO3 requires: C, 72.22; H, 7.07; N, 4.68%); δH (300 MHz, DMSO-d6) 
1.27 (s, 9H, tBu), 4.27 (d, 2H, J = 5.2 Hz, Hα), 6.60 (d, 2H, J = 9.0 Hz, H3), 6.93 (d, 
2H, J = 8.4 Hz, HAr2), 6.99 (t, 1H, J = 5.2 Hz, NH), 7.25 (d, 2H, J = 8.4 Hz, HAr3), 
7.64 (d, 2H, J = 9.0 Hz, H2); δC (75 MHz, CDCl3) 29.25, 47.62, 79.07, 112.01, 
117.97, 124.89, 128.55, 132.77, 133.35, 152.84, 155.23, 172.85; νmax/cm-1 (solid 
state) = 3427 (NH), ~2969 (COOH), 1736 (CO); ESI-MS m/z 322.1 [M+Na]+; ESI-
HRMS found m/z 322.1420 [M+Na]+ C18H20NaNO3 requires 322.1414. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(4-tert-
butoxybenzylamino)benzoic acid 22l  
To a refluxing suspension of 4-(tert-butoxybenzylamino)benzoic acid 21l (1.12 g, 
3.7 mmol) and sodium bicarbonate (0.47 g, excess) in tetrahydrofuran (15 mL) 
was added dropwise a solution of Fmoc-chloride (1.06 g, 4.1 mmol) in 
tetrahydrofuran (5 mL). The reaction mixture was then stirred at reflux 
overnight. The solvents were evaporated and the product was then purified by 
Flash column chromatography (ethyl acetate – hexane gradient) to yield pure 
target material (1.10 g, 57%) as a white amorphous solid; RF 0.27 (ethyl acetate – 
hexane 1-1); δH (500 MHz, MeOD) 1.32 (s, 9H, tBu), 4.16 (t, 1H, J = 5.0 Hz, FHβ), 
4.67 (d, 2H, J = 5.0 Hz, FHα), 4.88 (s, 2H, Hα), 6.85 (d, 2H, J = 8.4 Hz, HAr2), 6.91 
(d, 2H, J = 8.1 Hz, HAr3), 6.94 (d, 2H, J = 7.6 Hz, H3), 7.25 (t, 2H, J = 7.5 Hz, FH4), 
7.37 (t, 2H, J = 7.2 Hz, FH3), 7.42 (d, 2H, J = 7.2 Hz, FH5), 7.76 (d, 2H, J = 7.4 Hz, 
FH2), 7.83 (d, 2H, J = 7.6 Hz, H2); δC (75 MHz, MeOD) 26.17, 48.57, 53.97, 68.22, 
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81.66, 120.94, 125.17, 125.84, 128.00, 128.09, 128.73, 129.52, 129.77, 131.37, 
133.65, 142.78, 145.08, 155.88, 156.78, 169.12 (missing 1 13C resonance); 
νmax/cm-1 (solid state) = ~3004 (COOH), 1736 (CO), 1365 (C-N), 1216 (C-O); ESI-
HRMS found m/z 544.2092 [M+Na]+ C33H31NaNO5 requires 544.2094. 
4-(2-tert-Butoxy-2-oxoethylamino)benzoic acid 21n 
tert-Butyl-2-(nitrooxy)acetate 24: To stirred a solution of tert-butylbromoacetate 
(1.51 mL, 8.8 mmol) in dry acetonitrile (20 mL), under a N2 atmosphere, was 
added silver nitrate (3.00 g, 11.6 mmol). The solution was stirred in the dark at 
room temperature for 72 h. The reaction mixture was filtered, concentrated and 
extracted between Et2O (3 x 50 mL) and water (50 mL). The combined organic 
fractions were dried (Na2SO4) and concentrated and target material isolated 
(1.26 g, 7.0 mmol, 80%) as a colourless oil.  
tert-Butyl-2-oxoacetate 25: To a stirred solution of tert-butoxycarbonylmethyl 
nitrate (1.16 g, 6.5 mmol) in anhydrous dimethylsulfoxide (20 mL), under N2, was 
added sodium acetate (0.54 g, 6.6 mmol). The reaction mixture was stirred at 
room temperature for 30 min. The reaction mixture was then poured into brine 
(150 mL) and extracted with CH2Cl2 (6 x 50 mL). The combined organic fractions 
were washed with saturated NaHCO3 (100 mL) and brine (100 mL), dried 
(Na2SO4) and concentrated and crude target material isolated as a yellow oil. The 
resultant crude product was taken directly and immediately onto the next step 
without purification.  
4-Aminobenzoic acid (0.75 g, 5.5 mmol) and tert-butyl 2-oxoacetate (0.72 g, 5.5 
mmol) were stirred in methanol (30 mL) at room temperature for 2 h, prior to 
addition of picoline-borane complex (0.85 g, 7.9 mmol) and left to stir overnight. 
The reaction mixture was concentrated and target material precipitated from 
methanol/water. Target material was isolated (0.69 g, 2.7 mmol, 49%) as a pale 
cream crystalline solid; m.p. 176-177 oC; RF 0.25 (20% Et2O in dichloromethane); 
δH (300 MHz, MeOD) 1.48 (s, 9H, tBu), 3.88 (s, 2H, CH2), 6.60 (d, 2H, J = 9.1 Hz, 
ArCH), 7.82 (d, 2H, J = 9.2 Hz, ArCH); δC (75 MHz, MeOD) 28.7, 46.9, 83.2, 112.9, 
119.8, 133.1, 154.2, 171.0, 172.3; νmax/cm-1 (solid state) = 3406 (NH), ~2900 
(COOH), 1731, 1668 (CO); HRMS calculated for C13H18NO4 [M+H]+ 252.1230, 
found 252.1231; ESI-HRMS found m/z 274.1051 [M+Na]+ C13H17NNaO4 274.1050. 
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4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(2-tert-butoxy-2-
oxoethyl)amino)benzoic acid 22n  
To a refluxing solution of 4-(2-tert-butoxy-2-oxoethylamino)benzoic acid (0.50 g, 
1.6 mmol) and sodium hydrogencarbonate (0.67 g, excess) in chloroform (20 mL) 
was added dropwise a solution of Fmoc chloride (0.62 g, 2.4 mmol) in chloroform 
(20 mL) over 2 h. The reaction mixture was then stirred at reflux for a further 20 
h. Excess sodium hydrogencarbonate was filtered off and column 
chromatography (Stationary Phase: Silica, 100 g; Mobile Phase: dichloromethane 
to 20% diethyl ether in dichloromethane) yielded pure target material (0.41 g, 
0.9 mmol, 54%) as an amorphous solid; m.p. 76-77 °C; RF 0.22 (20% diethyl ether 
in dichloromethane); δH (500 MHz, CDCl3) 1.46 (s, 9H, tBu), 4.16 (broad s, 1H, 
FHβ), 4.27 (broad s, 2H, Hα), 4.50 (d, 2H, J = 6.7 Hz, FHα), 7.23-7.37 (m, 8H, 
ArCH), 7.72 (d, 2H, J = 8.1 Hz, ArCH), 8.07 (d, 2H, J = 8.4 Hz, ArCH); δC (75 MHz, 
CDCl3) 28.0, 47.0, 52.4, 68.1, 82.4, 120.0, 124.9, 126.4, 127.0, 127.7, 131.1, 132.4, 
141.3, 143.5, 146.8, 154.8, 168.2, 169.4; νmax/cm-1 (solid state) = ~3000 (broad, 
COOH), 1736, 1715, 1690, 1605 (CO); ESI-HRMS found m/z 474.1924 [M+H]+ 
C28H28NO6 requires 474.1911, found m/z 491.2190 [M+NH4]+ C28H31N2O6 
requires 491.2177, found m/z 496.1721 [M+Na]+ C28H27NNaO6 requires 
496.1731. 
4-(3-Fluorobenzylamino)benzoic acid 21o 
4-Aminobenzoic acid (3.88 g, 28.3 mmol), 3-fluorobenzaldehyde (3.0 mL, 28.3 
mmol) and picoline-borane complex (3.33 g, 31.1 mmol) were stirred at room 
temperature in methanol (90 mL) for 14 hours. A white precipitate formed. The 
reaction mixture was filtered, and the filtrate acidified (~pH 4) with 1N 
hydrochloric acid then left to crystallise to yield the desired compound (4.10 g, 
59%) as colourless crystals; RF 0.37 (40% hexane in ethyl acetate); m.p. 170-
172 oC; (Found: C, 68.20; H, 4.95; N, 5.75%; C14H12FNO2 requires: C, 68.56; H, 
4.93; N, 5.71%); δH (300 MHz, DMSO-d6) 4.36 (d, 2H, J = 6.1 Hz, Hα), 6.59 (d, 2H, J 
= 8.9 Hz, H3), 7.03-7.20 (m, 4H, NH, HAr2, HAr3, HAr5), 7.34-7.41 (m, 1H, HAr4), 
7.66 (d, 2H, J = 8.9 Hz, H2); δC (75 MHz, DMSO-d6) 45.05 (CH2), 111.15 (ArC-H3), 
114.92 (ArC-HAr4), 115.20 (ArC-HAr2), 117.21 (ArC-HAr6), 128.97 (ArC-HAr5), 
131.04 (ArC-H2), 135.51 (ArC-COOH), 152.21 (ArC-F), 159.52 (ArC-CH2), 160.73 
Chapter 6: Experimental Section 
 
129 
 
(ArC-NH), 167.41 (COOH); νmax/cm-1 (solid state) = 3427 (NH), ~3002 (COOH), 
1736 (CO), 1365 (C-N), 1216 (C-O); ESI-HRMS found m/z 244.0788 [M-H]- 
C14H11FNO2 requires 244.0779. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(3-fluorobenzylamino)benzoic 
acid 22o  
To a refluxing solution of 3-(fluorobenzylamino)benzoic acid 21o (2.61 g, 10.6 
mmol) in tetrahydrofuran (40 mL) was added dropwise a solution of Fmoc-
chloride (2.89 g, 11.2 mmol) in tetrahydrofuran (10 mL). The reaction mixture 
was then stirred at reflux overnight. The solvents were evaporated, then the 
residue was purified by column chromatography (Stationary phase: silica, Mobile 
phase: dichloromethane–hexane 1-1 then neat dichloromethane then 3% 
methanol in dichloromethane) to afford the target material as a white solid 
(3.41 g, 69%); RF 0.45 (7% methanol in dichloromethane); (Found: C, 73.75; H, 
4.75; N, 2.95%; C29H22FNO4 requires: C, 74.51; H, 4.74; N, 3.00%); δH (300 MHz, 
CDCl3) 4.12 (t, 1H, J = 5.8 Hz, FHβ), 4.60 (d, 2H, J = 5.8 Hz, FHα), 4.80 (s, 2H, Hα), 
6.84 (m, 2H, HAr4, HAr6), 6.93 (m, 1H, HAr5), 7.07 (d, 2H, J = 8.6 Hz, H3), 7.18-
7.24 (m, 3H, HAr2, FH4), 7.29 (d, 2H, J = 7.2 Hz, FH5), 7.36 (t, 2H, J = 7.5 Hz, FH3), 
7.70 (d, 2H, J = 7.5 Hz, FH2), 7.98 (d, 2H, J = 8.6 Hz, H2); δC (125 MHz, CDCl3) 
47.17 (CH-CH2), 53.29 (CH2), 67.63 (CH2-CH), 114.45 (ArC-HAr4), 114.62 (ArC-
HAr2), 119.97 (ArC-FH2), 124.74 (ArC-H3), 126.38 (ArC-HAr6), 127.04 (ArC-
FH3), 127.74 (ArC-FH5), 130.14 (ArC-FH4), 130.21 (ArC-COOH), 131.07 (ArC-
HAr5), 139.70 (ArC-H2), 141.38 (ArC-F1), 143.50 (ArC-F6), 146.42 (ArC-CH2), 
160.07 (ArC-N), 161.95 (COO-N), 163.91 (ArC-F), 171.07 (COOH); νmax/cm-1 (solid 
state) = ~3016 (COOH), 1739 (CO), 1365 (C-N), 1216 (C-O); ESI-HRMS found m/z 
466.1476 [M-H]- C29H22FNO4 requires 466.1460. 
4-((4-(Trifluoromethyl)benzyl)amino)benzoic acid 21p 
4-Aminobenzoic acid (3.00 g, 21.9 mmol), 4-trifluoromethylbenzaldehyde (3.00 
mL, 21.9 mmol) and picoline-borane complex (2.57 g, 24.1 mmol) were stirred at 
room temperature in methanol (20 mL) for 14 hours. A white precipitate formed. 
The reaction mixture was filtered, and the filtrate acidified with 1N hydrochloric 
acid (~15 mL) to induce further precipitation. The combined precipitates were 
dried under high vacuum to yield the desired compound (3.91 g, 61%) as a 
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colourless powder; RF 0.40 (10% methanol in dichloromethane); m.p. 181-182 oC; 
δH (500 MHz, CDCl3) 4.51 (s, 2H, Hα), 6.49 (d, 2H, J = 9.1 Hz, H3), 7.47 (d, 2H, J = 
7.5 Hz, HAr2), 7.63 (d, 2H, J = 7.5 Hz, HAr3), 7.92 (d, 2H, J = 9.1 Hz, H2); δC (125 
MHz, CDCl3) 50.19 (CH2), 115.46 (ArC-H3), 121.82 (ArC-COOH), 129.32 (ArC-
HAr3), 130.51 (ArC-HAr2), 131.55 (ArC-CF3), 133.14 (q, CF3), 135.69 (ArC-H2), 
148.53 (ArC-CH2), 156.98 (ArC-NH), 173.62 (COOH); νmax/cm-1 (solid state) = 
3414 (NH), ~3000 (COOH), 1690 (CO), 1120-1180 (CF3); ESI-MS m/z 296 
[M+H]+; ESI-HRMS found m/z 294.0755 [M-H]- C15H11F3NO2 requires 294.0747. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(4-
((trifluoromethyl)benzyl)amino))benzoic acid 22p  
To a refluxing solution of 21p (3.91 g, 13.3 mmol) in tetrahydrofuran (60 mL) 
was added dropwise a solution of Fmoc-Cl (3.78 g, 14.7 mmol) in tetrahydrofuran 
(20 mL). The reaction mixture was stirred at reflux for 14 hours. The solvents 
were evaporated and the residue was crystallised (tetrahydrofuran - 
dichloromethane) to yield the target compound (6.50 g, 91%) as yellow crystals; 
RF 0.37 (ethyl acetate - hexane 1-1); m.p. 144-145 oC; (Found: C, 69.3; H, 4.3; N, 
2.6; C30H22F3NO4 requires: C, 69.6; H, 4.2; N, 2.7%); δH (500 MHz, CDCl3) 4.11 (t, 
1H, J = 5.1 Hz, FHβ), 4.64 (d, 2H, J = 5.1 Hz, FHα), 4.82 (s, 2H, Hα), 7.06 (d, 2H, J = 
8.4 Hz, H3), 7.14 (d, 2H, J = 7.9 Hz, HAr2/3), 7.21 (t, 2H, J = 7.4 Hz, FH4), 7.30 (d, 
2H, J = 7.4 Hz, FH5), 7.37 (t, 2H, J = 7.5 Hz, FH3), 7.50 (d, 2H, J = 7.9 Hz, HAr3/2), 
7.69 (d, 2H, J = 7.5, FH2), 7.97 (d, 2H, J = 8.4, H2); δC (125 MHz, CDCl3) 47.58 (CH-
CH2), 53.76 (CH2), 67.92 (CH2-CH), 120.40 (ArC-FH2), 125.09 (ArC-H3), 126.00 
(ArC-HAr3), 126.05 (ArC-FH3), 126.58 (ArC-COOH), 127.45 (ArC-FH5), 128.02 
(ArC-FH4), 128.16 (ArC-HAr2), 129.95 (q, CF3), 130.35 (ArC-CF3), 131.54 (ArC-
H2), 141.54 (ArC-CH2), 141.79 (ArC-F6), 143.83 (ArC-F1), 146.75 (ArC-N), 
155.42 (NCOO-CH2), 171.68 (COOH); νmax/cm-1 (solid state) = ~3000 (COOH), 
1710 (CO), 1230-1120 (CF3); ESI-MS m/z 540 [M+Na]+; ESI-HRMS found 
516.1435 m/z [M-H]- C30H21F3NO4 requires 516.1428. 
tert-butyl 5-methoxy-3-formyl-1H-indole-1-carboxylate 23q 
To a stirred suspension of 5-methoxy-1H-indole-3-carboxaldehyde (0.50 g, 2.8 
mmol) in dichloromethane (20 mL) was added Boc-anhydride (0.65 g, 3.0 mmol), 
followed by triethylamine (0.44 mL, 3.1 mmol). The resulting mixture was stirred 
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at room temperature under a nitrogen atmosphere for 40 hours. The solvent was 
evaporated to afford a brown oil from which the title compound was precipitated 
using methanol to afford a cream amorphous solid (0.57 g, 2.1 mmol, 72%); RF 
0.45 (ethyl acetate - hexane 1-1); δH (300 MHz, DMSO-d6) 1.65 (s, 9H, tBu), 3,81 
(s, 3H, OMe), 7.05 (dd, 1H, J1 = 9.1 Hz, J2 = 2.6 Hz, H7), 7.62 (d, 1H, J = 2.6 Hz, H4), 
7.99 (d, 1H, J = 9.1 Hz, H6), 8.63  (s, 1H, H2), 10.05 (s, 1H, CHO); δC (75 MHz, 
DMSO-d6) 27.49 (CH3-C), 55.31 (O-CH3), 85.40 (OC-CH3), 103.45 (ArC-H4), 114.63 
(ArC-H6), 115.80 (ArC-H7), 120.40 (ArC-CO), 126.51 (ArC-H2), 129.71 (ArC-C-
CO), 138.55 (ArC-N), 148.25 (NCOO-tBu), 156.68 (ArC-OCH3), 187.11 (CO); ESI-
HRMS found m/z 298.1036 [M+Na]+ C15H17NaNO4 requires 298.1050. 
4-(((5-Methoxy-1H-indol-3-yl)methyl)amino)benzoic acid 21q 
4-Aminobenzoic acid (0.28 g, 2.1 mmol), 23q (0.57 g, 2.1 mmol) and picoline-
borane complex (0.23 g, 2.2 mmol) were stirred at room temperature in 
methanol (10 mL) for 14 hours. The solvent was evaporated and the product was 
isolated by slow precipitation from chloroform – diethylether, then dried under 
high vacuum to yield the desired compound (0.62 g, 75%) as a colourless solid; RF 
0.27 (10% methanol in dichloromethane); δH (300 MHz, DMSO-d6) 1.60 (s, 9H, 
tBu), 3.79 (s, 3H, OMe), 4.42 (d, 2H, J = 5.7 Hz, Hα), 6.69 (d, 2H, J = 8.8 Hz, H3), 
6.93 (dd, 1H, J1 = 8.8 Hz, J2 = 2.7 Hz, HAr7), 6.97 (t, 1H, J = 5.7 Hz, NH), 7.26 (d, 1H, 
J = 2.5 Hz, HAr4), 7.63 (s, 1H, HAr2), 7.67 (d, 2H, J = 8.8 Hz, H2), 7.90 (d, 1H, J = 8.8 
Hz, HAr6); δC (75 MHz, DMSO-d6) 27.65 (CH3-C), 55.41 (CH2), 64.89 (O-CH3), 
83.49 (C-CH3), 102.53 (ArC-HAr4), 111.14 (ArC-H3), 112.98 (ArC-HAr6), 115.43 
(ArC-CH2), 117.12 (ArC-HAr7), 118.21 (ArC-COOH), 124.24 (ArC-HAr2), 129.44 
(ArC-N), 130.19 (ArC-C-CH2), 131.03 (ArC-H2), 148.97 (NCOO-tBu), 152.33 (ArC-
O), 155.40 (ArC-NH), 167.44 (COOH); νmax/cm-1 (solid state) =  3381 (NH), ~3016 
(COOH),  1738 (CO), 1365 (C-N), 1217 (C-O);  ESI-MS m/z  419.5 [M+Na]+; ESI-
HRMS found m/z 395.1598 [M-H]- C22H23N2O5 requires 395.1612. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(5-methoxy-1-(tert-
butoxycarbonyl)-1H-indol-3-yl)methyl)amino)benzoic acid 22q 
To a refluxing suspension of 21q (0.50 g, 1.3 mmol) and NaHCO3 (0.21 g, excess) 
in tetrahydrofuran (10 mL) was added dropwise a solution of Fmoc-Cl (0.33 g, 1.3 
mmol) in tetrahydrofuran (3 mL). The reaction mixture was stirred at reflux for 
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1.5 hour. The excess bicarbonate was filtered then the solvent was evaporated 
and the product was isolated by slow precipitation from chloroform - 
diethylether (0.27 g, 34%) as a white solid; RF 0.25 (ethyl acetate - hexane 1-1); 
δH (300 MHz, DMSO-d6) 1.56 (s, 9H, tBu), 3.67 (s, 3H, OMe), 4.19 (t, 1H, J = 6.1 Hz, 
FHβ), 4.52 (d, 2H, J = 6.1 Hz, FHα), 4.96 (s, 2H, Hα), 6.87 (d, 1H, J = 2.2 Hz, HAr4), 
6.92 (dd, 1H, J1 = 8.8 Hz, J2 = 2.5 Hz, HAr6), 7.12 (d, 2H, J = 8.2 Hz, FH5), 7.15 (t, 
2H, J = 7.2 Hz, FH4), 7.30-7.36 (m, 5H, FH3, H3, HAr2), 7.78 (d, 2H, J = 8.2 Hz, 
FH2), 7.79 (d, 2H, J = 8.8 Hz, H2), 7.86 (d, 1H, J = 8.6 Hz, HAr7); δC (75 MHz, 
DMSO-d6) 27.58 (CH3-C), 44.21 (CH2-N), 46.45 (CH-CH2), 55.08 (CH3-O), 67.05 
(CH2-CH), 83.69 (C-CH3), 101.99 (ArC-HAr4), 113.16 (ArC-HAr6), 115.50 (ArC-
CH2), 116.56 (ArC-HAr7), 119.97 (ArC-FH2), 124.77 (ArC-H3), 124.97 (ArC-
HAr2), 126.50 (ArC-COOH), 126.82 (ArC-FH3), 127.49 (ArC-FH5), 128.39 (ArC-
FH4), 129.23 (ArC-NCOOtBu), 129.71 (ArC-C-CH2), 129.81 (ArC-H2), 140.71 (ArC-
F6), 143.51 (ArC-F1), 144.71 (ArC-N), 148.77 (ArC-NCOOCH2), 154.29 (ArC-O), 
155.34 (COO-CH2), 166.70 (COOH); νmax/cm-1 (solid state) =  ~3016 (COOH), 
1738 (CO), 1365 (C-N), 1217 (C-O); ESI-MS m/z  617.3 [M-H]-; ESI-HRMS found 
m/z 617.2284 [M-H]- C37H33N2O7 requires 617.2293. 
t-butyl 5-bromo-3-formyl-1H-indole-1-carboxylate 23r 
To a stirred suspension of 5-bromo-1H-indole-3-carboxaldehyde (1.00 g, 4.5 
mmol) in dichloromethane (20 mL) was added Boc-anhydride (1.02 g, 4.7 mmol), 
followed by triethylamine (0.7 mL, 4.9 mmol). The resulting mixture was stirred 
at room temperature under a nitrogen atmosphere for 20 hours. A white 
precipitate was formed. The reaction mixture was filtered and the solid was dried 
under high vacuum to afford the title compound (1.45 g, 4.5 mmol, quant.) as a 
white amorphous solid; RF 0.65 (ethyl acetate - hexane 1-1); (Found: C, 51.90; H, 
4.25; N, 4.25; Br, 24.75; C14H14BrNO3 requires: C, 51.87; H, 4.35; N, 4.32; Br, 
24.65%); δH (300 MHz, MeOD) 1.64 (s, 9H, tBu), 7.44 (dd, 1H, J1 = 9.0 Hz, J2 = 3.0 
Hz,  H7), 7.96 (d, 1H, J = 9.0 Hz, H6), 8.15 (s, 1H, H2), 8.38 (d, 1H, J = 3.0 Hz, H4), 
9.99 (s, 1H, H9); δC (75 MHz, DMSO-d6) 27.48 (CH3-C), 85.99 (C-CH3), 117.04 
(ArC-Br), 117.09 (ArC-HAr7), 119.54 (ArC-CO), 123.52 (ArC-HAr4), 127.37 (ArC-
HAr2), 128.53 (ArC-C-CO), 134.14 (ArC-HAr6), 139.22 (ArC-N), 187.12 (COOH), 
(1 13C resonance missing); νmax/cm-1 (solid state) =  1738 (CO), 1365 (C-N), 1217 
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(C-O); ESI-HRMS found m/z 346.0051 [M+Na]+ C14H14BrNaNO3 requires 
346.0049. 
4-(((5-bromo-1-(tert-butoxycarbonyl)-1H-indol-3-
yl)methyl)amino)benzoic acid 21r 
4-Aminobenzoic acid (0.59 g, 4.3 mmol), 23r (1.40 g, 4.3 mmol) and picoline-
borane complex (0.53 g, 5.0 mmol) were stirred at room temperature in 
methanol (20 mL) for 14 hours. The solvent was evaporated and the product was 
precipitated from chloroform, then dried under high vacuum to yield the desired 
compound (1.72 g, 89%) as a white powder; RF 0.25 (10% methanol in 
dichloromethane); δH (300 MHz, MeOD) 1.67 (s, 9H, tBu), 4.48 (s, 2H, Hα), 6.71 (d, 
2H, J = 8.8 Hz, H3), 7.44 (dd, 1H, J1 = 8.9 Hz, J2 = 2.1 Hz, HAr7), 7.63 (s, 1H, HAr2), 
7.81 (d, 2H, J = 8.8 Hz, H2), 7.84 (d, 1H, J = 2.1 Hz, HAr4), 8.05 (d, 1H, J = 8.9 Hz, 
HAr6); δC (75 MHz, DMSO-d6) 27.85 (CH3-C), 54.92 (CH2), 84.86 (C-CH3), 111.15 
(ArC-H3), 116.48 (ArC-CH2), 117.13 (ArC-Br), 118.37 (ArC-HAr7), 119.38 (ArC-
COOH), 124.76 (ArC-HAr4), 125.39 (ArC-HAr2), 128.14 (ArC-C-CH2), 130.62 
(ArC-H2), 132.03 (ArC-HAr6), 133.49 (ArC-N), 148.71 (N-COO), 152.12 (ArC-NH), 
168.62 (COOH); νmax/cm-1 (solid state) =  3398 (NH), ~1747 (COOH),  1364 (C-N), 
1216 (C-O); ESI-MS m/z  467.1 [M+Na]+. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(5-bromo-1-(tert-
butoxycarbonyl)-1H-indol-3-yl)methyl)amino)benzoic acid 22r 
To a refluxing suspension of 21r (0.83 g, 1.8 mmol) and NaHCO3 (0.31 g, excess) 
in tetrahydrofuran (60 mL) was added dropwise a solution of Fmoc-Cl (0.53 g, 2.1 
mmol) in tetrahydrofuran (8 mL). The reaction mixture was stirred at reflux for 2 
hours. The excess bicarbonate was filtered then the solvent was evaporated and 
the product was isolated by column chromatography (ethyl acetate – hexane) 
followed by slow precipitation from chloroform - diethylether (0.41 g, 33%) as a 
pale yellow amorphous solid; RF 0.25 (ethyl acetate - hexane 1-1); δH (300 MHz, 
CDCl3) 1.64 (s, 9H, tBu), 4.13 (t, 1H, J = 6.2 Hz, FHβ), 4.58 (d, 2H, J = 6.2 Hz, FHα), 
4.89 (s, 2H, Hα), 7.11 (d, 2H, J = 8.2 Hz, H3), 7.18 (t, 2H, J = 7.4 Hz, FH4), 7.25 (d, 
2H, J = 7.4 Hz, FH5), 7.26-7.28 (m, 1H, HAr4), 7.32 (t, 2H, J = 7.4 Hz, FH3), 7.42 
(dd, 1H, J1 = 8.9 Hz, J2 = 1.9 Hz, HAr7), 7.48 (s, 1H, HAr2), 7.61 (d, 2H, J = 7.5 Hz, 
FH2), 7.99 (d, 1H, J = 7.4 Hz, HAr6), 8.01 (d, 2H, J = 8.2 Hz, H2); δC (75 MHz, CDCl3) 
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28.14 (CH3-C), 29.73 (CH2), 46.99 (CH-CH2), 67.73 (CH2-CH), 77.24 (C-CH3), 
105.00 (ArC-CH2), 115.94 (ArC-Br), 116.17 (ArC-HAr7), 116.73 (ArC-FH2), 
119.90 (ArC-HAr4), 122.16 (ArC-H3), 124.66 (ArC-HAr2), 124.78 (ArC-FH3), 
126.93 (ArC-COOH), 127.62 (ArC-FH5), 127.67 (ArC-FH4), 131.07 (ArC-C-CH2), 
131.25 (ArC-H2), 141.28 (ArC-HAr6)141.37 (ArC-N-COOtBu), 142.70 (ArC-F6), 
143.47 (ArC-F1), 149.13 (ArC-N-CH2), 154.25 (COOtBu), 154.88 (NCOO-CH2), 
170.39 (COOH); νmax/cm-1 (solid state) = ~3027 (COOH), 1750 (CO), 1364 (C-N), 
1216 (C-O); ESI-MS m/z  665.3 [M-H]-; ESI-HRMS found m/z 665.1291 [M-H]- 
C36H30BrN2O6 requires 665.1293. 
tert-butyl 5-chloro-3-formyl-1H-indole-1-carboxylate 23s 
To a stirred suspension of 5-chloro-1H-indole-3-carboxaldehyde (1.00 g, 5.6 
mmol) in tetrahydrofurane (20 mL) was added Boc-anhydride (1.28 g, 5.9 mmol), 
followed by triethylamine (0.9 mL, 6.2 mmol). The resulting mixture was stirred 
at room temperature under a nitrogen atmosphere for 20 hours. A white 
precipitate was formed. The reaction mixture was filtered and the solid was dried 
under high vacuum to afford the title compound (0.87 g, 3.1 mmol, 56%) as a 
white amorphous solid; RF 0.55 (ethyl acetate - hexane 1-1); (Found: C, 60.15; H, 
4.95; N, 4.85; Cl, 12.75; C14H14ClNO3 requires: C, 60.11; H, 5.04; N, 5.01; Cl, 
12.67%); δH (300 MHz, DMSO-d6) 1.66 (s, 9H, tBu), 7.49 (dd, 1H, J1 = 9.0 Hz, J2 = 
2.5 Hz, H7), 8.09 (d, 1H, J = 9.0 Hz, H6), 8.11 (d, 1H, J = 2.5 Hz, H4), 8.74 (s, 1H, 
H2), 10.06 (s, 1H, H9); δC (75 MHz, DMSO-d6) 27.47 (CH3-C), 85.96 (C-CH3), 
116.62 (ArC-HAr7), 119.65 (ArC-CO), 120.49 (ArC-HAr4), 125.83 (ArC-HAr6), 
126.85 (ArC-HAr2), 128.97 (ArC-Cl), 133.79 (ArC-C-CO), 139.32 (ArC-N), 147.97 
(N-COO), 187.05 (CO); νmax/cm-1 (solid state) =  1738 (CO), 1365 (C-N), 1216 (C-
O); ESI-HRMS found m/z 302.0548 [M+Na]+ C14H14ClNaNO3 requires 302.0554. 
4-(((5-chloro-1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)amino)benzoic 
acid 21s 
4-Aminobenzoic acid (0.43 g, 3.1 mmol), 23s (0.87 g, 3.1 mmol) and picoline-
borane complex (0.37 g, 3.4 mmol) were stirred at room temperature in 
methanol-dichloromethane (2-1, 10 mL) for 20 hours. The solvent was 
evaporated and the product was precipitated from chloroform, then dried under 
high vacuum to yield the desired compound (0.80 g, 67%) as a colourless 
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powder; RF 0.37 (ethyl acetate - hexane 1-1); δH (300 MHz, DMSO-d6) 1.61 (s, 9H, 
tBu), 4.44 (d, 2H, J = 5.8 Hz, Hα), 6.69 (d, 2H, J = 8.8 Hz, H3), 6.98 (t, 1H, J = 5.8 Hz, 
NH), 7.36 (dd, 1H, J1 = 8.9 Hz, J2 = 2.1 Hz, HAr7), 7.66 (d, 2H, J = 8.8 Hz, H2), 7.76 
(s, 1H, HAr2), 7.85 (d, 1H, J = 2.1 Hz, HAr4), 8.01 (d, 1H, J = 8.9 Hz, HAr6); δC (75 
MHz, DMSO-d6) 27.60 (CH3-C), 54.89 (CH2), 84.24 (C-CH3), 111.15 (ArC-H3), 
116.18 (ArC-CH2), 117.23 (ArC-HAr7), 117.87 (ArC-COOH), 119.37 (ArC-HAr4), 
124.36 (ArC-HAr6), 125.34 (ArC-HAr2), 127.14 (ArC-Cl), 130.72 (ArC-C-CH2), 
131.03 (ArC-H2), 133.43 (ArC-NCOO), 148.72 (N-COO), 152.18 (ArC-NH), 167.42 
(COOH); νmax/cm-1 (solid state) =  3398 (NH), ~3016 (COOH),  1747 (CO), 1364 
(C-N), 1216 (C-O). 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(5-chloro-1-(tert-
butoxycarbonyl)-1H-indol-3-yl)methyl)amino)benzoic acid 22s 
To a refluxing suspension of 21s (0.27 g, 0.7 mmol) and NaHCO3 (0.11 g, excess) 
in tetrahydrofuran (7 mL) was added dropwise a solution of Fmoc-Cl (0.18 g, 0.7 
mmol) in tetrahydrofuran (2 mL). The reaction mixture was stirred at reflux for 2 
hours. The excess bicarbonate was filtered then the solvent was evaporated and 
the product was isolated by column chromatography (ethyl acetate – hexane) 
followed by slow precipitation from chloroform - diethylether (0.26 g, 71%) as a 
pale yellow amorphous solid; RF 0.25 (ethyl acetate - hexane 1-1); δC (500 MHz, 
DMSO-d6) 1.56 (s, 9H, tBu), 4.19 (t, 1H, J = 5.8 Hz, FHβ), 4.56 (d, 2H, J = 5.8 Hz, 
FHα), 4.93 (s, 2H, Hα), 7.07 (d, 2H, J = 7.7 Hz, H3), 7.15 (t, 2H, J = 7.3 Hz, FH4), 
7.31 (d, 2H, J = 7.7 Hz, FH5), 7.33-7.36 (m, 4H, ArCH), 7.41 (d, 1H, J = 1.8 Hz, 
HAr4), 7.75 (d, 2H, J = 8.2 Hz, FH2), 7.76 (d, 2H, J = 8.8 Hz, H2), 7.97 (d, 1H, J = 8.2 
Hz, HAr7); δC (125 MHz, DMSO-d6) 27.55 (CH3-C), 43.93 (CH2), 46.55 (CH-CH3), 
66.94 (CH3-CH), 84.42 (C-CH3), 103.35 (ArC-CH2), 106.93 (ArC-HAr7), 116.23 
(ArC-HAr4), 124.48 (ArC-FH2), 124.69 (ArC-H3), 125.91 (ArC-HAr2), 126.37 
(ArC-Cl), 126.80 (ArC-FH3), 127.11 (ArC-COOH), 127.33 (ArC-FH5), 128.35 (ArC-
FH4), 129.80 (ArC-C-CH2), 130.19 (ArC-H2), 131.04 (ArC-HAr6), 133.23 (ArC-N-
COOtBu), 140.65 (ArC-F6), 143.53 (ArC-F1), 144.57 (ArC-N-CH2), 148.50 
(COOtBu), 154.29 (N-COOCH2), 166.64 (COOH); νmax/cm-1 (solid state) = ~3016 
(COOH), 1738 (CO), 1365 (C-N), 1217 (C-O); ESI-HRMS found m/z 621.1804 [M-
H]- C36H30ClN2O6 requires 621.1798. 
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4-(((Naphthalen-1-yl)methyl)amino)benzoic acid 21t  
4-Aminobenzoic acid (0.88 g, 6.4 mmol), 1-naphthaldehyde (1.00 g, 6.4 mmol) 
and picoline-borane complex (0.82 g, 7.7 mmol) were stirred at room 
temperature in methanol (20 mL) for 14 hours. A white precipitate formed. The 
precipitate was filtered and dried under high vacuum to yield the desired 
compound (1.35 g, 70%) as a colourless amorphous solid; RF 0.65 (10% methanol 
in dichloromethane); δH (300 MHz, DMSO-d6) 4.78 (d, 2H, J = 5.4 Hz, Hα), 6.70 (d, 
2H, J = 8.5 Hz, H3), 7.08 (t, 1H, J = 5.4 Hz, NH), 7.44-7.49 (m, 2H, ArCH), 7.55-7.59 
(m, 2H, ArCH), 7.67 (d, 2H, J = 8.5 Hz, H2), 7.86 (d, 1H, J = 6.6 Hz, ArCH), 7.97 (d, 
1H, J = 7.5 Hz, HAr2/4), 8.12 (d, 1H, J = 8.1 Hz, HAr4/2); δC (75 MHz, DMSO-d6) 
44.52 (CH2), 111.43 (ArC-H3), 117.50 (ArC-COOH), 123.92 (ArC-H), 125.42 (ArC-
H), 125.81 (ArC-H), 126.18 (ArC-H), 126.7 (ArC-H), 127.89 (ArC-H), 128.90 (ArC-
H), 131.42 (ArC-H2), 131.51 (ArC), 133.77 (ArC), 134.53 (ArC-CH2), 152.90 (ArC-
NH), 167.87 (COOH); νmax/cm-1 (solid state) = 3423 (NH), ~3000 (COOH), 1658 
(CO); ESI-MS m/z 300 [M+Na]+; ESI-HRMS found m/z 278.1184 [M+H]+ 
C18H16NO2 requires 278.1176. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)(naphthalen-1-
yl)methyl)amino)benzoic acid 22t 
To a refluxing solution of 21t (1.30 g, 4.3 mmol) in tetrahydrofuran (10 mL) was 
added dropwise a solution of Fmoc-Cl (1.18 g, 4.6 mmol) in tetrahydrofuran (10 
mL). The reaction mixture was stirred at reflux for 15 hours. The solvent was 
then removed under reduced pressure and the residue purified by column 
chromatography (30% ethyl acetate in hexane) to afford the title compound as a 
white amorphous solid (1.89 g, 87%); RF 0.27 (ethyl acetate - hexane 1-1); δH 
(300 MHz, CDCl3) 4.08 (t, 1H, J = 6.3 Hz, FHβ), 4.55 (d, 2H, J = 6.3 Hz, FHα),  5.34 
(s, 2H, Hα), 7.08-7.13 (m, 3H, ArCH), 7.09 (d, 2H, J = 8.1 Hz, H3), 7.17 (d, 2H, J = 
7.2 Hz, ArCH), 7.24-7.32 (m, 3H, ArCH), 7.51-7.55 (m, 2H, ArCH),  7.61 (d, 2H, J = 
7.5 Hz, ArCH), 7.75 (d, 1H, J = 8.1 Hz, ArCH), 7.83-7.89 (m, 1H, ArCH),  7.92 (d, 2H, 
J = 8.3 Hz, H2), 7.93-8.00 (m, 1H, ArCH); δC (75 MHz, CDCl3) 47.44 (CH-CH2), 
52.12 (CH2), 68.25 (CH2-CH), 120.31 (ArC-FH2), 123.52 (ArC-H3), 125.17 (ArC-
COOH), 125.71 (ArC-H), 126.01 (ArC-H), 126.358 (ArC-H), 126.41 (ArC-H), 
126.95 (ArC-H), 127.30 (ArC-H), 127.34 (ArC-H), 128.04 (ArC-H), 128.77 (ArC-H), 
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129.27 (ArC-H), 131.29 (ArC-H2), 131.37 (ArC), 132.41 (ArC), 134.17 (ArC-CH2), 
141.66 (ArC-F6), 143.88 (ArC-F1), 146.28 (ArC-N), 155.41 (N-COO), 171.74 
(COOH); ESI-HRMS found m/z 500.1854 [M+H]+ C33H26NO4 requires 500.1862. 
4-(((2-Methylnaphthalen-1-yl)methyl)amino)benzoic acid 21u 
4-Aminobenzoic acid (0.81 g, 5.9 mmol), 2-methyl-1-naphthaldehyde (1.00 g, 5.9 
mmol) and picoline-borane complex (0.72 g, 6.8 mmol) were stirred at room 
temperature in methanol (20 mL) for 14 hours. A white precipitate formed. The 
reaction mixture was filtered, and the filtrate acidified with 1N hydrochloric acid 
(~10 mL) to induce further precipitation. The combined precipitates were dried 
under high vacuum to yield the desired compound (1.60 g, 94%) as a colourless 
powder; RF 0.65 (10% methanol in dichloromethane); m.p. 209-211 oC; δH (300 
MHz, DMSO-d6) 2.52 (s, 3H, CH3), 4.61 (s, 2H, Hα), 6.55 (br s, 1H, NH), 6.78 (d, 2H, 
J = 8.9 Hz, H3),  7.43 (d, 1H, J = 8.4 Hz, HAr3), 7.46-7.56 (m, 2H, HAr6-HAr7), 7.73 
(d, 2H, J = 8.9 Hz, H2), 7.85 (d, 1H, J = 8.4 Hz, HAr4), 7.92 (d, 1H, J = 7.8 Hz, 
HAr5/8), 7.97 (d, 1H, J = 8.4 Hz, HAr8/5); δC (75 MHz, DMSO-d6) 19.92 (CH3), 
40.64 (CH2), 111.27 (ArC-H3), 117.36 (ArC-COOH), 124.04 (ArC-H), 125.23 (ArC-
H), 126.86 (ArC-H), 128.14 (ArC-H), 128.62 (ArC-H), 129.43 (ArC-H),131.01 (ArC-
H2), 131.45 (ArC), 132.38 (ArC), 135.37 (ArC-CH2), 153.07 (ArC-NH), 167.94 
(COOH); νmax/cm-1 (solid state) = 3373 (NH), ~3000 (COOH), 1738 (CO); ESI-MS 
m/z 314 [M+Na]+; ESI-HRMS found m/z 292.1332 [M+H]+ C19H18NO2 requires 
292.1327. 
4-((((9H-Fluoren-9-yl)methoxy)carbonyl)((2-methylnaphthalen-1-
yl)methyl)amino)benzoic acid 22u 
To a refluxing solution of 21u (1.60 g, 5.5 mmol) in tetrahydrofuran (10 mL) was 
added dropwise a solution of Fmoc-Cl (1.50 g, 5.8 mmol) in tetrahydrofuran (10 
mL). The reaction mixture was stirred at reflux for 15 hours. The solvents were 
evaporated and the residue crystallized from a mixture of tetrahydrofuran – 
hexane to yield the target compound as pale yellow crystals (2.43 g, 83%); RF 
0.53 (10% methanol in dichloromethane); m.p. 183-185 oC; δH (500 MHz, CDCl3) 
2.07 (s, 3H, CH3), 4.03 (t, 1H, J = 6.5 Hz, FHβ), 4.49 (d, 2H, J = 6.5 Hz, FHα), 5.38 (s, 
2H, Hα), 6.70 (d, 2H, J = 8.5 Hz, H3), 7.05 (d, 1H, J = 8.5 Hz, ArCH), 7.11-7.14 (m, 
4H, ArCH), 7.27-7.31 (m, 2H, ArCH), 7.41 (t, 1H, J = 7.0 Hz, FH3/4), 7.48-7.51 (m, 
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1H, ArCH), 7.60-7.64 (m, 3H, ArCH), 7.75 (d, 1H, J = 8.0 Hz, ArCH), 7.80 (d, 2H, J = 
8.5 Hz, H2), 8.15 (d, 1H, J = 8.5 Hz, ArCH); δC (125 MHz, CDCl3) 19.97 (CH3), 46.21 
(CH-CH2), 47.06 (CH2-N), 67.76 (CH2-CH), 119.87 (ArC-FH2), 119.97 (ArC-H3), 
123.78 (ArC-COOH), 124.86 (ArC-H), 125.02 (ArC-H), 126.93 (ArC-H), 127.63 
(ArC-H), 128.17 (ArC-H), 128.55 (ArC-H), 128.63 (ArC-H), 128.85 (ArC-H), 130.67 
(ArC-H), 132.44 (ArC-H2), 132.65 (ArC-CH3), 135.92 (ArC-CH2), 141.29 (ArC-F6), 
143.60 (ArC-F1), 144.96 (ArC-N), 155.22 (N-COO), 171.25 (COOH); νmax/cm-1 
(solid state) = ~3000 (COOH), 1738 (CO); ESI-MS m/z 536 [M+Na]+; ESI-HRMS 
found m/z 512.1879 [M-H]- C34H26NO4 requires 512.1867. 
4-(Cyclohexylmethylamino)benzoic acid 21w     
4-Aminobenzoic acid (1.50 g, 10.9 mmol), cyclohexanaldehyde (1.3 mL, 10.9 
mmol) and picoline-borane complex (1.35 g, 12.0 mmol) were stirred at room 
temperature in methanol (60 mL) for 14 hours. A white precipitate formed. The 
reaction mixture was filtered, and the filtrate acidified with 1N hydrochloric acid 
(~ pH 4) to induce further precipitation. The combined precipitates were dried 
under high vacuum to yield the desired compound (2.09 g, 82%) as a white 
powder; RF 0.48 (40% hexane in ethyl acetate); (Found: C, 71.90; H, 8.25; N, 
6.00%; C14H19NO2 requires: C, 72.07; H, 8.21; N, 6.00%); δH (500 MHz, MeOD) 
1.03 (dd, 2H, J1 = 11.7 Hz, J2 = 2.6 Hz, Hγ), 1.21-1.36 (m, 3H, Hδ, Hε), 1.63 (m, 1H, 
Hβ), 1.72 (d, 1H, J = 11.1 Hz, Hε’), 1.78 (d, 2H, J = 12.9 Hz, Hδ’), 1.87 (d, 2H, J = 11.7 
Hz, Hγ’), 3.01 (d, 2H, J = 6.8 Hz, Hα), 6.59 (d, 2H, J = 8.9 Hz, H3), 7.79 (d, 2H, J = 8.9 
Hz, H2); δC (75 MHz, MeOD) 27.15 (CHδ), 27.71 (CHε), 32.31 (CHγ), 38.70 (CHβ), 
50.70 (CHα), 111.98 (ArC-H3), 117.55 (ArC-COOH), 132.77 (ArC-H2), 154.83 
(ArC-NH), 170.87 (COOH); νmax/cm-1 (solid state) = 3417 (NH), ~3015 (COOH), 
1738 (CO), 1365 (C-N), 1217 (C-O); ESI-MS m/z 232 [M-H]-; ESI-HRMS found m/z 
234.1484 [M+H]+ C14H20NO2 requires 234.1489. 
4-((((9H-Fluoren-9-
yl)methoxy)carbonyl)(cyclohexylmethyl)amino)benzoic acid 22w    
To a refluxing solution of 4-(cyclohexylmethylamino)benzoic acid 21w (2.09 g, 
8.9 mmol) in tetrahydrofuran (30 mL) was added dropwise a solution of Fmoc-
chloride (2.65 g, 9.9 mmol) in tetrahydrofuran (5 mL). The reaction mixture was 
then stirred at reflux overnight. The solvents were evaporated, then the residue 
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was purified by column chromatography (Stationary phase : silica; Mobile phase : 
ethyl acetate–hexane 2-3 to neat ethyl acetate) then crystallised from 
dichloromethane–hexane to yield the pure target material (2.33 g, 57%) as 
colourless platelets; RF 0.25 (ethyl acetate–hexane 2-3); m.p. 150-152 oC; (Found: 
C, 75.50; H, 6.30; N, 3.10%; C29H29NO4 requires: C, 76.46; H, 6.42; N, 3.07%); δH 
(500 MHz, CDCl3) 0.72-0.84 (m, 2H, Hγ), 1.04-1.12 (m, 3H, Hδ, Hε), 1.35 (m, 1H, 
Hβ), 1.52 (d, 2H, J = 12.3 Hz, Hδ’), 1.51-1.66 (m, 3H, Hγ’, Hε’), 3.46 (d, 2H, J = 7.0 
Hz, Hα), 4.12 (t, 1H, J = 5.6 Hz, FHβ), 4.56 (d, 2H, J = 5.6 Hz, FHα), 7.15 (d, 2H, J = 
8.1 Hz, H3), 7.24 (t, 2H, J = 7.4 Hz, FH4), 7.34 (d, 2H, J = 7.4 Hz, FH5), 7.38 (t, 2H, J 
= 7.4 Hz, FH3), 7.72 (d, 2H, J = 7.5 Hz, FH2), 8.03 (d, 2H, J = 8.1 Hz, H2); δC (75 
MHz, CDCl3) 25.67 (CHδ), 26.33 (CHε), 30.47 (CHγ), 36.50 (CHβ), 47.24 (CH-CH2), 
55.89 (CHα), 67.04 (CH2-CH), 119.92 (ArC-FH2), 124.79 (ArC-H3), 126.84 (ArC-
FH3), 126.92 (ArC-COOH), 126.99 (ArC-FH5), 127.65 (ArC-FH4), 131.01 (ArC-
H2), 141.40 (ArC-F6), 143.71 (ArC-F1), 147.08 (ArC-N), 155.21 (N-COO), 171.23 
(COOH); νmax/cm-1 (solid state) = 3426 (NH), ~3015 (COOH), 1737 (CO), 1365 (C-
N), 1216 (C-O); ESI-HRMS found m/z 478.2007 [M+Na]+ C29H29NaNO4 requires 
478.1989. 
 
6.1.2 Solid phase synthesis experimental and N-alkylated oligobenzamides 
characterisation (Chapters 2 and 3)  
127 mg of Fmoc-Gly-Wang resin (0.79 mmol g-1, 100-200 mesh; carrier: 
polystyrene, crosslinked with 1% DVB) from NovaSyn was used throughout for 
the p53-targeted library. The sub-library of oligobenzamides targeting the Bcl-2 
family made use of:  Fmoc-Leu-Wang resin (0.64 mmol g-1), Fmoc-Ile-Wang resin 
(0.59 mmol g-1), Fmoc-Val-Wang resin (0.61 mmol g-1) and Fmoc-Asp(OtBu)-
Wang resin (0.29 mmol g-1). All solvents used were HPLC grade, anhydrous 
chloroform on molecular sieves was purchased from Acros Organics. 1-Chloro-
N,N,2-trimethyl-1-propenylamine (Ghosez’s reagent) was purchased from Sigma-
Aldrich. The reactions were all carried out on a CEM Liberty® automated 
microwave assisted peptide synthesiser. For each monomer the concentration of 
the preactivation mixture was about 1 mmol mL-1. The volume of the reaction 
mixture in the reaction vessel was 2.5 mL. The resin was swelled in Corning® 
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tubes in DMF for at least 30 minutes prior to coupling. Before coupling each 
amino acid, standard washing and deprotection cycles are carried out on the 
synthesiser. A filtered drain takes place in between every wash as follows: wash 
the reaction vessel from the top (‘DMF top’, 5 mL), then from the bottom (‘DMF 
bottom’, 7 mL), then ‘DMF top’ (5 mL), then add the deprotection mixture (6 mL), 
microwave method for the deprotection (cf. Fmoc deprotection paragraph); ‘DMF 
top’ (5 mL), ‘DMF bottom’ (7 mL) and finally ‘DMF top’ (5 mL) wash. 
Coupling  
Prior to the reaction, each fully protected monomer was dissolved in anhydrous 
chloroform (2.5 mL per coupling, i.e. 5 mL for a double coupling) in a dry 50 mL 
Corning® tube (stored in an oven at 60 °C for at least 24 hours), and preactivated 
with 0.9 eq. of Ghosez’s reagent at room temperature for 1-3 hours under a 
nitrogen atmosphere. For each monomer, a double coupling of 20 minutes was 
carried out under microwave heating at 60 °C. When required, sodium 
bicarbonate (50 mg, 0.59 mmol, excess) was added to the resin tube prior to 
swelling. 
Fmoc deprotection  
Before coupling of each monomer and after the last coupling reaction, two 
deprotection cycles were carried out on the CEM synthesiser using 6 mL of a 25% 
piperidine solution in DMF, under microwave heating at 75 °C. The initial 
deprotection lasts 30 seconds and is followed by a ‘DMF top’ wash and filtered 
drain. After a second addition of deprotection mixture, the deprotection is 
maintained under microwave heating for 3 minutes, and is again followed by 
DMF washes. 
Cleavage 
The cleavage step was carried out manually, in 1.5 mL ‘Extract-Clean’ 
polypropylene reservoirs fitted with 20 µm polyethylene frits, both available 
from Alltech. Triisopropylsilane (TIPS) was first investigated as a scavenger for 
this cleavage step, but proved to introduce a large amount of impurities in the 
isolated compound (observable on the 1H-NMR spectrum). It was also shown not 
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to be required, as cleavage without TIPS provided clean LC-MS and 1H-NMR 
spectra. As a result, no scavenger was used during this step. The resin was 
transferred to a reservoir then washed with CH2Cl2, then 1 mL of a 1-1 mixture of 
TFA in CH2Cl2 was added and the mixture was allowed to stir at room 
temperature for 30 minutes then the content of the reservoir was collected and 
the procedure was repeated. The resulting solution was then concentrated under 
reduced pressure to afford the target compound.  
 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-cyclopropylmethyl-4-aminobenzoyl)-
N-isobutyl-4-aminobenzoyl)-glycine 26 
> 90% pure by NMR, isolated crude yield: 60 mg; δH (300 MHz, MeOD) 0.01 (m, 
2H, 2-Hγ/γ'), 0.35 (m, 2H, 2-Hγ'/γ), 0.92-1.00 (m, 1H, 2-Hβ), 0.96 (d, 6H, J = 6.7 
Hz, 3-Hγ), 1.86 (m, 1H, 3-Hβ), 3.70 (d, 2H, J = 7.1 Hz, 3-Hα), 3.84 (d, 2H, J = 7.4 Hz, 
2-Hα), 4.05 (s, 2H, 1-Hα), 4.37 (s, 2H, 4-Hα), 6.52 (d, 2H, J = 8.7 Hz, 2-H3), 6.99 (d, 
2H, J = 8.3 Hz, 3-H2), 7.02 (d, 2H, J = 8.5 Hz, 2-H2), 7.17 (d, 2H, J = 8.4 Hz, 3-H3), 
7.20 (d, 2H, J = 8.4 Hz, 1-H3), 7.27-7.34 (m, 5H, HAr2-4), 7.72 (d, 2H, J = 8.5 Hz, 1-
H2); ESI-HRMS found m/z 631.2910 [M-H]- C38H39N4O5 requires 631.2926. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-benzyl-4-aminobenzoyl)-N-isobutyl-4-
aminobenzoyl)-glycine 27 
> 80% pure by NMR, isolated crude yield: 66 mg; δH (300 MHz, CDCl3) 0.85 (d, 6H, 
J = 6.6 Hz, 3-Hγ), 1.81 (m, 1H, 3-Hβ), 3.71 (d, 2H, J = 7.3 Hz, 3-Hα), 3.87 (d, 2H, J = 
5.2 Hz, 1-Hα), 4.34 (s, 2H, 2-Hα), 4.99 (s, 2H, 4-Hα), 6.65 (d, 2H, J = 8.4 Hz, 2-H3), 
6.88 (d, 2H, J = 8.2 Hz, 3-H2), 7.01 (d, 2H, J = 8.4 Hz, 2-H2), 7.08 (d, 2H, J = 8.4 Hz, 
3-H3),  7.13 (d, 2H, J = 7.7 Hz, 1-H3), 7.16-7.22 (m, 6H, 1-HAr3-5 and 2-HAr3-5), 
7.24-7.29 (m, 4H, 1-HAr2,6 and 2-HAr2,6), 7.52 (d, 2H, J = 8.2 Hz, 1-H2), 7.80 (t, 
1H, J = 5.2 Hz, NH); ESI-HRMS found m/z 667.2912 [M-H]- C41H39N4O5 requires 
667.2926.  
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-phenethyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 28  
> 90% pure by NMR, isolated crude yield: 58 mg; δH (300 MHz, MeOD) 0.98 (d, 
6H, J = 6.7 Hz, 3-Hγ), 1.89 (m, 1H, 3-Hβ), 2.88 (m, 2H, 2-Hβ), 3.85 (d, 2H, J = 7.5 Hz, 
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3-Hα), 4.01 (m, 2H, 2-Hα), 4.34 (s, 2H, 1-Hα), 4.90 (s, 2H, 4-Hα), 6.37 (d, 2H, J = 
8.9 Hz, 2-H3), 6.78 (d, 2H, J = 8.7 Hz, 3-H2), 6.93 (d, 2H, J = 8.7 Hz, 2-H2), 7.14-
7.35 (m, 14H, ArCH),  7.77 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS m/z 681.2 [M-H]-; ESI-
HRMS found m/z 681.3072 [M-H]- C42H41N4O5 requires 681.3082. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 30 
> 90% pure by NMR, isolated crude yield: 72 mg; δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 6.7 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.6 Hz, 3-Hα), 4.07 (s, 2H, 
1-Hα), 4.35 (s, 2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.50 (d, 2H, J = 8.8 Hz, 2-H3), 6.89 (d, 
2H, J = 8.5 Hz, 3-H2), 7.07 (d, 2H, J = 8.8 Hz, 2-H2), 7.15 (d, 2H, J = 8.5 Hz, 3-H3), 
7.16 (d, 2H, J = 8.7 Hz, 1-H3), 7.27-7.39 (m, 6H, 1-HAr2-6 and 2-HAr6), 7.44 (t, 1H, 
J = 7.7 Hz, 2-HAr5), 7.54 (d, 1H, J = 7.7 Hz, 2-HAr4), 7.60 (s, 1H, 2-HAr2), 7.73 (d, 
2H, J = 8.7 Hz, 1-H2); ESI-HRMS found m/z 735.2791 [M-H]- C42H38FN4O5 requires 
735.2800. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-4-chlorobenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 31 
Purified by Flash chromatography, > 95% pure by NMR, isolated yield: 4 mg; δH 
(300 MHz, MeOD) 0.83 (d, 6H, J = 6.7 Hz, 3-Hγ), 1.73 (m, 1H, 3-Hβ), 3.71 (d, 2H, J = 
7.3 Hz, 3-Hα), 3.89 (s, 2H, 1-Hα), 4.21 (s, 2H, 2-Hα), 4.91 (s, 2H, 4-Hα), 6.24 (d, 2H, 
J = 8.8 Hz, 2-H3), 6.74 (d, 2H, J = 8.5 Hz, 3-H2), 6.88 (d, 2H, J = 8.8 Hz, 2-H2), 7.01-
7.20 (m, 13H, ArCH), 7.64 (d, 2H, J = 8.3 Hz, 1-H2); ESI-MS m/z 701.3 [M-H]-; ESI-
HRMS found m/z 701.2525 [M-H]- C41H38ClN4O5 requires 701.2536. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-4-methylthiobenzyl-4-aminobenzoyl)-
N-isobutyl-4-aminobenzoyl)-glycine 32  
> 70% pure by NMR, isolated crude yield: 60 mg; δH (300 MHz, MeOD) 0.96 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.86 (m, 1H, 3-Hβ), 2.45 (s, 3H, SMe), 3.83 (d, 2H, J = 7.3 Hz, 
3-Hα), 4.10 (s, 2H, 1-Hα), 4.41 (s, 2H, 2-Hα), 5.02 (s, 2H, 4-Hα), 6.59 (d, 2H, J = 8.7 
Hz, 2-H3), 6.86 (d, 2H, J = 7.9 Hz, 3-H2), 7.08-7.18 (m, 10H, ArCH), 7.27-7.30 (m, 
1H, ArCH), 7.33-7.37 (m, 4H, ArCH), 7.74 (d, 2H, J = 8.2 Hz, 1-H2); ESI-MS m/z 
715.5 [M+H]+; ESI-HRMS found m/z 713.2830 [M-H]- C42H41N4O5S requires 
713.2803. 
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N-(N-(N-(Benzyl-4-aminobenzoyl)-N-4-hydroxybenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 33  
Purified by MS-directed prep HPLC, > 95% pure by NMR, isolated crude yield: 68 
mg; δH (300 MHz, MeOD) 0.96 (d, 6H, J = 6.8 Hz, 3-Hγ), 1.87 (m, 1H, 3-Hβ), 3.83 (d, 
2H, J = 7.7 Hz, 3-Hα), 4.10 (s, 2H, 1-Hα), 4.37 (s, 2H, 2-Hα), 4.96 (s, 2H, 4-Hα), 6.50 
(d, 2H, J = 8.3 Hz, 2-H3), 6.65 (d, 2H, J = 8.7 Hz, 3-H2), 6.83 (d, 2H, J = 8.3 Hz, 2-
H2),  6.98 (d, 2H, J = 8.5 Hz, 3-H3), 7.05 (d, 2H, J = 8.5 Hz, ArCH), 7.10-7.13 (m, 2H, 
ArCH), 7.16 (d, 2H, J = 8.1 Hz, ArCH), 7.25 (d, 2H, J = 8.5 Hz, ArCH), 7.30-7.35 (m, 
4H, ArCH), 7.74 (d, 2H, J = 8.3 Hz, 1-H2); ESI-MS m/z 685.5 [M+H]+; ESI-HRMS 
found m/z 683.2885 [M-H]- C41H39N4O6 requires 683.2875. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-2-carboxymethyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 36  
> 90% pure by NMR, isolated crude yield: 63 mg; δH (300 MHz, MeOD) 0.97 (d, 
6H, J = 6.7 Hz, 3-Hγ), 1.87 (m, 1H, 3-Hβ), 3.85 (d, 2H, J = 7.3 Hz, 3-Hα), 4.05 (s, 2H, 
1-Hα), 4.37 (s, 2H, 2-Hα), 4.48 (s, 2H, 4-Hα), 6.45 (d, 2H, J = 8.8 Hz, 2-H3), 6.99 (d, 
2H, J = 8.7 Hz, 3-H2), 7.03 (d, 2H, J = 8.4 Hz, 2-H2), 7.20 (d, 2H, J = 8.1 Hz, 3-H3), 
7.1 (d, 2H, J = 8.1 Hz, 1-H3), 7.25-7.36 (m, 5H, 1-HAr2-6), 7.75 (d, 2H, J = 8.4 Hz, 1-
H2); ESI-MS m/z 635.6 [M-H]-; ESI-HRMS found m/z 635.2517 [M-H]- C36H35N4O7 
requires 635.2511. 
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-(2-methyl)butyl-4-aminobenzoyl)-glycine 37   
> 95% pure by NMR, isolated crude yield: 76 mg; δH (300 MHz, MeOD) 0.88 (t, 3H, 
J = 7.5 Hz, 3-Hδ), 0.92 (d, 3H, J = 6.7 Hz, 3-Hε), 1.18 (m, 1H, 3-Hγ), 1.44 (m, 1H, 3-
Hγ’), 1.61 (m, 1H, 3-Hβ), 3.87 (d, 2H, J = 7.3 Hz, 3-Hα), 4.08 (s, 2H, 1-Hα), 4.35 (s, 
2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.42 (d, 2H, J = 8.8 Hz, 2-H3), 6.88 (d, 2H, J = 8.4 Hz, 
3-H2), 7.03 (d, 2H, J = 8.8 Hz, 2-H2), 7.14 (d, 2H, J = 8.5 Hz, 3-H3), 7.16 (d, 2H, J = 
8.5 Hz, 1-H3), 7.29-7.34 (m, 5H, 1-HAr2-6), 7.36 (d, 1H, J = 8.0 Hz, 2-HAr6), 7.43 
(t, 1H, J = 7.0 Hz, 2-HAr5), 7.53 (d, 1H, J = 8.0 Hz, 2-HAr4), 7.59 (s, 1H, 2-HAr2), 
7.71 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 783.2505 [M-H]- 
C43H39ClF3N4O5 requires 783.2567. 
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N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 41 
Crude: 70% pure; isolated crude yield: 44 mg then purified by Flash 
chromatography (6 mg), > 90% pure by NMR; δH (300 MHz, MeOD) 0.94 (d, 6H, J 
= 6.7 Hz, 1-Hγ), 0.98 (d, 6H, J = 6.6 Hz, 3-Hγ), 1.78-1.92 (m, 2H, 1-Hβ, 3-Hβ), 2.89 
(d, 2H, J = 6.8 Hz, 1-Hα), 3.82 (d, 2H, J = 6.8 Hz, 3-Hα), 4.02 (s, 2H, 2-Hα), 5.13 (s, 
2H, 4-Hα), 6.34 (d, 2H, J = 8.7 Hz, 2-H3), 6.91 (d, 2H, J = 8.4 Hz, 3-H2), 7.02 (d, 2H, 
J = 8.9 Hz, 2-H2), 7.17 (d, 2H, J = 8.7 Hz, 3-H3), 7.21 (d, 2H, J = 8.9 Hz, 1-H3), 7.41 
(d, 2H, J = 8.0 Hz, 2-HAr3), 7.57 (d, 2H, J = 8.9 Hz, 2-HAr2), 7.79 (d, 2H, J = 8.7 Hz, 
1-H2); ESI-MS found m/z 701.2 [M-H]-; ESI-HRMS found m/z 701.2926 [M-H]- 
C39H40F3N4O5 requires 701.2956. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(2-methyl)naphth-1-yl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 42 
> 95% pure by NMR, i solated crude yield: 70 mg; δH (300 MHz, MeOD) 0.90 (d, 
6H, J = 6.9 Hz, 3-Hγ), 1.79 (m, 1H, 3-Hβ), 3.76 (d, 2H, J = 6.9 Hz, 3-Hα), 4.14 (s, 2H, 
2-Hα), 4.32 (s, 2H, 1-Hα), 5.53 (s, 2H, 4-Hα), 6.40-6.45 (m, 4H, ArCH), 6.90 (d, 2H, 
J = 8.2 Hz, 3-H2), 6.99 (d, 2H, J = 8.2 Hz, 2-H2), 7.05 (d, 2H, J = 8.5 Hz, 3-H3), 7.15 
(d, 1H, J = 8.7 Hz, 1-H3), 7.25 (m, 1H, ArCH), 7.29-7.31 (m, 4H, ArCH), 7.40-7.51 
(m, 2H, ArCH), 7.69 (d, 1H, J = 8.9 Hz, ArCH), 7.72 (d, 2H, J = 8.3 Hz, ArCH), 7.82 (d, 
1H, J = 8.0 Hz, 1-H2), 8.12 (d, 1H, J = 8.5 Hz, ArCH); ESI-HRMS found m/z 
731.3222 [M-H]- C46H43N4O5 requires 731.3239. 
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-4-chlorobenzyl-4-aminobenzoyl)-
N-isobutyl-4-aminobenzoyl)-glycine 43 
> 90% pure by NMR, isolated crude yield: 58 mg, purified by precipitation: 12 mg; 
δH (300 MHz, MeOD) 0.94 (d, 6H, J = 6.7 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 2.91 (t, 2H, 
J = 7.6 Hz, 1-Hβ), 3.45 (t, 2H, J = 7.6 Hz, 1-Hα), 3.82 (d, 2H, J = 7.4 Hz, 3-Hα), 4.12 
(s, 2H, 2-Hα), 5.04 (s, 2H, 4-Hα), 6.53 (d, 2H, J = 8.7 Hz, 2-H3), 6.88 (d, 2H, J = 8.6 
Hz, 3-H2), 7.10 (d, 2H, J = 8.8 Hz, 2-H2), 7.15 (d, 2H, J = 8.6 Hz, 3-H3), 7.16-7.21 
(m, 4H, ArCH), 7.22-7.31 (m, 7H, ArCH), 7.74 (d, 2H, J = 8.7 Hz, ArCH); ESI-MS 
found m/z 717.3 [M+H]+. 
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N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-3-fluorobenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 44 
> 80% pure by NMR, isolated crude yield: 71 mg; δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 6.8 Hz, 3-Hγ), 1.02 (d, 6H, J = 6.4 Hz, 1-Hγ), 1.86 (m, 1H, 3-Hβ), 1.95 (m, 1H, 
1-Hβ), 2.99 (t, 2H, J = 7.2 Hz, 3-Hα), 3.83 (t, 2H, J = 7.2 Hz, 1-Hα), 4.13 (s, 2H, 2-
Hα), 5.08 (s, 2H, 4-Hα), 6.60 (d, 2H, J = 8.3 Hz, 2-H3), 6.90 (d, 2H, J = 8.3 Hz, 3-H2), 
6.96-6.99 (m, 2H, ArCH), 7.02 (d, 1H, J = 8.9 Hz, ArCH), 7.13-7.16 (m, 4H, 2-H2, 3-
H3), 7.18 (d, 2H, J = 8.7 Hz, 1-H3), 7.26 (m, 1H, ArCH), 7.75 (d, 2H, J = 8.3 Hz, 1-
H2); ESI-HRMS found m/z 651.2960 [M-H]- C38H40FN4O5 requires 651.2988. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-4-fluorobenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 45 
> 80% pure by NMR, isolated crude yield: 62 mg; δH (300 MHz, MeOD) 0.90 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.80 (m, 1H, 3-Hβ), 3.76 (d, 2H, J = 7.2 Hz, 3-Hα), 4.03 (s, 2H, 
2-Hα), 4.33 (s, 2H, 1-Hα), 4.98 (s, 2H, 4-Hα), 6.49 (d, 2H, J = 8.7 Hz, 2-H3), 6.79 (d, 
2H, J = 8.3 Hz, 3-H2), 6.90 (d, 2H, J = 8.5 Hz, 2-H2), 6.92 (d, 2H, J = 8.7 Hz, ArCH), 
7.02 (d, 2H, J = 8.5 Hz, ArCH), 7.07 (d, 2H, J = 8.3 Hz, ArCH), 7.09 (d, 2H, J = 8.3 Hz, 
ArCH), 7.13 (d, 2H, J = 8.2 Hz, ArCH), 7.15 (d, 2H, J = 8.3 Hz, ArCH), 7.22 (m, 1H, 1-
HAr4), 7.26-7.30 (m, 4H, 1-HAr2,3), 7.67 (d, 2H, J = 8.3 Hz, 1-H2); ESI-HRMS 
found m/z 685.2804 [M-H]- C41H38FN4O5 requires 685.2832. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-3-fluorobenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 46 
> 95% pure by NMR, isolated crude yield: 68 mg;  δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 6.7 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.4 Hz, 3-Hα), 4.07 (s, 2H, 
2-Hα), 4.36 (s, 2H, 1-Hα), 5.06 (s, 2H, 4-Hα), 6.47 (d, 2H, J = 8.8 Hz, 2-H3), 6.88 (d, 
2H, J = 8.5 Hz, 3-H2), 6.92-7.00 (m, 3H, 2-HAr4,5,6), 7.05 (d, 2H, J = 8.6 Hz, 2-H2), 
7.14 (d, 2H, J = 8.5 Hz, 3-H3), 7.16 (d, 2H, J = 8.6 Hz, 1-H3), 7.21-7.27 (m, 2H, 1-
HAr2), 7.29-7.36 (m, 3H, 1-HAr3,4), 7.34 (s, 1H, 2-HAr2), 7.75 (d, 2H, J = 8.5 Hz, 1-
H2); ESI-HRMS found m/z 685.2849 [M-H]- C41H38FN4O5 requires 685.2832. 
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N-(N-(N-(Benzyl-4-aminobenzoyl)-N-naphth-1-yl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 47 
 > 90% pure by NMR, isolated crude yield: 71 mg; Crude: 85% pure; δH (300 MHz, 
MeOD) 0.89 (d, 6H, J = 6.6 Hz, 3-Hγ), 1.77 (m, 1H, 3-Hβ), 3.75 (d, 2H, J = 7.6 Hz, 
3-Hα), 4.10 (m, 2H, 1-Hα), 4.40 (s, 2H, 2-Hα), 5.55 (s, 2H, 4-Hα), 6.66 (d, 2H, J = 
8.8 Hz, 2-H3), 6.67 (d, 2H, J = 8.5 Hz, 3-H2), 6.97 (d, 2H, J = 8.5 Hz, ArCH), 7.05 (d, 
2H, J = 8.6 Hz, ArCH), 7.11 (d, 2H, J = 8.6 Hz, ArCH), 7.16 (d, 1H, J = 7.0 Hz, ArCH), 
7.25-7.31 (m, 2H, ArCH), 7.33-7.35 (m, 4H, ArCH), 7.45-7.55 (m, 2H, ArCH), 7.67 
(d, 2H, J = 8.5 Hz, 1-H2), 7.75 (d, 1H, J = 8.2 Hz, ArCH), 7.85 (dd, 1H, J1 = 7.2 Hz and 
J2 = 1.9 Hz, ArCH), 8.17 (d, 1H, J = 7.7 Hz, ArCH); ESI-HRMS found m/z 717.3080 
[M-H]- C45H41N4O5 requires 717.3082. 
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-3-aminopropyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 48 
Purified by column chromatography, > 85% pure by NMR, isolated yield: 6%; δH 
(300 MHz, MeOD) 0.91-0.99 (m, 12H, 1-Hγ and 3-Hγ), 1.73 (m, 1H, 1-Hβ), 1.82 
(m, 2H, 2-Hβ), 1.88 (m, 1H, 3-Hβ), 2.95 (m, 2H, 2-Hγ), 3.17 (t, 2H, J = 6.0 Hz, 2-Hα), 
3.86 (d, 2H, J = 8.0 Hz, 1-Hα), 4.09 (m, 2H, 3-Hα), 4.88 (s, 2H, 4-Hα, under solvent 
peak), 6.33 (d, 2H, J = 9.1 Hz, 2-H3), 6.99 (d, 2H, J = 8.7 Hz, 3-H2), 7.03 (d, 2H, J = 
8.7 Hz, 2-H2), 7.20-7.26 (m, 4H, 3-H3, 1-H3), 7.78 (d, 2H, J = 8.7 Hz, 1-H2); ESI-MS 
m/z 602.4 [M+H]+; ESI-HRMS found m/z 600.3182 [M-H]- C34H42N5O5 requires 
600.3191.  
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-4-fluorobenzyl-4-aminobenzoyl)-N-
propyl-4-aminobenzoyl)-glycine 49 
> 85% pure by NMR, isolated crude yield: 64 mg; δH (500 MHz, MeOD) 1.95 (t, 3H, 
J = 7.6 Hz, 3-Hγ), 1.63 (m, 2H, 3-Hβ), 3.91 (t, 2H, J = 7.6 Hz, 3-Hα), 4.10 (s, 2H, 1-
Hα), 4.41 (s, 2H, 2-Hα), 5.05 (s, 2H, 4-Hα), 6.67 (d, 2H, J = 7.8 Hz, 2-H3), 6.86 (d, 
2H, J = 8.5 Hz, 3-H2), 6.98 (t, 2H, J = 8.8 Hz, 1-HAr4), 7.12-7.15 (m, 6H, ArCH), 7.21 
(dd, 2H, J1 = 8.8 Hz and J2 = 5.4 Hz, ArCH), 7.31 (m, 1H, ArCH), 7.34-7.38 (m, 4H, 
ArCH), 7.73 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 671.2653 [M-H]- 
C40H36FN4O5 requires 671.2675. 
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N-(N-(N-(3-Fluorobenzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 50 
 > 85% pure by NMR, isolated crude yield: 71 mg; δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.83 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.4 Hz, 3-Hα), 4.14 (s, 2H, 
1-Hα), 4.37 (s, 2H, 2-Hα), 5.17 (s, 2H, 4-Hα), 6.37 (d, 2H, J = 8.8 Hz, 2-H3), 6.90 (d, 
2H, J = 8.2 Hz, 3-H2), 6.91 (d, 1H, J = 8.2 Hz, 1-HAr6), 7.02 (d, 2H, J = 8.8 Hz, 2-H2), 
7.15 (d, 2H, J = 8.5 Hz, 3-H3), 7.16 (d, 2H, J = 8.4 Hz, 1-H3), 7.23 (d, 1H, J = 8.5 Hz, 
ArCH), 7.29 (m, 1H, ArCH), 7.37 (m, 1H, HAr), 7.44 (t, 1H, J = 8.0 Hz, 2-HAr5), 7.53 
(d, 1H, J = 8.5 Hz, 2-HAr4), 7.60 (s, 1H, 2-HAr2), 7.72 (d, 1H, J = 8.5 Hz, ArCH), 7.73 
(d, 2H, J = 8.8 Hz, 1-H2); ESI-HRMS found m/z 755.2832 [M+H]+ C42H39F4N4O5 
requires 755.2851. 
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 51 
> 85% pure by NMR, isolated crude yield: 67 mg; δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 6.9 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.83 (d, 2H, J = 7.1 Hz, 3-Hα), 4.14 (s, 2H, 
1-Hα), 4.34 (s, 2H, 2-Hα), 5.18 (s, 2H, 4-Hα), 6.39 (d, 2H, J = 8.8 Hz, 2-H3), 6.90 (d, 
2H, J = 8.0 Hz, 3-H2), 7.02 (d, 2H, J = 8.8 Hz, 2-H2), 7.13 (d, 2H, J = 8.5 Hz, 3-H3), 
7.16 (d, 2H, J = 8.5 Hz, 1-H3), 7.28-7.32 (m, 4H, 1-HAr2,3,5,6), 7.37 (d, 1H, J = 8.2 
Hz, 2-HAr6), 7.44 (t, 1H, J = 7.9 Hz, 2-HAr5), 7.53 (d, 1H, J = 8.2 Hz, 2-HAr4), 7.60 
(s, 1H, 2-HAr2), 7.70 (d, 2H, J = 8.8 Hz, 1-H2); ESI-MS found m/z 772.2 [M+H]+. 
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 52 
> 85% pure by NMR, isolated crude yield: 74 mg; δH (300 MHz, MeOD) 0.94 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.3 Hz, 3-Hα), 4.14 (s, 2H, 
1-Hα), 4.33 (s, 2H, 2-Hα), 5.17 (s, 2H, 4-Hα), 6.41(d, 2H, J = 8.8 Hz, 2-H3), 6.87-
6.92 (m, 2H, ArCH), 6.98-7.07 (m, 2H, ArCH), 7.13-7.17 (m, 4H, ArCH), 7.28 (d, 2H, 
J = 8.7 Hz, ArCH), 7.36 (dd, 1H, J1 = 8.8 Hz and J2 = 5.8 Hz, ArCH), 7.45 (d, 2H, J = 
8.2 Hz, ArCH), 7.52-7.57 (m, 2H, ArCH), 7.60 (s, 1H, 2-HAr2), 7.70-7.74 (m, 2H, 
ArCH); ESI-HRMS found m/z 753.2734 [M-H]- C42H37F4N4O5 requires 753.2706. 
 
Chapter 6: Experimental Section 
 
148 
 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-5-bromoindol-3-yl-4-aminobenzoyl)-
N-isobutyl-4-aminobenzoyl)-glycine 53 
> 85% pure by NMR, isolated crude yield: 73 mg; δH (300 MHz, MeOD) 0.93 (d, 
6H, J = 6.7 Hz, 3-Hγ), 1.86 (m, 1H, 3-Hβ), 3.81 (d, 2H, J = 7.4 Hz, 3-Hα), 4.07 (s, 2H, 
1-Hα), 4.33 (s, 2H, 2-Hα), 5.19 (s, 2H, 4-Hα), 6.48 (d, 2H, J = 8.6 Hz, 2-H3), 6.72 (d, 
2H, J = 8.4 Hz, 3-H2), 7.00-7.07 (m, 3H, ArCH), 7.10-7.18 (m, 4H, ArCH), 7.23 (d, 
2H, J = 8.9 Hz, ArCH), 7.28-7.34 (m, 4H, ArCH), 7.71 (d, 2H, J = 8.5 Hz, 1-H2), 7.78 
(d, 2H, J = 8.8 Hz, ArCH); ESI-HRMS found m/z 784.2137 [M-H]- C43H39BrN5O5 
requires 784.2140. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-cyclohexylmethyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 54 
> 80% pure by NMR, isolated crude yield: 69 mg; δH (300 MHz, MeOD) 0.91 (d, 
6H, J = 6.8 Hz, 3-Hγ), 0.91-0.95 (m, 2H, 2-Hε), 1.06-1.11 (m, 4H, 2-Hδ,δ'), 1.56-
1.66 (m, 5H, 2-Hγ,γ',β), 1.82 (m, 1H, 3-Hβ), 3.68 (d, 2H, J = 7.2 Hz, 3-Hα), 3.79 (d, 
2H, J = 7.6 Hz, 2-Hα), 4.01 (s, 2H, 1-Hα), 4.34 (s, 2H, 4-Hα), 6.50 (d, 2H, J = 8.5 Hz, 
2-H3), 6.91 (d, 2H, J = 8.3 Hz, 3-H2), 6.85 (d, 2H, J = 8.5 Hz, 2-H2), 7.13 (d, 2H, J = 
8.3 Hz, 3-H3), 7.14 (d, 2H, J = 8.3 Hz, 1-H3), 7.22 (m, 1H, 1-HAr4), 7.26-7.31 (m, 
4H, 1-HAr2,3), 7.68 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 673.3419 [M-
H]- C41H45N4O5 requires 673.3395. 
N-(N-(N-(3-Fluorobenzyl-4-aminobenzoyl)-N-phenethyl-4-aminobenzoyl)-
N-propyl-4-aminobenzoyl)-glycine 55 
> 75% pure by NMR, isolated crude yield: 57 mg; δH (300 MHz, MeOD) 0.94 (t, 3H, 
J = 7.4 Hz, 3-Hγ), 1.62 (m, 2H, 3-Hβ), 2.86 (t, 2H, J = 7.4 Hz, 3-Hα), 3.90 (t, 2H, J = 
7.5 Hz, 2-Hβ), 3.99 (t, 2H, J = 7.5 Hz, 2-Hα), 4.04 (s, 2H, 1-Hα), 4.34 (s, 2H, 4-Hα), 
6.43 (d, 2H, J = 8.7 Hz, 2-H3), 6.75 (d, 2H, J = 8.5 Hz, 3-H2), 6.93 (d, 2H, J = 8.7 Hz, 
2-H2), 7.12-7.16 (m, 6H, ArCH), 7.22-7.26 (m, 4H, ArCH), 7.29-7.33 (m, 4H, ArCH), 
7.74 (d, 2H, J = 8.7 Hz, 1-H2); ESI-HRMS found m/z 667.2893 [M-H]- C41H39N4O5 
requires 667.2926. 
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N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-cyclohexylmethyl-4-aminobenzoyl)-glycine 56 
> 90% pure by NMR, isolated crude yield: 72 mg; δH (300 MHz, MeOD) 1.04 (m, 
2H, 3-Hε), 1.13-1.23 (m, 4H, 3-Hδ,δ'), 1.55 (m, 1H, 3-Hβ), 1.65-1.74 (m, 4H, 3-
Hγ,γ'), 3.83 (d, 2H, J = 7.0 Hz, 3-Hα), 4.07 (s, 2H, 1-Hα), 4.37 (s, 2H, 2-Hα), 5.14 (s, 
2H, 4-Hα), 6.51 (d, 2H, J = 8.8 Hz, 2-H3), 6.88 (d, 2H, J = 8.4 Hz, 3-H2), 7.07 (d, 2H, 
J = 8.8 Hz, 2-H2), 7.12-7.16 (m, 4H, ArCH), 7.30-7.36 (m, 4H, ArCH), 7.41-7.46 (m, 
2H, ArCH), 7.53 (d, 1H, J = 8.6 Hz, 2-HAr4), 7.59 (s, 1H, 2-HAr2), 7.72 (d, 2H, J = 
8.5 Hz, 1-H2), 7.99 (s, 1H, NH); ESI-HRMS found m/z 775.3127 [M-H]- 
C45H42F3N4O5 requires 775.3113.  
N-(N-(N-(Cyclopropylmethyl-4-aminobenzoyl)-N-phenethyl-4-
aminobenzoyl)-N-3-fluorobenzyl-4-aminobenzoyl)-glycine 57 
> 95% pure by NMR, isolated crude yield: 68 mg; δH (300 MHz, CDCl3) 0.39 (m, 
2H, 1-Hγ), 0.71 (m, 2H, 1-Hγ'), 1.12 (m, 1H, 1-Hβ), 2.94 (t, 2H, J = 7.4 Hz, 2-Hβ), 
3.20 (d, 2H, J = 7.4 Hz, 1-Hα), 4.11-4.16 (m, 4H, 2-Hα and 3-Hα), 5.13 (s, 2H, 4-
Hα), 6.66 (d, 2H, J = 8.4 Hz, 2-H3), 6.92 (d, 2H, J = 8.5 Hz, 3-H2), 6.96-7.02 (m, 4H, 
ArCH), 7.15-7.18 (m, 4H, ArCH), 7.22-7.25 (m, 4H, ArCH), 7.27-7.29 (m, 2H, 
ArCH), 7.32 (d, 2H, J = 8.5 Hz, 1-H3), 7.56 (d, 2H, J = 8.5 Hz, 1-H2), 8.82 (t, 1H, J = 
5.8 Hz, Ar-NH); ESI-HRMS found m/z 697.2855 [M-H]- C42H38FN4O5 requires 
697.2832.  
N-(N-(N-(3-Fluorobenzyl-4-aminobenzoyl)-N-phenethyl-4-aminobenzoyl)-
N-cyclopropylmethyl-4-aminobenzoyl)-glycine 58 
> 90% pure by NMR, isolated crude yield: 69 mg; δH (300 MHz, CDCl3) 0.19 (m, 
2H, 3-Hγ), 0.48 (m, 2H, 3-Hγ'), 1.06 (m, 1H, 3-Hβ), 2.92 (t, 2H, J = 7.5 Hz, 2-Hβ), 
3.84 (d, 2H, J = 7.0 Hz, 3-Hα), 4.00 (m, 2H, 1-Hα), 4.11 (t, 2H, J = 7.5 Hz, 2-Hα), 
4.42 (s, 2H, 4-Hα), 6.64 (d, 2H, J = 8.5 Hz, 2-H3), 7.06 (d, 2H, J = 8.4 Hz, 3-H2), 
7.11-7.19 (m, 10H, ArCH), 7.24-7.28  (m, 4H, ArCH), 7.31-7.35  (m, 1H, ArCH), 
7.62 (d, 2H, J = 8.4 Hz, 1-H2), 8.78 (t, 1H, J = 4.8 Hz, Ar-NH); ESI-HRMS found m/z 
697.2859 [M-H]- C42H38FN4O5 requires 697.2832.  
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N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 59 
> 85% pure by NMR, isolated crude yield: 67 mg;  δH (300 MHz, MeOD) 0.94 (d, 
6H, J = 6.7 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 2.95 (t, 2H, J = 7.5 Hz, 1-Hβ), 3.45 (t, 2H, J 
= 7.5 Hz, 1-Hα), 3.82 (d, 2H, J = 7.5 Hz, 3-Hα), 4.12 (s, 2H, 2-Hα), 5.15 (s, 2H, 4-
Hα), 6.69 (d, 2H, J = 8.6 Hz, 2-H3), 6.92 (d, 2H, J = 8.5 Hz, 3-H2), 7.14-7.19 (m, 6H, 
ArCH), 7.23-7.32 (m, 5H, ArCH), 7.42 (d, 2H, J = 8.0 Hz, ArCH), 7.58 (d, 2H, J = 8.6 
Hz, ArCH), 7.73 (d, 2H, J = 8.6 Hz, 1-H2); ESI-HRMS found m/z 749.2967 [M-H]- 
C43H40F3N4O5 requires 749.2956. 
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-cyclohexylmethyl-4-
aminobenzoyl)-N-propyl-4-aminobenzoyl)-glycine 60 
> 85% pure by NMR, isolated crude yield: 60 mg; δH (300 MHz, MeOD) 0.96 (t, 3H, 
J = 7.2 Hz, 3-Hγ), 0.96-1.04 (m, 2H, 2-Hε), 1.10-1.19 (m, 2H, 2-Hδ), 1.47 (m, 2H, 2-
Hδ'), 1.60-1.73 (m, 7H, 3Hβ, 2-Hγ,γ',β), 3.73 (d, 2H, J = 7.1 Hz, 2-Hα), 3.93 (t, 2H, J 
= 7.6 Hz, 3-Hα), 4.06 (s, 2H, 1-Hα), 4.33 (s, 2H, 4-Hα), 6.40 (d, 2H, J = 8.8 Hz, 
2-H3), 6.93 (d, 2H, J = 8.5 Hz, 3-H2), 6.96 (d, 2H, J = 8.3 Hz, 1-HAr2), 7.02 (d, 2H, J 
= 8.8 Hz, 2-H2), 7.18 (d, 2H, J = 8.2 Hz, 1-HAr3), 7.21 (d, 2H, J = 8.5 Hz, 3-H3), 7.35 
(d, 2H, J = 8.5 Hz, 1-H3), 7.76 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 
677.3129 [M-H]- C40H42FN4O5 requires 677.3145. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-N-benzyl-4-
aminobenzoyl)-glycine 61 
> 75% pure by NMR, isolated crude yield: 58 mg; δH (500 MHz, CDCl3) 0.89 (d, 6H, 
J = 6.7 Hz, 2-Hγ), 1.81 (m, 1H, 2-Hβ), 3.78 (d, 2H, J = 7.6 Hz, 3-Hα), 3.97 (d, 2H, J = 
5.7 Hz, 1-Hα), 4.41 (s, 2H, 2-Hα), 5.13 (s, 2H, 4-Hα), 6.85 (d, 2H, J = 8.6 Hz, 2-H3), 
6.88 (d, 2H, J = 8.5 Hz, 3-H2), 7.11 (d, 2H, J = 8.6 Hz, 2-H2), 7.16 (d, 2H, J = 8.5 Hz, 
3-H3), 7.20 (d, 2H, J = 8.4 Hz, 1-H3), 7.24-7.32 (m, 10H, ArCH), 7.52 (d, 2H, J = 8.4 
Hz, 1-H2), 7.78 (t, 1H, J = 6.0 Hz, Ar-NH); ESI-HRMS found m/z 667.2926 [M-H]- 
C41H39N4O5 requires 667.2926. 
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N-(N-(N-(Benzyl-4-aminobenzoyl)-N-naphth-2-yl-4-aminobenzoyl)-N-
cyclopropylmethyl-4-aminobenzoyl)-glycine 62 
> 80% pure by NMR, isolated crude yield: 66 mg; δH (300 MHz, CDCl3) 0.15 (m, 
2H, 3-Hγ), 0.43 (m, 2H, 3-Hγ'), 0.86 (m, 1H, 3-Hβ), 3.78 (d, 2H, J = 7.0 Hz, 3-Hα), 
3.96 (d, 2H, J = 4.9 Hz, 1-Hα), 4.40 (s, 2H, 2-Hα), 5.22 (s, 2H, 4-Hα), 6.75 (d, 2H, J = 
8.4 Hz, 2-H3), 6.99 (d, 2H, J = 8.2 Hz, 3-H2), 7.06-7.11 (m, 4H, ArCH), 7.24 (s, 1H, 
2-HAr2), 7.34-7.37 (m, 5H, ArCH), 7.44-7.47 (m, 3H, ArCH), 7.59-7.65 (m, 3H, 
ArCH), 7.77 (d, 2H, J = 8.8 Hz, 1-H2), 7.74-7.81 (m, 2H, ArCH); ESI-HRMS found 
m/z 715.2929 [M-H]- C45H39N4O5 requires 715.2926. 
 N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-naphth-2-yl-4-
aminobenzoyl)-N-cyclopropylmethyl-4-aminobenzoyl)-glycine 63 
> 90% pure by NMR, isolated crude yield: 71 mg; δH (500 MHz, CDCl3) 0.42 (m, 
2H, 3-Hγ), 0.72 (m, 2H, 3-Hγ'), 0.86 (m, 1H, 3-Hβ), 3.19 (d, 2H, J = 7.4 Hz, 3-Hα), 
4.09 (d, 2H, J = 5.2 Hz, 1-Hα), 5.07 (s, 2H, 2-Hα), 5.27 (s, 2H, 4-Hα), 6.81 (d, 2H, J = 
8.2 Hz, 2-H3), 6.88 (d, 2H, J = 8.2 Hz, 3-H2), 7.13-7.19 (m, 4H, ArCH), 7.25 (d, 2H, J 
= 8.4 Hz, ArCH), 7.33-7.39 (m, 5H, ArCH), 7.45-7.48 (m, 2H, ArCH), 7.59 (d, 2H, J = 
8.2 Hz, ArCH), 7.66 (s, 1H, 2-HAr2), 7.78 (d, 2H, J = 8.4 Hz, 1-H2), 7.78-7.82 (m, 
1H, ArCH), 7.95 (t, 1H, J = 5.2 Hz, Ar-NH); ESI-HRMS found m/z 749.2560 [M-H]- 
C45H38ClN4O5 requires 749.2536. 
N-(N-(N-((3-Trifluoromethyl)benzyl-4-aminobenzoyl)-N-(3-
trifluoromethyl)benzyl-4-aminobenzoyl)-N-benzyl-4-aminobenzoyl)-
glycine 64 
> 90% pure by NMR, isolated crude yield: 83 mg; δH (300 MHz, MeOD) 4.05 (s, 
2H, 3-Hα), 4.43 (s, 2H, 1-Hα), 5.14 (s, 2H, 2-Hα), 5.16 (s, 2H, 4-Hα), 6.36 (d, 2H, J = 
8.8 Hz, 2-H3), 6.89 (d, 2H, J = 8.5 Hz, 3-H2), 7.00 (d, 2H, J = 8.5 Hz, 3-H3),  7.01 (d, 
2H, J = 8.6 Hz, 2-H2), 7.21 (d, 2H, J = 8.5 Hz, 1-H3), 7.24-7.28 (m, 6H, ArCH), 7.37 
(d, 1H, J = 7.8 Hz, ArCH), 7.42 (d, 1H, J = 7.7 Hz, ArCH), 7.46-7.51 (m, 2H, ArCH), 
7.57-7.59 (m, 3H, ArCH), 7.63 (d, 2H, J = 8.6 Hz, 1-H2); ESI-HRMS found m/z 
837.2558 [M-H]- C46H35F6N4O5 requires 837.2517. 
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N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-naphth-2-yl-4-aminobenzoyl)-
N-cyclopropylmethyl-4-aminobenzoyl)-glycine 65 
> 95% pure by NMR, isolated crude yield: 73 mg; δH (300 MHz, MeOD) 0.14 (m, 
2H, 3-Hγ), 0.45 (m, 2H, 3-Hγ'), 1.06 (m, 1H, 3-Hβ), 3.81 (d, 2H, J = 7.1 Hz, 3-Hα), 
4.09 (s, 2H, 1-Hα), 4.36 (s, 2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.45 (d, 2H, J = 8.8 Hz, 2-
H3), 6.88 (d, 2H, J = 8.4 Hz, 3-H2), 7.05 (d, 2H, J = 8.8 Hz, 2-H2),  7.17 (d, 2H, J = 8.4 
Hz, 3-H3), 7.19 (d, 2H, J = 8.5 Hz, 1-H3), 7.30-7.33 (m, 4H, 1-HAr2,3), 7.37 (d, 1H, J 
= 7.6 Hz, 2-HAr6), 7.43 (t, 1H, J = 7.6 Hz, 2-HAr5), 7.53 (d, 1H, J = 7.5 Hz, 2-HAr4), 
7.59 (s, 1H, 2-HAr2), 7.73 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 767.2263 
[M-H]- C42H35ClF3N4O5 requires 767.2254. 
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-naphth-2-yl-4-aminobenzoyl)-
N-propyl-4-aminobenzoyl)-glycine 66 
> 90% pure by NMR, isolated crude yield: 69 mg; δH (300 MHz, MeOD) 0.91 (t, 3H, 
J = 7.4 Hz, 3-Hγ), 1.59 (m, 2H, 3-Hβ), 3.87 (t, 2H, J = 7.5 Hz, 3-Hα), 4.09 (s, 2H, 1-
Hα), 4.33 (s, 2H, 2-Hα), 5.23 (s, 2H, 4-Hα), 6.41 (d, 2H, J = 8.8 Hz, 2-H3), 6.88 (d, 
2H, J = 8.5 Hz, 3-H2), 6.89 (d, 2H, J = 8.5 Hz, ArCH), 7.11 (d, 2H, J = 8.5 Hz, ArCH), 
7.12 (d, 2H, J = 8.8 Hz, ArCH), 7.28 (d, 1H, J = 8.8 Hz, ArCH), 7.33-7.38 (m, 2H, 
ArCH), 7.42-7.47 (m, 4H, ArCH), 7.63 (d, 2H, J = 8.2 Hz, 1-H3), 7.70 (d, 1H, J = 8.5 
Hz, ArCH), 7.72 (d, 1H, J = 8.5 Hz, ArCH), 7.79 (d, 2H, J = 8.2 Hz, 1-H2); ESI-HRMS 
found m/z 721.2843 [M-H]- C44H38FN4O5 requires 721.2832.  
N-(N-(N-(Naphth-2-yl-4-aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-N-
benzyl-4-aminobenzoyl)-glycine 67 
~ 70% pure by NMR, isolated crude yield: 61 mg; δH (300 MHz, CDCl3) 0.89 (d, 
6H, J = 6.6 Hz, 2-Hγ), 1.82 (m, 1H, 2-Hβ), 3.67 (d, 2H, J = 7.6 Hz, 2-Hα), 4.22 (s, 2H, 
1-Hα), 4.58 (s, 2H, 3-Hα), 5.14 (s, 2H, 4-Hα), 6.76 (d, 2H, J = 8.8 Hz, 2-H3), 6.83-
6.91 (m, 4H, ArCH), 7.08-7.22 (m, 5H, ArCH), 7.27-7.32 (m, 2H, ArCH), 7.46 (d, 2H, 
J = 8.5 Hz, ArCH), 7.48-7.54 (m, 4H, ArCH), 7.62 (s, 1H, ArCH), 7.72 (m, 1H, ArCH), 
7.77-7.85 (m, 3H, ArCH); ESI-MS found m/z 717.2 [M-H]-. 
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N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-(4-fluorobenzyl)-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 68 
~70% pure by NMR, no identifiable impurity on LC-MS; isolated crude yield: 62 
mg; δH (300 MHz, MeOD) 0.95 (d, 6H, J = 6.6 Hz, 3-Hγ), 1.85 (m, 1H, 3-Hβ), 3.82 (d, 
2H, J = 7.4 Hz, 3-Hα), 4.09 (s, 2H, 2-Hα), 4.36 (s, 2H, 1-Hα), 5.03 (s, 2H, 4-Hα), 6.37 
(d, 2H, J = 9.0 Hz, 2-H3), 6.84 (d, 2H, J = 8.5 Hz, 3-H2), 6.95 (d, 2H, J = 8.8 Hz, 
ArCH), 7.01 (d, 2H, J = 8.8 Hz, ArCH), 7.01-7.06 (m, 2H, ArCH), 7.13 (d, 2H, J = 8.5 
Hz, ArCH), 7.14-7.20 (m, 6H, ArCH), 7.75 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found 
m/z 703.1 [M-H]-; ESI-HRMS found m/z 705.2893 [M+H]+ C41H39F2N4O5 requires 
705.2883. 
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-(3-fluorobenzyl)-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 69 
> 85% pure by NMR, no identifiable impurity on LC-MS; isolated crude yield: 63 
mg; δH (300 MHz, MeOD) 0.95 (d, 6H, J = 6.6 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.83 (d, 
2H, J = 7.4 Hz, 3-Hα), 4.08 (s, 2H, 2-Hα), 4.32 (s, 2H, 1-Hα), 5.06 (s, 2H, 4-Hα), 6.38 
(d, 2H, J = 8.8 Hz, 2-H3), 6.87 (d, 2H, J = 8.5 Hz, 3-H2), 6.92-6.98 (m, 3H, ArCH), 
7.01-7.03 (m, 4H, ArCH), 7.14 (d, 2H, J = 8.2 Hz, ArCH), 7.16 (d, 2H, J = 8.2 Hz, 
ArCH), 7.23 (m, 1H, ArCH), 7.33-7.37 (m, 2H, ArCH), 7.73 (d, 2H, J = 8.8 Hz, 1-H2); 
ESI-MS found m/z 703.1 [M-H]-; ESI-HRMS found m/z 727.2716 [M+Na]+ 
C41H38F2N4NaO5 requires 727.2702. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-glycine 70 
> 85% pure by NMR, isolated crude yield: 71 mg; δH (300 MHz, MeOD) 0.88 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.93 (d, 3H, J = 6.6 Hz, 3-Hε), 1.18 (m, 1H, 3-Hβ), 1.46 (m, 1H, 3-
Hγ), 1.60 (m, 1H, 3-Hγ’), 3.87 (d, 2H, J = 7.4 Hz, 3-Hα), 4.07 (s, 2H, 1-Hα), 4.36 (s, 
2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.47 (d, 2H, J = 8.6 Hz, 2-H3), 6.89 (d, 2H, J = 8.5 Hz, 
3-H2), 7.06 (d, 2H, J = 8.6 Hz, 2-H2), 7.14 (d, 2H, J = 8.5 Hz, 3-H3), 7.15 (d, 2H, J = 
8.5 Hz, 1-H3), 7.25 (m, 1H, 1-HAr4), 7.29-7.35 (m, 4H, 1-HAr2,3), 7.37 (d, 1H, J = 
8.2 Hz, 2-HAr6), 7.44 (t, 1H, J = 7.5 Hz, 2-HAr5), 7.53 (d, 1H, J = 7.4 Hz, 2-HAr4), 
7.60 (s, 1H, 2-HAr2), 7.72 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found m/z 749.2 [M-H]-
; ESI-HRMS found m/z 773.2936 [M+Na]+ C43H41F3NaN4O5 requires 773.2921. 
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N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-glycine 71 
> 95% pure by NMR, isolated crude yield: 68 mg; δH (300 MHz, MeOD) 0.88 (t, 3H, 
J = 7.3 Hz, 3-Hδ), 0.93 (d, 3H, J = 6.9 Hz, 3-Hε), 1.19 (m, 1H, 3-Hβ), 1.45 (m, 1H, 3-
Hγ), 1.61 (m, 1H, 3-Hγ’), 3.87 (d, 2H, J = 7.4 Hz, 3-Hα), 4.07 (s, 2H, 1-Hα), 4.37 (s, 
2H, 2-Hα), 5.13 (s, 2H, 4-Hα), 6.47 (d, 2H, J = 8.8 Hz, 2-H3), 6.91 (d, 2H, J = 8.4 Hz, 
3-H2), 7.05 (d, 2H, J = 8.8 Hz, 2-H2), 7.14 (d, 2H, J = 8.4 Hz, 3-H3), 7.16 (d, 2H, J = 
8.5 Hz, 1-H3), 7.25 (m, 1H, 1-HAr4), 7.29-7.36 (m, 4H, 1-HAr2,3), 7.41 (d, 2H, J = 
8.2 Hz, 2-HAr2), 7.57 (d, 2H, J = 8.2 Hz, 2-HAr4), 7.73 (d, 2H, J = 8.5 Hz, 1-H2); ESI-
HRMS found m/z 751.3081 [M+H]+ C43H42F3N4O5 requires 751.3102. 
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-glycine 72 
> 95% pure by NMR, isolated crude yield: 73 mg; δH (300 MHz, MeOD) 0.88 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.93 (d, 3H, J = 6.9 Hz, 3-Hε), 1.18 (m, 1H, 3-Hβ), 1.46 (m, 1H, 3-
Hγ), 1.59 (m, 1H, 3-Hγ’), 3.87 (d, 2H, J = 7.4 Hz, 3-Hα), 4.08 (s, 2H, 1-Hα), 4.35 (s, 
2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.45 (d, 2H, J = 8.6 Hz, 2-H3), 6.88 (d, 2H, J = 8.2 Hz, 
3-H2), 7.03 (d, 2H, J = 8.6 Hz, 2-H2), 7.06 (d, 2H, J = 8.2 Hz, 3-H3), 7.15 (d, 2H, J = 
8.5 Hz, ArCH), 7.16 (d, 2H, J = 8.5 Hz, ArCH), 7.36 (d, 1H, J = 8.2 Hz, 2-HAr6), 7.37 
(d, 2H, J = 8.2 Hz, 1-HAr3), 7.44 (t, 1H, J = 7.7 Hz, 2-HAr5), 7.53 (d, 1H, J = 7.7 Hz, 
2-HAr4), 7.60 (s, 1H, 2-HAr2), 7.72 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found m/z 
767.3 [M-H]-; ESI-HRMS found m/z 767.2872 [M-H]- C43H39F4N4O5 requires 
767.2862. 
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-glycine 73 
> 95% pure by NMR, isolated crude yield: 67 mg; δH (300 MHz, MeOD) 0.87 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.92 (d, 3H, J = 6.6 Hz, 3-Hε), 1.18 (m, 1H, 3-Hβ), 1.45 (m, 1H, 3-
Hγ), 1.60 (m, 1H, 3-Hγ’), 2.92 (t, 2H, J = 7.45 Hz, 1-Hβ), 3.41 (t, 2H, J = 7.45 Hz, 1-
Hα), 3.86 (d, 2H, J = 7.2 Hz, 3-Hα), 4.11 (s, 2H, 2-Hα), 5.15 (s, 2H, 4-Hα), 6.55 (d, 
2H, J = 8.5 Hz, 2-H3), 6.89 (d, 2H, J = 8.2 Hz, 3-H2), 7.12 (d, 2H, J = 8.5 Hz, 2-H2), 
7.15 (d, 2H, J = 8.2 Hz, 3-H3), 7.17 (d, 2H, J = 8.5 Hz, 1-H3), 7.23 (m, 1H, 1-HAr4), 
7.27-7.30 (m, 4H, 1-HAr2-3), 7.38 (d, 1H, J = 8.0 Hz, 2-HAr6), 7.45 (t, 1H, J = 7.7 
Hz, 2-HAr5), 7.55 (d, 1H, J = 7.7 Hz, 2-HAr4), 7.61 (s, 1H, 2-HAr2), 7.73 (d, 2H, J = 
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8.5 Hz, 1-H2); ESI-MS found m/z 766.0 [M+H]+; ESI-HRMS found m/z 763.3126 
[M-H]- C44H42F3N4O5 requires 763.3113.  
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-(2-methyl)butyl-4-aminobenzoyl)-glycine 74 
> 95% pure by NMR, isolated crude yield: 76 mg; δH (300 MHz, MeOD) 0.88 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.93 (d, 3H, J = 6.7 Hz, 3-Hε), 1.19 (m, 1H, 3-Hβ), 1.46 (m, 1H, 3-
Hγ), 1.60 (m, 1H, 3-Hγ’), 3.87 (d, 2H, J = 7.4 Hz, 3-Hα), 4.08 (s, 2H, 1-Hα), 4.35 (s, 
2H, 2-Hα), 5.13 (s, 2H, 4-Hα), 6.41 (d, 2H, J = 8.7 Hz, 2-H3), 6.90 (d, 2H, J = 8.2 Hz, 
3-H2), 7.03 (d, 2H, J = 8.7 Hz, 2-H2), 7.15 (d, 2H, J = 8.2 Hz, 3-H3), 7.17 (d, 2H, J = 
8.5 Hz, 1-H3), 7.29-7.33 (m, 4H, 1-HAr2,3), 7.40 (d, 2H, J = 8.0 Hz, 2-HAr2), 7.57 
(d, 2H, J = 8.2 Hz, 2-HAr3), 7.70 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 
783.2554 [M-H]- C43H39ClF3N4O5 requires 783.2567.  
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-(2-methyl)butyl-4-aminobenzoyl)-glycine 75 
> 95% pure by NMR, isolated crude yield: 70 mg; δH (300 MHz, MeOD) 0.87 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.92 (d, 3H, J = 6.6 Hz, 3-Hε), 1.18 (m, 1H, 3-Hβ), 1.45 (m, 1H, 3-
Hγ), 1.59 (m, 1H, 3-Hγ’), 2.92 (t, 2H, J = 7.5 Hz, 1-Hβ), 3.39 (t, 2H, J = 7.5 Hz, 1-Hα), 
3.86 (d, 2H, J = 7.4 Hz, 3-Hα), 4.11 (s, 2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.52 (d, 2H, J = 
8.8 Hz, 2-H3), 6.92 (d, 2H, J = 8.5 Hz, 3-H2), 7.11 (d, 2H, J = 8.5 Hz, 2-H2), 7.16 (d, 
2H, J = 8.5 Hz, 3-H3), 7.18 (d, 2H, J = 8.5 Hz, 1-H3), 7.22 (m, 1H, 1-HAr4), 7.25-7.30 
(m, 4H, 1-HAr2,3), 7.42 (d, 2H, J = 8.1 Hz, 2-HAr2), 7.58 (d, 2H, J = 8.1 Hz, 2-HAr3), 
7.75 (d, 2H, J = 8.2 Hz, 1-H2); δC (75 MHz, MeOD) 11.52, 17.35, 28.01, 34.61, 
36.31, 42.39, 45.75, 54.17, 56.27, 112.07, 122.48, 126.39, 127.29, 128.31, 129.10, 
129.50, 129.86, 129.90, 130.24, 130.73, 132.33, 135.69, 140.92, 143.25, 146.42, 
147.33, 152.15, 169.34, 171.98, 172.47, 173.17; νmax/cm-1 (solid state) = ~3016 
(COOH),  1738 (CO), 1365 (C-N), 1217 (C-O); ESI-HRMS found m/z 763.3108 [M-
H]- C44H42F3N4O5 requires 763.3113.  
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-(3-fluorobenzyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-glycine 76  
> 90% pure by NMR, isolated crude yield: 66 mg; δH (300 MHz, MeOD) 0.91 (t, 3H, 
J = 7.8 Hz, 3-Hδ), 0.93 (d, 3H, J = 6.9 Hz, 3-Hε), 1.19 (m, 1H, 3-Hβ), 1.45 (m, 1H, 3-
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Hγ), 1.61 (m, 1H, 3-Hγ’), 3.87 (d, 2H, J = 7.4 Hz, 3-Hα), 4.08 (s, 2H, 1-Hα), 4.33 (s, 
2H, 2-Hα), 5.06 (s, 2H, 4-Hα), 6.38 (d, 2H, J = 8.5 Hz, 2-H3), 6.87 (d, 2H, J = 8.2 Hz, 
3-H2), 6.93 (d, 2H, J = 7.6 Hz, ArCH), 6.97 (d, 2H, J = 8.2 Hz, ArCH), 7.02 (d, 2H, J = 
8.5 Hz, ArCH), 7.14 (d, 2H, J = 8.2 Hz, ArCH), 7.15 (d, 2H, J = 8.2 Hz, ArCH), 7.25 (t, 
1H, J = 7.8 Hz, 2-HAr5), 7.29 (d, 1H, J = 7.8 Hz, 2-HAr6), 7.31 (s, 1H, 2-HAr2), 7.41 
(d, 1H, J = 7.7 Hz, 2-HAr4), 7.72 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found m/z 733.4 
[M-H]-; ESI-HRMS found m/z 733.2605 [M-H]- C42H39ClFN4O5 requires 733.2598.  
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-4-chlorobenzyl-4-
aminobenzoyl)-N-(2-methyl)butyl-4-aminobenzoyl)-glycine 77 
> 75% pure by NMR, , isolated crude yield: 71 mg; δH (300 MHz, MeOD) 0.87-0.94 
(m, 6H, 3-Hδ,ε), 1.19 (m, 1H, 3-Hβ), 1.44 (m, 1H, 3-Hγ), 1.60 (m, 1H, 3-Hγ’), 3.85 
(d, 2H, J = 7.5 Hz, 3-Hα), 4.14 (s, 2H, 1-Hα), 4.33 (s, 2H, 2-Hα), 5.06 (s, 2H, 4-Hα), 
6.37 (d, 2H, J = 8.8 Hz, 2-H3), 6.88 (d, 2H, J = 8.0 Hz, 3-H2), 7.12-7.18 (m, 6H, 
ArCH), 7.21-7.28 (m, 6H, ArCH), 7.29 (d, 2H, J = 8.8 Hz, ArCH), 7.72 (d, 2H, J = 8.2 
Hz, 1-H2); ESI-MS found m/z 749.7 [M-H]-; ESI-HRMS found m/z 749.2283 [M-H]- 
C42H39Cl2N4O5 requires 749.2303.  
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 78 
> 90% pure by NMR, isolated crude yield: 71 mg; δH (300 MHz, MeOD) 0.94 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.3 Hz, 3-Hα), 4.08 (s, 2H, 
1-Hα), 4.36 (s, 2H, 2-Hα), 5.13 (s, 2H, 4-Hα), 6.48 (d, 2H, J = 8.8 Hz, 2-H3), 6.90 (d, 
2H, J = 8.4 Hz, 3-H2), 7.02-7.08 (m, 4H, ArCH), 7.13-7.18 (m, 4H, ArCH), 7.34-7.37 
(m, 2H, ArCH), 7.40 (d, 2H, J = 7.7 Hz, ArCH), 7.56 (d, 2H, J = 8.2 Hz, ArCH), 7.73 (d, 
2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 753.2729 [M-H]- C42H37F4N4O5 
requires 753.2706. 
N-(N-(N-(4-Fluorobenzyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-cyclopropylmethyl-4-aminobenzoyl)-glycine 79 
> 90% pure by NMR, isolated crude yield: 65 mg; δH (300 MHz, MeOD) 0.14 (m, 
2H, 3-Hγ), 0.45 (m, 2H, 3-Hγ’), 1.06 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.0 Hz, 3-Hα), 
4.08 (s, 2H, 1-Hα), 4.35 (s, 2H, 2-Hα), 5.13 (s, 2H, 4-Hα), 6.45 (d, 2H, J = 8.8 Hz, 2-
H3), 6.89 (d, 2H, J = 8.4 Hz, 3-H2), 7.02-7.10 (m, 4H, ArCH), 7.16-7.21 (m, 4H, 2-
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H2 and 3-H3), 7.34 (m, 2H, ArCH), 7.40 (d, 2H, J = 7.7 Hz, ArCH), 7.56 (d, 2H, J = 
8.0 Hz, 2-HAr3), 7.75 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 751.2535 [M-
H]- C42H37F4N4O5 requires 751.2549. 
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-propyl-4-aminobenzoyl)-glycine 80 
> 90% pure by NMR, isolated crude yield: 69 mg; δH (300 MHz, MeOD) 0.94 (t, 3H, 
J = 7.4 Hz, 3-Hγ), 1.61 (m, 2H, 3-Hβ), 3.89 (t, 2H, J = 7.5 Hz, 3-Hα), 4.07 (s, 2H, 1-
Hα), 4.37 (s, 2H, 2-Hα), 5.14 (s, 2H, 4-Hα), 6.51 (d, 2H, J = 8.8 Hz, 2-H3), 6.87 (d, 
2H, J = 8.4 Hz, 3-H2), 7.06 (d, 2H, J = 8.8 Hz, 2-H2), 7.12-7.17 (m, 6H, ArCH), 7.32-
7.35 (m, 4H, ArCH), 7.43 (t, 1H, J = 7.8 Hz, 2-HAr4), 7.53 (d, 1H, J = 8.1 Hz, ArCH), 
7.59 (s, 1H, 2-HAr2), 7.73 (d, 2H, J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 721.2651 
[M-H]- C41H36F3N4O5 requires 721.2643. 
N-(N-(N-(Cyclohexylmethyl-4-aminobenzoyl)-N-naphth-2-yl-4-
aminobenzoyl)-N-phenethyl-4-aminobenzoyl)-glycine 81 
> 85% pure by NMR, isolated crude yield: 75 mg; δH (300 MHz, CDCl3) 1.04 (m, 
2H, 1-Hε), 1.23-1.36 (m, 4H, 1-Hδ,δ’), 1.65-1.89 (m, 5H, 1-Hγ,γ’,β), 2.93 (t, 2H, J = 
8.2 Hz, 3-Hβ), 2.99 (d, 2H, J = 6.9 Hz, 1-Hα), 4.10 (t, 2H, J = 8.2 Hz, 3-Hα), 4.13 (s, 
2H, 2-Hα), 5.25 (s, 2H, 4-Hα), 6.56 (d, 2H, J = 8.2 Hz, 2-H3), 6.91 (d, 2H, J = 8.3 Hz, 
3-H2), 6.93 (d, 2H, J = 8.2 Hz, 2-H2), 7.07 (d, 2H, J = 8.3 Hz, 3-H3), 7.13 (d, 2H, J = 
8.7 Hz, 1-H3), 7.16-7.20 (m, 2H, 3-HAr2), 7.21-7.28 (m, 3H, 3-HAr3,4), 7.36 (d, 1H, 
J = 8.2 Hz, ArCH), 7.44-7.48 (m, 2H, ArCH), 7.64 (s, 1H, 2-HAr1), 7.66 (d, 2H, J = 8.7 
Hz, 1-H2), 7.73-7.83 (m, 3H, ArCH); ESI-MS found m/z 773.4 [M+H]+; ESI-HRMS 
found m/z 771.3543 [M-H]- C49H47N4O5 requires 771.3552.  
 N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(3-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-cyclopropylmethyl-4-aminobenzoyl)-glycine 82 
> 75% pure by NMR, isolated crude yield: 70 mg; δH (500 MHz, CDCl3) 0.17 (m, 
2H, 3-Hγ), 0.46 (m, 2H, 3-Hγ'), 1.05 (m, 1H, 3-Hβ), 3.81 (d, 2H, J = 7.1 Hz, 3-Hα), 
3.99 (d, 2H, J = 4.2 Hz, 1-Hα), 4.44 (s, 2H, 2-Hα), 5.12 (s, 2H, 4-Hα), 6.74 (d, 2H, J = 
8.2 Hz, 2-H3), 7.03 (d, 2H, J = 8.0 Hz, 3-H2), 7.12 (d, 2H, J = 8.0 Hz, ArCH), 7.14 (d, 
2H, J = 8.0 Hz, ArCH), 7.25 (d, 2H, J = 8.5 Hz, ArCH), 7.34-7.37 (m, 5H, 1-HAr2-4), 
7.39 (d, 2H, J = 8.0 Hz, 1-H3), 7.52 (m, 2H, ArCH), 7.60 (d, 2H, J = 8.0 Hz, 1-H2), 
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7.75 (m, 1H, Ar-NH); ESI-HRMS found m/z 733.2672 [M-H]- C42H36F3N4O5 
requires 733.2643. 
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-3-fluorobenzyl-4-aminobenzoyl)-N-
2-isobutyl-4-aminobenzoyl)-glycine 83 
> 80% pure by NMR, isolated crude yield: 49 mg; δH (300 MHz, MeOD) 0.93 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.78 (m, 1H, 3-Hβ), 2.83 (t, 2H, J = 7.7 Hz, 1-Hβ), 3.83 (d, 2H, 
J = 7.7 Hz, 3-Hα), 4.06 (t, 2H, J = 7.7 Hz, 1-Hα), 4.18 (s, 2H, 2-Hα), 5.07 (s, 2H, 4-
Hα), 6.39 (d, 2H, J = 8.8 Hz, 2-H3), 6.88 (d, 2H, J = 8.2 Hz, 3-H2), 7.12 (d, 2H, J = 8.5 
Hz, ArCH), 7.15 (d, 2H, J = 8.2 Hz, ArCH), 7.19 (d, 2H, J = 8.5 Hz, ArCH), 7.23-7.30 
(m, 7H, ArCH), 7.71 (d, 2H, J = 8.2 Hz, 1-H2), 7.75-7.80 (m, 2H, ArCH); ESI-HRMS 
found m/z 699.2986 [M-H]- C42H40FN4O5 requires 699.2988.  
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-3-fluorobenzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 84 
> 85% pure by NMR, isolated crude yield: 61 mg; δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 5.9 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.83 (d, 2H, J = 6.9 Hz, 3-Hα), 4.08 (s, 2H, 
1-Hα), 4.33 (s, 2H, 2-Hα), 5.06 (s, 2H, 4-Hα), 6.36 (d, 2H, J = 8.7 Hz, 2-H3), 6.87 (d, 
2H, J = 8.7 Hz, 3-H2), 6.95 (d, 2H, J = 8.2 Hz, ArCH), 7.01 (d, 2H, J = 7.7 Hz, ArCH), 
7.11-7.17 (m, 5H, ArCH), 7.23 (t, 1H, J = 7.8 Hz, 2-HAr5), 7.28-7.31 (m, 4H, 1-
HAr2,3), 7.72 (d, 2H, J = 8.2 Hz, 1-H2); ESI-HRMS found m/z 719.2463 [M-H]- 
C41H37ClFN4O5 requires 719.2442.  
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-4-fluorobenzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 85 
> 85% pure by NMR, isolated crude yield: 60 mg; δH (300 MHz, MeOD) 0.95 (d, 
6H, J = 6.1 Hz, 3-Hγ), 1.85 (m, 1H, 3-Hβ), 3.83 (d, 2H, J = 7.1 Hz, 3-Hα), 4.08 (s, 2H, 
1-Hα), 4.32 (s, 2H, 2-Hα), 5.03 (s, 2H, 4-Hα), 6.35 (d, 2H, J = 8.2 Hz, 2-H3), 6.83-
6.88 (m, 4H, ArCH), 6.97 (d, 2H, J = 7.1 Hz, ArCH), 6.99 (d, 2H, J = 7.7 Hz, ArCH), 
7.12-7.21 (m, 6H, ArCH), 7.30 (d, 2H, J = 7.0 Hz, ArCH), 7.72 (d, 2H, J = 7.1 Hz, 1-
H2); ESI-HRMS found m/z 719.2432 [M-H]- C41H37ClFN4O5 requires 719.2442.  
 
 
Chapter 6: Experimental Section 
 
159 
 
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-4-fluorobenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 86 
> 90% pure by NMR, isolated crude yield: 61 mg; δH (300 MHz, MeOD) 0.94 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 2.91 (t, 2H, J = 7.4 Hz, 1-Hβ), 3.39 (t, 2H, J 
= 7.4 Hz, 1-Hα), 3.82 (d, 2H, J = 7.4 Hz, 3-Hα), 4.11 (s, 2H, 1-Hα), 5.04 (s, 2H, 4-
Hα), 6.51 (d, 2H, J = 8.8 Hz, 2-H3), 6.86 (d, 2H, J = 8.5 Hz, 3-H2), 6.98 (t, 2H, J = 8.8 
Hz, ArCH), 7.08 (d, 2H, J = 8.8 Hz, 2-H2), 7.14 (d, 2H, J = 8.5 Hz, 3-H3), 7.16-7.23 
(m, 5H, ArCH), 7.24-7.27 (m, 2H, ArCH), 7.29 (d, 2H, J = 8.1 Hz, 1-H3), 7.73 (d, 2H, 
J = 8.5 Hz, 1-H2); ESI-HRMS found m/z 699.2981 [M-H]- C42H40FN4O5 requires 
699.2988.  
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-(2-methyl)naphth-1-yl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 87 
> 95% pure by NMR, isolated crude yield: 58 mg; δH (300 MHz, MeOD) 0.90 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.79 (m, 1H, 3-Hβ), 2.89 (t, 2H, J = 7.4 Hz, 1-Hβ), 3.36 (t, 2H, J 
= 7.4 Hz, 1-Hα), 3.75 (d, 2H, J = 7.4 Hz, 3-Hα), 4.15 (s, 2H, 1-Hα), 4.90 (s, 3H, 2-
Me), 5.54 (s, 2H, 4-Hα), 6.43 (d, 2H, J = 8.2 Hz, 2-H3), 6.53 (d, 2H, J = 8.5 Hz, ArCH), 
6.90 (d, 2H, J = 8.2 Hz, ArCH), 7.02 (d, 2H, J = 8.8 Hz, ArCH), 7.06 (d, 2H, J = 8.8 Hz, 
ArCH), 7.14 (d, 1H, J = 8.5 Hz, ArCH), 7.19-7.29 (m, 5H, ArCH), 7.48 (m, 1H, ArCH), 
7.69 (d, 2H, J = 8.2 Hz, ArCH), 7.73 (d, 2H, J = 8.5 Hz, ArCH), 7.82 (d, 1H, J = 8.2 Hz, 
ArCH), 8.13 (d, 1H, J = 8.5 Hz, ArCH); ESI-HRMS found m/z 745.3383 [M-H]- 
C47H45N4O5 requires 745.3395.  
N-(N-(N-(4-Chlorobenzyl-4-aminobenzoyl)-N-naphth-2-yl-4-aminobenzoyl)-
N-isobutyl-4-aminobenzoyl)-glycine 88  
> 80% pure by NMR, isolated crude yield: 71 mg; δH (500 MHz, MeOD) 0.94 (d, 
6H, J = 6.4 Hz, 3-Hγ), 1.83 (m, 1H, 1-Hβ), 3.81 (d, 2H, J = 7.3 Hz, 3-Hα), 4.10 (s, 2H, 
1-Hα), 4.35 (s, 2H, 2-Hα), 5.24 (s, 2H, 4-Hα), 6.41 (d, 2H, J = 8.7 Hz, 2-H3), 6.90 (d, 
2H, J = 8.2 Hz, 3-H2), 7.06 (d, 2H, J = 8.7 Hz, 2-H2), 7.11 (d, 2H, J = 8.2 Hz, ArCH), 
7.14 (d, 2H, J = 7.8 Hz, ArCH), 7.30-7.36 (m, 4H, ArCH), 7.39 (m, 1H, ArCH), 7.45 
(d, 2H, J = 7.8 Hz, ArCH), 7.64 (s, 1H, 2-HAr2), 7.70 (d, 2H, J = 8.2 Hz, ArCH), 7.77 
(d, 2H, J = 8.7 Hz, ArCH), 7.81 (d, 1H, J = 8.2 Hz, ArCH); ESI-HRMS found m/z 
751.2664 [M-H]- C45H40ClN4O5 requires 751.2693.  
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N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-(5-bromoindol-3-yl)-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 89 
> 80% pure by NMR, isolated crude yield: 53 mg; δH (300 MHz, MeOD) 0.93 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.65 (s, 9H, tBu), 1.92 (m, 1H, 3-Hβ), 2.90 (t, 2H, J = 7.2 Hz, 1-
Hβ), 3.81 (d, 2H, J = 7.1 Hz, 3-Hα), 4.03 (t, 2H, J = 7.2 Hz, 1-Hα), 4.10 (s, 2H, 2-Hα), 
5.20 (s, 2H, 4-Hα), 6.42 (d, 2H, J = 8.6 Hz, 2-H3), 6.59 (d, 2H, J = 8.8 Hz, 3-H2), 6.85 
(d, 2H, J = 8.6 Hz, 2-H2), 7.03 (d, 2H, J = 8.8 Hz, 3-H3), 7.13 (d, 1H, J = 8.9 Hz, 2-
HAr6), 7.20 (d, 2H, J = 8.2 Hz, 1-H3), 7.24-7.29 (m, 5H, 1-HAr2-4), 7.41 (s, 1H, 2-
HAr4), 7.72 (d, 1H, J = 8.8 Hz, 2-HAr7), 7.77 (d, 2H, J = 8.5 Hz, 1-H2), 7.82 (s, 1H, 2-
HAr2); ESI-MS found m/z 900.7 [M+H]+; ESI-HRMS found m/z 898.2781 [M-H]- 
C49H49BrN5O7 requires 898.2781.  
N-(N-(N-(Phenethyl-4-aminobenzoyl)-N-4-amidobenzoyl)-N-isobutyl-4-
aminobenzoyl)-glycine 90 
> 95% pure by NMR, isolated crude yield: 18 mg; δH (300 MHz, MeOD) 0.98 (d, 
6H, J = 6.6 Hz, 3-Hγ), 1.92 (m, 1H, 3-Hβ), 2.92 (t, 2H, J = 7.4 Hz, 1-Hβ), 3.43 (t, 2H, J 
= 7.4 Hz, 1-Hα), 3.89 (d, 2H, J = 7.4 Hz, 3-Hα), 4.06 (s, 2H, 4-Hα), 6.69 (d, 2H, J = 
8.8 Hz, 2-H3), 7.28 (d, 2H, J = 8.0 Hz, 3-H2), 7.28-7.31 (m, 7H, 1-HAr2-4, 2-H2), 
7.57 (d, 2H, J = 8.5 Hz, 3-H3), 7.75 (d, 2H, J = 8.8 Hz, 1-H3), 7.78 (d, 2H, J = 8.5 Hz, 
1-H2); ESI-MS found m/z 593.3 [M+H]+; ESI-HRMS found m/z 591.2598 [M-H]- 
C35H35N4O5 requires 591.2613.  
N-(N-(N-(Benzyl-4-aminobenzoyl)-N-(4-trifluoromethyl)benzyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-glycine 91 
> 80% pure by NMR, isolated crude yield: 69 mg; δH (300 MHz, MeOD) 0.94 (d, 
6H, J = 6.9 Hz, 3-Hγ), 1.84 (m, 1H, 3-Hβ), 3.82 (d, 2H, J = 7.4 Hz, 3-Hα), 4.07 (s, 2H, 
2-Hα), 4.36 (s, 2H, 1-Hα), 5.13 (s, 2H, 4-Hα), 6.44 (d, 2H, J = 8.8 Hz, 2-H3), 6.89-
6.94 (m, 2H, ArCH), 6.99-7.06 (m, 2H, ArCH), 7.12-7.18 (m, 4H, ArCH), 7.30 (dd, 
2H, J1 = 8.5 Hz, J2 = 2.5 Hz, 1-HAr2), 7.33-7.39 (m, 3H, ArCH), 7.43 (d, 2H, J = 8.8 
Hz, ArCH), 7.56 (d, 2H, J = 7.8 Hz, ArCH), 7.70-7.75 (m, 2H, ArCH); ESI-HRMS 
found m/z 735.2776 [M-H]- C42H38F3N4O5 requires 735.2800. 
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N-(N-(N-(Propyl-4-aminobenzoyl)-N-phenethyl-4-aminobenzoyl)-N-
cyclohexylmethyl-4-aminobenzoyl)-valine 92 
> 85% pure by NMR, isolated crude yield: 70 mg; δH (300 MHz, CDCl3) 0.97-1.17 
(m, 5H, 3-Hδ,δ’,ε,), 1.02 (d, 6H, J = 7.4 Hz, 4-Hγ), 1.11 (t, 3H, J = 7.2 Hz, 1-Hγ), 1.61-
1.77 (m, 7H, 1-Hβ, 3-Hγ,γ’,β), 1.86 (m, 1H, 4-Hβ), 2.95 (m, 2H, 2-Hβ), 3.29 (t, 2H, J 
= 8.2 Hz, 1-Hα), 3.70 (dd, 1H, J1 = 13.8 Hz, J2 = 6.6 Hz, 3-Hα), 4.00 (m, 2H, 2-Hα), 
4.26 (m, 1H, 3-Hα’), 4.34 (d, 1H, J = 6.6 Hz, 4-Hα), 6.81 (d, 2H, J = 7.2 Hz, 2-H3), 
7.03 (d, 2H, J = 8.4 Hz, 3-H2), 7.19 (d, 2H, J = 8.4 Hz, 3-H3), 7.25 (d, 2H, J = 7.2 Hz, 
2-H2), 7.28-7.32 (m, 5H, 2-HAr2-4), 7.37 (d, 2H, J = 8.5 Hz, 1-H3), 7.59 (d, 2H, J = 
8.5 Hz, 1-H2); ESI-MS found m/z 715.3 [M-H]-; ESI-HRMS found m/z 715.3853 
[M-H]- C44H51N4O5 requires 715.3865. 
N-(N-(N-(Propyl-4-aminobenzoyl)-N-cyclohexylmethyl-4-aminobenzoyl)-N-
propyl-4-aminobenzoyl)-isoleucine 93 
> 90% pure by NMR, isolated crude yield: 61 mg; δH (300 MHz, CDCl3) 0.93-1.05 
(m, 15H, 1-Hγ, 2-Hδ,δ’,ε, 3-Hγ, 4-Hγ), 1.08 (d, 3H, J = 6.9 Hz, 4-Hε), 1.11-1.16 (m, 
2H, 4-Hγ), 1.30 (m, 1H, 3-Hβ), 1.60-1.70 (m, 7H, 1-Hβ, 2-Hβ,γ,γ’), 1.83 (m, 1H, 2-
Hβ), 2.07 (m, 1H, 4-Hβ), 3.29 (t, 2H, J = 7.9 Hz, 3-Hα), 3.59 (dd, 1H, J1 = 13.4 Hz, J2 
= 6.6 Hz, 2-Hα), 3.63 (m, 1H, 2-Hα’), 4.03 (m, 2H, 1-Hα), 4.47 (d, 1H, J = 6.6 Hz, 4-
Hα), 6.96 (d, 2H, J = 7.2 Hz, 2-H3), 7.06 (d, 2H, J = 8.2 Hz, 3-H2), 7.07 (d, 2H, J = 7.2 
Hz, 2-H2), 7.27 (d, 2H, J = 8.5 Hz, 3-H3), 7.32 (d, 2H, J = 8.3 Hz, 1-H3), 7.59 (d, 2H, J 
= 8.3 Hz, 1-H2); ESI-MS found m/z 667.3 [M-H]-; ESI-HRMS found m/z 667.3867 
[M-H]- C40H51N4O5 requires 667.3865.  
N-(N-(N-(3-Fluorobenzyl-4-aminobenzoyl)-N-phenethyl-4-aminobenzoyl)-
N-propyl-4-aminobenzoyl)-leucine 94 
> 90% pure by NMR, isolated crude yield: 70 mg; δH (300 MHz, CDCl3) 0.93 (t, 3H, 
J = 7.4 Hz, 3-Hγ), 0.94 (d, 6H, J = 7.4 Hz, 4-Hδ), 1.55-1.72 (m, 5H, 3-Hβ, 4-Hβ,γ), 
2.91 (t, 2H, J = 7.2 Hz, 2-Hβ), 3.82 (m, 1H, 3-Hα), 3.98 (t, 2H, J = 7.4 Hz, 2-Hα), 4.20 
(m, 1H, 3-Hα’), 4.34 (s, 2H, 1-Hα), 4.44  (m, 1H, 4-Hα), 6.63 (d, 2H, J = 7.9 Hz, 2-
H3), 6.98 (d, 2H, J = 8.2 Hz, 3-H2), 7.10 (d, 2H, J = 7.9 Hz, 2-H2), 7.11 (d, 2H, J = 8.2 
Hz, 3-H3), 7.13-7.19 (m, 7H, ArCH), 7.23 (d, 1H, J = 6.9 Hz, 1-HAr4), 7.27 (d, 2H, J = 
8.1 Hz, 1-H3), 7.30 (m, 1H, 1-HAr5), 7.59 (d, 2H, J = 8.1 Hz, 1-H2); ESI-MS found 
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m/z 741.2 [M-H]-; ESI-HRMS found m/z 741.3456 [M-H]- C45H46FN4O5 requires 
741.3458.  
N-(N-(N-(2-Methylbutyl-4-aminobenzoyl)-N-(2-methyl)butyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-isoleucine 95 
> 95% pure by NMR, isolated crude yield: 63 mg; δH (300 MHz, MeOD) 0.71-0.81 
(m, 9H, 1-Hδ, 2-Hδ, 4-Hδ), 0.83-0.89 (m, 9H, 1-Hε, 3-Hγ), 0.91-0.95 (m, 6H, 2-Hε, 
4-Hε), 1.03-1.15 (m, 3H, 1-Hγ, 1-Hβ), 1.22-1.33 (m, 2H, 2-Hγ), 1.37-1.45 (m, 4H, 4-
Hγ, 2-Hβ, 3-Hβ), 1.56-1.69 (m, 1H, 4-Hβ), 2.89 (dd, 1H, J1 = 12.6 Hz and J2 = 7.4 Hz, 
1-Hα), 3.02 (dd, 1H, J1 = 12.6 Hz and J2 = 7.4 Hz, 1-Hα’), 3.68 (d, 2H, J = 7.1 Hz, 3-
Hα), 3.79 (d, 2H, J = 7.4 Hz, 2-Hα), 4.45 (d, 1H, J = 6.4 Hz, 4-Hα), 6.55 (d, 2H, J = 8.0 
Hz, 2-H3), 6.91 (d, 2H, J = 8.5 Hz, 3-H2), 6.97 (d, 2H, J = 8.5 Hz, 2-H2), 7.10 (d, 2H, J 
= 8.5 Hz, 3-H3), 7.11 (d, 2H, J = 8.5 Hz, 1-H3), 7.63 (d, 2H, J = 8.5 Hz, 1-H2); ESI-
HRMS found m/z 697.4356 [M-H]- C42H57N4O5 requires 697.4334.  
Valine-N-(N-(N-(isobutyl-4-aminobenzoyl)-N-(isobutyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 96  
> 90% pure by NMR, isolated crude yield: 62 mg; δH (300 MHz, MeOD) 0.80 (d, 
6H, J = 7.1 Hz, 2-Hγ), 0.87 (d, 6H, J = 7.1 Hz, 3-Hγ), 0.92 (d, 6H, J = 6.6 Hz, 4-Hγ), 
0.96 (d, 6H, J = 6.6 Hz, 1-Hγ), 1.66-1.80 (m, 2H, 2-Hβ, 3-Hβ), 1.84-1.98 (m, 2H, 1-
Hβ, 4-Hβ), 3.71-3.80 (m, 4H, 3-Hα, 4-Hα), 3.83-3.86 (m, 2H, 2-Hα), 4.07-4.11 (m, 
1H, 1-Hα), 4.09 (s, 2H, 5-Hα), 7.04 (d, 2H, J = 8.5 Hz, 2-H3), 7.18 (d, 2H, J = 7.9 Hz, 
3-H2), 7.21 (d, 2H, J = 7.9 Hz, 3-H3), 7.25 (d, 2H, J = 8.5 Hz, 2-H2), 7.34 (d, 2H, J = 
8.3 Hz, 1-H3), 7.77 (d, 2H, J = 8.3 Hz, 1-H2); ESI-MS found m/z 700.5 [M+H]+; ESI-
HRMS found m/z 698.3916 [M-H]- C40H52N5O6 requires 698.3923.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-(2-methylbutyl-4-aminobenzoyl)-N-
2- methylbutyl-4-aminobenzoyl)-isoleucine 97 
> 95% pure by NMR, isolated crude yield: 63 mg; δH (300 MHz, MeOD) 0.83 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.87 (d, 3H, J = 6.6 Hz, 3-Hε), 0.89 (t, 3H, J = 7.4 Hz, 2-Hδ), 0.94 
(d, 3H, J = 6.9 Hz, 2-Hε), 0.97 (d, 3H, J = 7.7 Hz, 4-Hε), 1.02 (d, 6H, J = 6.6 Hz, 1-Hγ), 
1.03 (t, 3H, J = 6.6 Hz, 4-Hδ), 1.09-1.26 (m, 2H, 3-Hγ), 1.29-1.41 (m, 2H, 2-Hγ), 
1.43-1.54 (m, 2H, 4-Hγ), 1.56-1.68 (m, 2H, 3-Hβ, 1-Hβ), 1.95 (m, 1H, 2-Hβ), 2.04 
(m, 1H, 4-Hβ), 3.00 (d, 2H, J = 6.9 Hz, 1-Hα), 3.78 (d, 2H, J = 7.1 Hz, 2-Hα), 3.89 (d, 
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2H, J = 7.4 Hz, 3-Hα), 4.55 (d, 1H, J = 6.3 Hz, 4-Hα), 6.60 (d, 2H, J = 8.7 Hz, 2-H3), 
7.01 (d, 2H, J = 8.2 Hz, 3-H2), 7.05 (d, 2H, J = 8.7 Hz, 2-H2), 7.20 (d, 2H, J = 8.2 Hz, 
3-H3), 7.21 (d, 2H, J = 8.5 Hz, 1-H3), 7.74 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found 
m/z 683.5 [M-H]-; ESI-HRMS found m/z 683.4182 [M-H]- C41H55N4O5 requires 
683.4178.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-naphth-2-yl-4-aminobenzoyl)-N-2- 
methylbutyl-4-aminobenzoyl)-isoleucine 98 
> 95% pure by NMR, isolated crude yield: 70 mg; δH (300 MHz, MeOD) 0.85 (t, 3H, 
J = 7.4 Hz, 3-Hδ), 0.89 (d, 3H, J = 6.9 Hz, 3-Hε), 0.98 (t, 3H, J = 7.4 Hz, 4-Hδ), 1.02 
(d, 6H, J = 7.2 Hz, 1-Hγ), 1.04 (d, 3H, J = 7.4 Hz, 4-Hε), 1.15 (m, 1H, 3-Hγ), 1.30-
1.47 (m, 2H, 3-Hγ', 4-Hγ), 1.54-1.68 (m, 2H, 4-Hγ', 1-Hβ), 1.94 (m, 1H, 3-Hβ), 2.03 
(m, 1H, 4-Hβ), 2.99 (d, 2H, J = 6.9 Hz, 1-Hα), 3.84 (d, 2H, J = 7.1 Hz, 3-Hα), 4.58 (d, 
1H, J = 6.3 Hz, 4-Hα), 5.24 (s, 2H, 2-Hα), 6.59 (d, 2H, J = 8.7 Hz, 2-H3), 6.90 (d, 2H, J 
= 8.4 Hz, 3-H2), 7.11 (d, 2H, J = 8.7 Hz, 2-H2), 7.14 (d, 2H, J = 8.4 Hz, 3-H3), 7.15 (d, 
2H, J = 8.5 Hz, 1-H3), 7.36 (m, 1H, ArCH), 7.43-7.46 (m, 2H, ArCH), 7.64 (s, 1H, 3-
HAr2), 7.70 (d, 2H, J = 8.5 Hz, 1-H2), 7.74-7.78 (m, 2H, ArCH), 7.81 (m, 1H, 2- 
ArCH); ESI-MS found m/z 755.5 [M+H]+; ESI-HRMS found m/z 753.4007 [M-H]- 
C47H53N4O5 requires 753.4021.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-N-
naphth-2-yl-4-aminobenzoyl)-valine 99 
> 95% pure by NMR, isolated crude yield: 73 mg; δH (300 MHz, MeOD) 0.83 (t, 3H, 
J = 7.4 Hz, 2-Hδ), 0.86 (d, 3H, J = 6.6 Hz, 2-Hε), 0.99 (d, 6H, J = 6.7 Hz, 1-Hγ), 1.01 
(d, 6H, J = 6.8 Hz, 4-Hγ), 1.14 (m, 1H, 2-Hγ), 1.37 (m, 1H, 2-Hγ'), 1.53 (m, 1H, 1-
Hβ), 1.91 (m, 1H, 2-Hβ), 2.23 (m, 1H, 4-Hβ), 2.96 (d, 2H, J = 6.9 Hz, 1-Hα), 3.76 (d, 
2H, J = 7.2 Hz, 2-Hα), 4.43 (d, 1H, J = 6.3 Hz, 4-Hα), 5.36 (s, 2H, 3-Hα), 6.56 (d, 2H, J 
= 8.5 Hz, 2-H3), 7.01 (d, 2H, J = 8.5 Hz, 3-H2), 7.04 (d, 2H, J = 8.5 Hz, 2-H2), 7.09 (d, 
2H, J = 8.5 Hz, 3-H3), 7.32 (d, 2H, J = 8.5 Hz, 1-H3), 7.43-7.51 (m, 3H, ArCH), 7.63 
(d, 2H, J = 8.5 Hz, 1-H2), 7.69 (s, 1H, ArCH), 7.76 (m, 1H, ArCH), 7.81-7.83 (m, 2H, 
ArCH); ESI-MS found m/z 740.1 [M-H]-; ESI-HRMS found m/z 739.3878 [M-H]- 
C46H51N4O5 requires 739.3865.  
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N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-N-4-
chlorobenzyl-4-aminobenzoyl)-valine 100 
> 95% pure by NMR, isolated crude yield: 69 mg; δH (300 MHz, MeOD) 0.83 (t, 3H, 
J = 7.2 Hz, 2-Hδ), 0.86 (d, 3H, J = 7.2 Hz, 2-Hε), 1.01 (d, 6H, J = 6.9 Hz, 1-Hγ), 1.04 
(d, 6H, J = 7.4 Hz, 4-Hγ), 1.13 (m, 1H, 2-Hγ), 1.39 (m, 1H, 2-Hγ'), 1.52 (m, 1H, 1-
Hβ), 1.94 (m, 1H, 2-Hβ), 2.28 (m, 1H, 4-Hβ), 2.98 (d, 2H, J = 6.9 Hz, 1-Hα), 3.78 (d, 
2H, J = 6.9 Hz, 2-Hα), 4.46 (d, 1H, J = 6.3 Hz, 4-Hα), 5.17 (s, 2H, 3-Hα), 6.59 (d, 2H, J 
= 8.5 Hz, 2-H3), 7.01 (d, 2H, J = 8.2 Hz, 3-H2), 7.03 (d, 2H, J = 8.5 Hz, 2-H2), 7.05 (d, 
2H, J = 8.2 Hz, 3-H3), 7.28 (d, 2H, J = 8.2 Hz, 1-H3), 7.28-7.30 (m, 4H, 3-HAr2,3), 
7.67 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found m/z 724.8 [M+H]+; ESI-HRMS found 
m/z 723.3346 [M-H]- C42H48ClN4O5 requires 723.3319.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-4-chlorobenzyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-isoleucine 101 
> 95% pure by NMR, isolated crude yield: 61 mg; δH (300 MHz, MeOD) 0.92 (d, 
6H, J = 6.6 Hz, 1-Hγ), 0.98 (t, 3H, J = 7.8 Hz, 4-Hδ), 1.01 (d, 6H, J = 6.9 Hz, 3-Hγ), 
1.04 (d, 3H, J = 6.9 Hz, 4-Hε), 1.35 (m, 1H, 1-Hβ), 1.63 (m, 1H, 3-Hβ), 1.85 (m, 1H, 
4-Hγ), 1.94 (m, 1H, 4-Hγ'), 2.05 (m, 1H, 4-Hβ), 2.98 (d, 2H, J = 6.9 Hz, 1-Hα), 3.82 
(d, 2H, J = 7.4 Hz, 3-Hα), 4.57 (d, 1H, J = 6.1 Hz, 4-Hα), 5.03 (s, 2H, 2-Hα), 6.55 (d, 
2H, J = 8.5 Hz, 2-H3), 6.88 (d, 2H, J = 8.2 Hz, 3-H2), 7.11 (d, 2H, J = 8.5 Hz, 2-H2), 
7.15 (d, 2H, J = 8.2 Hz, 3-H3), 7.17-7.20 (m, 4H, 2-HAr2,3), 7.26 (d, 2H, J = 8.5 Hz, 
1-H3), 7.74 (d, 2H, J = 8.5 Hz, 1-H2); ESI-MS found m/z 723.8 [M-H]-; ESI-HRMS 
found m/z 723.3324 [M-H]- C42H48ClN4O5 requires 723.3319.  
N-(N-(N-(Carboxymethyl-4-aminobenzoyl)-N-2-methylbutyl-4-
aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-valine 102 
> 80% pure by NMR, isolated crude yield: 56 mg; δH (300 MHz, MeOD) 0.82 (t, 3H, 
J = 7.4 Hz, 2-Hδ), 0.85 (d, 3H, J = 5.9 Hz, 2-Hε), 0.96 (d, 6H, J = 6.6 Hz, 3-Hγ), 1.05 
(d, 6H, J = 6.6 Hz, 4-Hγ), 1.03-1.08 (m, 2H, 2-Hγ), 1.51 (m, 1H, 2-Hβ), 1.87 (m, 1H, 
3-Hβ), 2.30 (m, 1H, 4-Hβ), 3.76 (m, 2H, 2-Hα), 3.85 (d, 2H, J = 7.4 Hz, 3-Hα), 3.91 
(s, 2H, 1-Hα), 4.52 (m, 1H, 4-Hα), 6.37 (d, 2H, J = 8.5 Hz, 2-H3), 6.98 (d, 4H, J = 8.2 
Hz, 3-H2, 2-H2), 7.20 (d, 4H, J = 8.0 Hz, 3-H3, 1-H3), 7.77 (d, 2H, J = 8.5 Hz, 1-H2); 
ESI-HRMS found m/z 657.3280 [M-H]- C37H45N4O7 requires 657.3294.  
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N-(N-(N-(Carboxymethyl-4-aminobenzoyl)-N-2-methylbutyl-4-
aminobenzoyl)-N-2-methylbutyl-4-aminobenzoyl)-valine 103 
> 80% pure by NMR, isolated crude yield: 52 mg; δH (300 MHz, MeOD) 0.86 (t, 3H, 
J = 7.1 Hz, 2-Hδ), 0.88 (t, 3H, J = 7.1 Hz, 3-Hδ), 0.86-0.90 (m, 2H, 3-Hγ), 0.94 (d, 6H, 
J = 6.9 Hz, 3-Hε, 2-Hε), 1.05 (d, 6H, J = 6.3 Hz, 4-Hγ), 1.03-1.08 (m, 2H, 2-Hγ), 1.49 
(m, 1H, 3-Hβ), 1.61 (m, 1H, 2-Hβ), 2.29 (m, 1H, 4-Hβ), 3.77 (m, 2H, 2-Hα), 3.82 (s, 
2H, 1-Hα), 3.90 (d, 2H, J = 7.2 Hz, 3-Hα),  4.52 (m, 1H, 4-Hα), 6.35 (d, 2H, J = 8.5 
Hz, 2-H3), 6.98 (d, 2H, J = 8.3 Hz, 3-H2), 7.04 (d, 2H, J = 8.5 Hz, 2-H2), 7.20 (d, 2H, J 
= 8.3 Hz, 3-H3), 7.21 (d, 2H, J = 8.3 Hz, 1-H3), 7.78 (d, 2H, J = 8.3 Hz, 1-H2); ESI-
HRMS found m/z 671.3423 [M-H]- C38H47N4O7 requires 671.3450.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-(2-methyl)butyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-aspartic acid 104 
> 90% pure by NMR, isolated crude yield: 52 mg; δH (300 MHz, MeOD) 0.84 (t, 3H, 
J = 7.4 Hz, 2-Hδ), 0.88 (d, 3H, J = 6.6 Hz, 2-Hε), 0.96 (d, 6H, J = 6.6 Hz, 1-Hγ), 1.04 
(d, 6H, J = 6.6 Hz, 3-Hγ), 1.14 (m, 2H, 2-Hγ), 1.40 (m, 1H, 2-Hβ), 1.87 (m, 1H, 3-
Hβ), 1.97 (m, 1H, 1-Hβ), 2.90 (m, 2H, 4-Hβ), 3.02 (d, 2H, J = 6.9 Hz, 2-Hα), 3.77 (d, 
2H, J = 7.4 Hz, 3-Hα), 3.84 (d, 2H, J = 7.4 Hz, 1-Hα), 4.98 (m, 1H, 4-Hα), 6.65 (d, 2H, 
J = 8.5 Hz, 2-H3), 7.01 (d, 2H, J = 8.2 Hz, 3-H2), 7.07 (d, 2H, J = 8.5 Hz, 2-H2), 7.21 
(d, 2H, J = 8.2 Hz, 3-H3), 7.22 (d, 2H, J = 8.5 Hz, 1-H3), 7.73 (d, 2H, J = 8.2 Hz, 1-
H2); ESI-HRMS found m/z 671.3444 [M-H]- C38H47N4O7 requires 671.3450.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-naphth-2-yl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-isoleucine 105 
> 95% pure by NMR, isolated crude yield: 71 mg; δH (300 MHz, MeOD) 0.91 (d, 
6H, J = 6.9 Hz, 1-Hγ), 0.98 (t, 3H, J = 7.4 Hz, 4-Hδ), 1.02 (d, 6H, J = 6.9 Hz, 3-Hγ), 
1.03 (d, 3H, J = 6.9 Hz, 4-Hε), 1.35 (m, 1H, 1-Hβ), 1.62 (m, 1H, 3-Hβ), 1.82 (m, 1H, 
4-Hγ), 1.95 (m, 1H, 4-Hγ'), 2.04 (m, 1H, 4-Hβ), 2.99 (d, 2H, J = 6.9 Hz, 1-Hα), 3.79 
(d, 2H, J = 7.4 Hz, 3-Hα), 4.58 (d, 1H, J = 6.3 Hz, 4-Hα), 5.24 (s, 2H, 2-Hα), 6.58 (d, 
2H, J = 8.8 Hz, 2-H3), 6.90 (d, 2H, J = 8.5 Hz, 3-H2), 7.11 (d, 2H, J = 8.8 Hz, 2-H2), 
7.15 (d, 2H, J = 8.5 Hz, 3-H3), 7.16 (d, 2H, J = 8.5 Hz, 1-H3), 7.36 (m, 1H, ArCH), 
7.43-7.46 (m, 2H, ArCH), 7.63 (s, 1H, ArCH), 7.71 (d, 2H, J = 8.5 Hz, 1-H2), 7.73-
7.78 (m, 2H, ArCH), 7.81 (m, 1H, ArCH); ESI-HRMS found m/z 739.3831 [M-H]- 
C46H51N4O5 requires 739.3865.  
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N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-N-
isobutyl-4-aminobenzoyl)-glycine 106 
> 95% pure by NMR, isolated crude yield: 53 mg; δH (300 MHz, MeOD) 0.90 (d, 
6H, J = 6.6 Hz, 3-Hγ), 0.96 (d, 6H, J = 6.9 Hz, 1-Hγ), 1.03 (d, 6H, J = 6.6 Hz, 2-Hγ), 
1.79 (m, 1H, 3-Hβ), 1.87 (m, 1H, 1-Hβ), 1.96 (m, 1H, 2-Hβ), 3.01 (d, 2H, J = 6.9 Hz, 
3-Hα), 3.73 (d, 2H, J = 7.6 Hz, 1-Hα), 3.85 (d, 2H, J = 7.7 Hz, 2-Hα), 4.11 (s, 2H, 4-
Hα), 6.66 (d, 2H, J = 8.8 Hz, 2-H3), 7.01 (d, 2H, J = 8.5 Hz, 3-H2), 7.07 (d, 2H, J = 8.8 
Hz, 2-H2), 7.20 (d, 4H, J = 8.5 Hz, 3-H3, 1-H3), 7.74 (d, 2H, J = 8.5 Hz, 1-H2); ESI-
HRMS found m/z 599.3240 [M-H]- C35H43N4O5 requires 599.3239.  
N-(N-(N-(Isobutyl-4-aminobenzoyl)-N-isobutyl-4-aminobenzoyl)-N-naphth-
2-yl-4-aminobenzoyl)-leucine 107 
> 90% pure by NMR, isolated crude yield: 70 mg; δH (300 MHz, MeOD) 0.89 (d, 
6H, J = 6.6 Hz, 2-Hγ), 0.95 (d, 6H, J = 6.9 Hz, 4-Hδ), 0.97 (m, 1H, 4-Hγ), 0.99 (d, 6H, 
J = 6.6 Hz, 1-Hγ), 1.72 (m, 2H, 4-Hβ), 1.79 (m, 1H, 2-Hβ), 1.92 (m, 1H, 1-Hβ), 2.96 
(d, 2H, J = 6.9 Hz, 1-Hα), 3.73 (d, 2H, J = 7.4 Hz, 2-Hα), 4.59 (d, 1H, J = 6.9 Hz, 4-
Hα), 5.35 (s, 2H, 3-Hα), 6.56 (d, 2H, J = 8.5 Hz, 2-H3), 7.02 (d, 2H, J = 8.5 Hz, 3-H2), 
7.03 (d, 2H, J = 8.5 Hz, 2-H2), 7.09 (d, 2H, J = 8.8 Hz, 3-H3), 7.31 (d, 2H, J = 8.8 Hz, 
1-H3), 7.43-7.51 (m, 3H, ArCH), 7.62 (d, 2H, J = 8.8 Hz, 1-H2), 7.69 (s, 1H, ArCH), 
7.76 (m, 1H, ArCH), 7.83 (d, 2H, J = 8.8 Hz, ArCH); ESI-MS found m/z 741.4 
[M+H]+; ESI-HRMS found m/z 739.3875 [M-H]- C46H51N4O5 requires 739.3865.  
 
6.2 Biophysical assessment of the proteomimetics (Chapters 3 and 4) 
6.2.1 Molecular cloning and protein expression 
Expression and purification of hDM217-126 L33E.  
The hDM217–126 construct was initially provided by John Robinson at the 
University of Zürich. The pET14b plasmid (Novagen) containing cDNA encoding 
hDM2 residues Ser17 to Asn126, with a single mutation L33E (for increased 
protein stability in vivo [Vassilev et al., Science, 2004, 303, 844-848]; mutagenesis 
by T. Burnley, Edwards lab), was transformed into E. coli BL21 (DE3) GOLD.  
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 Protein production in 2xYT medium with ampicillin (100 mg mL-1) was 
induced with IPTG (0.5 mM) when the optical density of the cell suspension 
reached OD600 = 0.6. Induced cells were grown at 18 °C for 12 h and harvested by 
centrifugation at 6000 rpm for 10 min. Cells were resuspended in buffer A (20 
mM Tris, 500 mM NaCl, pH 7.9) with 0.1% Triton X-100, disrupted by 20 kPsi on 
a Cell Disruptor (Constant System Ltd.) and sonicated in the presence of DNaseI, 
1 U mL-1 (EPICENTRE biotechnologies) and 5 mM MgCl2. Cell lysate was 
centrifuged at 17 000 rpm for 30 min. Supernatant was loaded onto a Ni2+-
nitriloacetic acid (NTA) column equilibrated with buffer A. His6-tagged hDM2 
recombinant fragment was washed with 50 mL buffer A and buffer A with 60 mM 
imidazole added. The protein was eluted with 120 mM and 300 mM imidazole 
and the column was washed with 1 M imidazole in buffer A. Fractions containing 
protein were detected by 16% SDS-PAGE and concentrated to 5 mL then loaded 
onto a SuperdexTM 75 column and washer with buffer B (25 mM Tris, 150 mM 
NaCl, 5% glycerol, 1 mM EDTA, 1 mM DTT, pH 7.3). The purified protein was 
concentrated to a final concentration of 191 µM and stored at -80 °C until use. 
 
 
 
SDS-PAGE gel of hDM2 17-126 L33E  
after Superdex purification. 
From the left: broad range markers (2-212 kDa), 
191 μM hDM2, 240.6 μM hDM2 
Molecular cloning of recombinant hDMX 
 
 
The cDNA coding for hDMX was used as a template in PCR using the primers 
listed in Table E1 to introduce a BamHI restriction site 5’ and XhoI restriction site 
3’ to the hDMX (26-110) sequence. The PCR product was purified and digested 
with BamHI-HF and XhoI (New England Biolabs) following the manufacturers 
recommended protocol. hDMX (26-110) was then ligated into both pET-SUMO-
28a and pET28b-GFP-P that had been cut with BamHI-HF and XhoI using T4 DNA 
ligase (Invitrogen). Ligation products were transformed into DH5α cells. Colony 
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PCR was subsequently used to check for the presence of the insert and the 
identity of the insert confirmed by DNA sequencing (Beckman Coulter Genomics). 
 
Table E1. Primers used during PCR on the hDMX cDNA 
Primer Name Sequence (5’-3’) 
hDMX-BamHI-HF AAAGGATCCCAGGTACGACCAAAACTG 
hDMX-EcoRI TTTGAATTCCTAGGCTAAAGTGACAAGATTC 
 
 
Expression and purification of GFP-P-hDMX26-110 
 
The sequenced recombinant hDMX construct was transformed into E. coli BL21 
(DE3) STAR cells. Protein production in 2xYT medium with kanamycin (100 mg 
mL-1) was induced with IPTG (0.5 mM) when the optical density of the cell 
suspension reached OD600 = 0.6. Induced cells were grown at 18 °C for 14 h and 
harvested by centrifugation at 7000 rpm for 12 min. Cells were resuspended in 
buffer A (20 mM Tris, 500 mM NaCl, pH 7.9) with 0.1% Triton X-100, disrupted 
by 20 kPsi on a Cell Disruptor (Constant System Ltd.) and sonicated in the 
presence of DNaseI, 1 U mL-1 (EPICENTRE biotechnologies) and 5 mM MgCl2. Cell 
lysate was centrifuged at 4 000 rpm for 10 min. Supernatant was loaded onto a 
Ni2+-nitriloacetic acid (NTA) column equilibrated with buffer A. His6-tagged GFP-
P-hDMX recombinant fragment was washed with 15 mL buffer A and buffer A 
with 60 mM imidazole added. The protein was eluted with 120 mM and 300 mM 
imidazole and the column was washed with 1 M imidazole in buffer A. Fractions 
containing protein were detected by 15% SDS-PAGE and the purified His-Tev-
GFP-P-hDMX protein was then incubated overnight with PreScission protease in 
order to cleave the GPF-tag. Examination of the 15% SDS-PAGE after Sephadex 
column purification showed the cleavage did not work. This construct can 
however be used to express GFP-tagged hDMX for future FRET assays. 
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Molecular cloning of SUMO-hDMX26-110 
 
The sequenced recombinant GFP-tagged hDMX plasmid was digested with 
BamHI-HF and XhoI (New England Biolabs) following the manufacturers 
recommended protocol. hDMX (26-110) was then ligated into pET-SUMO-28a 
that had been cut with BamHI-HF and XhoI using T4 DNA ligase (Invitrogen). 
Ligation products were transformed into DH5α cells. Colony PCR was 
subsequently carried out and no insert was detected. It was reasoned that the 
PCR might not be working properly, so the whole procedure was repeated, but 
skipping the initial PCR step. After the ligation, the presence of the insert was 
checked using 2 diagnostic digests, one with HindIII-Xba and the second with 
BglII. Both digests confirmed the presence of the insert in 7 colonies, which was 
further validated on two colonies by DNA sequencing (Beckman Coulter 
Genomics). 
 
Table E2. Primers used during PCR on the hDMX cDNA 
Primer Name Sequence (5’-3’) 
hDMX-BamHI-HF AAAGGATCCCAGGTACGACCAAAACTG 
hDMX-XhoI TTTCTCGAGCTAGGCTAAAGTGACAAGATTC 
 
 
Expression and purification of SUMO-hDMX26-110 
 
The sequenced recombinant SUMO-hDMX construct was transformed into E. coli 
BL21 (DE3) Rosetta cells. Protein production in 2xYT medium with kanamycin 
(100 mg mL-1) was induced with IPTG (0.5 mM) when the optical density of the 
cell suspension reached OD600 = 0.6. Induced cells were grown at 18 °C for 14 h 
and harvested by centrifugation at 7000 rpm for 15 min. Cells were resuspended 
in buffer A (20 mM Tris, 500 mM NaCl, pH 7.9) with 0.1% Triton X-100, disrupted 
by 20 kPsi on a Cell Disruptor (Constant System Ltd.) and sonicated in the 
presence of DNaseI, 1 U mL-1 (EPICENTRE biotechnologies) and 5 mM MgCl2. Cell 
lysate was centrifuged at 4 000 rpm for 25 min. Supernatant was loaded onto a 
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Ni2+-nitriloacetic acid (NTA) column equilibrated with buffer A. His6-tagged GFP-
P-hDMX recombinant fragment was washed with 15 mL buffer A and buffer A 
with 60 mM imidazole added. The protein was eluted with 120 mM and 300 mM 
imidazole and the column was washed with 1 M imidazole in buffer A. Fractions 
containing protein were detected by 15% SDS-PAGE. Fractions were then 
concentrated to 5 mL then purified on a Sephadex gel filtration column. 
Examination of the fractions by 15% SDS-PAGE revealed that the SUMO-tag was 
mostly cleaved off, which might be due to intrinsic instability of the fusion 
protein. It was then decided to combine all the hDMX containing fractions and 
complete the cleavage by incubating overnight with SUMO protease. Purification 
by Ni2+-nitriloacetic acid (NTA) column (this time collecting the flow through, as 
the His-tag was cleaved off along with SUMO) provided pure, untagged hDMX 
protein, as confirmed by 15% SDS-PAGE. All the fractions were combined and 
concentrated to 2 mL. The resulting protein was then tested for binding in a 
preliminary fluorescence anisotropy assay, but unfortunately no binding to p53 
was detected. This protein was thus not suitable for use in the library screening. 
 
Expression and purification of  Mcl-1172-327 
The molecular cloning on recombinant SUMO-Mcl-1, along with the Sumo 
cleavage, protein expression and purification were carried out by Dr. A. Bartlett 
to yield untagged Mcl-1172-327. (Two batches were made, with final concentrations 
of 143.3 µM and 240.7 µM). 
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6.2.2  Fluorescence anisotropy competition assay 
p5315-31 transactivation domain peptide (Ac-SQETFSDLWKLLPENNVC-NH2) 
(p53) and its fluorescein-labelled analogue (Ac-SQETFSDLWKLLPENNVC(Flu)-
NH2) (p5315-31Flu) were purchased from Peptide Protein Research Ltd. 
Fluorescence anisotropy assays were performed in 96- or 384-well plates 
(Greiner Bio-one). Each experiment was run in triplicate and the fluorescence 
anisotropy measured using a Perkin Elmer EnVisionTM 2103 MultiLabel plate 
reader, with excitation at 480 nm and emission at 535 nm (5 nM bandwidth). 
All experiments were performed in assay buffer: 40 mM phosphate buffer at pH 
7.49, containing 200 mM NaCl and 0.02 mg mL-1 bovine serum albumin (BSA). 
Stocks of ligand (typically at 450 μM in 90:10 (v/v) assay buffer:DMSO) were 
used to prepare a 24-point serial dilution of ligand across the plate, tracer 
peptide (p5315-31-Flu) and hDM217-126 L33E were then added to each well to give a 
final concentration of 54.5 nM and 154.2 nM, respectively. For control wells the 
tracer peptide was replaced with an identical volume of assay buffer. The total 
volume in each well was 150 μL. In all experiments the G factor, or ratio between 
the efficiency of the S(ame) and P(erpendicular) channels, was set to 1.  
 
Determination of the association constant between the p53 tracer and hDM2: 
The procedure followed was described in our previous paper on O-alkylated 
aromatic oligoamides [J. P. Plante et al., Chem. Commun., 2009, 5091-5093]. 
Briefly: hDM2 was serially diluted (10 µM – 0.89 nM) into a solution of p53-Flu 
(54.5 nM in assay buffer) - the total volume of each well was 150 µL. Each 
experiment was run in triplicate and the data for both the perpendicular (P) and 
same (S) channel were corrected by substracting the corresponding control wells. 
These corrected values were used to calculate the total intensity and anisotropy 
for each point (Equations 1 and 2). The average anisotropy from 3 replicates was 
plotted against the ligand concentration and fitted to a logistic model using Origin 
8.6 to determine the minimum and maximum anisotropies (rmin and rmax). Using 
equation 3, the data for the anisotropy was converted to fraction bound and 
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multiplied by the p5315-31-Flu concentration then fitted in origin 8.6 (equation 4, 
cf. binding curve below) to give the dissociation constant Kd = 164.4 ± 10.8 nM. 
 
  I = 2PG + S       Equation 1 
  
           Equation 2 
 
minmax
min
)(
)(
rrrr
rr
Lb




   Equation 3 
2
]}][2[4])[]2[{(])[]2[{( 211 FLhDMFLhDMkFLhDMk
y

  Equation 4 
 
r = anisotropy, I = total intensity, P = perpendicular intensity, S = parallel 
intensity, Lb = fraction ligand bound, λ  = Ibound/Iunbound = 1 (intensity variation), 
[FL] = concentration of fluorescent ligand (i.e. p5315-31Flu), k1 = Kd, y = 
Lb*p5315-31-Flu and x = [added titrant], G is an instrument factor set to 1. 
 
 
 
Direct titration of p5315-35-Flu with increasing concentrations of hDM2, plotted in 
Origin 8.6. 
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Determination of the association constant between the Noxa B tracer and 
Mcl-1 
Using the same protocol and mathematical treatment as for the p53/hDM2 
interaction, a Kd of 32.5 ± 1.14 nM was determined (this titration was carried out 
by D. J. Yeo). 
 
 
Direct titration of FITC-Noxa B with increasing concentrations of Mcl-1, plotted in 
Origin 8.  
 
Displacement of the tracer by an unlabelled Noxa B peptide (150 nM 
protein – 50 nM tracer) 
 
 
 
Displacement of the FITC-Noxa B tracer (50 nM) by an unlabelled Noxa B peptide 
(carried out myself). 
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Single point fluorescence anisotropy screening for inhibition of the 
p53/hDM2 interaction 
A one point assay was carried out at a fixed concentration of inhibitor (10 µM), 
p5315-35-Flu (54.5 nM) and hDM2 (154.5 nM) in phosphate buffer. Each 
compound was assessed in triplicate and left to equilibrate for 1.5 hour in the 
dark. No protein denaturation was observed over time, as evidenced by the 
control/blank experiment lacking ligand in which the p53 tracer remains fully 
bound to the protein. A positive control was present on each test plate (Nutlin-3a 
in this case) at the same concentration as the test compounds. A set of controls 
was present at two diagonally opposed corner of the plate. A typical plate layout 
is represented in Figure E2. The anisotropy values were then determined and a 
percentage of efficiency was calculated for each compound relative to Nutlin-3a’s 
efficiency.  
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Figure E2. 96-well plate layout for single point screening 
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Automated single point fluorescence anisotropy screening for inhibition of 
the p53/hDM2 and Noxa B/MCl-1 interactions 
The same protocol and robot method was used for testing against both targeted 
interactions. Single point assays using the automated method on the Hamilton 
Microlab Star robot were carried out in 384-well plates (Perkin Elmer). Stock 
solutions of compounds to be tested were plated in a V-bottomed 96-well plate 
(source plate). The robot was programmed to prepare 3 test wells for each 
compound and one blank. The method initially transferred 10 μM of assay buffer 
to each well of the test plate. Subsequently 30 μL of protein was added to each 
well, followed by 15 μL tracer (or buffer for control wells). Protein and tracer 
were added in first in order to minimize the use of pipette tips. The stock 
compounds (typically at 100 μM in 99:1 (v/v) assay buffer: DMSO; 5 µL per well) 
were then transferred from the source plate. The first and last rows of each plate 
were not used in order to minimize error on the measurements due to uneven 
evaporation of the solution. Blanks and controls were present at either side of the 
plate, and the values were averaged in the intensity/anisotropy calculations. The 
final concentrations of tracer and protein were identical to those in the manual 
single point assay (100 nM protein and 50 nM tracer). The total volume in each 
well was 60 μL. 
 
Fluorescence anisotropy competition assay titrations 
Titrations carried out manually generally made use of 96-well plates. Initially, 50 
µL of assay buffer were transferred into each well of the test plate. The compound 
was then serially diluted (100 µM- 9 nM, typically from 450 μM in 90:10 (v/v) 
assay buffer: DMSO) across both plates.  A solution of p53-Flu in assay buffer was 
then added (50 µL, 54.5 nM final concentration), followed by hDM2 (50 µL, 154 
nM final concentration) - the total volume of each well was 150 µL. The plates 
were then left to incubate for 1.5 hour in the dark and at room temperature prior 
to fluorescence polarization measurement. The results were analysed as 
described for the determination of the binding between the p53 tracer and hDM2, 
except the anisotropy values were plotted to a logistic model in Origin 8.6 
(equation 5) and the IC50 was extracted directly from this curve. 
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Where rmin and rmax are the minimum and maximum anisotropies determined 
from the protein titration, x0 is the midpoint or IC50 and p is the power.  
 
Automated method for competition assay titrations (Chapter 4) 
Competition assay titrations prepared using the automated method were carried 
out in 384-well plates (Perkin Elmer). The Hamilton Microlab Star robot was 
programmed to prepare serial dilutions of each compound in triplicate. The 
method initially transferred 20 μM of assay buffer to each well of the test plate. 
The stock compound (typically at 450 μM in 90:10 (v/v) assay buffer: DMSO) was 
then transferred from the source plate and used to prepare a serial dilution 
across the test plate. Subsequently 20 μL of tracer (or buffer for control wells) 
was added to each well, followed by 20 μL protein. The final concentrations of 
tracer and protein were identical to those in the manual competition assay. The 
total volume in each well was 60 μL. 
 
High content imaging 
The high content imaging experiment were carried out by Dr. H. Martin (Leeds 
Institute for Molecular Medicine) and in collaboration with Dr. D. Tomlinson 
(Astbury Centre for Molecular Biology, University of Leeds).  
 
6.3 Solid phase synthesis of a library of oligoureas 
General conditions 
Unless otherwise noted, materials were obtained from commercial suppliers and 
used without further purification. NovaPEG Rink amide resin was purchased 
from Novabiochem. All organic solvents for solid phase synthesis were of 
analytical grade. Anhydrous THF was obtained from Sigma Aldrich and 
anhydrous dichloromethane was distilled over CaH2. RP-HPLC-quality 
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acetonitrile (CH3CN) and MilliQ water were used for RP-HPLC analyses and 
purification. Thin layer chromatography (TLC) was performed on silica gel 60 
F254 (Merck) with detection by UV light and charring with 1% ninhydrin in 
ethanol followed by heating. Flash column chromatography was carried out on 
silica gel (40-63 µm, Merck). 1H NMR and 13C NMR spectra were recorded on an 
Avance II NMR spectrometer (Bruker Biospin) with a vertical 7.05T narrow-
bore/ultrashield magnet operating at 300 MHz for 1H observation and 75 MHz 
for 13C observation by means of a 5-mm direct BBO 1H/19F_XBB_H probe with Z 
gradient capabilities. Chemical shifts are reported in parts per million (ppm) 
relative to the 1H residual signal of the deuterated solvent used. 1H NMR splitting 
patterns with observed first-order coupling are designated as singlet (s), doublet 
(d), triplet (t), or quartet (q). Coupling constants (J) are reported in hertz (Hz). 
Analytical RP-HPLC analyses were performed on a Dionex U3000SD using a 
Macherey-Nagel Nucleodur column (4.6 × 100 mm, 3µm) at a flow rate of 
1mL·min-1. The mobile phase was composed of 0.1% (v/v) TFA-H2O (Solvent A) 
and 0.1% TFA-CH3CN (Solvent B). Semi-preparative purifications were 
performed on a Dionex U3000SD using a Macherey-Nagel Nucleodur column 
(10 × 250 mm, 5 µm). A gradient elution of 30 to 100% of B in 20 min at a flow 
rate of 4 mL min-1 was applied. Column effluent was monitored by UV detection 
at 200 nm and 254 nm. ESI-MS analyses were carried out on a ThermoElectron 
LCQ Advantage spectrometer equipped with an ion trap mass analyzer and 
coupled with a ThermoElectron Surveyor HPLC system.Solid phase syntheses of 
oligoureas and hybrids with microwave irradiation were conducted on the 
Discover® System from CEM (CEM µWaves S.A.S., Orsay, France). 
 
6.3.1 Monomer building blocks 
(R)-benzyl (1-(tert-butoxy)-3-hydroxypropan-2-yl)carbamate 120a 
The N-protected α-amino acid 119a (5.00 g, 16.9 mmol) was dissolved in THF 
(50 mL) under nitrogen and cooled to 0 °C. After addition of isobutyl 
chloroformate (2.4 mL, 17.8 mmol) and N-methylmorpholine (2.1 mL, 18.6 
mmol), the mixture was stirred at 0 °C for 30 min. The resulting white suspension 
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was then filtered off and the filtrate was added at 0 °C to a solution of NaBH4 
(1.28 g, 33.9 mmol) in water (30 mL). The reaction mixture was left to react 
overnight and then a 1M solution of KHSO4 (50 mL) was added. The resulting 
aqueous solution was extracted twice with EtOAc (50 mL). The combined organic 
layers were washed twice with 1M KHSO4 (50 mL), twice with a saturated 
solution of NaHCO3 (50 mL), once with brine (50 mL), dried over sodium sulfate 
and concentrated under reduced pressure then dried under high vacuum. The 
resulting colourless oil (4.80 g, quant.) did not require further purification. δH 
(CDCl3, 300 MHz) 1.20 (s, 9H), 3.63 (d, 2H, J = 3.0 Hz), 3.75 (dd, 1H, J = 10.6 and 
4.1 Hz), 3.83 (m, 1H), 3.89 (d, 1H, J = 10.6 Hz), 5.15 (s, 2H), 5.55 (d, 1H, J = 7.2 Hz), 
7.34 – 7.41 (m, 5H). 
(R)-2-amino-3-(tert-butoxy)propan-1-ol 121a 
To a round bottom flask containing N-Z protected alcohol 120a (4.80 g, 16.9 
mmol) and 10% Pd/C was gently added MeOH (140 mL). The reaction was 
stirred overnight under 1 bar H2 atmnosphere (balloon). After filtration over 
Millipore filter paper, the filtrate was concentrated under reduced pressure to 
quantitavely furnish the target material as a pale yellow oil (2.49 g, 16.9 mmol, 
quant.). The amino derivative was not isolated and was directly engaged in the 
next step.  
(R)-2-azido-3-(tert-butoxy)propan-1-ol 122a 
To a solution of amine 121a (2.49 g, 16.9 mmol) in MeOH (80 mL) were 
successively added K2CO3 (2.91 g, n + 0.5 mmol), CuSO4.5H2O (0.043 g, 0.1 mmol), 
and imidazole-1-sulfonyl azide hydrochloride (4.30 g, 20.5 mmol). The reaction 
mixture was stirred at room temperature for 2 hours and then filtered to remove 
the remaining K2CO3, concentrated under reduced pressure and dissolved in 
CH2Cl2 (80 mL). The resulting solution was washed twice with 1M KHSO4 (50 
mL), then with brine (50 mL), dried over sodium sulfate and concentrated under 
reduced pressure to furnish after silica gel purification (EtOAc – cyclohexane 3-7) 
the desired azide as a colourless oil (1.84 g, 10.62 mmol, 62%); δH (CDCl3, 300 
MHz) 1.25 (s, 9H), 3.60-3.64 (m, 3H), 3.69-3.75 (m, 1H), 3.77-3.83 (m, 1H); δC 
(CDCl3, 75 MHz) 27.31, 62.26, 62.90, 63.46, 74.00. 
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(R)-2-(2-azido-3-(tert-butoxy)propyl)isoindoline-1,3-dione 123a 
To a solution of triphenylphosphine (2.78 g, 10.6 mmol) in anhydrous THF (20 
mL) at 0 °C and under positive N2 atmosphere pressure were successively added 
DIAD (2.1 mL, 10.6 mmol) and phthalimide (1.56 g, 10.6 mmol). Azido alcohol 
122a (1.84 g, 10.6 mmol) was dissolved in anhydrous THF (10 mL) then added 
dropwise and the reaction mixture was stirred and allowed to reach room 
temperature. After 4 hours the reaction was complete. THF was evaporated 
under reduced pressure and the resulting material was purified by column 
chromatography (EtOAc – cyclohexane 2-8) to yield the desired azide (2.71 g, 9.0 
mmol, 84%)as a pale yellow oil; δH (CDCl3, 300 MHz) 1.24 (s, 9H), 3.56-3.61 (m, 
1H), 3.64-3.68 (m, 1H), 3.73-3.80 (m, 1H), 3.85-3.96 (m, 2H), 7.76-7.78 (m, 2H), 
7.89-7.92 (m, 2H). 
(R)-2-azido-3-(tert-butoxy)propan-1-amine 124a 
To a solution of azido phthalimide 123a (2.71 g, 9.0 mmol) in MeOH (45 mL) was 
added hydrazine hydrate (1.3 mL, 26.9 mmol). The reaction mixture was refluxed 
for 4 hours then left to stir at room temperature overnight, with apparition of a 
white precipitate. The reaction mixture was filtered off, washed with MeOH and 
the filtrate was concentrated under reduced pressure. The crude material was 
dissolved in EtOAc (80 mL). The organic layer was washed twice with 1M KHSO4 
(2 × 25 mL). The combined aqueous phases were washed with EtOAc (2 × 25 mL) 
then neutralized by addition of solid NaHCO3 until pH 8. The aqueous phase was 
finally extracted with CH2Cl2 (5 × 25 mL) and the combined organic layers were 
washed with brine (20 mL), dried over Na2SO4 and concentrated under reduced 
pressure to give the desired amine 124a as a yellow oil (1.04 g, 6.0 mmol, 67%). 
The crude material was directly engaged in the activation step without further 
purification. 
(R)-2,5-dioxopyrrolidin-1-yl (2-azido-3-(tert-butoxy)propyl)carbamate 116 
To a stirred suspension of disuccinimidyl carbonate (1.81 g, 7.1 mmol) in 
anhydrous CH2Cl2 (50 mL) was added dropwise a solution of azido amine 124a 
(1.02 g, 5.9 mmol) in anhydrous CH2Cl2 (40 mL). The resulting mixture was 
stirred at room temperature for 3 hours, then the solvent was evaporated under 
reduced pressure and the crude material dissolved in EtOAc (70 mL). The organic 
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phase was washed with 1M KHSO4 (2 × 30 mL) then with brine (30 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to give activated 
carbamate 116 (1.84 g, 5.8 mmol, 99%) as a pale yellow oil; δH (CDCl3, 300 MHz) 
1.24 (s, 9H), 2.85 (s, 4H), 3.35 (ddd, 1H, J = 5.3, 6.4 and 13.8 Hz), 3.49 (ddd, 1H, J = 
5.3, 6.4 and 13.8 Hz), 3.58-3.60 (m, 2H), 3.73 (m, 1H), 5.75 (t, 1H, J = 5.3 Hz); δC 
(CDCl3, 75 MHz) 25.49, 27.28, 43.05, 60.18, 62.82, 74.10, 151.52, 169.63. 
(S)-tert-butyl(1-cyclohexyl-3-hydroxypropan-2-yl)carbamate 120b 
The N-protected α-amino acid 119b (3.00 g, 11.1 mmol) was dissolved in THF 
(35 mL) under nitrogen and cooled to 0 °C. After addition of isobutyl 
chloroformate (1.5 mL, 11.6 mmol) and N-methylmorpholine (1.3 mL, 12.2 
mmol), the mixture was stirred at 0 °C for 30 min. The resulting white suspension 
was then filtered off and the filtrate was added at 0 °C to a solution of NaBH4 
(0.84 g, 22.1 mmol) in water (20 mL). The reaction mixture was left to react 
overnight and then a 1M solution of KHSO4 (35 mL) was added. The resulting 
aqueous solution was extracted twice with EtOAc (35 mL). The combined organic 
layers were washed twice with 1M KHSO4 (35 mL), twice with a saturated 
solution of NaHCO3 (35 mL), once with brine (35 mL), dried over sodium sulfate 
and concentrated under reduced pressure then dried under high vacuum. The 
resulting colourless oil (2.48 g, 88%) did not require further purification. δH 
(CDCl3, 300 MHz) 0.94 (m, 2H), 1.21 (m, 2H), 1.34 (m, 2H), 1.48 (s, 9H), 1.65-1.76 
(m, 5H), 1.84 (m, 2H), 3.53 (dd, 1H, J = 6.4 and 11.3 Hz), 3.70 (m, 1H), 3.78 (br s, 
1H), 4.58 (br d, 1H, J = 5.4 Hz). 
(S)-2-amino-3-cyclohexylpropan-1-ol 121b 
N-Boc protected amino alcohol 120b (2.48 g, 9.72 mmol) was dissolved in pure 
TFA (7.0 mL) and left to react without stirring for 30 min. The TFA was then 
removed under reduced pressure and the TFA salt was dried under high vacuum 
overnight. The resulting crude material was not isolated and directly engaged in 
the next step.  
(S)-2-azido-3-cyclohexylpropan-1-ol 122b 
To a solution of amine 121b (9.72 mmol) in MeOH (50 mL) were successively 
added K2CO3 (3.03 g, n + 0.5 mmol), CuSO4.5H2O (24 mg, 0.1 mmol), and 
imidazole-1-sulfonyl azide hydrochloride (2.45 g, 11.7 mmol). The reaction 
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mixture was stirred at room temperature for 2 hours and then filtered to remove 
the remaining K2CO3, concentrated under reduced pressure and dissolved in 
CH2Cl2 (50 mL). The resulting solution was washed twice with 1M KHSO4 (2 × 30 
mL), then with brine (30 mL), dried over sodium sulfate and concentrated under 
reduced pressure to furnish after silica gel purification (EtOAc – cyclohexane 3-7) 
the desired azide as a colourless oil (0.78 g, 4.26 mmol, 44%); δH (CDCl3, 300 
MHz) 0.96 (m, 2H), 1.23 (m, 2H), 1.35 (m, 2H), 1.47 (m, 2H), 1.68-1.82 (m, 5H), 
3.54-3.63 (m, 2H), 3.73 (m, 1H); δC (CDCl3, 75 MHz) 26.08, 26.22, 26.44, 32.83, 
33.76, 34.33, 38.00, 61.89, 65.76. 
(S)-2-(2-azido-3-cyclohexylpropyl)isoindoline-1,3-dione 123b 
To a solution of triphenylphosphine (1.12 g, 4.3 mmol) in anhydrous THF (15 mL) 
at 0 °C and under positive N2 atmosphere pressure were successively added DIAD 
(0.9 mL, 4.3 mmol) and phthalimide (0.63 g, 4.3 mmol). Azido alcohol 122b (0.78 
g, 4.3 mmol) was dissolved in anhydrous THF (10 mL) then added dropwise and 
the reaction mixture was stirred and allowed to reach room temperature. After 4 
hours the reaction was complete. THF was evaporated under reduced pressure 
and the resulting material was purified by column chromatography (EtOAc – 
cyclohexane 2-8) to yield the desired azide (1.01 g, 3.1 mmol, 71%) as a yellow 
oil; δH (CDCl3, 300 MHz) 0.98 (m, 2H), 1.27 (m, 2H), 1.47 (m, 2H), 1.55 (m, 2H), 
1.68-1.85 (m, 5H), 3.72 (m, 1H), 3.81-3.88 (m, 2H), 7.76-7.79 (m, 2H), 7.90-7.93 
(m, 2H); δH (CDCl3, 75 MHz) 26.04, 26.23, 26.42, 32.67, 33.68, 34.39, 39.59, 41.71, 
58.01, 123.52, 131.88, 134.21, 168.21. 
(S)-2-azido-3-cyclohexylpropan-1-amine 124b 
To a solution of azido phthalimide 123b (1.01 g, 3.1 mmol) in MeOH (20 mL) was 
added hydrazine hydrate (0.44 mL, 9.1 mmol). The reaction mixture was refluxed 
for 4 hours then left to stir at room temperature overnight, with apparition of a 
white precipitate. The reaction mixture was filtered off, washed with MeOH and 
the filtrate was concentrated under reduced pressure. The crude material was 
dissolved in EtOAc (40 mL). The organic layer was washed twice with 1M KHSO4 
(2 × 15 mL). The combined aqueous phases were washed with EtOAc (2 × 10 mL) 
then neutralized by addition of solid NaHCO3 until pH 8. The aqueous phase was 
finally extracted with CH2Cl2 (5 × 15 mL) and the combined organic layers were 
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washed with brine (10 mL), dried over Na2SO4 and concentrated under reduced 
pressure to give the desired amine 124b as a colourless oil (0.32 g, 1.78 mmol, 
58%). The crude material was directly engaged in the activation step without 
further purification. 
(S)-2,5-dioxopyrrolidin-1-yl (2-azido-3-cyclohexylpropyl)carbamate 117 
To a stirred suspension of disuccinimidyl carbonate (0.55 g, 2.1 mmol) in 
anhydrous CH2Cl2 (20 mL) was added dropwise a solution of azido amine 124b 
(0.32 g, 1.8 mmol) in anhydrous CH2Cl2 (15 mL). The resulting mixture was 
stirred at room temperature for 3 hours, then the solvent was evaporated under 
reduced pressure and the crude material dissolved in EtOAc (30 mL). The organic 
phase was washed with 1M KHSO4 (2 × 10 mL) then with brine (10 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to give activated 
carbamate 117 (0.42 g, 1.3 mmol, 73%) as a pale pink solid; δH (CDCl3, 300 MHz) 
0.93 (m, 2H), 1.22 (m, 2H), 1.41 (m, 2H), 1.51 (m, 2H), 1.64-1.82 (m, 5H), 2.87 (s, 
4H), 3.15 (m, 1H), 3.51 (m, 1H), 3.69 (m, 1H); δC (CDCl3, 75 MHz) 25.49, 26.02, 
26.14, 26.36, 32.89, 33.52, 34.26, 39.33, 45.69, 59.37, 151.59, 169.63. 
(S)-tert-butyl (1-(3,4-dichlorophenyl)-3-hydroxypropan-2-yl)carbamate 
120c 
The N-protected α-amino acid 119c (0.70 g, 2.1 mmol) was dissolved in THF (10 
mL) under nitrogen and cooled to 0 °C. After addition of isobutyl chloroformate 
(0.29 mL, 2.2 mmol) and N-methylmorpholine (0.25 mL, 2.3 mmol), the mixture 
was stirred at 0 °C for 30 min. The resulting white suspension was then filtered 
off and the filtrate was added at 0 °C to a solution of NaBH4 (0.16 g, 4.2 mmol) in 
water (3 mL). The reaction mixture was left to react overnight and then a 1M 
solution of KHSO4 (6 mL) was added. The resulting aqueous solution was 
extracted twice with EtOAc (10 mL). The combined organic layers were washed 
twice with 1M KHSO4 (2 × 7 mL), twice with a saturated solution of NaHCO3 (2 × 
7 mL), once with brine (7 mL), dried over sodium sulfate and concentrated under 
reduced pressure then dried under high vacuum. The resulting white solid (0.61 
g, 1.9 mmol, 90%) did not require further purification. δH (CDCl3, 300 MHz) 1.45 
(s, 9H), 2.85 (d, 2H, J = 7.2 Hz), 3.59 (dd, 1H, J = 4.3 and 10.9 Hz), 3.71 (dd, 1H, J = 
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4.3 and 10.9 Hz), 3.85 (m, 1H), 4.81 (br d, 1H, J = 8.3 Hz), 7.10 (dd, 1H, J = 1.9 and 
8.3 Hz), 7.35 (d, 1H, J = 1.9 Hz), 7.40 (d, 1H, J = 8.3 Hz). 
(S)-2-amino-3-(3,4-dichlorophenyl)propan-1-ol 121c 
N-Boc protected amino alcohol 120c (0.61 g, 1.89 mmol) was dissolved in pure 
TFA (2.0 mL) and left to react without stirring for 1 hour. The TFA was then 
removed under reduced pressure and the TFA salt was dried under high vacuum 
overnight. The resulting crude oil was not isolated and directly engaged in the 
next step.  
(S)-2-azido-3-(3,4-dichlorophenyl)propan-1-ol 122c 
To a solution of amine 121c (1.89 mmol) in MeOH (10 mL) were successively 
added K2CO3 (0.64 g, n + 0.5 mmol where n is the total number of moles of acid 
present in the reaction mixture), CuSO4.5H2O (4.6 mg, 0.019 mmol), and 
imidazole-1-sulfonyl azide hydrochloride (0.47 g, 2.22 mmol). The reaction 
mixture was stirred at room temperature overnight and then filtered to remove 
the remaining K2CO3, concentrated under reduced pressure and dissolved in 
EtOAc (20 mL). The resulting solution was washed twice with 1M KHSO4 (2 × 10 
mL), then with brine (10 mL), dried over sodium sulfate and concentrated under 
reduced pressure to furnish after silica gel purification (EtOAc – cyclohexane 3-7) 
the desired azide as a colourless oil (0.30 g, 1.23 mmol, 67%); δH (CDCl3, 300 
MHz) 2.80 (dd, 1H, J = 7.7 and 14.0 Hz), 2.90 (dd, 1H, J = 5.5 and 13.8 Hz), 3.62 (m, 
1H), 3.68-3.80 (m, 2H), 7.13 (dd, 1H, J = 1.7 and 8.3 Hz), 7.38 (m, 1H), 7.43 (d, 1H, 
J = 8.2 Hz). 
(S)-2-(2-azido-3-(3,4-dichlorophenyl)propyl)isoindoline-1,3-dione 123c 
To a solution of triphenylphosphine (0.32 g, 1.2 mmol) in anhydrous THF (5 mL) 
at 0 °C and under positive N2 atmosphere pressure were successively added DIAD 
(0.24 mL, 1.2 mmol) and phthalimide (0.18 g, 1.2 mmol). Azido alcohol 122c 
(0.30 g, 1.2 mmol) was dissolved in anhydrous THF (1 mL) then added dropwise 
and the reaction mixture was stirred and allowed to reach room temperature. 
After 4 hours the reaction was complete. THF was evaporated under reduced 
pressure and the resulting material was purified by column chromatography 
(EtOAc – cyclohexane 2-8) to yield the desired azide (0.27 g, 0.74 mmol, 60%) as 
a yellow oil; δH (CDCl3, 300 MHz) 2.83 (dd, 1H, J = 8.7 and 14.2 Hz), 2.94 (dd, 1H, J 
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= 5.3 and 14.2 Hz), 3.80 (dd, 1H, J = 5.3 and 13.6 Hz), 3.91 (dd, 1H, J = 8.3 and 14.0 
Hz), 4.06 (m, 1H), 7.14 (dd, 1H, J = 1.9 and 8.3 Hz), 7.39-7.42 (m, 2H), 7.78 (dd, 
2H, J = 3.0 and 5.3 Hz), 5.90 (dd, 2H, J = 3.0 and 5.3 Hz). 
(S)-2-azido-3-(3,4-dichlorophenyl)propan-1-amine 124c 
To a solution of azido phthalimide 123c (0.27 g, 0.74 mmol) in MeOH (5 mL) was 
added hydrazine hydrate (0.11 mL, 2.3 mmol). The reaction mixture was refluxed 
for 4 hours then left to stir at room temperature overnight, with apparition of a 
white precipitate. The reaction mixture was filtered off, washed with MeOH and 
the filtrate was concentrated under reduced pressure. The crude material was 
dissolved in EtOAc (10 mL). The organic layer was washed twice with 1M KHSO4 
(2 × 5 mL). The combined aqueous phases were washed with EtOAc (2 × 50 mL) 
then neutralized by addition of solid NaHCO3 until pH 8. The aqueous phase was 
finally extracted with CH2Cl2 (5 × 5 mL) and the combined organic layers were 
washed with brine (5 mL), dried over Na2SO4 and concentrated under reduced 
pressure to give the desired amine 6c as a colourless oil (0.15 g, 0.53 mmol, 
73%). The crude material was directly engaged in the activation step without 
further purification. 
 (S)-2,5-dioxopyrrolidin-1-yl (2-azido-3-(3,4-dichlorophenyl)propyl) 
carbamate 118 
To a stirred suspension of disuccinimidyl carbonate (0.16 g, 0.63 mmol) in 
anhydrous CH2Cl2 (5 mL) was added dropwise a solution of azido amine 124c 
(0.15 g, 0.53 mmol) in anhydrous CH2Cl2 (3 mL). The resulting mixture was 
stirred at room temperature for 3 hours, then the solvent was evaporated under 
reduced pressure and the crude material dissolved in EtOAc (20 mL). The organic 
phase was washed with 1M KHSO4 (2 × 10 mL) then with brine (10 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to give activated 
carbamate 118 (0.15 g, 0.38 mmol, 72%) as a pale yellow solid; δH (CDCl3, 300 
MHz) 2.82 (s, 4H), 2.89 (d, 2H, J = 7.2 Hz), 3.17 (m, 1H), 3.46 (m, 1H), 3.84 (m, 
1H), 7.19 (d, 2H, J = 7.8 Hz), 7.26 (d, 2H, J = 7.8 Hz), 7.37 (s, 1H); δC (CDCl3, 75 
MHz) 25.48, 38.41, 44.93, 62.94, 76.64, 77.07, 77.49, 127.23, 128.86, 129.32, 
136.20, 139.24, 142.26, 151.63, 169.82. 
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6.3.2 Microwave assisted solid phase synthesis of oligoureas 
The NovaPEG Rink amide resin (0.10 g, 0.049 mmol) was placed in a 
polypropylene SPE tube (CEM), suspended in DMF (2 mL) and the first activated 
monomer (0.074 mmol, 1.5 equiv relative to resin loading) and DIEA (26 µL, 
0.148 mmol) were successively added. The tube was then placed inside the 
microwave reactor (CEM Discover) and irradiated (25 W maximum power, 70 °C, 
ramp 5 min, hold 15 min). All microwave experiments were conducted at 
atmospheric pressure. The temperature was maintained by modulation of power 
and controlled with a fiber optic sensor. Coupling with the activated monomer 
was repeated once. The tube was then removed from the microwave reactor and 
the resin was filtered off, washed four times with DMF (3 mL) and two times with 
DCM (3 mL). The coupling efficiency was monitored using chloranil test. 
Reduction of the azide group was next done with microwave assistance by 
swelling the resin in a mixture of dioxane/water (70:30, v/v, 2 mL) and adding 
1M PMe3 solution in THF (0.490 mL, 10 equiv relative to the resin loading), 
irradiating with 25 W power, heating at 70 °C for 30 min. The reaction was 
repeated once. The resin was then filtered off, washed with the dioxane/water 
mixture (2 × 3 mL) and DMF (3 × 3 mL). The preceding acylation steps and 
reduction of azides were repeated. End-capping was carried out once in presence 
of isopropylisocyanate (3 equiv) and DIEA (3 equiv) and under microwave 
assistance (25 W, 70 °C, 15 min). Resin was filtered off, washed with DMF (2 × 2 
mL) and DCM (2 × 2 mL) and dried. The resin was finally swelled in pure TFA and 
left to react for 120 min. After that time, the resin was filtered off, washed with 
DCM and the filtrate was evaporated under reduced pressure.  
 
Purification 
All oligoureas were purified by preparative HPLC, the gradient elution is specified 
for each compound and a typical flow rate of 4 mL·min-1 was applied. Column 
effluent was monitored by UV detection at 200 nm and 254 nm. Oligoureas 129 – 
135 were purified and characterized by Dr. C. Casassus (Guichard group). A 
representative analytical HPLC trace was included for compound 125. 
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Oligourea 125 (iPr-UPhe-UPhe-UAla-UTrp-UOrn-ULeu) 
Oligourea 125 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 4 × 23.3 mg, UAla 2 × 17.6 mg, UTrp 2 × 
33.4 mg, UOrn 2 × 28.1 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per coupling, isopropyl 
isocyanate 2 × 14 µL. HPLC purity of crude product 80%. Yield after 
cleavage/purification 3.8%; white powder; RP-HPLC tR 5.66 min (gradient, 30-
100% of B in 10 min); ESI-HRMS found m/z 1055.4 [M+H]+, C49H83N17O7 requires 
1055.66. 
 
Oligourea 126 (iPr-UPhe-UOrn-UAla-UTrp-UOrn-ULeu) 
Oligourea 126 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, UOrn 4 × 28.1 mg, UAla 2 × 
17.6 mg, UTrp 2 × 33.4 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per coupling, isopropyl 
isocyanate 2 × 14 µL. HPLC purity of crude product 50%. Yield after 
cleavage/purification 2.6%; white powder; RP-HPLC tR 4.06 min (gradient, 30-
100% of B in 10 min); ESI-MS found m/z 512.3 [M+2H]2+; ESI-HRMS found m/z 
1022.6781 [M+H]+, C53H83N16O7 requires 1022.67. 
Oligourea 127 (UPhe-UOrn-UAla-UTrp-UOrn-ULeu) 
Oligourea 127 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, UOrn 4 × 28.1 mg, UAla 2 × 
17.6 mg, UTrp 2 × 33.4 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per coupling. HPLC 
purity of crude product 40%. Yield after cleavage/purification 3%; white powder; 
RP-HPLC tR 2.68 min (gradient, 30-100% of B in 10 min). 
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Oligourea 128 (UPhe-UOrn-UTrp-UAla-UOrn-ULeu) 
Oligourea 128 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, UOrn 4 × 28.1 mg, UTrp 2 × 
33.4 mg, UAla 2 × 17.6 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per coupling. HPLC 
purity of crude product 60%. Yield after cleavage/purification 4%; white powder; 
RP-HPLC tR 1.08 min (gradient, 30-100% of B in 10 min). 
Oligourea 129 (αPhe-UOrn-UAla-UTrp-UOrn-ULeu) 
Oligourea 129 was prepared following the standard procedure using the 
following amount of each reagents: αPhe 2 × 95 mg, UOrn 4 × 28.1 mg, UAla 2 × 
17.6 mg, UTrp 2 × 33.4 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per coupling. For α-
amino acids, a single coupling of 30 min was carried out using 5 equiv of amino 
acid per coupling, 5 equiv of BOP i.e. 108 mg and 7 equiv of DIEA i.e. 60 µL. HPLC 
purity of crude product 80%. Yield after cleavage/purification 7.4%; white 
powder; RP-HPLC tR 1.20 min (gradient, 30-100% of B in 10 min). 
Oligourea 130 (αPhe-UOrn-UAla-UTrp-UOrn-αLeu-αSer) 
Oligourea 130 was prepared following the standard procedure using the 
following amount of each reagents: αPhe 95 mg, UOrn 4 × 28.1 mg, UAla 2 × 17.6 
mg, UTrp 2 × 33.4 mg, αLeu 87 mg, αSer(OtBu) 94 mg, DIEA 26 µL per coupling. 
For α-amino acids, a single coupling of 30 min was carried out using 5 equiv of 
amino acid per coupling, 5 equiv of BOP i.e. 108 mg and 7 equiv of DIEA i.e. 60 µL. 
HPLC purity of crude product 80%. Yield after cleavage/purification 0.65%; 
white powder; RP-HPLC tR 1.08 min (gradient, 30-100% of B in 10 min). 
Oligourea 131 (iPr-UPhe-USer-UAla-UTrp-UOrn-ULeu) 
Oligourea 131 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, USer 2 × 22.7 mg, UAla 2 × 
17.6 mg, UTrp 2 × 33.4 mg, UOrn 2 × 28.1 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per 
coupling, isopropyl isocyanate 2 × 14 µL. HPLC purity of crude product 75%. 
Yield after cleavage/purification 6.7%; white powder; RP-HPLC tR 4.57 min 
(gradient, 30-100% of B in 10 min); ESI-HRMS found m/z 995.4 [M+H]+, 
C47H79N16O8 requires 995.63. 
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Oligourea 132 (UPhe-USer-UAla-UTrp-UOrn-ULeu) 
Oligourea 132 was prepared following the standard procedure. HPLC purity of 
crude product 75%. Yield after cleavage/purification 1.1%; white powder; RP-
HPLC tR 1.11 min (gradient, 30-100% of B in 10 min). 
Oligourea 133 (iPr-UPhe-UOrn-UAla-UTrp-USer-ULeu) 
Oligourea 133 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, UOrn 2 × 28.1 mg, UAla 2 × 
17.6 mg, UTrp 2 × 33.4 mg, USer 2 × 22.7 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per 
coupling, isopropyl isocyanate 2 × 14 µL. HPLC purity of crude product 80%. 
Yield after cleavage/purification 8.1%; white powder; RP-HPLC tR 4.41 min 
(gradient, 30-100% of B in 10 min); ESI-MS found m/z 498.6 [M+2H]+, ESI-HRMS 
found m/z 995.6 [M+H]+, C47H79N16O8 requires 995.63. 
Oligourea 134 (UPhe-UOrn-UAla-UTrp-USer-ULeu) 
Oligourea 134 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, UOrn 2 × 28.1 mg, UAla 2 × 
17.6 mg, UTrp 2 × 33.4 mg, USer 2 × 22.7 mg, ULeu 2 × 20.8 mg, DIEA 26 µL per 
coupling. HPLC purity of crude product 60%. Yield after cleavage/purification 
4.7%; white powder; RP-HPLC tR 2.08 min (gradient, 30-100% of B in 10 min). 
Oligourea 135 (iPr-UPhe-USer-ULeu-UTrp-UOrn-ULeu) 
Oligourea 135 was prepared following the standard procedure using the 
following amount of each reagents: UPhe 2 × 23.3 mg, USer 2 × 22.7 mg, ULeu 4 × 
20.8 mg, UTrp 2 × 33.4 mg, UOrn 2 × 28.1 mg, DIEA 26 µL per coupling, isopropyl 
isocyanate 2 × 14 µL. HPLC purity of crude product 60%. Yield after 
cleavage/purification 5.5%; white powder; RP-HPLC tR 2.08 min (gradient, 30-
100% of B in 10 min); ESI-MS found m/z 520.2 [M+2H]+; ESI-HRMS found m/z 
1037.3 [M+H]+, C50H85N16O8 requires 1037.68. 
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Appendix I  
 
 
Repeat of the single point screen against compounds 60, 67-71 
 
Repeat of the single point assay on selected compounds from the third set of 
compounds (60 – 77, Fig. 3.9, Chapter 3). This subset was re-tested to confirm 
the hit identification. Compounds 68-69 and 70-71 were two pairs of trimers 
with side chains matching those of the p53 helix which displayed very different 
relative efficiencies in the single point assay, but this gap in efficiencies only 
translated to a small difference in IC50s in the dose-response assay.  
 
 
These compounds were tested in the single point assay conditions described in 
the Experimental Section. Initially, the relative efficiencies for 68/69 and 70/71 
were: 86%/37% and 34%/81% respectively, and 25% for 67. The repeat 
provided: 71%/56% and 51%/69% respectively and 25% for 67.  
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Appendix II  
 
Automated single point assay against p53/hDM2 
 
 
 
 
Results from the single point screening at 10 µM against hDM2 presented as 
a %Nutlin-3a efficiency. Bars in blue correspond to compounds initially 
designed to target the p53/hDM2 PPI (bearing 3 side chains). Red bars 
correspond to compounds initially designed to target the Bcl-2 family (bearing 4 
side chains, mostly aliphatic). Most potent from initial screens are indicated by 
purple dots. 
 
The broad range of relative efficiencies that correspond to these hits indicated 
that results from this automated screening failed to reproduce results from the 
initial screens carried out manually in 96-well plates. Some compounds and in 
particular 93 gave an even higher anisotropy than the protein + tracer; these 
compounds might be inducing aggregation.  
-0.015 
-0.013 
-0.011 
-0.009 
-0.007 
-0.005 
-0.003 
-0.001 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
1
0
 
1
1
 
1
2
 
1
3
 
1
4
 
1
5
 
1
6
 
1
7
 
1
8
 
1
9
 
2
0
 
2
1
 
2
2
 
2
3
 
2
4
 
2
5
 
2
6
 
2
7
 
2
8
 
2
9
 
3
0
 
3
1
 
3
2
 
3
3
 
3
4
 
3
5
 
3
6
 
3
7
 
3
8
 
3
9
 
4
0
 
4
1
 
4
2
 
4
3
 
4
4
 
4
5
 
4
6
 
4
7
 
4
8
 
4
9
 
5
0
 
5
1
 
5
2
 
5
3
 
5
4
 
5
5
 
5
6
 
5
7
 
5
8
 
5
9
 
6
0
 
6
1
 
6
2
 
6
3
 
6
4
 
6
5
 
B
1
 
B
2
 
B
3
 
B
4
 
B
5
 
B
6
 
B
7
 
B
8
 
B
9
 
B
1
0
 
B
1
1
 
B
1
2
 
B
1
3
 
B
1
4
 
B
1
5
 
B
1
6
 
D
M
SO
 
P
ro
t+
Tr
ac
er
 
P
+T
+N
u
tl
in
 
Raw Anisotropy at 10 µM/hDM2 
-30 
-10 
10 
30 
50 
70 
90 
110 
4
1
 
4
3
 
4
5
 
4
6
 
4
8
 
4
9
 
5
1
 
5
3
 
3
3
 
3
6
 
5
7
 
5
9
 
2
7
 
6
2
 
6
4
 
6
6
 
6
8
 
7
0
 
7
2
 
7
3
 
7
5
 
7
7
 
7
8
 
8
0
 
8
2
 
8
4
 
8
6
 
8
8
 
3
1
 
9
2
 
9
4
 
9
6
 
9
8
 
1
0
0
 
1
0
2
 
1
0
4
 
1
0
6
 
D
M
SO
 
N
u
tl
in
-3
a 
%Nutlin efficiency at 10 µM 
Referemces 
 
200 
 
Appendix III  
 
Selectivity study for compound 102 
 
 
Dose-response curves for compound 102 against both PPIs (red: p53/hDM2, black: 
Noxa B/Mcl-1). 
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Appendix IV 
 
Investigating a potential interaction between an oligourea and the p53-Flu 
tracer 
In this experiment, an oligourea (132) was serially diluted from 150 μM down to 
13 nM, then the tracer was added at a constant concentration of 81.7 nM. In the 
case where there is no interaction between the oligourea and the tracer, the 
anisotropy should remain constant over the range of concentration tested; 
otherwise, a dose-dependent variation of the anisotropy should be observed.  
 
 
Investigating potential interaction between oligourea compounds and the 
p53 tracer. a. Intensity for the 3 repeats. b. Plot of the average anisotropy 
against the concentration in oligourea. 
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Appendix V 
Dose-response curves for oligoureas 129, 130, 131, 132 
 
 
Overlay of dose-response curves for oligoureas 127, 129 and 130. 
 
 
Overlay of dose-response curves for oligoureas 131 and 132. 
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Appendix VI  
 
Attempt to obtain the complete binding curve for oligourea 135, using  
50 nM hDM2 and 54 nM p53-Flu (concentration in the wells). 
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